0001493152-23-010263.txt : 20230331 0001493152-23-010263.hdr.sgml : 20230331 20230331161115 ACCESSION NUMBER: 0001493152-23-010263 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 84 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230331 DATE AS OF CHANGE: 20230331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Motus GI Holdings, Inc. CENTRAL INDEX KEY: 0001686850 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 814042793 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38389 FILM NUMBER: 23787730 BUSINESS ADDRESS: STREET 1: 1301 EAST BROWARD BOULEVARD STREET 2: 3RD FLOOR CITY: FT. LAUDERDALE STATE: FL ZIP: 33301 BUSINESS PHONE: 786-459-1831 MAIL ADDRESS: STREET 1: 1301 EAST BROWARD BOULEVARD STREET 2: 3RD FLOOR CITY: FT. LAUDERDALE STATE: FL ZIP: 33301 FORMER COMPANY: FORMER CONFORMED NAME: Eight-Ten Merger Corp. DATE OF NAME CHANGE: 20161006 10-K 1 form10-k.htm
0001686850 false FY http://fasb.org/us-gaap/2022#Revenues http://fasb.org/us-gaap/2022#Revenues 0001686850 2022-01-01 2022-12-31 0001686850 2022-06-30 0001686850 2023-03-27 0001686850 2022-12-31 0001686850 2021-12-31 0001686850 2021-01-01 2021-12-31 0001686850 us-gaap:CommonStockMember 2020-12-31 0001686850 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001686850 us-gaap:RetainedEarningsMember 2020-12-31 0001686850 2020-12-31 0001686850 us-gaap:CommonStockMember 2021-12-31 0001686850 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001686850 us-gaap:RetainedEarningsMember 2021-12-31 0001686850 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001686850 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001686850 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001686850 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001686850 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001686850 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001686850 us-gaap:CommonStockMember 2022-12-31 0001686850 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001686850 us-gaap:RetainedEarningsMember 2022-12-31 0001686850 us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-12-31 0001686850 us-gaap:TransferredOverTimeMember 2022-01-01 2022-12-31 0001686850 us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-12-31 0001686850 us-gaap:TransferredOverTimeMember 2021-01-01 2021-12-31 0001686850 mots:NewWarrantsMember 2022-01-01 2022-12-31 0001686850 mots:NewWarrantsMember 2021-01-01 2021-12-31 0001686850 us-gaap:OfficeEquipmentMember srt:MinimumMember 2022-01-01 2022-12-31 0001686850 us-gaap:OfficeEquipmentMember srt:MaximumMember 2022-01-01 2022-12-31 0001686850 mots:ComputersAndSoftwareMember srt:MinimumMember 2022-01-01 2022-12-31 0001686850 mots:ComputersAndSoftwareMember srt:MaximumMember 2022-01-01 2022-12-31 0001686850 mots:MachineryMember srt:MinimumMember 2022-01-01 2022-12-31 0001686850 mots:MachineryMember srt:MaximumMember 2022-01-01 2022-12-31 0001686850 us-gaap:EquipmentMember srt:MinimumMember 2022-01-01 2022-12-31 0001686850 us-gaap:EquipmentMember srt:MaximumMember 2022-01-01 2022-12-31 0001686850 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0001686850 mots:ContingentRoyaltyObligationMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001686850 mots:ContingentRoyaltyObligationMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001686850 mots:ContingentRoyaltyObligationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001686850 mots:ContingentRoyaltyObligationMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001686850 mots:ContingentRoyaltyObligationMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001686850 mots:ContingentRoyaltyObligationMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001686850 mots:ContingentRoyaltyObligationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001686850 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001686850 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-12-31 0001686850 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001686850 us-gaap:MeasurementInputDiscountRateMember 2022-01-01 2022-12-31 0001686850 us-gaap:MeasurementInputDiscountRateMember 2021-01-01 2021-12-31 0001686850 us-gaap:OfficeEquipmentMember 2022-12-31 0001686850 us-gaap:OfficeEquipmentMember 2021-12-31 0001686850 mots:ComputersAndSoftwareMember 2022-12-31 0001686850 mots:ComputersAndSoftwareMember 2021-12-31 0001686850 mots:MachineryMember 2022-12-31 0001686850 mots:MachineryMember 2021-12-31 0001686850 us-gaap:EquipmentMember 2022-12-31 0001686850 us-gaap:EquipmentMember 2021-12-31 0001686850 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001686850 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001686850 mots:OfficeMember mots:FortLauderdaleMember 2022-01-01 2022-12-31 0001686850 mots:OfficeMember country:IL 2022-01-01 2022-12-31 0001686850 mots:KreosLoanAgreementMember 2021-07-15 2021-07-16 0001686850 mots:KreosLoanAgreementMember mots:TrancheAMember 2021-07-15 2021-07-16 0001686850 mots:TrancheBMember mots:KreosLoanAgreementMember 2021-07-15 2021-07-16 0001686850 mots:TrancheCMember 2021-07-15 2021-07-16 0001686850 mots:TrancheCMember 2021-01-01 2021-12-31 0001686850 mots:KreosLoanAgreementMember 2022-01-01 2022-12-31 0001686850 mots:KreosLoanAgreementMember 2022-12-31 0001686850 mots:KreosLoanAgreementMember 2021-07-16 0001686850 us-gaap:WarrantMember mots:KreosLoanAgreementMember 2022-12-31 0001686850 mots:KreosLoanAgreementMember 2021-12-31 0001686850 us-gaap:ConvertibleDebtMember 2022-12-31 0001686850 us-gaap:LongTermDebtMember 2022-12-31 0001686850 2011-12-31 2016-12-31 0001686850 mots:IsraeliNationalAuthorityForTechnicalInnovationMember 2022-01-01 2022-12-31 0001686850 mots:IsraeliNationalAuthorityForTechnicalInnovationMember 2021-01-01 2021-12-31 0001686850 mots:RoyaltyPaymentRightsCertificatesMember 2022-01-01 2022-12-31 0001686850 us-gaap:PrivatePlacementMember 2022-01-01 2022-12-31 0001686850 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-12-31 0001686850 us-gaap:RoyaltyMember 2022-01-01 2022-12-31 0001686850 mots:SharedSpaceAgreementsMember mots:OrchestraBioMedIncMember 2020-01-31 0001686850 srt:MinimumMember 2022-01-01 2022-12-31 0001686850 srt:MaximumMember 2022-01-01 2022-12-31 0001686850 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001686850 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001686850 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0001686850 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001686850 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001686850 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001686850 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001686850 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001686850 us-gaap:StockOptionMember 2022-12-31 0001686850 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001686850 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001686850 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001686850 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001686850 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001686850 mots:TwoThousandSixteenEquityIncentivePlanMember us-gaap:CommonStockMember 2016-12-01 2016-12-31 0001686850 mots:TwoThousandSixteenEquityIncentivePlanMember 2022-01-01 0001686850 mots:TwoThousandSixteenEquityIncentivePlanMember srt:MaximumMember 2022-01-01 0001686850 mots:TwoThousandSixteenEquityIncentivePlanMember 2022-12-31 0001686850 mots:ServicesAgreementMember mots:WarrantsMember 2020-02-29 0001686850 mots:ServicesAgreementMember mots:ReplacementWarrantsMember 2020-02-29 0001686850 mots:ServicesAgreementMember 2020-02-29 0001686850 us-gaap:WarrantMember 2020-02-29 0001686850 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-02-29 0001686850 us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2020-02-06 0001686850 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-02-06 0001686850 mots:NonEmployeeMember 2022-01-04 2022-01-05 0001686850 mots:NonEmployeeMember 2022-01-05 0001686850 mots:NonEmployeeMember 2022-01-01 2022-12-31 0001686850 mots:NonEmployeeMember 2021-01-01 2021-12-31 0001686850 mots:EquityDistributionAgreementMember srt:MaximumMember 2021-03-01 2021-03-31 0001686850 mots:EquityDistributionAgreementMember 2022-01-01 2022-12-31 0001686850 mots:EquityDistributionAgreementMember 2021-01-01 2021-03-31 0001686850 mots:EquityDistributionAgreementMember 2023-01-01 2023-03-14 0001686850 us-gaap:StockOptionMember 2020-12-31 0001686850 us-gaap:StockOptionMember 2020-01-01 2020-12-31 0001686850 us-gaap:WarrantMember 2020-12-31 0001686850 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001686850 us-gaap:StockOptionMember 2021-12-31 0001686850 us-gaap:WarrantMember 2021-12-31 0001686850 us-gaap:WarrantMember 2022-12-31 0001686850 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001686850 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001686850 mots:FederalMember 2022-01-01 2022-12-31 0001686850 mots:StateMember 2021-01-01 2021-12-31 0001686850 mots:FederalMember 2018-01-01 2018-12-31 0001686850 country:IL 2022-01-01 2022-12-31 0001686850 us-gaap:SubsequentEventMember srt:MinimumMember 2023-01-01 2023-03-31 0001686850 us-gaap:SubsequentEventMember srt:MaximumMember 2023-01-01 2023-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2022

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________ to ________

 

Commission file number: 001-38389

 

Motus GI Holdings, Inc.

(Exact name of registrant as specified in its charter)

 

delaware   81-4042793

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

     

1301 East Broward Boulevard, 3rd Floor

Ft. Lauderdale, FL

   33301
(Address of principal executive offices)   (Zip code)

 

Registrant’s telephone number, including area code: (954) 541-8000

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share   MOTS   NASDAQ Capital Market

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of June 30, 2022, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was approximately $14.6 million based on the closing price of the registrant’s Common Stock on June 30, 2022.

 

The number of shares outstanding of the registrant’s Common Stock, par value of $0.0001 per share, as of March 27, 2023 was 4,778,873.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None.

 

 

 

 

 

 

Motus GI Holdings, Inc.

ANNUAL REPORT ON FORM 10-K

 

For the Year Ended December 31, 2022

 

    Page
PART I    
Item 1 Business 2
Item 1A Risk Factors 24
Item 1B Unresolved Staff Comments 53
Item 2 Properties 53
Item 3 Legal Proceedings 53
Item 4 Mine Safety Disclosures 53
     
PART II    
Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 54
Item 6 Reserved 54
Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations 54
Item 7A Quantitative and Qualitative Disclosures About Market Risk 60
Item 8 Financial Statements and Supplementary Data 60
Item 9 Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 60
Item 9A Controls and Procedures 61
Item 9B Other Information 61
Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 61
     
PART III    
Item 10 Directors, Executive Officers and Corporate Governance 62
Item 11 Executive Compensation 66
Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 72
Item 13 Certain Relationships and Related Transactions, and Director Independence 75
Item 14 Principal Accounting Fees and Services 77
     
PART IV    
Item 15 Exhibits, Financial Statement Schedules 79
Item 16 Form 10-K Summary 83
     
EXHIBIT INDEX  
     
SIGNATURES 84

 

i

 

 

PART I

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This report on Form 10-K contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “can,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential” and other similar words and expressions of the future.

 

There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to:

 

  ● our limited operating history and need for additional capital;
     
  ● our ability to execute our strategic restructuring program aimed at capital preservation, reduction in cash expenditures and reduction of our workforce;
     
  ● our ability to enter into and consummate strategic alternatives, including any acquisition, merger, reverse merger, other business combination, sale of assets, licensing and other strategic transactions;
     
  ● our history of operating losses in each year since inception and expectation that we will continue to incur operating losses for the foreseeable future;
     
  ● our current and future capital requirements to support our development and commercialization efforts for the Pure-Vu System and our ability to satisfy our capital needs;
     
  ● our ability to remain compliant with the requirements of The Nasdaq Capital Market for continued listing;
     
  ● our dependence on the Pure-Vu System, our sole product;
     
  ● our ability to commercialize the Pure-Vu System;
     
  ● our Pure-Vu System and the procedure to cleanse the colon in preparation for colonoscopy are not currently separately reimbursable through private or governmental third-party payors;
     
  ● our ability to obtain approval or certification from regulatory agents or other competent entities in different jurisdictions for the Pure-Vu System;
     
  ● our dependence on third-parties to manufacture the Pure-Vu System;
     
  ● our ability to maintain or protect the validity of our patents and other intellectual property;
     
  ● our ability to retain key executives and medical and science personnel;
     
  ● our ability to internally develop new inventions and intellectual property;
     
  ● interpretations of current laws and the passages of future laws;
     
  ● acceptance of our business model by investors;
     
  ● the accuracy of our estimates regarding expenses and capital requirements;
     
  ● our ability to adequately support growth;
     
  ● our ability to predict the financial impact of inflation on costs such as labor, freight and materials; and
     
  ● our ability to project in the short term the hospital medical device environment considering the global pandemic and strains on hospital systems

 

1
 

 

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. Please see “Part I—Item 1A—Risk Factors” for additional risks which could adversely impact our business and financial performance.

 

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith and we believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs or projections will result or be achieved or accomplished.

 

ITEM 1. BUSINESS

 

Overview

 

We have developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the “FDA”) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (“GI”) endoscopy procedures. The Pure-Vu System is also CE marked in the European Economic Area (EEA) for use in colonoscopy. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Through irrigation and evacuation of debris, the Pure-Vu System is designed to provide better-quality exams. Challenges exist for inpatient colonoscopy and endoscopy, particularly for patients who are elderly, with comorbidities, or active bleeds, where the ability to visualize, diagnose and treat is often compromised due to debris, including fecal matter, blood, or blood clots. We believe this is especially true in high acuity patients, like GI bleeding where the existence of blood and blood clots can impair a physician’s view and removing them can be critical in allowing a physician the ability to identify and treat the source of bleeding on a timely basis. We believe use of the Pure-Vu System may lead to positive outcomes and lower costs for hospitals by safely and quickly improving visualization of the colon and upper GI tract, potentially enabling effective diagnosis and treatment without delay. In multiple clinical studies to date, involving the treatment of challenging inpatient and outpatient cases, the Pure-Vu System has consistently helped achieve adequate bowel cleanliness rates greater than 95% following a reduced prep regimen. We also believe that the technology may be useful in the future as a tool to help reduce user dependency on conventional pre-procedural bowel prep regimens. Based on our review and analysis of 2019 market data and 2021 projections for the U.S. and Europe, as obtained from iData Research Inc., we believe that during 2022 approximately 1.5 million inpatient colonoscopy procedures were performed in the U.S. and approximately 4.8 million worldwide. Upper GI bleeds occurred in the U.S. at a rate of approximately 400,000 cases per year in 2019, according to iData Research Inc. The Pure-Vu System has been assigned an ICD-10 code in the US. The system does not currently have unique codes with any private or governmental third-party payors in any other country or for any other use; however, we may pursue reimbursement activities in the future, particularly in the outpatient colonoscopy market. We received 510(k) clearance in February 2022 from the FDA for our Pure-Vu EVS System and have commenced initial commercialization of this product.

 

 

Strategic Review and Restructuring

 

As previously announced in January 2023, we have initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. We have engaged Lake Street Capital Markets LLC (“Lake Street Capital”) to advise us in this process. Potential strategic alternatives that we may consider are expected to include an acquisition, merger, reverse merger, other business combination, sale of assets, licensing and other strategic transactions.

 

To support these objectives, we commenced a strategic restructuring program aimed at capital preservation. We have reduced our quarterly cash expenditures by approximately 35% by eliminating approximately 45% of our workforce during the first quarter of 2023. In connection with the restructuring, we expect to incur a non-recurring charge of approximately $1.0 to $2.0 million in the first quarter of 2023. In addition, the non-management members of the Board agreed to defer their Board fees until a future date.

 

2
 

 

The restructuring is intended to position us to continue to explore all strategic alternatives, continue supporting our existing customers utilizing Pure-Vu EVS for colonoscopies, as well as targeting pipeline opportunities with contracted health systems. In addition, we intend to continue to advance our Pure-Vu EVS Gastro development program, which is designed for use during an Upper GI endoscopy to improve visualization by clearing debris and may help improve procedure times and outcomes especially in high acuity situations like an upper GI bleed. We intend to seek U.S. regulatory approval for the Pure-Vu EVS Gastro device in the second half of 2023.

 

We intend to continue to evaluate and identify other areas of our business to enhance efficiencies and improve processes, with a goal to further lower our operating expenses and capital needs. There can be no assurance that this strategic review process will result in any changes to our current business plans or lead to any specific action or transaction. We do not intend to discuss or disclose further developments during this strategic review process unless and until the Board has approved a specific action or we otherwise determine that further disclosure is appropriate.

 

Market Overview

 

Colonoscopies are one of the most frequently performed medical procedures with over 20 million colonoscopies performed in the United States each year and more than 54 million worldwide, per 2019 iData Research Inc. Based on our review and analysis of this market data as well as 2021 projections for the U.S. and Europe, as obtained from iData Research Inc., we estimate that during 2023 approximately 1.5 million inpatient colonoscopy procedures in a hospital setting will be performed in the U.S. Hospital based colonoscopies are typically performed to help diagnose and treat lower gastrointestinal (GI) bleeding, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), anemia or infection. A majority of total colonoscopies in the U.S. and worldwide are performed as outpatient procedures at an ambulatory endoscopy center and/or hospital outpatient departments, with the bulk of procedures performed to detect and prevent colorectal cancer (CRC). According to the CDC (2018), approximately 31% of eligible patients are still not current with their CRC screening in the U.S. Over the past few decades, CRC has been demonstrated to be one of the most preventable cancers if detected early through the use of colonoscopy screening.

 

   

 

Despite the pervasiveness and effectiveness of colonoscopy, a key ongoing clinical challenge of the procedure is that patients are required to undergo a potent pre-procedure bowel preparation regimen to try to ensure that the colon is fully cleansed to enable clear visualization of the tissue. Successful bowel preparation is one of the most important factors in delivering a thorough, high quality exam and is well documented to have a direct impact on the adenoma detection rate (ADR), the rate of detecting pre-cancer anomalies in the colon tissue, which in turn predicts a decrease in CRC risk. An inadequately prepared colon can impact the diagnostic accuracy of the procedure and can lead to procedures having to be repeated earlier than the medical guidelines advise or can lead to failed procedures especially in the inpatient setting. Rescheduling the procedure is inconvenient to the patient (and many patients fail to come for their follow-up), creates inefficiencies in the provider’s workflow, and increases the length of hospital stay, each of which results in increased healthcare costs. The preparation regimen typically requires patients to be on a liquid diet for over 24 hours, drink up to four liters of a purgative, spend up to 12 hours prior to the exam periodically going to the bathroom to empty their bowels, and disrupting their daily activities, which could include missing work or other activities. The regimens can be highly disruptive and uncomfortable for many patients. In fact, approximately 57% of patients cite not wanting to take the bowel preparation as the number one deterrent for the procedure, as noted by Harewood et al., American Journal of Gastroenterology (2002). Further, it is estimated by HRA Healthcare Research & Analytics (2015) that approximately 23% of outpatients present with inadequately prepped colons, resulting in a number of colonoscopies that yield poor diagnostic accuracy or failed colonoscopies that must be repeated. For inpatients, this figure jumps to approximately 51% according to a recently published study by the Cleveland Clinic. It has also been reported that patients requiring frequent colonoscopies, such as CRC survivors and other surveillance patients, account for approximately 21% of the outpatient colonoscopies performed annually in the U.S., per Lieberman D.A. et.al., American Society for Gastrointestinal Endoscopy (2005).

 

3
 

 

Inpatient Opportunity: improving efficiencies and shortening time to complete a successful colonoscopy

 

Inpatient colonoscopy is usually performed to diagnose the source of various gastrointestinal conditions such as lower GI bleeding or bowel pain. For an inpatient hospital stay, the Centers for Medicare & Medicaid Services, or CMS, uses a prospective payment system, or PPS, based upon the MS-DRG payment groupings, to pay for hospital services with the goal of encouraging efforts to minimize their costs. The DRG assignment is influenced by a combination of factors such as a patient’s sex, diagnosis at the time of discharge and procedures performed. Based on patient specific information, all hospital expenses for their care during an inpatient stay are packaged and assigned to one of over 700 MS-DRGs (“Medicare Severity – Diagnostics Related Groups”). According to Decision Driver Analytics, a reimbursement consulting agency, when a colonoscopy is performed as the primary procedure (no other procedures or complicating diagnosis), MSDRGs 395, 394 or 393 would apply which pay between $3,861 (without complications or major comorbidities) and $9,421 (with major complications and comorbidities), which are average figures subject to adjustment. The National Inpatient Sample (“NIS”) and other literature sources note that the cost for a standard hospital bed averages $2,298 and the cost for an intensive care unit (“ICU”) bed averages $6,546 per day in the U.S, so reducing the length of stay can save the hospital significant expense.

 

An inpatient colonoscopy is generally more problematic than an outpatient procedure due primarily to the acuity of the patient who often struggles to complete a satisfactory pre-procedural bowel prep, which can lead to lower rates of successful completion of the procedure and a higher frequency of repeat procedures. Inpatients are difficult to prep as shown by inadequate bowel prep rates. Published studies have found that the inpatient population experiences rates of insufficiently prepped colons at the time of colonoscopy as high as 55%. This has been shown to lead directly to significantly longer hospital stays and other additional costs due to the need for repeated preps, repeated colonoscopies, and additional diagnostic procedures. This is exemplified in a recently published study by the Cleveland Clinic that showed an inadequate preparation rate of 51% in the study population of 8,819 inpatients. The study noted that the 51% of the study population that were inadequately prepped stayed one day extra in the hospital compared to patients with adequate preparation. Another study, from Northwestern University Hospital System, showed an average hospital stay extension of two days and cost increase of as much as $8,000 per patient as a result of challenges associated with bowel preparation. We believe the Pure-Vu System may improve outcomes and lower costs for hospitals by potentially reducing the time to a successful colonoscopy, minimizing delayed and incomplete procedures, and improving the quality of an exam.

 

 

Our Pure-Vu Solution

 

Our system consists of a workstation controller and a single-use, disposable sleeve that fits over most standard and slim colonoscopes. Together with the colonoscope, the Pure-Vu System performs rapid, effective, and efficient intra-procedural cleaning without compromising procedural workflow and techniques. The over-sleeve has an umbilical section that connects the disposable to the workstation. The workstation, through a series of peristaltic pumps activated by foot pedals, delivers an irrigation medium of air and water that creates a pulsed vortex inside the colon to break up fecal matter while simultaneously evacuating the colon content into waste receptacles already used in a standard colonoscopy procedure. The proprietary smart sense suction (evacuation) system in the device has sensors built in that can detect the formation of a blockage and automatically clear it allowing the physician to remove significant debris from the patient. The Pure-Vu System has been clinically demonstrated to be capable of cleaning poorly prepared colons in minutes. We have built and continue to extend our intellectual property portfolio designed to protect key aspects of the system, including the pulsed vortex irrigation and auto-purge functions.

 

4
 

 

 

In June 2019, the 510(k) premarket notification for the second-generation (“Gen 2”) of the Pure-Vu System was reviewed and cleared by the FDA. We received the initial CE Certificate of Conformity, allowing us to affix the CE Mark to the Gen 2 Pure-Vu System in March 2020. We received a supplement to the initial CE Certificate of Conformity in January 2021.

 

 

On February 14, 2022, we announced the 510(k) clearance by the FDA of our Pure-Vu EVS System. The Pure-Vu EVS offers usability advancements over the previous versions, including enhanced physician navigation and control, on-demand bedside loading, expanded cleansing capacity, and a smaller workstation footprint.

 

We also implemented an improved manufacturing cost structure in 2022 that we believe better positions the Company to increase margins, and establish strategic relationships in the US and other more cost sensitive global markets over time.

 

Pre-Clinical and Clinical Data & Safety

 

The Pure-Vu System has been studied in multiple clinical studies in study subjects receiving a reduced prep regime as well as a study focused on the inpatient population. The Pure-Vu System was used in two multi-center clinical studies in the EU and Israel, and also a single center study in the US. The first study involved 49 subjects and was completed in the second quarter of 2016. The second study was completed in June 2017 and involved 46 subjects. The subjects in these studies had a restricted diet for 18-24 hours and received a split dose of 20mg of over-the-counter Dulcolax® (bisocodyl). They did not take any liquid purgative traditionally prescribed for bowel preparation. The clinical data showing performance of the Pure-Vu System in these studies using the BBPS, is shown below. The clinical results from the 2016 study were presented at the United European Gastroenterology Week (“UEGW”) in October 2016 and the second study was published in the peer review journal Endoscopy in 2018. The clinical results from the 2017 study were presented at the UEGW in October 2017, showing similar results, as shown below. This study has been published in Endoscopy, one of the top peer reviewed journals in the EU.

 

5
 

 

The third clinical study in the outpatient setting was presented at the American College of Gastroenterology (“ACG”) Annual Meeting in October 2018. This study was performed in the United States and showed that the Pure-Vu System demonstrated safe and effective colonic cleaning in the per protocol analysis of 46 subjects receiving a reduced prep regimen. The study was initially designed to compare two different minimal bowel preparation regimens. Initially subjects were randomized to receive one of two minimal bowel preparations: three doses of 17 gr. MiraLAX each mixed in 8.5 oz. of clear liquids or two doses of 7.5 oz. magnesium citrate (MgC) each taken with 19.5 oz. of clear liquid. A study amendment early on replaced the MiraLAX arm, due to obvious inferior Boston Bowel Preparation Scale (“BBPS”), a validated assessment instrument, scoring from the outset. The replacement arm consisted of two doses of 5 oz. MgC taken with 16 oz. of clear liquid. All subjects were allowed to eat a low residue diet on the day prior and were asked to avoid seeds and nuts for five days prior to their procedure. Study objectives evaluated for each study arm included: (1) improvement of colon cleansing from presentation baseline to completion of the procedure (as assessed by the BBPS) through the use of the Pure-Vu System, (2) time required to reach the cecum, (3) total procedure time, and (4) safety. No significant differences were found between the three groups with regard to demographics or indication for colonoscopy. No serious adverse events related to the device were reported. The use of the Pure-Vu System enabled successful intraprocedural cleansing of the colon and ensured successful completion of all colonoscopies performed (100% success rate). Although there were only 46 subjects in the study, there was a highly significant difference in the study population (p value <0.0001) between the baseline preparation and that seen post cleansing with the Pure-Vu System. The use of the Pure-Vu System added some time to the procedure, but the total procedure time was approximately 25 minutes in this study.

 

REDUCE Study

 

The Reduce study (“Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement”), was first presented at Digestive Disease Week (DDW) conference in May of 2019 and a full manuscript, titled “A multi-center, prospective, inpatient feasibility study to evaluate the use of an intra-colonoscopy cleansing device to optimize colon preparation in hospitalized subjects: the REDUCE study”, was published in the peer review journal BMC Gastroenterology in Q2 of 2021. The REDUCE study was a multi-center inpatient prospective trial designed to evaluate Pure-Vu System’s ability to consistently and reliably improve bowel preparation to facilitate a successful colonoscopy in a timely manner in patients who were indicated for a diagnostic colonoscopy. The study enrolled 95 hospitalized subjects on schedule regardless of their level of pre-procedural bowel preparation. The primary endpoint for the study was improvement of bowel preparation from baseline to post procedure as assessed by the Boston Bowel Preparation Scale (“BBPS”), which assesses the cleanliness of the each of the three segments of the colon on a 0 to 3 scale and requires a minimum score of 2 or better per segment to be considered adequately prepped.

 

For inpatients that received the Pure-Vu System, adequate bowel preparation improved from a baseline of 38% to 96% in segments evaluated. The analysis from the REDUCE study showed statistically significant improvement in every segment of the colon after Pure-Vu System use. The per segment BBPS improved from an average baseline of 1.74, 1.74 and 1.5 to 2.89, 2.91 and 2.86 respectively with a statistically significant p value of .001 for all three segments of the colon. The primary indication for patients enrolled in the study (68%) was a GI bleed. Acute GI bleeds can lead to hemodynamic instability and is a critical population to treat in an urgent fashion. Physicians were able to achieve a successful clinical outcome in 97% of subjects in the study.

 

The chart below shows the outcome of the primary endpoint using the BBPS both pre and post use of the Pure-Vu System in a side-by-side fashion. It can be seen from the data that the high cleansing level achieved with the Pure-Vu System is consistent across the various studies:

 

 

6
 

 

Current Additional Clinical Studies

 

In Q2 2022, we completed the EU study of subjects who have had a history of poor bowel preparation and were scheduled for either screening, diagnostic, or surveillance colonoscopy across two sites, including the Radboud University Medical Center (Netherlands) and GastroZentrum Lippe (Germany). The subjects underwent a low volume bowel preparation, with just 2x150ml picoprep. The subjects were also allowed to eat a low fiber diet for two days prior to the colonoscopy as opposed to the typical clear liquid diet the day before a colonoscopy. The subjects then received intra-procedural bowel cleansing with the Pure-Vu System. The primary endpoint for the study is improvement of the bowel preparation from baseline to post procedure as assessed by the Boston Bowel Preparation Scale (BBPS), which assesses the cleanliness of each of the three segments of the colon on a zero to three scale and requires a minimum score of two or better per segment to be considered adequately prepped. The results of the study were presented at the Digestive Disease Week meeting in May 2022 and showed a statistically significant improvement of subjects who were adequality prepped from a baseline of 31.8% to 97.7% after the use of Pure-Vu with a p-value of <0.0001.

 

Cost Effectiveness Analysis and Independent Studies

 

In 2021, we announced the publication of a sponsored Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource Allocation, which is titled, “Colonoscopy in poorly prepped colons. A cost effectiveness analysis comparing standard of care to a new cleansing technology.” This study suggests that, assuming a national average compliance rate for colonoscopy in the U.S. at 60%, as reported by the American Cancer Society in 2017, the use of Pure Vu has the potential to provide the US healthcare system lifetime savings of $833-$922 per patient depending on the insurer when compared to the standard of care. Sponsorship of analysis and development of the manuscript was provided by us.

 

In 2021, we also announced the presentation of results from an independent single-center study of the Pure-Vu System as an adjunct to colon cleansing in subjects with inadequate bowel preparation (IBP) in a poster presentation at the 2021 American College of Gastroenterology (ACG) Annual Scientific Meeting.

 

In the independent study, the Pure-Vu System was used in 40 subjects (14 inpatient procedures (35%) and 26 outpatient procedures (65%)) with IBP to complete the colonoscopy. The indication for colonoscopy was either diagnostic or colorectal cancer (CRC) screening/surveillance. Pure-Vu was used as an adjunct to IBP to allow completion of procedure in 37 subjects. In subjects with IBP, the mean BBPS score improved from 3.1 (range: 0-6) to 8.5 (range 5-9) after intra-procedural cleansing. Three subjects had active lower gastrointestinal bleeding (LGIB), and the Pure-Vu System was used without bowel preparation to promptly detect the etiology and possibly treat. When used in emergency colonoscopy without bowel preparation, procedures could be completed in all three subjects detecting and treating diverticular and post-polypectomy bleeding in one subject each and diagnosing severe right sided ischemic colitis in another. The study authors concluded the utility of the Pure-Vu System without prior bowel preparation in LGIB needs further study. Use of Pure-Vu System did not interfere with the performance of endoscopic interventions including biopsy, cold/hot snare polypectomy, or EMR. Besides minor mucosal trauma in two cases, no major complications were observed with the Pure-Vu System.

 

Further, at the ACG meeting in October 2022, results from an independent single center in the VA system were presented on the use of Pure-Vu EVS on 45 subjects over a 6-month period as either a rescue method for those with endoscopically visualized inadequate preparation or used initially with those subjects with high suspicion for being poorly prepped. The study showed an improvement from an average of 4.8 on the BBPS at baseline to 8.7 after the use of Pure-Vu EVS (below 6 is considered inadequate with 9 being the top of the range). The conclusion from the investigator stated, “Use of this intraprocedural cleansing device increases examination quality, extends surveillance intervals, improves resource utilization”.

 

7
 

 

Intellectual Property

 

Our IP position comprises a portfolio covering highly innovative technologies rooted in systems and methods for cleaning body cavities with or without the use of an endoscope. Currently we have eighteen granted or allowed patents in the U.S., nineteen patents in Asia (Japan, China and Hong Kong), and ten patents in the EU, with patent protection until at least 2040. In addition, we have eleven pending patent applications in various regions of the world with a focus on the U.S., EU and Japan. We have registered trademarks for Motus GI and for the Pure-Vu System in the U.S., EU and other international jurisdictions. We also have a pending trademark application in the U.S. to MICRO-PREP.

 

Our portfolio of patents and patent applications focuses on cleaning body cavities in a safe and efficient manner, insertion, movement and steering of an endoscopic device within the body cavity in a predetermined direction; coordinated positioning of an endoscope with a suction device and cleaning systems with automatic self-purging features. Coverage includes critical aspects of our system that we believe are key to cleaning the colon or other body cavities effectively and efficiently. These aspects include cleansing jet methodologies, sensing and control of evacuation to avoid clogging, designs for easy attachment to endoscopes and cleaning segments under water.

 

Our commercial success depends in part on our ability to obtain and maintain patent and other proprietary protection for Pure-Vu and to operate without infringing the proprietary right of others and to prevent others from infringing our proprietary rights. We strive to protect our intellectual property through a combination of patents and trademarks, as well as through confidentiality provisions in our contracts. With respect to the Pure-Vu System, we endeavor to obtain and maintain patent protection in the United States and internationally on identified and potentially patentable aspects of the system. We cannot be sure that the patents will be granted with respect to any patent applications we may own or license in the future, nor can we be sure that our existing patents or any patents we may own or license in the future will be useful in protecting our technology.

 

In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. For example, significant aspects of our proprietary technology platform are based on unpatented trade secrets and know-how. Trade secrets and know-how can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and commercial partners. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third-party. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our contractors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.

 

We also plan to continue to seek trademark protection in the United States and outside of the United States where available and when appropriate. We intend to use these registered marks in connection with our research and development as well as our product candidates.

 

Competition

 

We do not believe that there are currently any direct competitors in the market, nor any known competing medical device under development, using similar technology to our technology. Currently the major colonoscope manufacturers (i.e., Olympus Corp, Pentax Medical, Fujifilm Medical) as well as some smaller equipment manufacturers (i.e., Medivators, Erbe) sell a lesser powered irrigation pump that can pump fluid through the auxiliary water jet or working channel of a colonoscope. Potentially competitive is an intra-procedural device under development by Medjet Ltd. MedJet’s device goes through the working channel of a scope, is used mostly for spot cleaning a small amount of debris and does not have the capability to fully clean the colon of large amounts of fecal matter. The MedJet product also requires the physician to remove it from the working channel during the procedure if they need to remove significant debris, polyps or take a biopsy, impacting the workflow of the procedure. There is also a device under development by a company named OTTek Ltd. The device is called the FIOT (Flow in Over Tube). The tube is noted as being able to create a channel between the endoscope and the inside of the over tube to facilitate the removal of debris. The competitive products mentioned are not currently separately reimbursed by private or government payors. There are over ten different preparation regimens used prior to colonoscopy today. Some are prescription medications and others are over-the-counter. Typically, the over-the-counter regimens are not indicated for colonoscopy prep but for issues of motility, such as constipation, but are still widely prescribed by physicians for colonoscopy prep. Depending on the insurance a patient has, the prescription prep may be covered in part but many of them require the patient to pay out-of-pocket.

 

8
 

 

The medical device and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We have indirect competitors in a number of sectors, many of which have substantially greater name recognition, commercial infrastructures and financial, technical and personnel resources than Motus GI. Currently, the colonoscopy market is dominated by Olympus Corp, who controls a majority of the market, with Pentax Medical and FujiFilm Medical taking most of the rest of the U.S. colonoscope market. Boston Scientific, Medtronic GI Solutions, Conmed Corporation, Steris, Ambu A/S, and other smaller players sell ancillary devices and accessories into the marketplace as well. These established competitors may invest heavily to quickly discover and develop novel devices that could make our Pure-Vu System obsolete or uneconomical. These include but are not limited to capsule endoscopy, virtual colonoscopy using CT scans, etc. These technologies may require the same level of prep as conventional colonoscopies and if a polyp or abnormality is detected, the patient may still need to undergo a colonoscopy. Other screening tests for colon cancer specifically include fecal occult blood tests and DNA stool tests such as the Cologuard test from Exact Sciences. However, Cologuard is not a replacement for diagnostic colonoscopies or surveillance colonoscopies in high-risk individuals and has a lower specificity than standard colonoscopies. While none of these testing alternatives may ever fully replace the colonoscopy, over time, they may take market share away from conventional colonoscopies for specific purposes and may lower the potential market opportunity for us.

 

Any new product that competes with an approved product may need to demonstrate compelling advantages in efficacy, cost, convenience, tolerability and safety to be commercially successful. Other competitive factors, including new competitive entrants, could force us to lower prices or could result in reduced sales. In addition, new products developed by others could emerge as competitors to the Pure-Vu System. If we are not able to compete effectively against our current and future competitors, our business will not grow and our financial condition and operations will suffer.

 

Research and Development

 

We have research and development capabilities in electrical and mechanical engineering with laboratories in our facility in Israel for development and prototyping, and electronics design and testing. We also use consultants and third-party design houses to complement our internal capabilities.

 

We have received, and may receive in the future, grants from the Government of the State of Israel through the Israeli National Authority for Technological Innovation (the “IIA”) (formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry (the “OCS”)), for the financing of a portion of our research and development expenditures pursuant to the Israeli Law for the Encouragement of Research, Development and Technological Innovation in Industry 5744-1984 (the “Research Law”), and the regulations previously promulgated thereunder, as well as the IIA’s rules and benefit tracks which apply to companies receiving IIA funding (collectively, including the Research Law, the “IIA Regulations”).

 

As of December 31, 2022, we had received grants from the IIA in the aggregate amount of $1.3 million and had a contingent obligation to the IIA up to an aggregate amount of approximately $1.4 million (assuming no increase, per the IIA Regulations, as described below). As of December 31, 2022, we paid a minimal amount to the IIA. We may apply for additional IIA grants in the future. However, as the funds available for IIA grants out of the annual budget of the State of Israel are subject to the pre-approval of the IIA and have been reduced in the past and may be further reduced in the future, we cannot predict whether we will be entitled to – or approved for – any future grants, or the amounts of any such grants (if approved).

 

In exchange for these grants, we are required to pay royalties to the IIA of 4% (which may be increased under certain circumstances) from our revenues generated (in any fashion) from know-how developed using IIA grants(and any derivatives of such IIA funded know-how), up to an aggregate of 100% (which may be increased under certain circumstances) of the U.S. dollar-linked value of the grant, plus interest at the rate of 12-month LIBOR.

 

The IIA Regulations also require that products developed with IIA grants be manufactured in Israel at a rate (scope) which will not be less than the rate of manufacturing and added value in Israel that were set forth in the relevant grant applications submitted to the IIA. Furthermore, the IIA Regulations require that the know-how resulting from research and development according to an IIA-approved plan, not being the product developed within the framework of such approved plan, and any right deriving therefrom may not be transferred outside of Israel (including by way of certain licenses), unless prior approval is received from the IIA. We received a general approval for such transfer. The transfer outside of Israel of manufacturing which is connected with the IIA-funded knowhow at a greater scope than the scope set forth in the general approval will result in a higher royalty repayment rate and may further result in increased royalties (up to three times the aggregate amount of the IIA grants plus interest thereon). In addition, the transfer outside of Israel of IIA-funded knowhow may trigger additional payments to the IIA (up to six times the aggregate amount of the IIA grants plus interest thereon). Even following the full repayment of any IIA grants, we must nevertheless continue to comply with the requirements of the IIA Regulations. The foregoing restrictions and requirements for payment may impair our ability to transfer or sell our technology assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any IIA-funded know-how outside of Israel.

 

9
 

 

Furthermore, companies that receive IIA funding are generally required to ensure that all rights in the IIA-backed product are retained by them. This means that, generally, all know-how which is derived from the research and development conducted pursuant to an IIA approved plan, and every right derived from it, must be owned by the recipient of the IIA funding from the date such know-how is generated. Companies that receive IIA funding are further subject to reporting requirements and other technical requirements, which are intended to allow the IIA to ensure that the IIA Regulations are being complied with.

 

If we fail to comply with any of the conditions and restrictions imposed by the IIA Regulations, or by the specific terms under which we received the grants, we may be required to refund any grants previously received together with interest and penalties, and, in certain circumstances, may be subject to criminal charges.

 

For additional information, see “Part I—Item 1A—Risk Factors—Risks Related to Our Operations in Israel.”

 

Manufacturing and Supply

 

We have established relationships with research facilities, contract manufacturing organizations, or CMOs, and our collaborators to manufacture and supply our product for our initial U.S. market launch targeting early adopter hospitals and for our broader commercialization. Currently, the workstation and loading fixture component of our Pure-Vu System is manufactured by Sanmina Corporation at their facilities in Israel. We may enter into formal supply agreements for the manufacture of the workstation component and loading fixture of our Pure-Vu System with Sanmina Corporation as we continue to establish higher volume capabilities and our commercialization efforts grow. The disposable portion of the Pure-Vu EVS is manufactured by Sterling Industries in their Michigan, U.S. facility. We entered into a supply agreement with Sterling Industries in Q2 of 2021. The disposable portion of our Gen 2 Pure-Vu System is manufactured by Polyzen, Inc., at their facilities in North Carolina, U.S., pursuant to a supply agreement we entered into with Polyzen, Inc. in September 2017. Both Sterling Industries and Polyzen use Medacys in Shenzhen, China as key sub-supplier for the injection molded parts in the Pure Vu disposables. These manufacturing suppliers have extensive experience in medical devices and in dealing with regulatory bodies and other competent entities. These suppliers have ISO 13485 certified quality systems. We have an agreement in place with a third-party logistics provider in the U.S. who is ISO 13485 certified and specializes in medical devices and equipment. They provide warehousing, shipping and back office support to meet our commercial needs.

 

For additional information, see “Part I—Item 1—Business—Research and Development” above, and “Part I—Item 1A—Risk Factors—Risks Related to Our Operations in Israel.”

 

U.S. Market Entry Strategy

 

Our initial launch strategy in the United States is focused on the acute care hospital market. We have been building clinical champions amongst key Gastroenterologists, and other GI and nursing floor leadership and staff. Additionally, we articulate the clinical and economic value of the Pure-Vu System technology to key members of hospital administration. After a pre-defined product evaluation period, we seek to work within the Value Analysis Committee approval process, currently utilized within most U.S. hospitals and integrated delivery networks (IDNs). Following successful implementation at the flagship location within an IDN, we then seek to gain further expansion of the Pure-Vu System within other network hospital locations. On September 29, 2022, the Company announced that it has officially been recognized as a sole source provider and small business by the Veterans Health Administration (VHA). The VHA is the largest integrated health care system in the U.S., and provides care to over nine million veterans. The special designation will provide the Company with direct access to the VHA’s procurement arm, thereby streamlining the purchasing and contracting process. As we continue to grow our network expansion, we continue to support our customers with robust training on the effective use of our Pure-Vu System technology through our training and in-servicing programs.

 

In addition to working with a third-party logistics provider specializing in medical devices to provide front and back office support to successfully fulfill customer orders, our commercial organization has implemented a robust customer relationship management tool to track account progress and help provide accurate forecasting for operations. We anticipate the sales cycle to be in the range of approximately six months. Timing of hospital capital budget availability may impact this anticipated cycle. Our primary focus is on gaining system placements in the acute care hospital market, driving utilization of our Pure-Vu System disposable sleeve, growing top line revenues and appropriately scaling the commercial organization.

 

Market Expansion Opportunities

 

While our time, effort and attention are primarily focused on driving adoption in the U.S. hospital market, we have identified several follow-on market expansion opportunities that are currently being evaluated, including the upper GI endoscopy and targeted outpatient markets, as described below.

 

10
 

 

Upper GI Endoscopy Market

 

In 2021, we announced that we received 510(k) clearance from the FDA for a version of the Pure-Vu System that is compatible with gastroscopes used during upper gastrointestinal (GI) endoscopy procedures to remove blood, blood clots and debris in order to provide a clear field-of-view for the endoscopist. The device is designed to integrate with therapeutic gastroscopes to enable safe and rapid cleansing during the procedure, while preserving established procedural workflow and techniques.

 

Upper GI bleeds occurred in the U.S. at a rate of approximately 400,000 cases per year in 2019, according to iData Research Inc. Approximately 50% of these patients have blood and blood clots that impair a physician’s view during the procedure, thereby making it difficult to rapidly identify the bleeding source. We believe removing adherent blood clots from the field of view is a significant need in allowing a physician the ability to identify and treat the bleed source. The mortality rate of this condition can reach up to approximately 13%, as noted in Thad Wilkins, MD, et al., American Family Physician (2012).

 

The Company has conducted a controlled series of Upper GI initial pilot procedures in the US market, which is intended to inform the development of a Pure-Vu EVS version of the Upper GI solution for eventual submission to FDA for marketing approval in the US. The Company successfully completed multiple pre-clinical tests in both porcine and cadaver models to evaluate Pure-Vu EVS platform for use in upper GI bleeding with multiple U.S. physicians. The results of these tests show that the Gastro version of Pure-Vu EVS can effectively break up and suction blood and blood clots, as well as frees up a gastroscope’s working channel for other therapeutic tools. By eliminating the need to utilize existing irrigation and suction through the working channel of the gastroscope, physicians can use tools in tandem with Pure-Vu EVS. For example, the use of snares to break up large clots and then immediately suction out the smaller pieces using the large Pure-Vu EVS smart sense suction channel. In addition, during cases with significant bleeding, Pure-Vu EVS allows the physician to clean the area of interest and immediately apply therapy to achieve hemostasis, since the physician can have their therapeutic device prepositioned in the gastroscope’s working channel and deliver it before the blood flow covers the area of interest after cleansing.

 

The Company plans on conducting additional pre-clinical and clinical tests for Pure-Vu EVS Gastro device in the first half of 2023. The results of these tests are expected to support submission of a 510(K) application to the U.S. Food and Drug Administration (FDA) in the second half of 2023.

 

 

High Medical Need Outpatient Market

 

Our targeted Outpatient market focused on those patients at risk for inadequate prep presents a large potential commercial market opportunity for the Pure-Vu System. Based on our review and analysis of 2019 market data and 2021 projections for the U.S. and Europe, as obtained from iData Research Inc., and estimates from HRA Healthcare Research & Analytics - Market Research, May 2015, we believe there are ~4.7M targeted outpatient colonoscopies performed in the U.S. each year and ~11.7M worldwide. These colonoscopy patients can often times have an inadequate preparation, which may lead to repeat procedures earlier than the medical guidelines suggest. We believe use of the Pure-Vu System has the potential to reduce the need for such repeat procedures if used for patients at risk for inadequate prep in the outpatient colonoscopy market. We may seek to obtain reimbursement coverage for this market through exploration of programs with both private and public payers focused on new technology platforms.

 

 

Additionally, if we choose to explore either market, we may be able to leverage our existing hospital and physician relationships developed through our inpatient colonoscopy sales force to facilitate such expansion.

 

11
 

 

In 2021, the Center for Medicare and Medicaid Services (“CMS”) granted the Pure-Vu System a permanent ICD-10 code for inpatient uses. This coding effort is part of a broader strategy to potentially obtain reimbursement for certain inpatient and outpatient procedures where the Pure-Vu System can help facilitate visualization of inadequately prepared colons in high medical need patients.

 

Employees

 

As of December 31, 2022, we had 43 full time employees and 6 part time employees. All of our employees are engaged in administration, finance, clinical, research and development, engineering, regulatory or sales and marketing functions. We believe our relations with our employees are good. In addition, we utilize and will continue to utilize consultants, clinical research organizations and third parties to perform our pre-clinical studies, clinical studies, manufacturing and regulatory functions.

 

Under Israeli law, we and our employees in Israel are subject to Israeli protective labor provisions governing certain matters such as the length of the workday, minimum wages for employees, annual leave, sick pay, determination of severance pay and advance notice of termination of employment, as well as the procedures for hiring and dismissing employees and equal opportunity and anti-discrimination laws. While none of our employees in Israel is party to any collective bargaining agreements, expansion orders issued by the Israeli Ministry of Economy and Industry may make certain industry-wide collective bargaining agreements applicable to us. These agreements affect matters such as the length of the workday and week, recuperation pay, travel expenses and pension rights. We have never experienced labor-related work stoppages and believe that our good and positive relationships with our employees are a significant part of our operations.

 

Israeli law generally requires the payment of severance pay by employers upon the retirement, death or dismissal of an employee. We fund our ongoing Israeli severance obligations by making monthly payments to the employees’ respective insurance policies. All of our current employees in Israel have agreed, as part of their employment agreements, that, upon termination of their employment, they will be entitled to receive only the amounts accrued in the insurance policies with respect to severance pay.

 

Furthermore, Israeli employees and employers are required to pay predetermined sums to the National Insurance Institute, which is similar to the U.S. Social Security Administration. These amounts also include payments for national health insurance.

 

Regulatory Matters

 

Government Regulation

 

Our business is subject to extensive federal, state, local and foreign laws and regulations, including those relating to the protection of the environment, health and safety. Some of the pertinent laws have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of subjective interpretations. In addition, these laws and their interpretations are subject to change, or new laws may be enacted.

 

Both federal and state governmental agencies continue to subject the healthcare industry to intense regulatory scrutiny, including heightened civil and criminal enforcement efforts. We believe that we have structured our business operations and relationships with our customers to comply with all applicable legal requirements. However, it is possible that governmental entities or other third parties could interpret these laws differently and assert otherwise. We discuss below the statutes and regulations that are most relevant to our business.

 

12
 

 

U.S. Food and Drug Administration regulation of medical devices.

 

The FDCA and FDA regulations establish a comprehensive system for the regulation of medical devices intended for human use. Our products include medical devices that are subject to these, as well as other federal, state, local and foreign, laws and regulations. The FDA is responsible for enforcing the laws and regulations governing medical devices in the United States.

 

The FDA classifies medical devices into one of three classes (Class I, Class II, or Class III) depending on their level of risk and the types of controls that are necessary to ensure device safety and effectiveness. The class assignment is a factor in determining the type of premarketing submission or application, if any, that will be required before marketing in the United States.

 

  ● Class I devices present a low risk and are not life-sustaining or life-supporting. The majority of Class I devices are subject only to “general controls” (e.g., prohibition against adulteration and misbranding, registration and listing, good manufacturing practices, labeling, and adverse event reporting. General controls are baseline requirements that apply to all classes of medical devices.)
     
  ● Class II devices present a moderate risk and are devices for which general controls alone are not sufficient to provide a reasonable assurance of safety and effectiveness. Devices in Class II are subject to both general controls and “special controls” (e.g., special labeling, compliance with performance standards, and post market surveillance. Unless exempted, Class II devices typically require FDA clearance before marketing, through the premarket notification (510(k)) process.)
     
  ● Class III devices present the highest risk. These devices generally are life-sustaining, life-supporting, or for a use that is of substantial importance in preventing impairment of human health or present a potential unreasonable risk of illness or injury. Class III devices are devices for which general controls, by themselves, are insufficient and for which there is insufficient information to determine that application of special controls would provide a reasonable assurance of safety and effectiveness. Class III devices are subject to general controls and typically require FDA approval of a premarket approval (“PMA”) application before marketing.

 

Unless it is exempt from premarket review requirements, a medical device must receive marketing authorization from the FDA prior to being commercially marketed, distributed or sold in the United States. The most common pathways for obtaining marketing authorization are 510(k) clearance and PMA.

 

510(k) pathway

 

The 510(k) review process compares a new device to a legally marketed device. Through the 510(k) process, the FDA determines whether a new medical device is “substantially equivalent” to a legally marketed device (i.e., predicate device) that is not subject to PMA requirements. “Substantial equivalence” means that the proposed device has the same intended use as the predicate device, and the same or similar technological characteristics, or if there are differences in technological characteristics, the differences do not raise different questions of safety and effectiveness as compared to the predicate, and the information submitted in the 510(k) demonstrates that the proposed device is as safe and effective as the predicate device.

 

To obtain 510(k) clearance, a company must submit a 510(k) application containing sufficient information and data to demonstrate that its proposed device is substantially equivalent to a legally marketed predicate device. These data generally include non-clinical performance testing (e.g., software validation, animal testing electrical safety testing), but may also include clinical data. Typically, it takes three to twelve months for the FDA to complete its review of a 510(k) submission; however, it can take significantly longer and clearance is never assured. During its review of a 510(k), the FDA may request additional information, including clinical data, which may significantly prolong the review process. After completing its review of a 510(k), the FDA may issue an order, in the form of a letter, that finds the device to be either (i) substantially equivalent and states that the device can be marketed in the United States, or (ii) not substantially equivalent and states that device cannot be marketed in the United States. Depending upon the reasons for the not substantially equivalent finding, the device may need to be approved through the PMA pathway (discussed below) prior to commercialization.

 

13
 

 

After a device receives 510(k) clearance, any modification that could significantly affect the safety or effectiveness of the device, or that would constitute a major change in its intended use, including significant modifications to any of our products or procedures, requires submission and clearance of a new 510(k) or approval of a PMA. The FDA relies on each manufacturer to make and document this determination initially, but the FDA can review any such decision and can disagree with a manufacturer’s determination. Modifications meeting certain conditions may be candidates for a streamlined FDA review known as Special 510(k) review, which the FDA intends to process within 30 days of receipt. If a device modification requires the submission of a 510(k), but the modification does not affect the intended use of the device or alter the fundamental technology of the device, then summary information that results from the design control process associated with the cleared device can serve as the basis for clearing the application. A Special 510(k) allows a manufacturer to declare conformance to design controls without providing new data. When a modification involves a change in material, the nature of the “new” material will determine whether a traditional or Special 510(k) is necessary. An Abbreviated 510(k) is another type of 510(k) that is intended to streamline the review of data through the reliance on one or more FDA-recognized consensus standards, special controls established by regulation, or FDA guidance documents. In most cases, an Abbreviated 510(k) includes one or more declarations of conformity to an FDA-recognized consensus standard. We may also make minor product enhancements that we believe do not require new 510(k) clearances. If the FDA disagrees with our determination regarding whether a new 510(k) clearance was required for these modifications, we may need to cease marketing and/or recall the modified device. The FDA may also subject us to other enforcement actions, including, but not limited to, issuing a warning letter or untitled letter to us, seizing our products, imposing civil penalties, or initiating criminal prosecution.

 

Premarket approval pathway

 

Unlike the comparative standard of the 510(k) pathway, the PMA approval process requires an independent demonstration of the safety and effectiveness of a device. PMA is the most stringent type of device marketing application required by the FDA. PMA approval is based on a determination by the FDA that the PMA contains sufficient valid scientific evidence to ensure that the device is safe and effective for its intended use(s). A PMA application generally includes extensive information about the device including the results of clinical testing conducted on the device and a detailed description of the manufacturing process.

 

After a PMA application is accepted for review, the FDA begins an in-depth review of the submitted information. FDA regulations provide 180 days to review the PMA and make a determination; however, in reality, the review time is normally longer (e.g., 1-3 years). During this review period, the FDA may request additional information or clarification of information already provided. Also during the review period, an advisory panel of experts from outside the FDA may be convened to review and evaluate the data supporting the application and provide recommendations to the FDA as to whether the data provide a reasonable assurance that the device is safe and effective for its intended use. In addition, the FDA generally will conduct a preapproval inspection of the manufacturing facility to ensure compliance with QSR, which imposes comprehensive development, testing, control, documentation and other quality assurance requirements for the design and manufacturing of a medical device.

 

Based on its review, the FDA may (i) issue an order approving the PMA, (ii) issue a letter stating the PMA is “approvable” (e.g., minor additional information is needed), (iii) issue a letter stating the PMA is “not approvable,” or (iv) issue an order denying PMA. A company may not market a device subject to PMA review until the FDA issues an order approving the PMA. As part of a PMA approval, the FDA may impose post-approval conditions intended to ensure the continued safety and effectiveness of the device including, among other things, restrictions on labeling, promotion, sale and distribution, and requiring the collection of additional clinical data. Failure to comply with the conditions of approval can result in materially adverse enforcement action, including withdrawal of the approval.

 

Most modifications to a PMA approved device, including changes to the design, labeling, or manufacturing process, require prior approval before being implemented. Prior approval is obtained through submission of a PMA supplement. The type of information required to support a PMA supplement and the FDA’s time for review of a PMA supplement vary depending on the nature of the modification.

 

Clinical trials

 

Clinical trials of medical devices in the United States, including clinical studies that assess new or modified uses for already marketed medical devices, are governed by the FDA’s Investigational Device Exemption (“IDE”) regulation. This regulation places significant responsibility on the sponsor of the clinical study including, but not limited to, choosing qualified investigators, monitoring the trial, submitting required reports, maintaining required records, and assuring investigators obtain informed consent, comply with the study protocol, control the disposition of the investigational device, submit required reports, etc.

 

14
 

 

Clinical trials of significant risk devices (e.g., implants, devices used in supporting or sustaining human life, devices of substantial importance in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health) require FDA and Institutional Review Board (“IRB”) approval prior to starting the trial. FDA approval is obtained through submission of an IDE application. Clinical trials of non-significant risk (“NSR”), devices (i.e., devices that do not meet the regulatory definition of a significant risk device) only require IRB approval before starting. The clinical trial sponsor is responsible for making the initial determination of whether a clinical study is significant risk or NSR; however, a reviewing IRB and/or FDA may review this decision and disagree with the determination.

 

An IDE application must be supported by appropriate data, such as performance data, animal and laboratory testing results, showing that it is safe to evaluate the device in humans and that the clinical study protocol is scientifically sound. There is no assurance that submission of an IDE will result in the ability to commence clinical trials. Additionally, after a trial begins, the FDA may place it on hold or terminate it if, among other reasons, it concludes that the clinical subjects are exposed to an unacceptable health risk.

 

As noted above, the FDA may require a company to collect clinical data on a device in the post-market setting.

 

The collection of such data may be required as a condition of PMA approval. The FDA also has the authority to order, via a letter, a post-market surveillance study for certain devices at any time after they have been cleared or approved.

 

Similar requirements may be applicable in other countries and jurisdictions, including in the European Economic Area or EEA (which includes the 27 EU Member States as well as Iceland, Liechtenstein and Norway) and in the United Kingdom.

 

Pervasive and continuing FDA regulation

 

After a device is placed on the market, regardless of its classification or premarket pathway, numerous additional FDA requirements generally apply. These include, but are not limited to:

 

  ● Establishment registration and device listing requirements;
     
  ● Quality System Regulation (“QSR”), which governs the methods used in, and the facilities and controls used for, the design, manufacture, packaging, labeling, storage, installation, and servicing of finished devices;
     
  ● Labeling requirements, which mandate the inclusion of certain content in device labels and labeling, and generally require the label and package of medical devices to include a unique device identifier (“UDI”), and which also prohibit the promotion of products for uncleared or unapproved, i.e., “off-label,” uses;
     
  ● Medical Device Reporting (“MDR”) regulation, which requires that manufacturers and importers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; and
     
  ● Reports of Corrections and Removals regulation, which requires that manufacturers and importers report to the FDA recalls (i.e., corrections or removals) if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; manufacturers and importers must keep records of recalls that they determine to be not reportable.

 

The FDA enforces these requirements by inspection and market surveillance. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include, but is not limited to, the following sanctions:

 

  ● Untitled letters or warning letters;
     
  ● Fines, injunctions and civil penalties;
     
  ● Recall or seizure of our products;
     
  ● Operating restrictions, partial suspension or total shutdown of production;
     
  ● Refusing our request for 510(k) clearance or premarket approval of new products;
     
  ● Withdrawing 510(k) clearance or premarket approvals that are already granted; and
     
  ● Criminal prosecution.

 

15
 

 

We are subject to either announced or unannounced device inspections by the FDA, as well as other regulatory agencies overseeing the implementation of and compliance with applicable state public health regulations. These inspections may include our suppliers’ facilities.

 

International

 

International sales of medical devices are subject to foreign government regulations, which vary substantially from country to country. In order to market our products in other countries, we must obtain regulatory approvals or certifications and comply with extensive safety and quality regulations in those countries. The time required to obtain approval or certification to market our products in a foreign country may be longer or shorter than that required for FDA clearance or approval, and the requirements may differ. Medical device manufacturers intending to market medical devices in the European Economic Area (the “EEA”), are required to affix the CE Mark to their medical devices, often after the intervention of a Notified Body and the issuing of a CE Certificate of Conformity. Many other countries, such as Australia, India, New Zealand, Pakistan and Sri Lanka, accept CE Certificates of Conformity or FDA clearance or approval, although others, such as Brazil, Canada and Japan require separate regulatory filings.

 

The EU Medical Devices Regulation (Regulation 2017/745 of the European Parliament and of the Council of April 5, 2017 on medical devices), or “EU MDR”, sets out the basic regulatory framework currently applicable to medical devices in the EEA. The EU MDR became applicable on May 26, 2021, repealing the prior Council Directive 93/42/EEC, or the “EU MDD”, which had been regulating medical devices in the EEA for the past over 20 years. This represented a major change in the regulatory landscape of medical devices in the EEA. The EU MDR sets out certain transitional provisions that allow for medical devices covered by the repealed EU MDD (called “legacy devices”) to still be marketed in the EEA for a certain period of time.

 

In the EEA, medical devices are currently required to comply with the General Safety and Performance Requirements (or “GSPR”) in Annex I of the EU MDR (for legacy devices, this corresponds to the Essential Requirements of Annex I of the EU MDD). Compliance with GSPR is a prerequisite for us to be able to affix the CE Mark to our medical devices, without which they cannot be commercialized in the EEA. To demonstrate compliance with the GSPR and obtain the right to affix the CE Mark, we must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. In the EEA medical devices are classified into four different risk classes: Class I (which is further divided into (i) devices that are placed on the market in sterile condition, (ii) have a measuring function, (iii) are reusable surgical instruments, and (iv) all others), IIa, IIb and III.

 

Apart from low risk medical devices (Class I if they have no measuring function, are not sterile, and are not reusable surgical instruments), where the manufacturer can issue an EU Declaration of Conformity based on a self-assessment of the conformity of the devices with the GSPR, a conformity assessment procedure requires the intervention of a Notified Body, which is an organization accredited by the competent authority of an EEA Member State to conduct conformity assessments. The Notified Body would typically audit and examine the products’ technical documentation and the quality management system for the manufacture, design and final inspection of our medical devices before issuing a CE Certificate of Conformity. After receiving the CE Certificate of Conformity from the Notified Body upon successful completion of the conformity assessment, we can draw up an EU Declaration of Conformity which allows us to affix the CE Mark to our products.

 

Under the EU MDR, confirmation of conformity with relevant GSPR under the normal conditions of intended use of the device, and the evaluation of the undesirable side-effects and of the acceptability of the benefit-risk-ratio, shall be based on clinical data providing sufficient clinical evidence, including where applicable post-market data. Manufacturers are required to specify and justify the level of clinical evidence necessary to demonstrate conformity with the relevant GSPR. This level of clinical evidence must be appropriate in view of the characteristics of the device and its intended purpose.

 

Besides its involvement in the initial conformity assessment procedure, the Notified Body is required to carry out an annual audit (surveillance audit) and is also required to randomly perform unannounced audits at least once every five years. The quality management system and technical documentation of manufacturers will be required to be recertified periodically, as CE Certificates of Conformity issued by a Notified Body remain valid only for the period indicated in them, in no case exceeding five years.

 

The conduct of clinical studies in the EEA is governed by detailed regulatory obligations. These include the requirement of prior authorization by the Competent Authorities of the country in which the study takes place and the requirement to obtain a positive opinion from the relevant competent Ethics Committee. The conduct of clinical studies (called “clinical investigations” under the EU MDR) is now mandatory for implantable devices and Class III medical devices (with certain exemptions).

 

16
 

 

The EU MDR also provides various requirements relating to post-market surveillance and vigilance, including the obligation for manufacturers to implement a post-market surveillance system, in a manner that is proportionate to the risk class and appropriate for the type of device. Once a device is on the EEA market, manufacturers must comply with certain vigilance requirements, such as the reporting serious incidents and field safety corrective actions (even those occurring outside the EEA) to the relevant competent authorities.

 

Further, the advertising and promotion of our products in the EEA is subject to the EU MDR, to the national laws of individual EEA Member States, Directive 2006/114/EC concerning misleading and comparative advertising, and Directive 2005/29/EC on unfair commercial practices, as well as other EEA Member State laws and industry codes governing the advertising and promotion of medical devices. These laws may limit or restrict the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with healthcare professionals.

 

The EU MDR, when compared with the EU MDD, imposes increased compliance obligations for us to access and then remain on the EEA market. Our current CE Certificate of Conformity is valid until May 27, 2024 in accordance with Article 120 of the EU MDR. This means that, if we want to keep selling our product in the EEA without interruption, we need to obtain a new CE Certificate of Conformity under the EU MDR before such expiry date. There are currently a relatively small number of Notified Bodies that have been accredited to conduct conformity assessments under the EU MDR. This may significantly delay our conformity assessment procedures in the future.

 

On February 16, 2023, the European Parliament adopted a legislative proposal for the amendment of the EU MDR, which is expected to modify the current transitional provisions of Article 120 of the EU MDR allowing an extension in the validity of certain CE Certificates of Conformity until 26 May 2026, 31 December 2027 and 31 December 2028 (depending on the risk classification of the devices and subject to certain conditions). The Council of the European Union still needs to formally accept the Parliament’s position, after which the amendment will be published in the Official Journal of the European Union following the signature of the act. This amendment to the EU MDR may have an impact in our current CE Certificate of Conformity, by extending its validity beyond May 27, 2024.

 

Brexit

 

The UK withdrew from the EU on January 31, 2020 (the withdrawal is commonly referred to as “Brexit”). Brexit has created significant uncertainty concerning the future relationship between the UK and the EU. On December 24, 2020, the EU and UK reached an agreement in principle on the framework for their future relationship, the “EU-UK Trade and Cooperation Agreement”. The Agreement primarily focuses on ensuring free trade between the EU and the UK in relation to goods, but does not specifically address medical devices. After the UK’s withdrawal from the EU, Great Britain (England, Scotland and Wales) is treated by the EU as a third country. Northern Ireland continues, with regard to EU regulations, to follow the EU regulatory rules. In light of the fact that the CE marking process is set out in EU law, which no longer applies in the UK, the UK has devised a new route to market culminating in a UK Conformity Assessed (UKCA) mark to replace the CE Mark. The route to market and the UKCA marking requirements are based on the requirements of the EU MDD. Northern Ireland continues to be covered by the regulations governing CE Marks. As part of the Agreement, the EU and the UK have agreed to continue to recognize declarations of conformity based on a self-assessment in the other territory.

 

Since January 1, 2021, the Medical Devices (EU Exit) Regulations 2020 introduced a number of changes to how medical devices are placed on the Great Britain’s market. The CE marking will continue to be recognized in Great Britain until July 2024, and certificates issued by Notified Bodies designated in the EEA will continue to be valid for the Great Britain market until July 2024. From July 2024, when the future UK Medical Device Regulations are expected to become applicable, manufacturers will have to obtain the UKCA mark to place a medical device on the Great Britain market. There are certain transition periods for existing CE and UKCA marked devices.

 

Other Regulatory Matters

 

Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the United States, the Centers for Medicare & Medicaid Services (“CMS”), other divisions of the Department of Health and Human Services, the Department of Justice, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety & Health Administration, the Environmental Protection Agency, and state and local governments. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Manufacturing, sales, promotion and other activities are also potentially subject to federal and state consumer protection and unfair competition laws.

 

The distribution of medical device products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of medical device products.

 

17
 

 

Third-Party Payor Coverage and Reimbursement

 

Our Pure-Vu System and the procedure to cleanse the colon in preparation for colonoscopy are not currently separately reimbursable through private or governmental third-party payors in any country. Significant uncertainty exists as to whether coverage and separate reimbursement of the Pure-Vu System will develop; but we sought new technology payments from Medicare under the hospital Inpatient and Outpatient Prospective Payment Systems and were denied in 2021. We intend to seek separate reimbursement for future versions of the system through private or governmental third-party payors in the future. In both the United States and foreign markets, our ability to commercialize the Pure-Vu System successfully, and to attract commercialization partners for the Pure-Vu System, depends in part on the availability of adequate coverage and reimbursement from third-party payors, including, in the United States, governmental payors such as the Medicare and Medicaid programs, managed care organizations, and private health insurers. Medicare is a federally funded program managed by the CMS, through local contractors that administer coverage and reimbursement for certain healthcare items and services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients whose income and assets fall below state defined levels and who are otherwise uninsured, and it is both federally and state funded and managed by each state. The federal government sets general guidelines for Medicaid and each state creates specific regulations or other guidelines that govern its individual program. Each payor, whether governmental or private, has its own process and standards for determining whether it will cover and reimburse a procedure or particular product. Private payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Therefore, achieving favorable Medicare coverage and reimbursement is usually a significant gating issue for successful introduction of a new product. The competitive position of the Pure-Vu System will depend, in part, upon the extent of coverage and adequate reimbursement for such product and for the procedures in which such product is used. Prices at which we or our customers seek reimbursement for the Pure-Vu System can be subject to challenge, reduction or denial by the government and other payors.

 

In the event we do receive approval for third-party or government reimbursement for our product, the marketability of such product may suffer if the government and commercial third-party payors fail to provide adequate coverage and reimbursement. An emphasis on cost containment measures in the United States has increased and we expect it will continue. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

 

State and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.

 

In addition, in some foreign countries, the proposed pricing for a medical device must be approved before it may be lawfully marketed. The requirements governing medical device pricing vary widely from country to country. For example, the EEA provides options for its Member States to restrict the range of medical devices for which their national health insurance systems provide reimbursement and to control the prices of medical devices. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of any of our medical devices to other therapies in order to obtain or maintain reimbursement or pricing approval. Other EEA countries allow companies to fix their own prices for medical devices, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new devices. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.

 

In recent years, a number of EEA countries have introduced so-called health technology assessments (HTA). HTA measures the added value of a new health technology, in our case a medical device, compared to existing ones. HTA’s assessment include cost implications for the patient and its impact on the organization of healthcare systems in the administration of treatment. An EU Regulation on HTA entered into force in January 2022 and will be applied three years later (January 2025). It offers the possibility for EEA countries’ HTA bodies to conduct Joint Clinical Assessments of new high-risk medical devices.

 

Historically, products launched in the European Union do not follow price structures of the United States and generally tend to be priced significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our medical devices is unavailable or limited in scope or amount, our revenues from sales by us or our strategic partners and the potential profitability of any of our medical devices in those countries would be negatively affected.

 

18
 

 

Other Healthcare Laws and Compliance Requirements

 

Healthcare providers, physicians, and third-party payors play a primary role in the recommendation and use of our current products and any future products for which we may obtain marketing approval for which payment is or may become available under any federal health care program. Arrangements with third party payors, healthcare providers and physicians will expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute products. In the United States, restrictions under applicable federal and state healthcare laws and regulations include, but are not limited to, the following:

 

  ●

The federal Anti-Kickback Statute (“AKS”) makes it illegal for any person, including a device manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration, directly or indirectly, in cash or in kind, that is intended to induce or reward, or in return for, the purchase, lease, recommendation, order, or arranging for the purchase, lease, or order, of any health care product or service for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. The term “remuneration” has been broadly interpreted to include anything of value, including cash, improper discounts, and free or reduced-price items and services. Violations of this law are punishable by up to ten years in prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it. There are a number of statutory exceptions and regulatory safe harbors protecting from prosecution some common activities like discounts, or engaging health care professionals to provide services to the company ; however, those exceptions and safe harbors are drawn narrowly, and there is no exception or safe harbor for many common business activities like educational grants or reimbursement support programs. Failure to meet all of the requirements of a particular statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute, but the legality of the arrangement will be evaluated on a case by case basis based on the totality of the facts and circumstances.

     
  ● The federal civil False Claims Act imposes liability, including through civil whistleblower or qui tam actions, against individuals or entities (including manufacturers) for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment of government funds, knowingly making, using, or causing to be made or used a false statement or record material to an obligation to pay money to the government, or knowingly concealing or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. Penalties for a False Claims Act violation include three times the actual damages sustained by the government, plus significant mandatory penalties per false claim or statement for violations for each separate false claim, and the potential for exclusion from participation in federal healthcare programs. Conduct that violates the False Claims Act also may implicate various federal criminal statutes. The government may deem manufacturers to have “caused” the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding- information to customers or promoting a product off-label. Claims which include items or services resulting from a violation of the federal Anti-Kickback Statute also are deemed false or fraudulent claims for purposes of the False Claims Act. Our marketing and activities relating to the reporting of wholesaler or estimated retail prices for our products and other information affecting federal, state and third-party reimbursement for our products, and the sale and marketing of our product and any future product candidates, are subject to scrutiny under this law.
     
  ● The Health Insurance Portability and Accountability Act of 1996, and its implementing regulations (collectively, “HIPAA”) imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers; knowingly and willfully embezzling or stealing from a healthcare benefit program; willfully obstructing a criminal investigation of a healthcare offense; and knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. HIPAA also imposes certain obligations, including contractual terms and technical safeguards, with respect to safeguarding the privacy, security and transmission of individually identifiable health information.
     
  ● The federal Physician Payments Sunshine Act and its implementing regulations, which requires that certain manufacturers of devices and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report information related to certain payments or other transfers of value made or distributed, directly or indirectly, to physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse midwives, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.

 

19
 

 

  ● Analogous state and foreign fraud and abuse laws and regulations, such as anti-kickback and false claims laws, which may apply to sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers, and state and local laws that require manufacturers to report information related to payments and other transfers of value to health care providers and state and local laws that require manufacturers to implement compliance programs or marketing codes. State laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts. Such laws are generally broad and are enforced by various state agencies and private actions.

 

Interactions between medical devices manufacturers and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians’ codes of professional conduct developed at both EEA level and in the individual EEA Member States. The provision of benefits or advantages to physicians to induce or encourage the recommendation, endorsement, purchase, supply, order or use of medical devices is generally prohibited in the EEA. Breach of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain EEA Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician’s employer, their competent professional organization, and/or the competent authorities of the individual EEA Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.

 

In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information, which are applicable to “business associates”—certain persons or entities that create, receive, maintain or transmit protected health information in connection with providing a specified service or performing a function on behalf of a covered entity.

 

Further, the legislative and regulatory landscape for privacy and data security continues to evolve, and there has been an increasing amount of focus on privacy and data security issues with the potential to affect our business. Congress and state legislatures also have been considering and enacting new legislation relating to privacy and data protection. For example, in California, the California Consumer Privacy Act (“CCPA”) created new transparency requirements and granted California residents several new rights with regard their personal information. In addition, in November 2020, California voters approved the California Privacy Rights Act (“CPRA”) ballot initiative which introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator, the California Privacy Protection Agency (“CPPA”). The amendments introduced by the CPRA go into effect on January 1, 2023, and new implementing regulations are expected to be introduced by the CPPA. Failure to comply with the CCPA may result in, among other things, significant civil penalties and injunctive relief, or potential statutory or actual damages. In addition, California residents have the right to bring a private right of action in connection with certain types of incidents. These claims may result in significant liability and potential damages. We implemented processes to manage compliance with the CCPA and continue to assess the impact of the CPRA, and other state legislation, on our business as additional information and guidance becomes available.

 

The Federal Trade Commission (“FTC”) also sets expectations for failing to take appropriate steps to keep consumers’ personal information secure, or failing to provide a level of security commensurate to promises made to individual about the security of their personal information (such as in a privacy notice) may constitute unfair or deceptive acts or practices in violation of Section 5(a) of the Federal Trade Commission Act (“FTC Act”). The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. With respect to privacy, the FTC also sets expectations that companies honor the privacy promises made to individuals about how the company handles consumers’ personal information; any failure to honor promises, such as the statements made in a privacy policy or on a website, may also constitute unfair or deceptive acts or practices in violation of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce promises as it interprets them, and events that we cannot fully control, such as data breaches, may be result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions.

 

20
 

 

EEA Member States and other jurisdictions where we operate have adopted data protection laws and regulations, which impose significant compliance obligations. For example, the General Data Protection Regulation (or “GDPR”) imposes strict obligations and restrictions on the ability to collect, analyze and transfer personal data, especially in the case of sensitive personal data (such as health data from clinical investigations) and safety reporting. The GDPR also imposes strict rules on the transfer of personal data out of the EEA, including to the U.S., and fines and penalties for failure to comply with the requirements of the GDPR and the related national data protection laws of the EEA countries, which can go to up to €20 million or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher. The obligations under the GDPR may therefore be onerous and adversely affect our business, financial condition, results of operations and prospects.

 

Switzerland has adopted similar restrictions. These obligations and restrictions concern, in particular, the consent of the individuals to whom the personal data relate, the information provided to the individuals, the transfer of personal data out of the EEA or Switzerland, security breach notifications, security and confidentiality of the personal data, as well as substantial potential fines for breaches of the data protection obligations.

 

Data protection authorities from the different EU Member States may interpret the GDPR and applicable related national laws differently and impose requirements additional to those provided in the GDPR. In addition, guidance on implementation and compliance practices may be updated or otherwise revised, which adds to the complexity of processing personal data in the EU. When processing personal data of subjects in the EU, we must comply with the applicable data protection laws. In particular, when we rely on third party service providers processing personal data of subjects in the EU, we must enter into suitable agreements with these providers and receive sufficient assurances that the providers meet the requirements of the applicable data protection laws, particularly the GDPR which imposes specific and relevant obligations.

 

Although there are legal mechanisms to allow for the transfer of personal data from the EEA to the US, decisions of the European Court of Justice have increased uncertainty around compliance with EU privacy law requirements. As a result of the decision in the Schrems case (Case C-362/14 Maximillian Schrems v. Data Protection Commissioner), it was no longer possible to rely on the safe harbor certification as a legal basis for the transfer of personal data from the EU to entities in the US.

 

However, in March 2022, the European Commission and the U.S. announced that they have agreed in principle on a new Trans-Atlantic Data Privacy Framework, as a successor arrangement to the EU-U.S. Privacy Shield. On December, 13 2022, the European Commission adopted a draft adequacy decision for the EU-U.S. Data Privacy Framework. This draft decision follows the signature of a US Executive Order by President Biden on October, 7 2022, along with the regulations issued by the U.S. Attorney General Merrick Garland. These two instruments implemented into U.S. law the agreement in principle announced by President von der Leyen and President Biden in March 2022. The draft adequacy decision, which reflects the assessment by the European Commission of the U.S. legal framework has now been published and transmitted to the EDPB for its opinion. The draft decision concludes that the U.S. ensures an adequate level of protection for personal data transferred from the EU to U.S. companies. The two sides are now expected to finalize the details of this agreement in principle and translate it into legal texts that will form the basis of a draft adequacy decision to be proposed by the European Commission.

 

Furthermore, following the UK’s exit from the EU, the UK became a third country to the EEA in terms of personal data transfers. The EC has adopted an Adequacy Decision concerning the level of personal data protection. However, personal data transfers from the EEA to the UK may nevertheless be at a greater risk than before because an Adequacy Decision may be suspended.

 

Following the Schrems II decision, the Swiss Federal Data Protection and Information Commissioner, or the FDPIC, also announced that the Swiss-U.S. Privacy Shield does not provide adequate safeguards for the purposes of personal data transfers from Switzerland to the U.S. While the FDPIC does not have authority to invalidate the Swiss-U.S. Privacy Shield regime, the FDPIC’s announcement casts doubt on the viability of the Swiss-U.S. Privacy Shield as a future compliance mechanism for Swiss-U.S. data transfers.

 

21
 

 

Compliance with data transfer obligations involves documenting detailed analyses of data access and protection laws in the countries in which data importers are located, which can be costly and time-consuming. Data importers must also expend resources in analyzing their ability to comply with transfer obligations, including implementing new safeguards and controls to further protect personal data. If we or our vendors fail to comply with applicable data privacy laws, or if the legal mechanisms we or our vendors rely upon to allow for the transfer of personal data from the EEA, the UK, or Switzerland to other countries not considered by the European Commission to provide an adequate level of data protection are not considered adequate, we could be subject to government enforcement actions and significant penalties against us, and our business could be adversely impacted if our ability to transfer personal data outside of the EEA, UK, or Switzerland is restricted, which could adversely impact our operating results.

 

The landscape of laws regulating personal data is constantly evolving, and compliance with these laws requires a flexible privacy framework and substantial resources, and compliance efforts will likely be an increasing and substantial cost in the future.

 

Current and future legislation

 

In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products.

 

In the EEA and as mentioned above, the EU MDR imposes increased compliance obligations for us to access and then remain on the EEA market. It introduced substantial changes to the obligations applicable to medical device manufacturers and Notified Bodies in the EEA. As a result, there are less Notified Bodies available to conduct conformity assessments under the EU MDR, which has significantly increased the time needed for companies to access the EEA market. Moreover, as the EU MDR only started to apply from May 2021, a number of guidance documents is still not available to guide manufacturers and Notified Bodies. The EU Regulation on health technology assessments (HTA) that entered into force in January 2022 and that will be applied three years later (January 2025) may also impact in the future the pricing and reimbursement of our product.

 

Additional laws and regulations governing international operations

 

If we further expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate, or to any employee of a public international organization, for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls.

 

22
 

 

Compliance with the FCPA is expensive and resource-intensive, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the medical device and pharmaceutical industries, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. In recent years, there has been a trend of increasing government investigations and litigations against companies operating in our industry, both in the United States and around the world. We may become involved in government investigations that arise in the ordinary course of our business.

 

Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.

 

The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The Securities and Exchange Commission, or SEC, also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA’s accounting provisions.

 

Our business activities outside of the U.S. are also subject to anti-bribery or anti-corruption laws, regulations, industry self-regulation codes of conduct and physicians’ codes of professional conduct or rules of other countries in which we operate, including the U.K. Bribery Act of 2010.

 

Post-Marketing Regulations

 

Following clearance or approval of a new product, a company and the product are subject to continuing regulation by the FDA and other foreign, federal and state regulatory authorities, including, among other things, monitoring and recordkeeping activities, reporting to applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting for uses or in patient populations not described in the product’s approved labeling (known as “off-label use”), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such off-label uses. Modifications or enhancements to the products or labeling or changes of site of manufacture are often subject to the approval of the FDA and other regulators or subject of review by a Notified Body in the EU, which may or may not be received or may result in a lengthy review process.

 

Implications of Being an Emerging Growth Company

 

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and, for as long as we continue to be an “emerging growth company,” we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to “emerging growth companies,” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, (the “Sarbanes-Oxley Act”), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an “emerging growth company” for up to five years from the date of our initial public offering in February 2018, which would be at the end of the current fiscal year, ending December 31, 2023, or until the earliest of (i) the last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion, (ii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our Common Stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three-year period. We intend to take advantage of these reporting exemptions described above until we are no longer an “emerging growth company.” Under the JOBS Act, “emerging growth companies” can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not “emerging growth companies.”

 

23
 

 

Corporate and Available Information

 

We are a Delaware corporation formed in September 2016 under the name Eight-Ten Merger Corp. In November 2016, we changed our name to Motus GI Holdings, Inc. We are the parent company of Motus GI Medical Technologies Ltd., an Israeli corporation, and Motus GI, LLC (formerly Motus GI, Inc.), a Delaware limited liability company. Motus GI, Inc. was converted from a Corporation into a Limited Liability Company effective January 1, 2021.

 

Our principal executive offices are located at 1301 East Broward Boulevard, 3rd Floor, Ft. Lauderdale, FL 33301. Our phone number is (954) 541-8000 and our web address is www.motusgi.com. Our website and the information contained on, or that can be accessed through, our website will not be deemed to be incorporated by reference into this Annual Report on Form 10-K or any other report we file with or furnish to the SEC.

 

We make available free of charge on or through the Investor Relations link on our website, www.motusgi.com, access to press releases and investor presentations, as well as all materials that we file electronically with the SEC, including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports, filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after electronically filing such materials with, or furnishing them to, the SEC. During the period covered by this Form 10-K, we made all such materials available through our website as soon as reasonably practicable after filing such materials with the SEC. The SEC maintains an Internet website, www.sec.gov, that contains reports, proxy and information statements and other information that we file electronically with the SEC.

 

“Motus GI,” “Pure-Vu,” and our other registered or common law trademarks, service marks or trade names appearing herein are the property of Motus GI Holdings, Inc. Some trademarks referred to in this report are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

 

ITEM 1A. RISK FACTORS

 

An investment in our Common Stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all other information in this Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission. The risks set forth below are not the only ones facing us. Additional risks and uncertainties may exist that could adversely impact our business, operations and financial conditions. If any one or more of the following risks actually materialize, our business, financial condition, reputation, operations and/or future prospects suffer. In such event, the value of our Common Stock could decline, and you could lose all or a substantial portion of the money that you pay for our Common Stock.

 

SUMMARY

 

The following summarizes key risks and uncertainties that could materially adversely affect us. You should read this summary together with the more detailed description of each risk factor contained below.

 

Risks relating to our strategic alternative process, including risks related to:

 

  ● the inability to identify and implement any strategic business combination or other transaction.
  ● the negative consequences of any strategic transaction that we may consummate.
  ● the operational and financial risks related to the negotiation and completion of a strategic transaction.
  ● if we fail to complete a strategic transaction we may need to pursue bankruptcy, dissolution or liquidation.

 

Risks relating to our financial position and need for capital, including risks relating to:

 

  ● the sustainability of our operations and ability to continue as a going concern.
  ● the recurring losses from operations since inception and possibility of never becoming profitable.
  ● our indebtedness to Kreos Capital VI (Expert Fund) LP and related restrictions under the Loan Agreement.
  ● the need for substantial additional capital to fund our operations, and if we fail to obtain such financing, we may not be able to complete the development and commercialization of any of our product candidates.
  ● the potential dilutive impact of issuing additional equity securities in connection with necessary capital raises.
  ● our ability to use net operating loss carryforward and other tax attributes may be limited.

 

24
 

 

Risks related to government regulation and third-party reimbursement, including risks related to:

 

  ● the impact of costly and complex current and future regulation.
  ● our ability to successfully obtain or maintain the necessary government approvals or third party certifications to market our Pure-Vu System both domestically and throughout the EEA.
  ● the need to obtain new 510(k) clearance or a new CE Certificate of Conformity in the event of new modifications which may require us to cease marketing or initiate recalls pending approval.
  ● the potential for product malfunctions causing death or serious injury, subjecting us to enforcement actions.
  ● the potential for recalls of our Pure-Vu System or the discovery of a serious safety issue with the product.
  ● our Pure-Vu System is not currently separately reimbursable through private or government third-party payors.
  ● the difficulty and increased costs of marketing approval and commercialization of our products due to recent and future legislation.
  ● the potential liability if we fail to comply with fraud and abuse laws.
  ● the potential liability and commercialization consequences if we engage in inappropriate promotion of our Pure-Vu System.
  ● the potential for civil and/or criminal sanctions related to potential non-compliance with anti-corruption laws.
  ● the laws and regulations governing international business operations and potential for adverse impacts on our business.

 

Risks related to our business operations, including risks related to:

 

  ● having only one product, and the lack of assurance that we will develop any additional products.
  ● being a medical technology company with a limited operating history.
  ● potential non-acceptance of the Pure-Vu System by physicians and patients.
  ● our ability to successfully commercialize our Pure-Vu System.
  ● our limited sales and marketing organization and related difficulties for commercializing our Pure-Vu System.
  ● the impact of any potential adverse side effects caused by our Pure-Vu System.
  ● the impact of any security breaches, computer malware, computer hacking and other security incidents.
  ● the breadth of data privacy laws and regulations.
  ● the difficulties associated with achieving commercialization.
  ● the difficulties related to training medical professionals on the safe and appropriate use of our products.
  ● competition in the marketplace.
  ● the potential for technological obsolescence.
  ● the potential reputational damage and unforeseen costs if defects were identified in our products.
  ● our ability to penetrate international markets.
  ● our dependence on third party manufacturers to manufacture our Pure-Vu System.
  ● the impact of Israeli regulations on outsourcing and development for our Pure-Vu System.

 

Risks related to our intellectual property rights, including risks related to:

 

  ● our ability to properly safeguard our intellectual property rights.
  ● the impact of potential intellectual property disputes.
  ● the impact of employment and confidentiality disputes.

 

General risks, including risks related to:

 

  ● the difficulties related to predicting and managing growth.
  ● our ability to attract and retain key personnel.
  ● the impact of product liability lawsuits.
  ● the uncertainties related to exchange rate fluctuations.
  ● the costs related to acquisition and investment activities.
  ● the outbreaks of communicable diseases, including COVID-19, which may materially affect our business, financial condition and results of operation.

 

25
 

 

Risks related to our capital stock, including risks related to:

 

  ● significant fluctuations in our quarterly operating results.
  ● the unpredictability of the trading market.
  ● a decrease in stock price related to a large sell-off.
  ● our ability to remain compliant with the requirements of The Nasdaq Capital Market for continued listing, including regaining compliance with the $2.5 million minimum stockholders’ equity requirement.
  ● the potential adverse effect on the liquidity of our Common Stock if we implement a reverse stock split.
  ● the frequency, nature and content of equity analyst report.
  ● the volatility of our share price.
  ● royalty payments due under the terms of the Royalty Payments Rights Certificates.
  ● reduced disclosure requirements as an “emerging growth company.”
  ● costs and management time devoted to operations after we are no longer an “emerging growth company.”
  ● our ability to manage internal controls to prevent fraud or errors.
  ● our failure to maintain internal control over financial reporting.
  ● our expectations that we will not pay dividends in the foreseeable future.
  ● the likelihood that upon dissolution, stockholder will lose some or all portions of their investment.
  ● the dilutive effect of additional issuances of preferred stock.
  ● our choice of forum in the state of Delaware may discourage stockholder suits against us.

 

Risks related to our operations in Israel, including risks related to:

 

  ● the impact of Israel’s political, economic and military instability on our research and development facilities and suppliers in the region.
  ● royalty and other payments to the Israeli government as required by certain research and development grant terms.
  ● the difficulties associated with enforcing a foreign court’s judgment and serving process in a foreign jurisdiction.
  ● the impact of potential patent litigation.

 

Risks Related to our Strategic Alternative Process

 

We may not be successful in identifying and implementing any strategic business combination or other transaction.

 

We have engaged Lake Street to assist us in seeking a strategic transaction to benefit our shareholders. We continue to evaluate various potential strategic options for us, including a merger, reverse merger, sale or other strategic transaction. However, there can be no assurance that we will be able to identify a counterparty willing to move forward with us or, if we do, successfully consummate any particular strategic transaction. The biotech industry is a competitive industry and thus there are numerous competitors of ours for strategic transactions with a limited number of parties seeking a transaction on terms that would be beneficial to our shareholders. The process of evaluating these strategic options may be very costly, time-consuming and complex and we have incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal and accounting fees and expenses and other related charges. We may also incur additional unanticipated expenses in connection with this process. A considerable portion of these costs will be incurred regardless of whether any such course of action is implemented or transaction is completed. Any such expenses will decrease the remaining cash available for use in our business and may diminish or delay any future distributions to our stockholders. Any delays in identifying a potential counterparty will cause our cash balance to continue to deplete, which could make us less attractive as a strategic counterparty. Our existing outstanding indebtedness with Kreos may also impact the interest of potential third parties and may negatively impact our ability to consummate a strategic transaction. The continued review of our strategic options may also create continued uncertainty for our employees and this uncertainty may adversely affect our ability to retain key employees necessary to maintain our ongoing operations or to execute any potential strategic options, which could have a material adverse effect on our business. Further, the market capitalization of our company is below the value of our cash and cash equivalents. Potential counterparties in a strategic transaction involving our company may place minimal or no value on our remaining assets. As a result, we may not be able to execute on a strategic transaction before our cash position gets reduced, as a result of running a public company, to the point that we will need to pursue the winding down and dissolution of the company.

 

Any strategic transactions that we may consummate in the future could have negative consequences.

 

Any strategic business combination or other transactions that we may consummate in the future could have a variety of negative consequences and we may implement a course of action or consummate a transaction that yields unexpected results that adversely affect our business and decrease the value of our company. There can be no assurances that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, be successfully consummated, lead to increased stockholder value, or achieve the results hoped for. Any failure of such potential transaction to achieve the anticipated results could significantly impair the ability of a shareholder to realize any benefit from any future strategic transaction.

 

If we are successful in completing any strategic transaction, we may be exposed to other operational and financial risks.

 

The negotiation and consummation of any strategic transaction may also require more time or greater cash resources than we anticipate and expose us to other operational and financial risks, including:

 

● increased near-term and long-term expenditures;

 

● our ability to service our outstanding indebtedness;

 

● exposure to unknown liabilities;

 

● higher than expected acquisition or integration costs;

 

● incurrence of substantial additional debt or dilutive issuances of equity securities to fund future operations;

 

● write-downs of assets or goodwill or incurrence of non-recurring, impairment or other charges;

 

● increased amortization expenses;

 

● difficulty and cost in combining the operations and personnel of any acquired business with our operations and personnel;

 

● impairment of relationships with key suppliers or customers of any acquired business due to changes in management and ownership;

 

● inability to retain key employees of our company or any acquired business; and

 

● possibility of future litigation.

 

Any of the foregoing risks could have a material adverse effect on our business, financial condition and prospects.

 

26
 

 

If a strategic transaction is not consummated, our Board may decide to file for bankruptcy protection or pursue a dissolution and liquidation of our remaining assets. In such an event, as a result of our outstanding indebtedness, the amount of cash available for distribution to our stockholders, if any, will depend heavily on the timing of such bankruptcy or liquidation as well as the amount of cash that will need to be reserved for our current debts, including repayment of amounts under our Loan Agreement (as defined below), and commitments and contingent liabilities and there may not be any cash or other assets to distribute to our stockholders.

 

There can be no assurance that a strategic transaction will be completed. If a strategic transaction is not completed, our Board may decide to file for bankruptcy protection or pursue a dissolution of the company and liquidation of all of our remaining assets. In such an event, the amount of cash available for distribution to our stockholders, if any, will depend heavily on the timing of such decision, as with the passage of time the amount of cash available for distribution will be reduced as we continue to fund our operations and service our outstanding indebtedness. The process of bankruptcy or liquidation may be lengthy and we cannot make any assurances regarding the timing of completing such a process. If our Board were to approve and recommend, and our stockholders were to approve, a dissolution and liquidation, we would be required under Delaware corporate law to pay our outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, including repayment of the indebtedness under our Loan Agreement, which debt is secured by our assets, prior to making any distributions in liquidation to our stockholders. There can be no assurance as to the amount of available cash that will be available to distribute to stockholders, if any, after paying our debts and other obligations and setting aside funds for reserves, nor as to the timing of any such distribution. Our financial commitments and contingent liabilities would include: (i) repayment of our outstanding indebtedness under our Loan Agreement; (ii) personnel costs, including severance; (iii) contractual obligations to vendors and clinical study sites; (iv) non-cancelable lease obligations; and (v) potential litigation against us.

 

As a result of the requirement to reserve for contingencies, a portion of our assets may need to be reserved pending the resolution of such obligations and the timing of any such resolution is uncertain. In addition, we may be subject to litigation or other claims related to a bankruptcy or dissolution and liquidation. If a dissolution and liquidation were pursued, our Board, in consultation with our advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of our common stock could lose all or a significant portion of their investment in the event of a bankruptcy, liquidation, dissolution or winding up.

 

We may become involved in securities class action litigation that could divert management’s attention and harm the company’s business, and insurance coverage may not be sufficient to cover all costs and damages.

 

In the past, securities class action litigation has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, or the announcement of negative events, such as discontinuations of clinical programs. These events may also result in investigations by the SEC. We may be exposed to such litigation or investigation even if no wrongdoing occurred. Litigation and investigations are usually expensive and divert management’s attention and resources, which could adversely affect our business and cash resources and our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive in any such transaction.

 

Risks Related to Our Financial Position and Need for Capital

 

There is substantial doubt about our ability to continue as a going concern, which will affect our ability to obtain future financing and may require us to curtail our operations.

 

Our financial statements as of December 31, 2022 were prepared under the assumption that we will continue as a going concern. The independent registered public accounting firm that audited our 2022 financial statements, in their report, included an explanatory paragraph referring to our recurring losses since inception and expressing management’s assessment and conclusion that there is substantial doubt in our ability to continue as a going concern. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our ability to continue as a going concern depends on our ability to obtain additional equity or debt financing, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate revenue. We cannot assure you, however, that we will be able to achieve any of the foregoing. See Note 2 to our Consolidated Financial Statements for further details.

 

We have incurred substantial operating losses in each year since our inception and expect to continue to incur substantial losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.

 

We expect to incur substantial expenses without corresponding revenues unless and until we expand our commercialization efforts. To date, as part of our initial U.S. market launch targeting early adopter hospitals, we have generated limited revenue from our Pure-Vu System, but we do not expect to generate significant revenue from product sales until we expand our commercialization efforts for the Pure-Vu System, which is subject to significant uncertainty. We expect to incur significant marketing expenses in the United States, Europe and elsewhere, and there can be no assurance that we will generate significant revenues or ever achieve profitability. Our net loss for the years ended December 31, 2022 and December 31, 2021 was approximately $18.6 million and $19.0 million, respectively. As of December 31, 2022, we had an accumulated deficit of approximately $141.4 million.

 

27
 

 

Our indebtedness to Kreos Capital VI (Expert Fund) LP may limit our flexibility in operating our business and adversely affect our financial health and competitive position. Our obligations to Kreos Capital VI (Expert Fund) LP are secured by substantially all of our assets. If we default on these obligations, Kreos Capital VI (Expert Fund) LP could foreclose on our assets, which could have a materially adverse effect on our business.

 

In July 2021, we entered into an Agreement for the Provision of a Loan Facility with Kreos Capital VI (Expert Fund) LP (the “Loan Agreement”). All obligations under the Loan Agreement are secured by a first priority security interest on substantially all of our personal property assets, including our material intellectual property and equity interests in our subsidiaries. As a result, if we default on any of our obligations under the Loan Agreement, Kreos Capital VI (Expert Fund) LP could foreclose on its security interest and liquidate some or all of the collateral, which would harm our business, financial condition and results of operations and could require us to reduce or cease operations.

 

In order to service this indebtedness and any additional indebtedness we may incur in the future, we will need to generate cash from our operating activities. Our ability to generate cash is subject, in part, to our ability to successfully execute our business strategy, as well as general economic, financial, competitive, regulatory and other factors beyond our control. If we are unable to generate sufficient cash to repay our debt obligations when they become due and payable, either when they mature, or in the event of a default, we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may negatively impact our business operations and financial condition and we may need to file for bankruptcy protection.

 

The Loan Agreement restricts our ability, among other things, in each case subject to certain exceptions, to:

 

  ● sell, transfer or otherwise dispose of any of our business assets or property;
  ● enter into transactions resulting in significant changes to the voting control of our stock;
  ● consolidate or merge with other entities or acquire other entities;
  ● incur additional indebtedness or create encumbrances on our assets;
  ● pay dividends, or make distributions on and, in certain cases, repurchase our capital stock;
  ● enter into certain transactions with our affiliates;
  ● repay subordinated indebtedness; or
  ● make certain investments.

 

In addition, we are required under the Loan Agreement to comply with various undertakings. The undertakings and restrictions and obligations in the Loan Agreement, as well as any future financing agreements that we may enter into, may restrict our ability to finance our operations, engage in business activities or expand or fully pursue our business strategies. Our ability to comply with these undertakings may be affected by events beyond our control, and we may not be able to meet those undertakings.

 

If we breach any of the undertakings or default on any of our obligations under the Loan Agreement all of the outstanding indebtedness under the Loan Agreement could become immediately due and payable, and/or Kreos Capital VI (Expert Fund) LP could foreclose on its security interest and liquidate some or all of the collateral, which would harm our business, financial condition and results of operations and could require us to reduce or cease operations.

 

If our indebtedness under the Loan Agreement were to be accelerated, there can be no assurance that our assets would be sufficient to repay in full that indebtedness. In addition, upon any distribution of assets pursuant to any liquidation, insolvency, dissolution, reorganization or similar proceeding, Kreos Capital VI (Expert Fund) LP will be entitled to receive payment in full from the proceeds of the collateral which secures our indebtedness before the holders of other indebtedness or holders of our Common Stock receive any distribution with respect thereto.

 

Our cash and cash equivalents will only fund our operations for a limited time and we will need to raise additional capital in order to support our development and commercialization efforts.

 

We are currently operating at a loss and expect our operating costs will increase significantly as we incur costs associated with commercialization activities related to our Pure-Vu System. The independent registered public accounting firm that audited our 2022 financial statements, in their report, included an explanatory paragraph referring to our recurring losses since inception and expressing management’s assessment and conclusion that there is substantial doubt in our ability to continue as a going concern. At December 31, 2022, we had cash and cash equivalents of approximately $14.0 million.

 

We will need to raise additional capital or generate substantial revenue in order to support our development and commercialization efforts.

 

28
 

 

If our available cash balances are insufficient to satisfy our liquidity requirements, including due to risks described herein, we may seek to raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements. We will need to raise additional capital, and we may also consider raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities, or for other reasons, including to:

 

  ● fund development and efforts of any future products;
  ● acquire, license or invest in technologies;
  ● acquire or invest in complementary businesses or assets; and
  ● finance capital expenditures and general and administrative expenses.

 

Our present and future funding requirements will depend on many factors, including:

 

  ● our revenue growth rate and ability to generate cash flows from operating activities;
  ● our sales and marketing and research and development activities;
  ● costs of and potential delays in product development;
  ● changes in regulatory oversight applicable to our products; and
  ● costs related to international expansion.

 

Except for our Loan Agreement with Kreos Capital VI (Expert Fund) LP and our Equity Distribution Agreement (as defined below) with Oppenheimer & Co. Inc. (“Oppenheimer”), we have no arrangements or credit facilities in place as a source of funds, and there can be no assurance that we will be able to raise sufficient additional capital on acceptable terms, or at all, and if we are not successful in raising additional capital, we may not be able to continue as a going concern. We may seek additional capital through a combination of private and public equity offerings (which, in limited circumstances, may require the prior written consent of Oppenheimer pursuant to our Equity Distribution Agreement), debt financings (which, except for limited circumstances, would require the prior written consent of Kreos Capital VI (Expert Fund) LP pursuant to our Loan Agreement), and strategic collaborations. Debt financing, if obtained, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, that could increase our expenses and require that our assets secure such debt. Equity financing, if obtained, could result in dilution to our then existing stockholders and/or require such stockholders to waive certain rights and preferences. If such financing is not available on satisfactory terms, or is not available at all, we may be required to delay, scale back or eliminate the development of business opportunities and our operations and financial condition may be materially adversely affected. We can provide no assurances that any additional sources of financing will be available to us on favorable terms, if at all. In addition, if we are unable to secure sufficient capital to fund our operations, we might have to enter into strategic collaborations that could require us to share commercial rights to the Pure-Vu System with third parties in ways that we currently do not intend or on terms that may not be favorable to us. If we choose to pursue additional indications and/or geographies for the Pure-Vu System or otherwise expand more rapidly than we presently anticipate, we may also need to raise additional capital sooner than expected.

 

Future capital raises may dilute our existing stockholders’ ownership and/or have other adverse effects on our operations.

 

If we raise additional capital by issuing equity securities, our existing stockholders’ percentage ownership will be reduced and these stockholders may experience substantial dilution. If we raise additional funds by issuing debt securities, these debt securities would have rights senior to those of our Common Stock and the terms of the debt securities issued could impose significant restrictions on our operations, including liens on our assets. If we raise additional funds through collaborations and licensing arrangements, we may be required to relinquish some rights to our technologies or products, or to grant licenses on terms that are not favorable to us.

 

29
 

 

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

 

Effective on December 1, 2016, Motus GI Medical Technologies LTD, and the holders of all issued and outstanding shares of capital stock of Motus GI Medical Technologies LTD (the “LTD Stockholders”), entered into a share exchange agreement (the “Share Exchange Agreement”) with us. Pursuant to the terms of the Share Exchange Agreement, as a condition of and contemporaneously with the initial closing (the “Initial Closing”) of the 2017 Private Placement, the LTD Stockholders sold to us, and we acquired, all of the issued and outstanding shares of capital stock of Motus GI Medical Technologies LTD (the “Share Exchange Transaction”) and Motus GI Medical Technologies LTD became our direct wholly-owned subsidiary. As a result of the Share Exchange Transaction, our ability to utilize our federal net operating loss carryforwards and federal tax credits may be limited under Sections 382 of the Internal Revenue Code of 1986, as amended (the “Code”). The limitations apply if an “ownership change,” as defined by Code Section 382, occurs. Generally, an ownership change occurs if the percentage of the value of the stock that is owned by one or more direct or indirect “five percent shareholders” increases by more than 50 percentage points over their lowest ownership percentage at any time during the applicable testing period (typically three years). In addition, future changes in our stock ownership, which may be outside of our control, may trigger an “ownership change” and, consequently, Code Section 382 limitations. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and other tax attributes to offset United States federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us.

 

Risks Related to Government Regulation and Third-Party Reimbursement

 

We are subject to complex and costly regulation.

 

Our product, and any products we may develop in the future, are subject to regulation by the FDA and other national, supranational, federal and state governmental authorities (both domestic and foreign). It can be costly and time-consuming to obtain regulatory clearance, approval, or certification to market a new or modified medical device or other product. Clearance and/or approval might not be granted on a timely basis, if at all. Regulations are subject to change as a result of legislative, administrative or judicial action, which may further increase our costs or reduce sales. Unless an exception applies, the FDA requires that the manufacturer of a new medical device or a new indication for use of, or other significant change in, an existing medical device obtain either FDA 510(k) pre-market clearance or pre-market approval before that product can be marketed or sold in the United States. Modifications or enhancements to a product that could significantly affect its safety or effectiveness, or that would constitute a major change in the intended use of the device, technology, materials, labeling, packaging, or manufacturing process may also require a new 510(k) clearance or possibly premarket approval. The FDA has indicated that it intends to continue to enhance its pre-market requirements for medical devices. Although we cannot predict with certainty the future impact of these initiatives, it appears that the time and cost to get medical devices to market could increase significantly.

 

In addition, we are subject to regulations that govern manufacturing practices, product labeling and advertising, and adverse-event reporting that apply after we have obtained clearance or approval to sell a product, and we also must take into account newly emerging risks associated with medical devices such as cybersecurity vulnerabilities. Our failure to maintain clearance for our Pure-Vu System, to obtain clearance or approval for new or modified products, or to adhere to regulations for manufacturing, labeling, advertising or adverse event reporting could adversely affect our results of operations and financial condition. Further, if we determine a product manufactured or marketed by us does not meet our specifications, published standards or regulatory requirements, we may seek to correct the product or withdraw the product from the market, which could have an adverse effect on our business. Many of our facilities and procedures, and those of our suppliers are subject to ongoing oversight, including periodic inspection by governmental authorities. Compliance with production, safety, quality control and quality assurance regulations can be costly and time-consuming.

 

The sales and marketing of medical devices is under increased scrutiny by the FDA and other enforcement bodies, as well as by the competent authorities in foreign jurisdictions, such as EEA Member States. If our sales and marketing activities fail to comply with FDA or foreign regulations or guidelines, or other applicable laws, we may be subject to regulatory inquiries, warning letters, or enforcement actions from the FDA, or other enforcement bodies and foreign competent authorities.

 

30
 

 

We may be unable to obtain or maintain governmental approvals or certifications to market our Pure-Vu System outside the United States and the European Economic Area countries.

 

To be able to market and sell our Pure-Vu System in other countries, we must obtain regulatory approvals or certifications and comply with the regulations of those countries. These regulations, including the requirements for approvals or certifications and the time required for regulatory review, vary from country to country. Many non-European markets, including major markets in South America and Asia Pacific, have allowed for expedited regulatory review and approval based on an existing CE Certificate of Conformity. The first-generation and second-generation of our Pure-Vu System have received CE Certificate of Conformity, allowing us to affix the CE Mark and market it in the EEA. We intend to target countries with a regulatory approval process with similar requirements to the EEA. However, obtaining and maintaining foreign regulatory approvals or certifications is complex and expensive and subject to delays, and management cannot be certain that we will receive and be able to maintain regulatory approvals or certifications in any foreign country in which we plan to market our Pure-Vu System or in the time frame in which we expect.

 

Modifications to our product may require new 510(k) clearance or may require us to cease marketing or recall the modified products until approvals are obtained.

 

After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, will require a new clearance or possibly premarket approval. Changes that do not rise to this level of significance, including certain manufacturing changes, may be made without FDA clearance upon documentation in the manufacturer’s files of the determination of the significance of the change. The FDA requires each manufacturer to make this determination initially, but the FDA can review any such decision and can disagree with the manufacturer’s determination. If the FDA disagrees with any determination that we may make in the future and requires us to seek new 510(k) clearance for modifications to any previously approved or cleared products for which we have concluded that new approvals are unnecessary, we may be required to cease marketing or distribution of our products or to recall the modified product until we obtain approval, and we may be subject to significant regulatory fines or penalties. In the future we may seek to expand the indication for which the Pure-Vu System is cleared or approved to allow us to actively promote the product and a less-prep regimen to patients. This would require us to perform one or more clinical trials to facilitate the approval of such expanded labeling, however, if such trials are unsuccessful or the FDA denies our expanded labeling, our revenues may be adversely affected.

 

In the EEA, we will be required to inform the Notified Body that carried out the conformity assessment of the medical devices we market or sell in the EEA of any planned changes to our quality management system or changes to our devices which could affect compliance with the GSPR set forth in the EU MDR, the safety and performance of the device or its conditions prescribed for use. The Notified Body will assess the changes and, if the assessment is favorable, issue a supplement to the CE Certificate of Conformity. The Notified Body may also determine that the planned changes require a new conformity assessment. For devices covered by CE Certificates of Conformity issued under the EU MDD (“legacy devices”), no significant changes in design or intended purpose are allowed after the date of application of the EU MDR (May 25, 2021). Any proposed changes to our products may oblige us to undertake future clinical and technical procedures and provide information in addition to that provided to support the initial conformity assessment.

 

If our product malfunctions, or causes or contributes to a death or a serious injury, we will be subject to medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.

 

Under the FDA medical device reporting regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious injury if the malfunction of the device or one of our similar devices were to recur. If we fail to report these events to the FDA within the required timeframes, or at all, the FDA could take enforcement action against us. Any such adverse event involving our product also could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business, and may harm our reputation and financial results. Similar strict regulatory requirements concerning safety reporting and post-market surveillance obligations apply in the EEA.

 

31
 

 

Our Pure-Vu System may in the future be subject to product recalls. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, including a third-country authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us.

 

The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture. In the case of the FDA, the authority to require a recall must be based on an FDA finding that there is reasonable probability that the device would cause serious injury or death. In addition, foreign governmental bodies have the authority to require the recall of our products in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found. The FDA requires that certain classifications of recalls be reported to the FDA within ten working days after the recall is initiated. A government-mandated or voluntary recall by us or a distributor could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing errors, design or labeling defects or other deficiencies and issues. A recall of our products would divert managerial and financial resources and have an adverse effect on our reputation, results of operations and financial condition, which could impair our ability to produce our product in a cost-effective and timely manner in order to meet our customers’ demands. We may also be subject to liability claims, be required to bear other costs, or take other actions that may have a negative impact on our future sales and our ability to generate profits. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA or another third-country competent authority. We may initiate voluntary recalls that we determine do not require notification of the FDA or another third-country competent authority. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA could take enforcement action for failing to report the recalls.

 

We are also required to follow detailed recordkeeping requirements for all firm-initiated medical device corrections and removals. In addition, in October 2014, the FDA issued guidance intended to assist the FDA and industry in distinguishing medical device recalls from product enhancements. Per the guidance, if any change or group of changes to a device addresses a violation of the Federal Food, Drug and Cosmetic Act (the “FDCA”), that change would generally constitute a medical device recall and require submission of a recall report to the FDA. Similar strict regulatory requirements concerning medical device recall and related reporting obligations apply in the EEA.

 

Our Pure-Vu System is not currently separately reimbursable through private or governmental third-party payors, which could limit market acceptance.

 

Our Pure-Vu System and the procedure to cleanse the colon in preparation for colonoscopy are not currently separately reimbursable through private or governmental third-party payors in any country. We sought new technology payments from Medicare under the hospital Inpatient and Outpatient Prospective Payment Systems and were denied in 2021. We intend to seek separate reimbursement through private or governmental third-party payors for future versions of the system, however coverage and reimbursement may not be available for any product that we commercialize and, even if available, the level of reimbursement may not be satisfactory. The commercialization of our Pure-Vu System depends on prospective patients’ ability to cover the costs of the procedure, and/or physician/hospital willingness to subsidize all or some of the costs of the procedure. We believe that a substantial portion of individuals who are candidates for the use of the Pure-Vu System worldwide do not have the financial means to cover its cost. Moreover, healthcare providers may be reluctant to make the initial investment in the system. A general regional or worldwide economic downturn could negatively impact demand for our Pure-Vu System. In the event that medically eligible patients deem the costs of our procedure to be prohibitively high or consider alternative treatment options to be more affordable, or healthcare providers deem the cost of the system to be too high, our business, results of operations and financial condition would be negatively impacted.

 

Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.

 

There have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products.

 

32
 

 

For example, in March 2010, the Affordable Care Act was enacted. The Affordable Care Act has substantially changed the way healthcare is financed by both governmental and private insurers and has significantly affected the health care industry. Certain provisions of the Affordable Care Act have been subject to judicial challenges as well as efforts to modify or invalidate them or to alter their interpretation and implementation. For example, the Tax Cuts and Jobs Act (TCJA) enacted on December 22, 2017, included a provision that eliminated the tax-based shared responsibility payment for individuals who fail to maintain minimum essential coverage under Section 5000A of the Internal Revenue Code of 1986, commonly referred to as the “individual mandate,” effective January 1, 2019. Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible, but the nature and extent of such potential changes or challenges are uncertain at this time. The implications of the Affordable Care Act, and efforts to modify or invalidate the Affordable Care Act or its implementing regulations, or portions thereof, and the uncertainty surrounding any other modification related to the Affordable Care Act or any other health care reform measure for our business and financial condition, if any, are not yet clear. It is possible that the Affordable Care Act as well as its possible modification or invalidation, in whole or in part or another health care reform measure could negatively impact our business.

 

If we or our sales personnel or distributors do not comply with fraud and abuse laws, including anti-kickback laws for any products approved in the U.S., or with similar foreign laws where we market our products, we could face significant liability.

 

There are numerous federal and state laws pertaining to healthcare fraud and abuse, including anti-kickback laws, false claims, and physician transparency laws. Our relationships with physicians and surgeons, hospitals and our independent distributors are subject to scrutiny under these laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, exclusion from participation in government healthcare programs, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. The risk of our being found in violation of these laws is increased by the fact that their provisions are open to a variety of evolving interpretations and enforcement discretion. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. For a fuller discussion of the applicable anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations applicable to our business, see Item 1 “Description of Business - Other Healthcare Laws and Compliance Requirements.”

 

Many foreign countries have enacted similar laws addressing fraud and abuse in the healthcare sector. The shifting commercial compliance environment and the need to build and maintain robust and expandable systems to comply with different compliance requirements in multiple jurisdictions increases the possibility that a healthcare company may run afoul of one or more of the requirements.

 

We may become liable for significant damages or be restricted from selling our products if we engage in inappropriate promotion of our Pure-Vu System.

 

Our promotional materials and training methods for our Pure-Vu System must comply with FDA and other foreign applicable laws and regulations, including the prohibition of the promotion of the “off-label” use of our Pure-Vu System, including by using our Pure-Vu System in a way not approved by the FDA or not consistent with the intended purpose for which Pure-Vu System is CE marked in the EEA. The Pure-Vu System is currently indicated to connect to standard colonoscopes to facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigated fluid, feces and other bodily fluids and matter. We do not currently promote a particular prep regimen as this is left up to the discretion of the physician since our current indication does not reference any preparation protocol. Healthcare providers may use our products off-label, as the FDA or the competent authorities in the EEA Member States do not restrict or regulate a physician’s choice of treatment within the practice of medicine. However, if the FDA or a competent authority in an EEA Member State determines that our promotional materials, training or marketing efforts constitute promotion of an off-label use, it could request that we modify our training or promotional materials or marketing efforts or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine and criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties. Although we do not intend to engage in any activities that may be considered off-label promotion of our products, the FDA or another regulatory agency could disagree and conclude that we have engaged, directly or indirectly, in off-label promotion. In addition, the off-label use of our products may increase the risk of product liability claims. Product liability claims are expensive to defend and could result in substantial damage awards against us and harm our reputation.

 

33
 

 

The failure to comply with anti-corruption laws could materially adversely affect our business and result in civil and/or criminal sanctions.

 

The U.S. Foreign Corrupt Practices Act (FCPA) and similar anti-corruption laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business. Because of the predominance of government-administered healthcare systems in many jurisdictions around the world, many of our customer relationships outside of the U.S. are with governmental entities and are therefore potentially subject to such laws.

 

Global enforcement of anti-corruption laws has increased in recent years, including investigations and enforcement proceedings leading to assessment of significant fines and penalties against companies and individuals. Our international operations create a risk of unauthorized payments or offers of payments by one of our employees, consultants, sales agents, or distributors. We maintain policies and programs to implement safeguards to educate our employees and agents on these legal requirements, and to prevent and prohibit improper practices. However, existing safeguards and any future improvements may not always be effective, and our employees, consultants, sales agents or distributors may engage in conduct for which we could be held responsible. In addition, regulators could seek to hold us liable for conduct committed by companies in which we invest or that we acquire. Any alleged or actual violations of these regulations may subject us to government scrutiny, criminal or civil sanctions and other liabilities, including exclusion from government contracting, and could disrupt our business, adversely affect our reputation and result in a material adverse effect on our business, results of operations, financial condition and cash flows.

 

Laws and regulations governing international business operations could adversely impact our business.

 

The U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC), and the Bureau of Industry and Security at the U.S. Department of Commerce (BIS), administer certain laws and regulations that restrict U.S. persons and, in some instances, non-U.S. persons, in conducting activities, transacting business with or making investments in certain countries, governments, entities and individuals subject to U.S. economic sanctions. Our international operations subject us to these laws and regulations, which are complex, restrict our business dealings with certain countries, governments, entities, and individuals, and are constantly changing. Further restrictions may be enacted, amended, enforced or interpreted in a manner that materially impacts our operations. Violations of these regulations are punishable by civil penalties, including fines, denial of export privileges, injunctions, asset seizures, debarment from government contracts and revocations or restrictions of licenses, as well as criminal fines and imprisonment. We have established policies and procedures designed to assist with our compliance with such laws and regulations. However, there can be no assurance that our policies and procedures will prevent us from violating these regulations in every transaction in which we may engage, and such a violation could adversely affect our reputation, business, financial condition, results of operations and cash flows.

 

Risks Related to Our Business Operations

 

Our Pure-Vu System is currently our sole product and we are completely dependent on the successful marketing and sale of this product. There is no assurance that we will be able to develop any additional products.

 

Our Pure-Vu System is currently our sole product and we are completely dependent on the success of this product. We may fail to successfully commercialize our product. Successfully commercializing medical devices such as ours is a complex and uncertain process, dependent on the efforts of management, distributors, outside consultants, physicians and general economic conditions, among other factors. Any factors that adversely impact the commercialization of our Pure-Vu System, including, but not limited to, competition or acceptance in the marketplace, will have a negative impact on our business, results of operations and financial condition. We cannot assure you that we will be successful in developing or commercializing any potential enhancements to our Pure-Vu System or any other products. Our inability to successfully commercialize our Pure-Vu System and/or successfully develop and commercialize additional products or any enhancements to our Pure-Vu System which we may develop would have a material adverse effect on our business, results of operations and financial condition.

 

34
 

 

We are a medical technology company with a limited operating history.

 

We are a medical technology company with a limited operating history. We received clearance from the FDA, and a Certificate of Conformity which allows us to affix the CE Mark in the EEA, for our first generation and second generation Pure-Vu System and began commercialization in fourth quarter of 2019, with the first commercial placements of our second generation Pure-Vu System as part of our initial U.S. market launch targeting early adopter hospitals. We expect that sales of our Pure-Vu System will account for substantially all of our revenue for the foreseeable future. However, we have limited experience in selling our products and we may be unable to successfully commercialize our Pure-Vu System for a number of reasons, including:

 

  ● market acceptance of our Pure-Vu System by physicians and patients will largely depend on our ability to demonstrate its relative safety, efficacy, cost-effectiveness and ease of use;
     
  ● our inexperience in marketing, selling and distributing our products;
     
  ● we may not have adequate financial or other resources to successfully commercialize our Pure-Vu System;
     
  ● we may not be able to manufacture our Pure-Vu System in commercial quantities or at an acceptable cost;
     
  ● the uncertainties associated with establishing and qualifying a manufacturing facility;
     
  ● patients will not generally receive separate reimbursement from third-party payors for the use of our Pure-Vu System for colon cleansing, which may reduce widespread use of our Pure-Vu System;
     
  ● the introduction and market acceptance of competing products and technologies;
     
  ● rapid technological change may make our Pure-Vu System obsolete;
     
  ● our inability to project in the short term the hospital medical device environment considering the global pandemic and strains on hospital systems; and
     
  ● our inability to predict the financial impact of inflation on costs such as labor, freight and materials

 

Potential investors should carefully consider the risks and uncertainties that a company with a limited operating history will face. In particular, potential investors should consider that we cannot assure you that we will be able to:

 

  ● successfully execute our current business plan for the commercialization of our Pure-Vu System, or that our business plan is sound;
     
  ● successfully contract for and establish a commercial supply of our product;
     
  ● achieve market acceptance of our Pure-Vu System; and
     
  ● attract and retain an experienced management and advisory team.

 

If we cannot successfully execute any one of the foregoing, our business may not succeed and your investment will be adversely affected.

 

The Pure-Vu System may not be accepted by physicians and patients.

 

Our Pure-Vu System for use during colonoscopy screenings to clean the colon through irrigation and evacuation of bowel contents is a new technology and may be perceived as more invasive than current colonoscopy screening procedures, and patients may be unwilling to undergo the procedure. Moreover, patients may be unwilling to depart from the current standard of care. In addition, physicians tend to be slow to change their medical treatment practices because of perceived liability risks arising from the use of new products. Physicians may not recommend or prescribe our Pure-Vu System until there is long-term clinical evidence to convince them to alter their existing treatment methods, there are recommendations from prominent physicians that our Pure-Vu System is safe and efficient and separate reimbursement or insurance coverage is available. We cannot predict when, if ever, physicians and patients may adopt the use of our Pure-Vu System. If our Pure-Vu System does not achieve an adequate level of acceptance by patients, physicians and healthcare payors, we may not generate significant product revenue and we may not become profitable.

 

35
 

 

If we are not able to successfully commercialize our Pure-Vu System, the revenue that we generate from its sales, if any, may be limited.

 

The commercial success of our Pure-Vu System will depend upon its acceptance by the medical community, including physicians, patients and health care payors. The degree of market acceptance of our Pure-Vu System will depend on a number of factors, including:

 

  ● demonstration of clinical safety and efficacy;
     
  ● relative convenience, burden and ease of administration;
     
  ● the prevalence and severity of any adverse effects;
     
  ● the willingness of physicians to prescribe the Pure-Vu System and of the target patient population to try new procedures;
     
  ● efficacy of our Pure-Vu System compared to competing procedures;
     
  ● the introduction of any new products and procedures that may in the future become available for colonoscopy preparation may be approved;
     
  ● pricing and cost-effectiveness;
     
  ● the inclusion or omission of our Pure-Vu System in applicable treatment guidelines;
     
  ● the effectiveness of our or any future collaborators’ sales and marketing strategies;
     
  ● limitations or warnings contained in FDA or Notified Body-approved labeling;
     
  ● our ability to obtain and maintain sufficient third-party coverage or reimbursement from government health care programs, including Medicare and Medicaid, private health insurers and other third-party payors; and
     
  ● the willingness of patients to pay out-of-pocket in the absence of third-party coverage or separate reimbursement.

 

If our Pure-Vu System does not achieve an adequate level of acceptance by physicians, health care payors and patients, we may not generate sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to educate the medical community and third-party payors on the benefits of our Pure-Vu System may require significant resources and may never be successful.

 

We currently have a limited sales and marketing organization. If we are unable to secure a sales and marketing partner and/or establish satisfactory sales and marketing capabilities, we may not successfully commercialize our Pure-Vu System.

 

At present, we have limited sales or marketing personnel. In order to commercialize devices that are approved for commercial sales, we must either collaborate with third parties that have such commercial infrastructure and/or continue to develop our own sales and marketing infrastructure. If we are not successful entering into appropriate collaboration arrangements, recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty successfully commercializing our Pure-Vu System, which would adversely affect our business, operating results and financial condition.

 

We may not be able to enter into collaboration agreements on terms acceptable to us or at all. In addition, even if we enter into such relationships, we may have limited or no control over the sales, marketing and distribution activities of these third parties. Our future revenues may depend heavily on the success of the efforts of these third parties. If we elect to establish a sales and marketing infrastructure we may not realize a positive return on this investment. In addition, we will have to compete with established and well-funded medical device companies to recruit, hire, train and retain sales and marketing personnel. Factors that may inhibit our efforts to commercialize our Pure-Vu System without strategic partners or licensees include:

 

  ● our inability to recruit and retain adequate numbers of effective sales and marketing personnel;
     
  ● the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to use our Pure-Vu System;
     
  ● the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and
     
  ● unforeseen costs and expenses associated with creating an independent sales and marketing organization.

 

36
 

 

Our Pure-Vu System may cause adverse side effects that prevent its widespread adoption or that may necessitate its withdrawal from the market.

 

Our Pure-Vu System is currently believed to have the same side effects as a standard colonoscopy, such as inducing trauma to the colon’s mucosa or, in rare cases, perforation of the colon. With more extensive use, the Pure-Vu System may be found to cause additional undesirable and unintended side effects or show a higher rate of side effects than a standard colonoscopy that may prevent or limit its commercial adoption and use. Even upon receiving clearance from the FDA, CE Certificates of Conformity by a Notified Body in the EEA and approvals from other regulatory authorities, our products may later exhibit adverse side effects that prevent widespread use or necessitate withdrawal from the market. The manifestation of such side effects could cause our business to suffer.

 

We rely on the proper function, availability and security of our information technology systems to operate our business and a cyber-attack or other breach or disruption of these systems could have a material adverse effect on our business and results of operations.

 

We rely on information technology systems to process, transmit and store electronic information in our day-to-day operations. The form and function of such systems may change over time as our business needs change. The nature of our business involves the receipt and storage of personal and financial information regarding our customers. We use our information technology systems to manage or support a variety of business processes and activities, including sales, shipping, billing, customer service, procurement and supply chain, manufacturing and accounts payable. In addition, we use enterprise information technology systems to record, process, and summarize transactions and other financial information and results of operations for internal reporting purposes and to comply with regulatory financial reporting, legal, and tax requirements. Our information technology systems may be susceptible to damage, disruptions or shutdowns due to computer viruses, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof, power outages, hardware failures, telecommunication failures, user errors or catastrophic events. Any failure by us to maintain or protect our information technology systems and data integrity, including from cyber-attacks, intrusions, disruptions or shutdowns, could result in the unauthorized access to customer data, theft of intellectual property or other misappropriation of assets or the loss of key data and information, or otherwise compromise our confidential or proprietary information and disrupt our operations. If our information technology systems are breached or suffer severe damage, disruption or shutdown and we are unable to effectively resolve the issues in a timely manner, our business and operating results may be materially and adversely affected. With the ever-changing threat landscape, and while we have implemented security measures to protect our information technology systems and infrastructure, there can be no assurance that such measures will prevent service interruptions or security breaches that could adversely affect our business.

 

If our efforts to maintain the privacy and security of our customer, employee, supplier or Company information are not successful, we could incur substantial additional costs and become subject to litigation, enforcement actions and reputational damage.

 

Our business, like that of most medical device companies, involves the receipt, storage and transmission of customer information and payment and reimbursement information, our employees, our suppliers and our Company. Our information systems are vulnerable to an increasing threat of continually evolving cybersecurity risks. Unauthorized parties may attempt to gain access to our systems or information through fraud or other means of deceiving our employees, business acquisitions, or third-party service providers. Hardware, software or applications we develop or obtain from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information and device security. Hardware or software applications developed by our business acquisitions may face risks associated with defects and vulnerabilities in their systems, or difficulties with the integration of the acquisitions into our information systems. The methods used to obtain unauthorized access, disable or degrade service or sabotage systems are also constantly changing and evolving, and may be difficult to anticipate or detect for long periods of time. The ever-evolving threats mean we must continually evaluate and adapt our systems and processes, and our efforts may not be adequate to safeguard against all data security breaches, misuse of data or sabotage of our systems. Any future significant compromise or breach of our data security, whether external or internal, or misuse of customer, employee, supplier or Company data, could result in additional significant costs, lost sales, fines, lawsuits and damage to our reputation. In addition, as the regulatory environment related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing requirements applicable to our business, compliance with those requirements could also result in additional costs. Further, many of our employees are working remotely in response to the COVID-19 pandemic and related government actions, which could expose us to greater risks related to cybersecurity and our information systems.

 

37
 

 

If we do not convince gastroenterologists that our products are attractive alternatives to the currently marketed medical devices and suitable for use in addressing bowel preparation or cleansing, we will not be commercially successful.

 

If we are not successful in convincing gastroenterologists of the merits of our products or educating them on the use of our products, they may not use our products and we will be unable to fully commercialize our products or reach profitability. Gastroenterologists may be hesitant to change their medical treatment practices for the following reasons, among others:

 

  ● lack of experience with our products and concerns regarding potential side effects;
     
  ● lack of clinical data currently available to support the safety and effectiveness of our products;
     
  ● lack or perceived lack of evidence supporting additional patient benefits;
     
  ● perceived liability risks generally associated with the use of new products and procedures; and
     
  ● the time commitment that may be required for training.

 

In addition, we believe recommendations and support of our products by influential gastroenterologists are important for market acceptance and adoption. If we do not receive support from such gastroenterologists or long term data does not show the benefits of using our products, gastroenterologists may not use our products. In such circumstances, we may not be able to grow our revenues or achieve profitability.

 

If we are unable to train gastroenterologists and their clinical staff on the safe and appropriate use of our products, we may be unable to achieve revenue growth or profitability.

 

An important part of our sales process includes the ability to train gastroenterologists and their clinical staff on the safe and appropriate use of our products. We have very limited experience in training and retaining qualified independent gastroenterologists to perform the colon cleansing procedure using our Pure-Vu System. If we are unable to attract gastroenterologists to our training programs, it may lead to a higher rate of injury, negative publicity and an increased risk of product liability, which would adversely affect our growth or profitability.

 

There is a learning process involved in gastroenterologists and their clinical staff becoming proficient in the use of our products. It is critical to the success of our commercialization efforts to train a sufficient number of gastroenterologists and to provide them with adequate instruction in the use of our Pure-Vu System. This training process may take longer than expected and may therefore affect our ability to increase sales. Following completion of training, we expect to rely on the trained gastroenterologists to advocate the benefits of our products in the broader marketplace. Convincing gastroenterologists to dedicate the time and energy necessary for adequate training is challenging, and we cannot assure you we will be successful in these efforts. If gastroenterologists and their clinical staff are not properly trained, they may misuse or ineffectively use our products. Such uses may result in unsatisfactory patient outcomes, patient injury, negative publicity or lawsuits against us, any of which would have a material adverse effect on our business, results of operations and financial condition.

 

We may face competition from other medical device companies in the future and our operating results will suffer if we fail to compete effectively.

 

The medical device industries are intensely competitive and subject to rapidly evolving technology and intense research and development efforts. We have competitors in a number of jurisdictions that have substantially greater name recognition, commercial infrastructures and financial, technical and personnel resources than we have. Established competitors may invest heavily to quickly discover and develop novel devices or procedures that could make our Pure-Vu System obsolete or uneconomical. Any new product that competes with a cleared medical device may need to demonstrate compelling advantages in efficacy, cost, convenience, tolerability and safety to be commercially successful. Other competitive factors could force us to lower prices or could result in reduced sales, including increased use of alternatives to colonoscopies such as capsule endoscopy systems, virtual colonoscopies using a CT scan, and other similar screening tests for colon cancer. While none of these testing alternatives may ever fully replace the colonoscopy, over time, they may take market share away from conventional colonoscopies for specific purposes and may lower the potential market opportunity for us. In addition, new devices developed by others could emerge as competitors to our Pure-Vu System. If we are not able to compete effectively against our current and future competitors, our business will not grow and our financial condition and operations will suffer.

 

38
 

 

Our products face the risk of technological obsolescence, which, if realized, could have a material adverse effect on our business.

 

The medical device industry is characterized by rapid and significant technological change. There can be no assurance that third parties will not succeed in developing or marketing technologies and products that are more effective than ours or that would render our technology and products obsolete or noncompetitive. Additionally, new, less invasive surgical procedures and medications could be developed that replace or reduce the importance of current procedures that use or could use our products. Accordingly, our success will depend in part upon our ability to respond quickly to medical and technological changes through the development of new products. Product development involves a high degree of risk, and we cannot assure you that our new product development efforts will result in any commercially successful products.

 

If defects are discovered in our products, we may incur additional unforeseen costs, hospitals may not purchase our products and our reputation may suffer.

 

Our products incorporate mechanical parts, any of which can contain errors or failures, especially when first introduced. In addition, new products or enhancements may contain undetected errors or performance problems that, despite testing, are discovered only after commercial shipment. Because our products are designed to be used to perform medical procedures, we expect that our customers will have an increased sensitivity to such defects. We cannot provide any assurances that our products will not experience component aging, errors or performance problems in the future. If we experience flaws or performance problems, any of the following could occur:

 

  ● delays in product shipments;
     
  ● loss of revenue;
     
  ● delay in market acceptance;
     
  ● diversion of our resources;
     
  ● damage to our reputation;
     
  ● product recalls;
     
  ● regulatory actions;
     
  ● increased service or warranty costs; or
     
  ● product liability claims.

 

Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.

 

Our future profitability will depend, in part, on our ability to commercialize our Pure-Vu System in foreign markets for which we intend to rely on collaborations with third parties. If we commercialize our Pure-Vu System in foreign markets, we would be subject to additional risks and uncertainties, including:

 

  ● our customers’ ability to obtain reimbursement for our Pure-Vu System in foreign markets;
     
  ● our inability to directly control commercial activities because we are relying on third parties;
     
  ● the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;
     
  ● different medical practices and customs in foreign countries affecting acceptance in the marketplace;

 

39
 

 

  ● import or export licensing requirements;
     
  ● longer accounts receivable collection times;
     
  ● longer lead times for shipping;
     
  ● language barriers for technical training;
     
  ● reduced protection of intellectual property rights in some foreign countries;
     
  ● foreign currency exchange rate fluctuations; and
     
  ● the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.

 

Foreign sales of our Pure-Vu System could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs, any of which may adversely affect our results of operations.

 

We are, and will be, completely dependent on third parties to manufacture our Pure-Vu System, and our commercialization of our Pure-Vu System could be halted, delayed or made less profitable if those third parties fail to obtain or maintain manufacturing approval from the FDA or comparable foreign regulatory authorities, fail to provide us with sufficient quantities of our Pure-Vu System device components or fail to do so at acceptable quality levels or prices.

 

We do not currently have, nor do we plan to acquire, the capability or infrastructure to manufacture our Pure-Vu System, as well as the other related device components for high volume commercial purposes. We do have capability to produce limited units for use in our clinical studies, if required. As a result, we are obligated to rely on contract manufacturers for the commercial supply of our product. We currently rely on several manufacturing partners to manufacture and produce the components of our Pure-Vu System, and the loss of the services of these manufacturers or an adverse change in the manufacturer’s business or our relationship could have a material adverse effect on our business. Our primary reliance on these manufacturers for all or substantially all of our manufacturing needs involves several risks, including the potential inability to obtain an adequate supply of components and limited control over pricing, quality and timely delivery of the components. In addition, replacing these manufacturers may be difficult and could result in an inability or delay in obtaining the components for our Pure-Vu System. As a result, if such a disruption were to occur we may be unable to fulfill customer orders or orders for trials, and our operating results may fluctuate from period to period, particularly if a disruption occurs near the end of a fiscal period. However, we anticipate engaging additional manufacturers for the production of the components of our Pure-Vu System as we expand our commercialization efforts.

 

The facilities used by our contract manufacturers to manufacture the Pure-Vu System must be compliant with FDA Quality System Regulation requirements and registered with the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with current Good Manufacturing Practices (“cGMPs”) for manufacture of medical devices, as issued in the Quality System Regulation (21 CFR Part 820). These cGMPs regulations cover all aspects of the manufacturing, testing, quality control and record keeping relating to the Pure-Vu System. If our contract manufacturers cannot successfully manufacture products that conform to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our products or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to maintain regulatory approval for or market the Pure-Vu System.

 

Our contract manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory requirements. We will not have control over our contract manufacturers’ compliance with these regulations and standards. Failure by any of our contract manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure to market the Pure-Vu System, delays, suspensions or withdrawals of approvals, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business. In addition, we will not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. Failure by our contract manufacturers to comply with or maintain any of these standards could adversely affect our ability to maintain regulatory approval for or market our Pure-Vu System.

 

40
 

 

If, for any reason, these third parties are unable or unwilling to perform, we may not be able to terminate our agreements with them, and we may not be able to locate alternative manufacturers or enter into favorable agreements with them and we cannot be certain that any such third parties will have the manufacturing capacity to meet future requirements. If these manufacturers, or any alternate manufacturers, experience any significant difficulties in their respective manufacturing processes for our product or should cease doing business with us, we could experience significant interruptions in supply or may not be able to create or maintain a commercial supply. Were we to encounter manufacturing issues, our ability to produce sufficient commercial supply might be negatively affected. Our inability to coordinate the efforts of our third party manufacturing partners or the lack of capacity available at our third party manufacturing partners, could impair our ability to supply our Pure-Vu System at required levels. If we face these or other difficulties with our manufacturing partners we could experience significant interruptions in the supply of our products if we decided to transfer the manufacture to one or more alternative manufacturers in an effort to deal with the difficulties.

 

Any manufacturing problem or the loss of a contract manufacturer could be disruptive to our operations and result in lost sales. Any reliance on suppliers may involve several risks, including a potential inability to obtain critical components and reduced control over production costs, delivery schedules, reliability and quality. Any unanticipated disruption to a future contract manufacturer caused by problems at suppliers could delay shipment of our Pure-Vu System, increase our cost of goods sold and result in lost sales.

 

The manufacture of our Pure-Vu System, and the technology developed thereunder, is subject to certain Israeli government regulations which may impair our ability to outsource or transfer development or manufacturing activities with respect to any product or technology outside of Israel.

 

We have received, and may receive in the future, grants from the Government of the State of Israel through the IIA for the financing of a portion of our research and development expenditures pursuant to the IIA Regulations.

 

The IIA Regulations also require that products developed with IIA grants be manufactured in Israel at a rate (scope) which will not be less than the rate of manufacturing and added value in Israel that were set forth in the relevant grant applications submitted to the IIA. Furthermore, the IIA Regulations require that the know how resulting from research and development according to an IIA-approved plan, not being the product developed within the framework of such approved plan, and any right deriving therefrom may not be transferred outside of Israel (including by way of certain licenses), unless prior approval is received from the IIA. We received approval for the transfer of manufacturing of the sleeves outside of Israel. The transfer outside of Israel of manufacturing which is connected with the IIA-funded knowhow will result in a higher royalty repayment rate and may further result in increased royalties (up to three times the aggregate amount of the IIA grants plus interest thereon). In addition, the transfer outside of Israel of IIA-funded knowhow may trigger additional payments to the IIA (up to six times the aggregate amount of the IIA grants plus interest thereon). Even following the full repayment of any IIA grants, we must nevertheless continue to comply with the requirements of the IIA Regulations. The foregoing restrictions and requirements for payment may impair our ability to transfer or sell our technology assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any IIA-funded know how outside of Israel.

 

Furthermore, companies that receive IIA funding are, generally required to ensure that all rights in the IIA-backed product are retained by them. This means that, generally, all knowhow which is derived from the research and development conducted pursuant to an IIA approved plan, and every right derived from it, must be owned by the recipient of the IIA funding from the date such knowhow is generated. Companies that receive IIA funding are further subject to reporting requirements and other technical requirements, which are intended to allow the IIA to ensure that the IIA Regulations are being complied with.

 

If we fail to comply with any of the conditions and restrictions imposed by the IIA Regulations, or by the specific terms under which we received the grants, we may be required to refund any grants previously received together with interest and penalties, and, in certain circumstances, may be subject to criminal charges.

 

For additional information, see “Part I—Item 1A—Risk Factors—Risks Related to Our Operations in Israel.”

 

41
 

 

Risks Relating to Our Intellectual Property Rights

 

We may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others.

 

We rely on a combination of patents, trademarks, copyrights, trade secrets and nondisclosure agreements to protect our proprietary intellectual property. Our efforts to protect our intellectual property and proprietary rights may not be sufficient. We cannot be sure that our pending patent applications will result in the issuance of patents to us, that patents issued to or licensed by us in the past or in the future will not be challenged or circumvented by competitors or that these patents will remain valid or sufficiently broad to preclude our competitors from introducing technologies similar to those covered by our patents and patent applications. In addition, our ability to enforce and protect our intellectual property rights may be limited in certain countries outside the United States, which could make it easier for competitors to capture market position in such countries by utilizing technologies that are similar to those developed or licensed by us.

 

Competitors also may harm our sales by designing products that mirror the capabilities of our products or technology without infringing our intellectual property rights. If we do not obtain sufficient protection for our intellectual property, or if we are unable to effectively enforce our intellectual property rights, our competitiveness could be impaired, which would limit our growth and future revenue.

 

We may in the future be a party to patent litigation and administrative proceedings that could be costly and could interfere with our ability to sell our Pure-Vu System.

 

Litigation related to infringement and other intellectual property claims, with or without merit, is unpredictable, can be expensive and time consuming and can divert management’s attention from our core business. If we lose this kind of litigation, a court could require us to pay substantial damages, and prohibit us from using technologies essential to our Pure-Vu System, any of which would have a material adverse effect on our business, results of operations and financial condition. If relevant patents are upheld as valid and enforceable and we are found to infringe, we could be prevented from selling our Pure-Vu System unless we can obtain a license to use technology or ideas covered by such patents or are able to redesign our Pure-Vu System to avoid infringement. We do not know whether any necessary licenses would be available to us on satisfactory terms, if at all, or whether we could redesign our Pure-Vu System or processes to avoid infringement.

 

Competing products may also appear in other countries in which our patent coverage might not exist or be as strong. If we lose a foreign patent lawsuit, we could be prevented from marketing our Pure-Vu System in one or more foreign countries.

 

We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.

 

As is commonplace in our industry, we employ and plan to employ individuals who were previously employed at other medical device companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject in the future to claims that our employees or prospective employees are subject to a continuing obligation to their former employers (such as non-competition or non-solicitation obligations) or claims that our employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.

 

General Company-Related Risks

 

We will need to grow the size of our organization, and we may experience difficulties in managing this growth.

 

As of December 31, 2022, we had 43 full time employees and 6 part time employees. As our marketing and commercialization plans and strategies develop, we will need to expand the size of our employee and consultant base for managerial, operational, sales, marketing, financial and other resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. In addition, our management may have to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. Our future financial performance and our ability to commercialize the Pure-Vu System and any other future product candidates and our ability to compete effectively will depend, in part, on our ability to effectively manage our future growth.

 

Our success will depend in part on our ability to manage our operations as we advance our products through clinical studies and to expand our development, regulatory and commercial capabilities or contract with third parties to provide these capabilities for us. Failure to achieve any of these goals could have a material adverse effect on our business, financial condition or results of operations.

 

42
 

 

If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. In addition, the loss of the services of certain key employees would adversely impact our business prospects.

 

We depend on key members of our management team. The loss of the services of Tim Moran, our Chief Executive Officer, Mark Pomeranz, our President and Chief Operating Officer, Andrew Taylor, our Chief Financial Officer or any member of our senior management team, could harm our ability to execute our commercial strategy for our Pure-Vu System and the strategic objectives for our company. We entered into employment agreements with our Chief Executive Officer, President and Chief Operating Officer, and Chief Financial Officer, but these agreements are terminable by the employees on short or no notice at any time without or with limited penalty. In addition, we do not maintain, and have no current intention of obtaining, “key man” life insurance on any member of our management team.

 

Recruiting and retaining qualified scientific and commercial personnel, including sales and marketing executives and field personnel, is also critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous medical device and pharmaceutical companies for similar personnel and based on our company profile. We also experience competition for the hiring of scientific personnel from universities and research institutions. If we fail to recruit and then retain these personnel, we may not be able to effectively execute our commercial strategy for the Pure-Vu System.

 

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of the Pure-Vu System.

 

We are, and may be in the future, subject to product liability claims and lawsuits, including potential class actions, alleging that our products have resulted or could result in an unsafe condition or injury. Any product liability claim brought against us, with or without merit, could be costly to defend and could result in settlement payments and adjustments not covered by or in excess of insurance. In addition, we may not be able to obtain insurance on terms acceptable to us or at all because insurance varies in cost and can be difficult to obtain. Our failure to successfully defend against product liability claims or maintain adequate insurance coverage could have an adverse effect on our results of operations and financial condition.

 

Exchange rate fluctuations between the U.S. dollar and the Israeli New Shekel (the “NIS”) and inflation may negatively affect our earnings and we may not be able to hedge our currency exchange risks successfully.

 

The U.S. dollar is our functional and reporting currency. However, a portion of our operating expenses, including personnel and facilities related expenses, are incurred in NIS. As a result, we are exposed to the risks that the NIS may appreciate relative to the U.S. dollar, or, if the NIS instead devalues relative to the U.S. dollar, that the inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely affected. Given our general lack of currency hedging arrangements to protect us from fluctuations in the exchange rates of the NIS and other foreign currencies in relation to the U.S. dollar (and/or from inflation of such foreign currencies), we may be exposed to material adverse effects from such movements. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation (if any) of the NIS against the U.S. dollar.

 

We may acquire other businesses or form joint ventures or make investments in other companies or technologies that could negatively affect our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense.

 

We may pursue acquisitions of businesses and assets. We also may pursue strategic alliances and joint ventures that leverage our intellectual property and industry experience to expand our offerings or distribution. We have no history of acquiring other companies or with forming strategic partnerships. We may not be able to find suitable partners or acquisition candidates, and we may not be able to complete such transactions on favorable terms, if at all. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Any future acquisitions also could result in the issuance of equity securities, incurrence of debt, contingent liabilities or future write-offs of intangible assets or goodwill, any of which could have a material adverse effect on our financial condition, results of operations, and cash flows. Integration of an acquired company also may disrupt ongoing operations and require management resources that we would otherwise focus on developing our existing business. We may experience losses related to investments in other companies, which could have a material negative effect on our results of operations and financial condition. We may not realize the anticipated benefits of any acquisition, technology license, strategic alliance, or joint venture.

 

43
 

 

To finance any acquisitions or joint ventures, we may choose to issue shares of our Common Stock as consideration, which would dilute the ownership of our stockholders. Additional funds may not be available on terms that are favorable to us, or at all. If the price of our Common Stock is low or volatile, we may not be able to acquire other companies or fund a joint venture project using our stock as consideration.

 

Global or regional pandemics, including outbreaks of communicable diseases, may materially and adversely affect our business, financial condition, revenues, and results of operations.

 

We may face risks related to health epidemics or outbreaks of communicable diseases. For example, the recent outbreak around the world of the highly transmissible and pathogenic coronavirus COVID-19. The outbreak of such communicable diseases could result in a widespread health crisis that could adversely affect general commercial activity and the economies and financial markets of many countries.

 

The continued impact resulting from the COVID-19 outbreak where we and our business partners have operations, or the perception that such an outbreak could occur, and the measures taken by our business partners, including restrictions with respect to business or hospital procedures, restrictions with respect to our access to our business partners, and/or restrictions imposed by the regulatory bodies or governments of countries or regions affected, could adversely affect our business, financial condition, revenues, and results of operations.

 

For example, the COVID-19 outbreak, or other similar outbreaks, could have an adverse effect on the overall productivity of our workforce and we may be required to take extraordinary measures to ensure the safety of our employees and those of our business partners. These measures could require that our employees refrain from traveling to their normal workplace for extended periods of time, which we have already experienced in certain locations as a result of the COVID-19 outbreak, which in turn could result in a decrease in our commercial activities, or result in higher costs or other inefficiencies.

 

Any serious disruption with our suppliers or customers due to such outbreaks could impair our ability to meet and/or generate demand for our product, which may negatively impact our revenue, financial condition and commercial operations. Such outbreaks could also result in delays in or the suspension of our business partners manufacturing operations.

 

Additionally, our business may be harmed if, in connection with an outbreak, our customers seek to limit or prevent access by our sales and clinical support teams to their facilities, which we have already experienced in certain locations as a result of the COVID-19 outbreak, or if our customers postpone elective procedures while their resources are diverted to addressing such an outbreak, or if capital spending by hospitals is curtailed or delayed in connection with such an outbreak, which we have already experienced as a result of the COVID-19 outbreak. An outbreak may also result in restrictions on domestic and international travel, which could have a negative impact on our customer engagement efforts, including through the cancellation or postponement of third-party conferences, trade shows and similar events, each of which we have already experienced as a result of the COVID-19 outbreak.

 

In addition to the risks identified above, we may face the risk of a resurgence of an outbreak, including a resurgence of the ongoing COVID-19 outbreak, in locations where we and our business partners have operations that were initially showing signs of improvement from such outbreak. Such resurgence may result in the recurrence of each of the risks and restrictions identified above, as well as new or unforeseen risks or restrictions imposed by our business partners, including with respect to our business partners operations or procedures and/or our access to such business partners, or imposed by the regulatory bodies and/or governments of countries or regions affected, all of which could adversely affect our business, financial condition, revenues, and results of operations.

 

Further, in our operations as a public company, prolonged government disruptions, global pandemics and other natural disasters or geopolitical actions could affect our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

 

44
 

 

Risks Related to our Capital Stock

 

Our quarterly operating results may be subject to significant fluctuations.

 

To date, as part of our initial U.S. market launch, we have generated limited revenue from our Pure-Vu System, but we do not expect to generate significant revenue from product sales until we expand our commercialization efforts for the Pure-Vu System, which is subject to significant uncertainty, and accordingly we may experience significant fluctuations in our quarterly operating results in the future. The rate of market acceptance of our Pure-Vu System could contribute to this quarterly variability. Our limited operating history complicates our ability to project quarterly revenue and any future revenue generated from sales of our Pure-Vu System may fluctuate from time to time. In addition, our expense levels are based, in part, on expectation of future revenue levels. A shortfall in expected revenue, if any, could, therefore, result in a disproportionate decrease in our net income. As a result, our quarterly operating results may be subject to significant fluctuations.

 

An active trading market for our Common Stock may not be sustained.

 

Prior to the closing of our IPO on February 16, 2018, there had been no public market for our Common Stock. Although our Common Stock is listed on the NASDAQ Capital Market, the market for our shares has demonstrated varying levels of trading activity. Furthermore, the current level of trading may not be sustained in the future. The lack of an active market for our Common Stock may impair investors’ ability to sell their shares at the time they wish to sell them or at a price that they consider reasonable, may reduce the fair market value of their shares and may impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire additional intellectual property assets by using our shares as consideration.

 

A sale of a substantial number of shares of our Common Stock in the public market could cause the market price of our Common Stock to drop significantly, even if our business is doing well.

 

Our stock price could decline as a result of sales of a large number of shares of our Common Stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.

 

In addition, in the future, we may issue additional shares of Common Stock or other equity or debt securities convertible into Common Stock in connection with a financing, acquisition, litigation settlement, employee arrangements or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause our stock price to decline.

 

45
 

 

If we fail to regain compliance with the requirements for continued listing on Nasdaq, our common stock could be delisted from trading, which would adversely affect the liquidity of our common stock and our ability to raise additional capital.

 

The Nasdaq Capital Market’s rules for listed companies requires us to meet certain financial, public float, bid price and liquidity standards on an ongoing basis in order to continue the listing of our Common Stock. In order to maintain our listing on Nasdaq, we must satisfy the continued listing requirements of Nasdaq for inclusion in the Nasdaq Capital Market, including among other things, a minimum stockholders’ equity of $2.5 million and a minimum bid price for our Common Stock of $1.00 per share.

 

On January 4, 2023, we received a letter from the Nasdaq Stock Market notifying us that we were no longer in compliance with the minimum stockholders’ equity requirement for continued listing under Nasdaq Listing Rule 5550(b)(1), which requires us to maintain stockholders’ equity of at least $2,500,000. On February 21, 2023, we submitted a plan to regain compliance and on March 9, 2023, the Staff notified the Company (the “Letter”) that it would be granted an extension until July 3, 2023, to demonstrate compliance with Listing Rule 5550(b)(1) to meet the continued listing requirements of The Nasdaq Capital Market, conditioned upon achievement of certain milestones included in a plan of compliance previously submitted to Nasdaq, including a plan to raise additional capital.

 

We intend to regain compliance with the applicable continued listing requirements of The Nasdaq Capital Market prior to the end of the compliance period set forth in the abovementioned letter. However, until Nasdaq has reached a final determination that we have regained compliance with all of the applicable continued listing requirements, there can be no assurances regarding the continued listing of our common stock on Nasdaq. In the event we fail to regain compliance within the compliance period, we would have the right to a hearing before an independent panel. The hearing request would halt any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing. The delisting of our common stock from Nasdaq would have a material adverse effect on our access to capital markets, and any limitation on market liquidity or reduction in the price of our common stock as a result of that delisting would adversely affect our ability to raise capital on terms acceptable to us, if at all.

 

If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our Common Stock, the price of our Common Stock could decline.

 

The trading market for our Common Stock relies in part on the research and reports that equity research analysts publish about us and our business. We do not control these analysts. The price of our Common Stock could decline if one or more equity analysts downgrade our Common Stock or if analysts issue other unfavorable commentary or cease publishing reports about us or our business.

 

46
 

 

Our share price may be volatile, which could subject us to securities class action litigation and our stockholders could incur substantial losses.

 

The market price for our Common Stock may be volatile and subject to wide fluctuations in response to factors including the following:

 

  ● actual or anticipated fluctuations in our quarterly or annual operating results;
     
  ● actual or anticipated changes in our growth rate relative to our competitors;
     
  ● failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public;
     
  ● issuance of new or updated research or reports by securities analysts;
     
  ● share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; additions or departures of key management or other personnel;
     
  ● disputes or other developments related to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;
     
  ● announcement or expectation of additional debt or equity financing efforts;
     
  ● sales of our Common Stock by us, our insiders or our other stockholders; and
     
  ● general economic, market or political conditions in the United States or elsewhere.

 

In particular, the market prices of early commercial-stage companies like ours have been highly volatile due to factors, including, but not limited to:

 

  ● any delay or failure to conduct a clinical trial for our product or receive approval from the FDA and other regulatory agents;
     
  ● developments or disputes concerning our product’s intellectual property rights;
     
  ● our or our competitors’ technological innovations;
     
  ● fluctuations in the valuation of companies perceived by investors to be comparable to us;
     
  ● announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures, capital commitments, new technologies or patents;
     
  ● failure to complete significant transactions or collaborate with vendors in manufacturing our product; and
     
  ● proposals for legislation that would place restrictions on the price of medical therapies.

 

These and other market and industry factors may cause the market price and demand for our Common Stock to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their shares of Common Stock and may otherwise negatively affect the liquidity of our Common Stock. In addition, the stock market in general, and NASDAQ Capital Markets and emerging growth companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. Such a lawsuit could also divert the time and attention of our management.

 

47
 

 

Pursuant to the terms of our outstanding Royalty Payment Rights Certificates and our outstanding Placement Agent Royalty Payment Rights Certificates, we may be obligated to pay significant royalties.

 

Pursuant to the terms of the Royalty Payment Rights Certificates (as defined in “Part III—Item 13—Certain Relationships and Related Transactions, and Director Independence— Royalty Payment Rights Certificates - Related Party Participation”) which were issued in connection with the conversion of all of our outstanding shares of Series A Convertible Preferred Stock upon the consummation of our IPO, we may be required to make certain royalty payments. After we generate sales of the current and potential future versions of the Pure-Vu System, including disposables, parts, and services, in excess of $20 million since our inception, then we will be required to pay to the holders of our Royalty Payment Rights Certificates a royalty equal to (i) three percent (3%) of our net sales, if any, in any calendar year, subject to a royalty cap amount per calendar year of $30 million. Additionally, after we receive any proceeds from the licensing of the current and potential future versions of the Pure-Vu System in excess of $3.5 million since our inception, then we will be required to pay to the holders of the Royalty Payment Rights Certificates a royalty equal to 5% of our licensing proceeds, if any, in any calendar year, subject to a royalty cap amount per calendar year of $30 million. The royalties will be payable up to the later of (i) the latest expiration date for our current patents (which is currently March 2038), or (ii) the latest expiration date of any pending patents as of the date of the initial closing of the 2017 Private Placement that may be issued in the future.

 

Pursuant to the terms of our Placement Agent Royalty Payment Rights Certificates issued in connection with the 2017 Private Placement, we will be required to pay the holders of the Placement Agent Royalty Payment Rights Certificates, in the aggregate, 10% of the amount of payments paid to the holders of the Royalty Payment Rights Certificates.

 

We are an “emerging growth company,” and will be able take advantage of reduced disclosure requirements applicable to “emerging growth companies,” which could make our Common Stock less attractive to investors.

 

We are an “emerging growth company,” as defined in the JOBS Act and, for as long as we continue to be an “emerging growth company,” we intend to take advantage of certain exemptions from various reporting requirements applicable to other public companies but not to “emerging growth companies,” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an “emerging growth company” for up to five years from the date of our initial public offering in February 2018, which would be at the end of the current fiscal year, ending December 31, 2023, or until the earliest of (i) the last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion, (ii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our Common Stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three year period.

 

We intend to take advantage of these reporting exemptions described above until we are no longer an “emerging growth company.” Under the JOBS Act, “emerging growth companies” can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not “emerging growth companies.”

 

We cannot predict if investors will find our Common Stock less attractive if we choose to rely on these exemptions. If some investors find our Common Stock less attractive as a result of any choices to reduce future disclosure, there may be a less active trading market for our Common Stock and our stock price may be more volatile.

 

48
 

 

We will incur significantly increased costs and devote substantial management time as a result of operating as a public company particularly after we are no longer an “emerging growth company.”

 

As a newly public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. For example, we are required to comply with certain of the requirements of the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection Act, as amended, as well as rules and regulations subsequently implemented by the SEC, including the establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. We expect that compliance with these requirements will increase our legal and financial compliance costs and will make some activities more time consuming and costly. In addition, we expect that our management and other personnel will need to divert attention from operational and other business matters to devote substantial time to these public company requirements. In particular, we expect to incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of Section 404 of the Sarbanes-Oxley Act. In addition, after we no longer qualify as an “emerging growth company,” as defined under the JOBS ACT we expect to incur additional management time and cost to comply with the more stringent reporting requirements applicable to companies that are deemed accelerated filers or large accelerated filers, including complying with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act. We have not yet completed the process of compiling the system and processing documentation needed to comply with such requirements. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. In that regard, we currently do not have an internal audit function, and we will need to hire or contract for additional accounting and financial staff with appropriate public company experience and technical accounting knowledge.

 

We cannot predict or estimate the amount of additional costs we may incur as a result of becoming a public company or the timing of such costs.

 

There may be limitations on the effectiveness of our internal controls, and a failure of our control systems to prevent error or fraud may materially harm our company.

 

Proper systems of internal controls over financial accounting and disclosure controls and procedures are critical to the operation of a public company. As we have a limited operating history, we only have 4 employees, and 2 contractors in our finance and accounting functions, which may result in a lack of segregation of duties and are at the very early stages of establishing, and we may be unable to effectively establish such systems, especially in light of the fact that we expect to operate as a publicly reporting company. This would leave us without the ability to reliably assimilate and compile financial information about our company and significantly impair our ability to prevent error and detect fraud, all of which would have a negative impact on our company from many perspectives.

 

Moreover, we do not expect that disclosure controls or internal control over financial reporting, even if established, will prevent all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Failure of our control systems to prevent error or fraud could materially adversely impact us.

 

If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our Common Stock may decline. In addition, because of our status as an emerging growth company, our independent registered public accountants are not required to provide an attestation report as to our internal control over financial reporting for the foreseeable future.

 

We are required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by our management on, among other things, the effectiveness of our internal control over financial reporting. This assessment includes disclosure of any material weaknesses identified by our management in our internal control over financial reporting. We will also be required to disclose changes made in our internal control and procedures on a quarterly basis.

 

A material weakness is defined as a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected and corrected on a timely basis.

 

49
 

 

We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective.

 

We are an “emerging growth company” as defined in the JOBS Act. For as long as we remain an emerging growth company, we are permitted and intend to take advantage of the exemptions contained in the JOBS Act, including that our independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes Oxley Act. We will remain an “emerging growth company” for up to five years from the date of our initial public offering in February 2018, which would be at the end of the current fiscal year, ending December 31, 2023, although if the market value of our Common Stock that is held by non-affiliates exceeds $700 million as of any June 30th before that time, we would cease to be an “emerging growth company” as of the following December 31st. At such time, our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level at which our controls are documented, designed or operating. In the past, we have identified material weaknesses in our controls which we subsequently remediated. We cannot assure investors that we will not have other material weaknesses in our internal control over financial reporting in the future.

 

If we identify material weaknesses in our internal control over financial reporting in the future or if we are unable to successfully remediate the identified material weaknesses or, if we are unable to comply with the requirements of Section 404 in a timely manner or assert that our internal control over financial reporting is effective, or, if applicable, our independent registered public accounting firm is unable to express an opinion on the effectiveness of our internal controls, we could lose investor confidence in the accuracy and completeness of our financial reports, which would cause the price of our Common Stock to decline, and we may be subject to investigation or sanctions by the SEC, or other regulatory authorities, which could require additional financial and management resources.

 

We do not currently intend to pay dividends on our Common Stock in the foreseeable future, and consequently, any gains from an investment in our Common Stock will likely depend on appreciation in the price of our Common Stock.

 

We have never declared or paid cash dividends on our Common Stock and do not anticipate paying any cash dividends to holders of our Common Stock in the foreseeable future. Consequently, investors must rely on sales of their Common Stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments. There is no guarantee that shares of our Common Stock will appreciate in value or even maintain the price at which our stockholders have purchased their shares.

 

Upon dissolution of our company, our stockholders may not recoup all or any portion of their investment.

 

In the event of a liquidation, dissolution or winding-up of our company, whether voluntary or involuntary, the proceeds and/or assets of our company remaining after giving effect to such transaction, and the payment of all of our debts and liabilities and distributions required to be made to holders of any outstanding preferred stock will then be distributed to the stockholders of our Common Stock on a pro rata basis. There can be no assurance that we will have available assets to pay to the holders of our Common Stock, or any amounts, upon such a liquidation, dissolution or winding-up of our company.

 

Our certificate of incorporation, as amended, allows for our board to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of the holders of our Common Stock.

 

Our board of directors has the authority to fix and determine the relative rights and preferences of preferred stock. Our board of directors has the authority to issue up to 10 million shares of our preferred stock without further stockholder approval. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation and the right to receive dividend payments before dividends are distributed to the holders of our Common Stock. In addition, our board of directors could authorize the issuance of a series of preferred stock that has greater voting power than our Common Stock or that is convertible into our Common Stock, which could decrease the relative voting power of our Common Stock or result in dilution to our existing stockholders.

 

50
 

 

Our certificate of incorporation, as amended, designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against us, and our directors and officers.

 

Our certificate of incorporation, as amended, provides that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty; (iii) any action asserting a claim against us, or any of our officers or directors, arising pursuant to, or a claim against us, or any of our officers or directors, with respect to the interpretation or application of any provision of the Delaware General Corporation Law, our certificate of incorporation, as amended, or our bylaws; or (iv) any action asserting a claim governed by the internal affairs doctrine. However, if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, the action may be brought in another state court sitting in the State of Delaware.

 

Risks Related to Our Operations in Israel

 

Our research and development facilities and some of our suppliers are located in Israel and, therefore, our business, financial condition and results of operation may be adversely affected by political, economic and military instability in Israel.

 

Our research and development facilities are located in northern Israel. In addition, most of our employees are residents of Israel. Accordingly, political, economic and military conditions in Israel may directly affect our business. Since the State of Israel was established in 1948, the State of Israel and its economy has experienced significant growth and expansion, coupled with an increase in the standard of living, and has developed one of the most advanced high-tech industries in the world. However, it continues to face many geo-political and other challenges that may affect companies located in Israel, such as ours. For example, a number of armed conflicts have occurred between Israel and its Arab neighbors. Although Israel has entered into peace agreements with Egypt and Jordan, comprehensive agreements with the Palestinian Authority, and other agreements with neighboring Arab countries regarding public normalization of relations, there continues to be unrest and terrorist activity in Israel with varying levels of severity, as well as ongoing hostilities and armed conflicts between Israel and the Palestinian Authority, and other groups in the West Bank and Gaza Strip, recent unrest was due to the United States’ relocation of its embassy from Tel Aviv to Jerusalem. The effects of these hostilities and violence on the Israeli economy and our operations are unclear, and we cannot predict the effect on us of a further increase in these hostilities or any future armed conflict, political instability or violence in the region. We could be harmed by any major hostilities involving Israel, the interruption or curtailment of trade between Israel and its trading partners, boycotts or a significant downturn in the economic or financial condition of Israel. The impact of Israel’s relations with its Arab neighbors in general, or on our operations in the region in particular, remains uncertain. The establishment of new fundamentalist Islamic regimes or governments more hostile to Israel could have serious consequences for the stability in the region, place additional political, economic and military confines upon Israel, materially adversely affect our operations and limit our ability to sell our products to countries in the region.

 

Additionally, several countries, principally in the Middle East, still restrict doing business with Israel and Israeli companies, and additional countries and groups have imposed or may impose restrictions on doing business with Israel and Israeli companies if hostilities in Israel or political instability in the region continues or increases. These restrictions may limit our ability to sell our products to companies in these countries. Furthermore, the Boycott, Divestment and Sanctions Movement, a global campaign attempting to increase economic and political pressure on Israel to comply with the stated goals of the movement, may gain increased traction and result in a boycott of Israeli products and services. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners, or significant downturn in the economic or financial condition of Israel, could adversely affect our business, results of operations and financial condition.

 

Our commercial insurance policy does not cover losses associated with armed conflicts and terrorist attacks. Although the Israeli government in the past covered the reinstatement value of certain damages that were caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained, or if maintained, will be sufficient to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business.

 

51
 

 

Our operations could also be disrupted by the obligations of some of our employees to perform military service. Some of our employees in Israel may be called upon to perform up to 54 days in each three year period (and in the case of military officers, up to 84 days in each three year period) of military reserve duty until they reach the age of 40 (and in some cases, depending on their specific military profession and rank up to 45 or even 49 years of age) and, in certain emergency circumstances, may be called to immediate and unlimited active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists and it is possible that there will be similar large-scale military reserve duty call-ups in the future. Our operations could be disrupted by the absence of a significant number of employees related to military service, which could materially adversely affect our business and results of operations.

 

Pursuant to the terms of the Israeli government grants we received for research and development expenditures, we are obligated to pay certain royalties on our revenues to the Israeli government. The terms of the grants require us to satisfy specified conditions and to make additional payments in addition to repayment of the grants upon certain events.

 

We have received, and may receive in the future, grants from the IIA for the financing of a portion of our research and development expenditures pursuant to the IIA Regulations.

 

As of December 31, 2022, we had received grants from the IIA in the aggregate amount of $1.3 million, and had a contingent obligation to the IIA up to an aggregate amount of approximately $1.4 million (assuming no increase, per the IIA Regulations, as described below). As of December 31, 2022, we paid a minimal amount to the IIA. We may apply for additional IIA grants in the future. However, as the funds available for IIA grants out of the annual budget of the State of Israel are subject to the pre-approval of the IIA and have been reduced in the past and may be further reduced in the future, we cannot predict whether we will be entitled to – or approved for – any future grants, or the amounts of any such grants (if approved).

 

In exchange for these grants, we are required to pay royalties to the IIA of 4% (which may be increased under certain circumstances) from our revenues generated (in any fashion) from knowhow developed using IIA grants, up to an aggregate of 100% (which may be increased under certain circumstances) of the U.S. dollar-linked value of the grant, plus interest at the rate of 12-month LIBOR.

 

The IIA Regulations also require that products developed with IIA grants be manufactured in Israel at a rate (scope) which will not be less than the rate of manufacturing and added value in Israel that were included in the relevant grant applications submitted to the IIA. Furthermore, the IIA Regulations require that the know-how resulting from research and development according to an IIA-approved plan, not being the product developed within the framework of such approved plan, and any right deriving therefrom may not be transferred outside of Israel (including by way of certain licenses), unless prior approval is received from the IIA. We received approval for the transfer of manufacturing of the sleeves outside of Israel. The transfer outside of Israel of manufacturing which is connected with the IIA-funded knowhow will result in a higher royalty repayment rate and may further result in increased royalties (up to three times the aggregate amount of the IIA grants plus interest thereon). Even following the full repayment of any IIA grants, we must nevertheless continue to comply with the requirements of the IIA Regulations. The foregoing restrictions and requirements for payment may impair our ability to transfer or sell our technology assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any IIA-funded know-how outside of Israel.

 

Furthermore, companies that receive IIA funding are generally required to ensure that all rights in the IIA-backed product are retained by them. This means that, generally, all know-how which is derived from the research and development conducted pursuant to an IIA approved plan, and every right derived from it, must be owned by the recipient of the IIA funding from the date such know-how is generated. Companies that receive IIA funding are further subject to reporting requirements and other technical requirements, which are intended to allow the IIA to ensure that the IIA Regulations are being complied with.

 

If we fail to comply with any of the conditions and restrictions imposed by the IIA Regulations, or by the specific terms under which we received the grants, we may be required to refund any grants previously received together with interest and penalties, and, in certain circumstances, may be subject to criminal charges.

 

52
 

 

It may be difficult to enforce a judgment of a U.S. court against us in Israel or the United States to assert U.S. securities laws claims in Israel or to serve process on these experts.

 

Motus GI Medical Technologies Ltd., our wholly owned subsidiary, is incorporated in Israel. Our Israeli experts reside in Israel, and substantially all of our technology and intellectual property assets are located in Israel. Therefore, a judgment obtained against us, or any of such persons, may not be collectible in the United States and may not be enforced by an Israeli court. It also may be difficult for you to affect service of process on such persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws on the grounds that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure would also be governed by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign court.

 

We may become subject to claims for payment of compensation for assigned service inventions by our current or former employees, which could result in litigation and adversely affect our business.

 

Under the Israeli Patents Law, 5727-1967, or the Patents Law, inventions conceived by an employee during the scope of his or her employment are regarded as “service inventions” and are owned by the employer, absent a specific agreement between the employee and employer giving the employee service invention rights. The Patents Law also provides that if no such agreement between an employer and an employee exists, which prescribes whether, to what extent, and on what conditions the employee is entitled to remuneration for his or her service inventions, then such matters may, upon application by the employee, be decided by a government-appointed compensation and royalties committee established under the Patents Law. A significant portion of our intellectual property has been developed by our employees in Israel in the course of their employment. Such employees have agreed to waive and assign to us all rights to any intellectual property created in the scope of their employment with us, and most of our current employees, including all those involved in the development of our intellectual property, have agreed to waive economic rights they may have with respect to service inventions.

 

However, despite such contractual obligations, we cannot assure you that claims will not be brought against us by current or former employees demanding remuneration in consideration for assigned alleged service inventions or any other intellectual property rights. If any such claims were filed, we could potentially be required to pay remuneration to our current or former employees for such assigned service inventions or any other intellectual property rights, or be forced to litigate such claims, which could negatively affect our business.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

Not applicable.

 

ITEM 2. PROPERTIES

 

We currently rent 7,836 square feet of space in Tirat Carmel, Israel. This facility is used for office space as well as laboratories for product development. We entered the lease on January 2015, and the lease was for a period of five-years. Annual rent is $82 thousand per year. The lease was set to expire on December 31, 2019. In July 2019, we exercised the option to extend the lease expiration to December 31, 2022. We entered into a new tenancy contract with the facility for a period of twelve months from January 1, 2023 to December 31, 2023. Rent is approximately $192 thousand for the twelve months.

 

On April 13, 2017, we entered into a lease for a facility in Fort Lauderdale, Florida, which we began occupying in October 2017. On December 20, 2017, we entered into a lease amendment upon remeasurement of the lease space. The facility currently consists of 4,554 square feet, which increased to 6,496 square feet by the second year of the lease. The term runs for seven years and two months from September 2017. Annual base rent was amended to $159 thousand per year, subject to annual increases of 2.75%. This facility is used for office space as well as laboratories for both quality assurance and product development. In January 2020, the Company entered into a license agreement (the “Shared Space Agreement”) with Orchestra BioMed, Inc. (OBIO), formerly a greater than 5% holder of the Company’s common stock and entity in which David Hochman, the Chairman of the Company’s board of directors, serves as the Chairman of the board of directors and Chief Executive Officer, and Darren Sherman, a member of the Company’s board of directors, serves as a director and as President and Chief Operating Officer. Pursuant to the Shared Space Agreement, the Company granted a license to OBIO for the use of portions of the office space not being used by the Company in the Company’s leased facility in Fort Lauderdale, Florida (the “Premises”), and a proportionate share of common areas of such Premises, which previously covered approximately 35% of the Premises and was to expand incrementally to approximately 60 to 70% of the Premises by September 2024. In May 2022, the Company entered into an amendment to the Shared Space Agreement. Pursuant to the amendment, the area covered by the Shared Space Agreement was expanded to 95% of the premises and the aggregate license fees will generally range from approximately $212 thousand to approximately $270 thousand in any given calendar year during the term of the Shared Space Agreement until the termination of the lease in November 2024.

 

We believe our facilities are adequate for our foreseeable needs.

 

ITEM 3. LEGAL PROCEEDINGS

 

We are not currently subject to any material legal proceedings; however, we may from time to time become a party to various legal proceedings arising in the ordinary course of our business. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this report, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

53
 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Market Information

 

Our Common Stock trades on the NASDAQ Capital Market under the symbol “MOTS”. Trading of our Common Stock commenced on February 14, 2018 in connection with our IPO. Prior to that time, there was no established public trading market for our Common Stock.

 

Holders of Record

 

As of February 14, 2023, we had approximately 122 holders of record of our Common Stock. This number does not include beneficial owners whose shares were held in street name. The actual number of holders of our Common Stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees.

 

ITEM 6. RESERVED

 

Not Applicable.

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION.

 

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and the other financial information included elsewhere in this report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this report, particularly those under “Risk Factors.”

 

Overview

 

We have developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the “FDA”) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (“GI”) endoscopy procedures. The Pure-Vu System is also CE marked in the European Economic Area (EEA) for use in colonoscopy. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Through irrigation and evacuation of debris, the Pure-Vu System is designed to provide better-quality exams. Challenges exist for inpatient colonoscopy and endoscopy, particularly for patients who are elderly, with comorbidities, or active bleeds, where the ability to visualize, diagnose and treat is often compromised due to debris, including fecal matter, blood, or blood clots. We believe this is especially true in high acuity patients, like GI bleeding where the existence of blood and blood clots can impair a physician’s view and removing them can be critical in allowing a physician the ability to identify and treat the source of bleeding on a timely basis. We believe use of the Pure-Vu System may lead to positive outcomes and lower costs for hospitals by safely and quickly improving visualization of the colon and upper GI tract, potentially enabling effective diagnosis and treatment without delay. In multiple clinical studies to date, involving the treatment of challenging inpatient and outpatient cases, the Pure-Vu System has consistently helped achieve adequate bowel cleanliness rates greater than 95% following a reduced prep regimen. We also believe that the technology may be useful in the future as a tool to help reduce user dependency on conventional pre-procedural bowel prep regimens. Based on our review and analysis of 2019 market data and 2021 projections for the U.S. and Europe, as obtained from iData Research Inc., we believe that during 2021 approximately 1.5 million inpatient colonoscopy procedures were performed in the U.S. and approximately 4.8 million worldwide. Upper GI bleeds occurred in the U.S. at a rate of approximately 400,000 cases per year in 2019, according to iData Research Inc. The Pure-Vu System has been assigned an ICD-10 code in the US. The system does not currently have unique codes with any private or governmental third-party payors in any other country or for any other use; however, we intend to pursue reimbursement activities in the future, particularly in the outpatient colonoscopy market. We received 510(k) clearance in February 2022 from the FDA for our Pure-Vu EVS System and have commenced initial commercialization of this product. We do not expect to generate significant revenue from product sales until we further expand our commercialization efforts, which is subject to significant uncertainty.

 

In January 2023, we committed to a restructuring initiative designed to position us to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. We have engaged Lake Street Capital to advise us in this process. Potential strategic alternatives that may be considered by us are expected to include an acquisition, merger, reverse merger, other business combination, sale of assets, licensing and other strategic transactions. The restructuring initiative primarily includes the reduction of our workforce. We intend to continue to evaluate and identify other areas of its business to enhance efficiencies and improve processes, with a goal to further lower its operating expenses and capital needs. We have reduced our quarterly cash expenditures by approximately 35% by eliminating approximately 45% of our workforce during the first quarter of 2023. In connection with the restructuring, we expect to incur a non-recurring charge of approximately $1.0 to $2.0 million in the first quarter of 2023.

 

54
 

 

Financial Operations Overview

 

We have generated limited revenues to date from the sale of products. We have never been profitable and have incurred significant net losses each year since our inception, including a loss of $18.6 million for the year ended December 31, 2022, and we expect to continue to incur net operating losses for the foreseeable future. As of December 31, 2022, we had $14.0 million in cash and cash equivalents and an accumulated deficit of $141.4 million. We expect our current spend level to continue in connection with ongoing operating activities, including expenditures in R&D, sales and marketing, clinical affairs and manufacturing. As described above, we committed to a restructuring initiative designed to reduce our expenses and position us to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. In addition, in order to continue to operate as a standalone company, we would need additional financing to support our continuing operations. We also have significant debt under our Loan Agreement with Kreos which could negatively impact our ability to operate or consummate a strategic transaction.

 

 If a strategic transaction is not completed, or if additional financing is not available, we may not be able to service our outstanding indebtedness and our payables and may have to file for bankruptcy protection or pursue a dissolution of the Company and liquidation of all of our remaining assets. In such an event, the amount of cash available for distribution to our stockholders, if any, will depend heavily on the timing of such decision, as with the passage of time the amount of cash available for distribution will be reduced as we continue to fund our operations and service our outstanding indebtedness. We cannot provide assurance as to the amount of cash that will be available to distribute to stockholders, if any, after paying our debts and other obligations and setting aside funds for reserves, nor as to the timing of any such distribution, if any.

 

We continue to seek to fund our operations through public or private equity or debt financings or other sources, which may include collaborations with third parties and evaluating other strategic alternative transactions including an acquisition, merger, reverse merger, other business combination, sale of assets, licensing and other transactions. The sale of equity and convertible debt securities may result in dilution to our shareholders and certain of those securities may have rights senior to those of our common shares. If we raise additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict our operations. Any other third party funding arrangement could require us to relinquish valuable rights. The source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress of our product and clinical development programs as well as commercial activities. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital or execute a strategic transaction as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenues to achieve profitability, and we may never do so. Additionally, the effects of inflation on costs such as labor, freight, and materials as well as the ongoing volatility in the financial markets may negatively affect the financial performance and the liquidity of the business. Furthermore, the potential impact of COVID-19, which continues to evolve, on the operation of our business, related to possible travel advisories and restrictions and production delays, are highly uncertain and cannot be predicted.

 

Critical Accounting Policies and Significant Judgement and Estimates

 

Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

 

While our significant accounting policies are described in more detail in Note 3 to our consolidated financial statements, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.

 

55
 

 

Revenue recognition

 

We generate revenue from the sale or lease of our Pure-Vu System Workstation (“Workstation”) and from the sale of our single-use disposable sleeves (“Disposables”), and related services, which are primarily support and maintenance services on our Workstations. See Note 3 for further discussion of revenue recognition.

 

Sales of our Workstation and Disposables are accounted for in accordance with ASC Topic 606 - Revenue from Contracts with Customers to depict the transfer of control to our customers in an amount reflecting the consideration to which we expect to be entitled to. Revenue from the sale of a Workstation is recognized after a customer commits to purchase the Workstation and the Workstation is delivered, which is when title is transferred. Disposables are identified as a separate performance obligation, and therefore, revenue from the sale of Disposables is recognized when the Disposables are delivered to the customer and title is transferred.

 

For contracts outside the scope of ASC 606, we determine income for proposed supply arrangements with an embedded lease in accordance with ASC 842 and certain components of sales within the proposed supply arrangement in accordance with ASC 606. We allocate the transaction price to the performance obligations within the proposed supply arrangements using the total estimated purchases method for both (i) arrangements that contain minimum purchase commitments and (ii) those arrangements that do not contain a minimum purchase commitment, but instead offer a volume discount for purchases that exceed a specified tier.

 

Inventory

 

Inventory is accounted for at lower of cost and net realizable value using the weighted average cost method. The determination of whether inventory costs will be realizable requires estimates by management. We perform an assessment of the realizability of inventory during each reporting period, including write-downs for potentially obsolete or excess inventory are made based on management’s analysis of inventory levels, historical obsolescence, future sales forecasts, and any changes in the commercial business. We write-down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Inventories that exceed estimated realization for the next twelve months from balance sheet date based on future sales forecasts are classified as long-term assets.

 

Share-based compensation

 

Our share-based compensation programs grant awards that have included stock options, warrants, and restricted stock units. Grants are awarded to employees and non-employees, including directors.

 

We account for our share-based compensation awards in accordance with ASC Topic 718, Compensation—Stock Compensation, or ASC 718. ASC 718 requires all stock-based payments to employees and non-employee directors, including grants of employee stock options and restricted stock units and modifications to existing stock options, to be recognized in the consolidated statements of comprehensive loss based on their fair values.

 

We account for forfeitures as they occur instead of estimating forfeitures at the time of grant and revising those estimates in subsequent periods if actual forfeitures differ from its estimates. Share-based compensation expense recognized in the financial statements is based on awards for which performance or service conditions are expected to be satisfied.

 

Our share-based awards are subject to service or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term.

 

We expense restricted stock unit awards to employees based on the fair value of the award on a straight-line basis over the associated service period of the award.

 

56
 

 

We estimate the fair value of our option awards to employees, directors and non-employees using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to the lack of complete company-specific historical and implied volatility data for the full expected term of the stock-based awards, we base our estimate of expected volatility on a representative group of publicly traded companies in addition to our own volatility data. For these analyses, we selected companies with comparable characteristics to our own, including enterprise value, risk profiles, position within the industry and with historical share price information sufficient to meet the expected life of the stock-based awards. We compute historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available. We have estimated the expected term of our employee stock options using the “simplified” method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of sufficient historical data. The risk-free interest rates for periods within the expected term of the option are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. We have never paid, and do not expect to pay, dividends in the foreseeable future.

 

Contingent Royalty Obligation

 

We estimate and record a contingent royalty obligation at fair value in relation to our royalty obligation, which is payable over the life of certain patents after certain conditions are met. Forecasted revenue over an expected life of the product is the largest driver of the estimated obligation at fair value, with other factors being growth rate, patent expiration assessments, and the discount rate. All these drivers are subject to a high degree of uncertainty which we determine at present based on a very limited-commercialized product.

 

Emerging Growth Company Status

 

Under Section 107(b) of the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

 

Recent Accounting Pronouncements

 

Refer to Note 3, “Significant Accounting Policies and Basis of Presentation”, in the accompanying notes to the consolidated financial statements for a discussion of recent accounting pronouncements.

 

Results of Operations

 

Comparison of Year Ended December 31, 2022 and 2021

 

Revenue

 

As of December 31, 2022, we have generated a limited amount of revenue from the sales of products. We do not expect to generate significant revenue from product sales until we further expand our commercialization efforts for the Pure-Vu EVS System, which is subject to significant uncertainty.

 

Revenue totaled $592.0 thousand for the year ended December 31, 2022, compared to $391.0 thousand for the year ended December 31, 2021. The increase of $201.0 thousand was primarily attributed to sales of the new EVS product launched in 2022.

 

Cost of Revenue

 

Cost of revenue for the year ended December 31, 2022 totaled $796.0 thousand, compared to $624.0 thousand for the year ended December 31, 2021. The increase of $172.0 thousand was primarily attributed to an increase of inventory impairment of $155.0 thousand and by an increase in the cost of the volume sold of our evaluation and commercial units of $17.0 thousand. Cost of revenue, net of impairments for the year ended December 31, 2022 totaled $198.0 thousand, compared to $181.0 thousand, which resulted in a gross profit of 67% and 54% for the year ended December 31, 2022 and 2021, respectively.

 

57
 

 

Research and Development

 

Research and development expenses consist of costs relating to the advancement of our development and clinical programs for the Pure-Vu System. We have research and development capabilities in electrical and mechanical engineering with laboratories in our facility in Israel for development and prototyping, and electronics design and testing. We also use consultants and third-party design houses to complement our internal capabilities.

 

Research and development expenses for the year ended December 31, 2022 totaled $5.6 million, compared to $5.3 million for the year ended December 31, 2021. The increase of $0.3 million was primarily attributable to increases of $0.4 million in payroll and related costs, $0.5 million of clinical trial costs, partially offset by decreases of $0.2 million in share-based compensation and $0.4 million in material costs.

 

Sales and Marketing

 

Sales and marketing expenses consist of costs primarily related to our sales and marketing personnel and infrastructure supporting the commercialization of the Pure-Vu System.

 

Sales and marketing expenses for the year ended December 31, 2022 totaled $4.4 million, compared to $3.1 million for the year ended December 31, 2021. The increase of $1.3 million was primarily attributable to increases of $1.3 million in payroll and related costs, $0.2 million in demonstrational product, $0.2 million in promotional and tradeshow, partially offset by a decrease of $0.3 million in professional services and $0.1 million in share-based compensation.

 

General and Administrative

 

General and administrative expenses consist primarily of costs associated with our overall operations and being a public company. These costs include personnel, legal and financial professional services, insurance, investor relations, and compliance related fees.

 

General and administrative expenses for the year ended December 31, 2022 totaled $7.6 million, compared to $9.3 million for the year ended December 31, 2021. The decrease of $1.7 million was primarily attributed to decreases of $0.4 million in payroll and related costs, $1.4 million in share-based compensation, and $0.2 million in investor and public relation costs, partially offset by an increase of $0.3 million in other general and administrative costs.

 

Other Income and Expenses

 

Other expense, net for the year ended December 31, 2022 totaled $0.7 million compared to other expense, net of $1.1 million for the year ended December 31, 2021. The decrease of $0.4 million in other expense, net was primarily attributable to an increase of $0.5 million in finance expense, offset by an increase of $0.7 million from the gain on the change in estimated fair value of contingent royalty obligation and a $0.2 million decrease in loss on extinguishment of debt extinguishment.

 

Liquidity and Capital Resources

 

To date, we have generated minimal revenues, experienced negative operating cash flows and have incurred substantial operating losses from our activities. We expect operating costs will increase significantly as we incur costs associated with commercialization activities related to the Pure-Vu System. As described above under “—Overview” and “—Financial Operations Overview,” we have adopted a restructuring program in January 2023 intended to reduce our operating costs and other expenses and have commenced a process to evaluate strategic alternatives. If a strategic transaction is not completed, or if additional financing is not available, we may not be able to service our outstanding indebtedness and our payables and may have to file for bankruptcy protection or pursue a dissolution of the company and liquidation of all of our remaining assets. In such an event, the amount of cash available for distribution to our stockholders, if any, will depend heavily on the timing of such decision, as with the passage of time the amount of cash available for distribution will be reduced as we continue to fund our operations and service our outstanding indebtedness. We cannot provide assurance as to the amount of cash that will be available to distribute to stockholders, if any, after paying our debts and other obligations and setting aside funds for reserves, nor as to the timing of any such distribution, if any.

 

In March 2021, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”), under which we may offer and sell from time to time common shares having an aggregate offering price of up to $25.0 million. During the year ended December 31, 2022, we sold approximately 2.2 million shares of our common stock under this agreement, resulting in net cash proceeds of $9.9 million, after deducting issuance costs of $0.4 million. From January 1, 2023 to March 14, 2023, the Company issued and sold approximately 119,104 common shares of our common stock under this agreement, resulting in net cash proceeds of approximately $118.0 thousand, after deducting issuance costs $4.0 thousand.

 

58
 

 

Rising inflation and financial market volatility may adversely impact our ability to enter into, modify, and negotiate favorable terms and conditions relative to equity and debt financing initiatives. The uncertain financial markets, potential disruptions in supply chains, and changing priorities could also affect our ability to enter into key agreements. COVID-19 and government measures taken in response have also had an impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as certain medical services and supplies, have spiked, while demand for other goods and services have fallen. The future progression of the outbreak and its longer-term effects on our business and operations continue to evolve and are still uncertain. We and our third-party contract manufacturers, contract research organizations, and clinical sites may also face disruptions in procuring items that are essential to our research and development activities, including, for example, medical and laboratory supplies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts related to the outbreak in certain parts of the world. These disruptions may negatively impact our sales, results of operations, financial condition, and liquidity into 2023.

 

Our ability to continue as a going concern for the next twelve months from the issuance of our Annual Report on Form 10-K, depends on our ability to execute our business plan, increase revenue and reduce expenditures. As of December 31, 2022, we had cash and cash equivalents of $14.0 million and an accumulated deficit of $141.4 million. Based on our current business plan, we believe our cash and cash equivalents as of December 31, 2022 will be sufficient to meet our anticipated cash requirements into Q2 2023. We will need to raise significant additional capital to continue to fund operations. We may seek to sell common or preferred equity, convertible debt securities or seek other debt financing. In addition, we may seek to raise cash through collaborative agreements or from government grants, as well as evaluate other strategic alternative transactions. The sale of equity and convertible debt securities may result in dilution to our shareholders and certain of those securities may have rights senior to those of our common shares. If we raise additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict our operations. Any other third-party funding arrangement could require us to relinquish valuable rights. The source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress of our product and clinical development programs as well as commercial activities. Funding may not be available when needed, at all, or on terms acceptable to us. Lack of necessary funds may require us, among other things, to delay, scale back or eliminate expenses including those associated with our planned product development, clinical trial and commercial efforts.

 

These factors raise substantial doubt about our ability to continue as a going concern. For more information, refer to Note 2 to our consolidated financial statements included elsewhere in this Annual Report.

 

Cash Flows

 

The following table provides information regarding our cash flows for each of the periods below:

 

   Years Ended December 31, 
   2022   2021 
   (in thousands) 
Net cash used in operating activities  $(17,467)  $(14,422)
Net cash used in investing activities   (224)   (470)
Net cash provided by financing activities   

9,170

    16,636 
Net (decrease) increase in cash and cash equivalents  $(8,521)  $1,744 

 

Operating Activities

 

During the year ended December 31, 2022, operating activities used $17.5 million of cash, due to our net loss of $18.6 million, offset by non-cash expenses principally related to share-based compensation expense of $1.8 million, depreciation and amortization of $0.5 million, amortization of debt issuance costs of $0.3 million, impairment of inventory of $0.6 million, amortization of operating lease right of use asset of $0.3 million and offset by a gain on the change in estimated fair value of contingent royalty obligation of $0.5 million, changes in net working capital items principally related to the decrease in inventory of $1.3 million, and the increase in accounts payable and accrued expenses of $0.7 million.

 

Investing Activities

 

During the year ended December 31, 2022, net cash used in investing activities was $0.2 million related to the purchase of fixed assets.

 

59
 

 

Financing Activities

 

During the year ended December 31, 2022, net cash provided by financing activities was $9.2 million, related to proceeds from issuance of common shares of $10.3 million, offset by repayments under term loans of $0.7 million and equity financing fees of $0.4 million.

 

Shelf Registration Statement

 

On March 16, 2021, we filed a shelf registration statement (File No. 333-254343) with the Securities and Exchange Commission (the “2021 Shelf Registration Statement”), which was declared effective on March 26, 2021, that allows us to offer, issue and sell up to a maximum aggregate offering price of $100.0 million of any combination of our Common Stock, preferred stock, warrants, debt securities, subscription rights and/or units from time to time, together or separately, in one or more offerings. As of December 31, 2022, we have not sold any securities under the 2021 Shelf Registration Statement, except as described below.

 

The 2021 Shelf Registration Statement includes a prospectus registering the at-the-market offering program pursuant to the Equity Distribution Agreement with Oppenheimer, under which we may offer and sell from time to time common shares having an aggregate offering price of up to $25.0 million. During the year ended December 31, 2022, we sold approximately 2.2 million shares of Common Stock pursuant to the above-described Equity Distribution Agreement, resulting in net cash proceeds of $9.9 million, after deducting issuance costs of $0.4 million.

 

Our ability to issue securities is subject to market conditions and other factors including, in the case of our debt securities, our credit ratings. Each issuance under the shelf registration statements will require the filing of a prospectus supplement identifying the amount and terms of the securities to be issued.

 

Contractual Obligations and Commitments

 

For Operating Leases and Other Commitments

 

For further information, refer to Note 5 and Note 7 of the Notes to the Consolidated Financial Statements included in Pages F-15 through F-17 of this Annual Report on Form 10-K.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, we are not required to provide the information required by this item.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

The consolidated financial statements required to be filed pursuant to this Item 8 are found on pages F-1 through F-25.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

60
 

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2022.

 

Management’s Annual Report on Internal Control Over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on criteria established in the framework in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the results of this evaluation, management has concluded that our internal control over financial reporting was effective at the reasonable assurance level as of December 31, 2022.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm because we are an “emerging growth company,” and may take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act.

 

Changes in Internal Control over Financial Reporting

 

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended December 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 9B. OTHER INFORMATION

 

None.

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

 

Not applicable.

 

61
 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

The following sets forth certain information with respect to our officers and directors.

 

Name   Age   Position(s)
Timothy P. Moran   51   Chief Executive Officer and Director
Mark Pomeranz   61   President, Chief Operating Officer and Director
Andrew Taylor   52   Chief Financial Officer
David Hochman   47   Chairman of the Board
Darren Sherman   51   Director
Shervin Korangy   48   Director
Gary J. Pruden   61   Director
Sonja Nelson   49   Director

 

Management

 

Timothy P. Moran, Chief Executive Officer and Director

 

Mr. Moran has served as Chief Executive Officer since October 1, 2018. Prior to joining us, from 2015 to September 2018, Mr. Moran served as President of the Americas, ConvaTec Group Plc (LON: CTEC) (“ConvaTec”), an international medical products and technologies company, offering products and services in the areas of wound and skin care, ostomy care, continence and critical care and infusion devices. Prior to his employment at ConvaTec, Mr. Moran held roles in sales, marketing and general management over the course of eighteen years at Covidien plc (“Covidien”), an Irish-headquartered global health care products company and manufacturer of medical devices and supplies. While at Covidien, until 2015, Mr. Moran served simultaneously as VP and General Manager of both the SharpSafety and Monitoring & Operating Room divisions. Following the 2015 acquisition of Covidien by Medtronic (NYSE:MDT), Mr. Moran was named the Global Vice President and General Manager of the Patient Care and Safety Division. Mr. Moran also served on the CEO Advisory Council for Advanced Medical Technology Association (AdvaMed), a medical device trade association. Mr. Moran earned a B.A. in Organizational Communication at The State University of New York at Geneseo. Mr. Moran was selected as a director because of his broad commercial experience and leadership in the medical technology sector.

 

Mark Pomeranz, President, Chief Operating Officer and Director

 

Mr. Pomeranz has served as Chief Operating Officer since September 24, 2018. Prior to his tenure as our Chief Operating Officer, Mr. Pomeranz served as our Chief Executive Officer from December 2016 through September 2018, and as the Chief Executive Officer of Motus GI Medical Technologies Ltd., our wholly owned subsidiary, from 2014 through September 2018. Prior to joining Motus GI Medical Technologies Ltd., from 2008 to 2014, Mr. Pomeranz was the founding CEO of Svelte Medical Systems, a start-up company that is currently commercializing a unique drug eluting stent platform. From 2007 to 2008 Mr. Pomeranz was the Vice President of Research and Development at Prescient Medical, Inc. From 1998 to 2007, Mr. Pomeranz served as Vice President at Cordis, a Johnson& Johnson Company, where his responsibilities included developing new technologies, exploring new market opportunities and leading major restructuring efforts to create cross-functional global commercialization teams. Prior to that, Mr. Pomeranz held a number of senior leadership roles, including positions at Cardiac Pathways Corporations from 1991 to 1998, and Cardiovascular Imaging Systems from 1989 to 1991, both of which were acquired by Boston Scientific Corporation. Mr. Pomeranz earned a M.Sc. in biomedical engineering from the University of Miami. Mr. Pomeranz was selected as a director due to his history as a director of Motus GI Medical Technologies Ltd. and his business and leadership experience in the medical technology sector; his broad scientific background is also seen as an asset to us.

 

62
 

 

Andrew Taylor, Chief Financial Officer

 

Mr. Taylor has served as our Chief Financial Officer since August 2017. Prior to joining us, Mr. Taylor served as the CFO and President of Angel Medical Systems from 2007 until 2017 and has served on the board of directors of Angel Medical Systems, Inc. since 2017. Angel Medical Systems is a medical device company that develops and manufactures ischemia monitoring and alerting systems. While at Angel Medical Systems, Mr. Taylor supervised the majority of the operations and employees in the United States and Brazil, while also overseeing the financial planning and analysis activities, capital raise and licensing efforts, and implementation of capital and operating budgets. From 2005 to 2007, Mr. Taylor was a Practice Leader for AC Lordi Consulting (now part of BDO USA, LLP), where he oversaw staff providing CFO and Controller consulting services. Prior to that, Mr. Taylor was the CFO of Safe3w, Inc. from 2001 to 2005 until its acquisition by iPass, Inc., where he led all accounting and finance functions as well as the fundraising efforts, and negotiated the sale of the company. From 1999 to 2001, Mr. Taylor served as the Vice President of Finance and Administration of Abridge, Inc., where he developed and managed processes for budgeting, forecasting and cash management. Prior to that, Mr. Taylor was a Senior Finance Associate at Delta Air Lines (NYSE: DAL), from 1998 to 1999. Mr. Taylor earned a B.A. in Political Science and Economics at McGill University and his MBA in Finance at Northeastern University, and is CFA Program Level II Candidate.

 

On December 31, 2018, Angel Medical Systems, Inc. filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). On February 11, 2019, the conditions of the Chapter 11 Plan of Reorganization (the “Bankruptcy Plan”) for Angel Medical Systems, Inc. were confirmed by the Bankruptcy Court. On March 29, 2019, the Bankruptcy Plan became effective and Angel Medical Systems, Inc. emerged from its Chapter 11 reorganization as a private company.

 

Directors

 

Timothy P. Moran, Chief Executive Officer and Director

 

See description under Management.

 

Mark Pomeranz, President, Chief Operating Officer and Director

 

See description under Management.

 

David P. Hochman, Chairman of the Board

 

Mr. Hochman has served as the Chairman of our board of directors since 2016, and as Chairman of the Board of Motus GI Medical Technologies Ltd., our wholly owned subsidiary, since 2011. Since January 2023, he has been Chairman and Chief Executive Officer of Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO), the parent company of Orchestra BioMed, Inc., a biomedical innovation company focused on bringing high-impact procedure-based therapeutic innovations to life through risk-reward sharing partnerships, which he founded and of which he has served as Chairman and Chief Executive Officer since May 2018. From 2006 until 2019, he served as Managing Partner of Orchestra Medical Ventures, LLC, an investment firm that employed a strategy to create, build and invest in medical technology companies intended to generate substantial clinical value. Mr. Hochman has also served as President of Accelerated Technologies, Inc., a medical device accelerator company previously managed by Orchestra Medical Ventures, LLC, and now a wholly owned subsidiary of Orchestra BioMed, Inc. Mr. Hochman has over twenty-four years of medical innovation, entrepreneurial, venture capital and investment banking experience. He was a co-founder of Caliber Therapeutics, Inc., a wholly owned subsidiary of Orchestra BioMed, Inc., and was on the Board of Caliber Therapeutics, Inc. from 2009 until 2018. He was a co-founder of BackBeat Medical, Inc., a wholly owned subsidiary of Orchestra BioMed, Inc., and served as its President and a member of its Board since inception in 2010 until 2018. He was a co-founder of FreeHold Surgical, Inc., a wholly owned subsidiary of Orchestra BioMed, Inc., and served as a member of its Board from 2011 until 2018. Mr. Hochman served as a board member of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, from 2013 until 2020. He also served as a director of Adgero Biopharmaceuticals Holdings, Inc until 2020 when it was acquired by Kintara Therapeutics, Inc. (NASDAQ: KTRA). Prior to joining Orchestra Medical Ventures LLC, Mr. Hochman was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on development stage healthcare companies. He was also Managing Director of Spencer Trask Ventures, Inc. during which time he led financing transactions for over twenty early-stage companies. From 1999 to 2006 Mr. Hochman was a board advisor of Health Dialog Services Corporation, a leader in collaborative healthcare management that was acquired in 2008 by the British United Provident Association. From 2005 to 2007, he was a co-founder and board member of PROLOR Biotech, Inc., a biopharmaceutical company developing longer lasting versions of approved therapeutic proteins, which was purchased by Opko Health (NYSE: OPK) in 2013. He is also President and a Board Member of the Mollie Parnis Livingston Foundation, a family foundation. He has a B.A. degree with honors from the University of Michigan. Mr. Hochman was selected as a director due to his history as a director of Motus GI Medical Technologies Ltd., our wholly owned subsidiary, his leadership experience at other public companies, including medical technology companies, his financial experience and his expertise in governance matters.

 

63
 

 

Darren Sherman, Director

 

Mr. Sherman has been a director of Motus GI Medical Technologies Ltd., our wholly owned subsidiary, since 2011 and has served on our board of directors since December 2016. Since May 2018, Mr. Sherman has been President, Chief Operations Officer and a member of the Board of Directors of Orchestra BioMed Holdings, Inc., (NASDAQ: OBIO)., a biomedical innovation company focused on bringing high-impact procedure-based therapeutic innovations to life through risk-reward sharing partnerships. Mr. Sherman has over 27 years of management and entrepreneurial experience in the medical technology industry spanning interventional cardiology, cardiac electrophysiology, sudden cardiac death, stroke, surgery, GI, and neurovascular therapies. From 2009 until December 2019, Mr. Sherman served as Managing Partner of Orchestra Medical Ventures, LLC, an investment firm that employed a strategy to create, build and invest in medical technology companies intended to generate substantial clinical value. Mr. Sherman has also served as Chief Technical Officer of Accelerated Technologies, Inc. (ATI), a medical device accelerator company managed by Orchestra Medical Ventures, LLC, from 2008 to 2019, and now a wholly owned subsidiary of Orchestra BioMed, Inc. From 2009 until March 2018, Mr. Sherman served as Chief Executive Officer and a director of Caliber Therapeutics, Inc., from 2012 until March 2019 served as Chief Executive Officer and a director of FreeHold Surgical, Inc., and from 2009 until March 2019 he served as a director of BackBeat Medical, Inc., each of which entities are now wholly owned subsidiary of Orchestra BioMed, Inc.. From 2009 until 2016, he served on the board of directors of Vivasure Medical Limited, a medical device company based in Galway, Ireland. Prior to joining Orchestra Medical Ventures, LLC, from February 2002 until March 2008, Mr. Sherman held various positions in executive management for Cordis Neurovascular (CNV), a Johnson & Johnson company, including Executive Director R&D and Director of Strategic Marketing for stroke products. From January 1997 until February 2002, Mr. Sherman played an integral role in the formation and development of Revivant Corp (acquired by Zoll Medical Corporation) while working at Fogarty Engineering. He was Revivant Corp’s first employee and managed the design, development, and testing of the AutoPulse device from concept through market introduction. From January 1995 until January 1997, Mr. Sherman held positions in research and development for Cardiac Pathways Corp., prior to its acquisition by Boston Scientific. Prior to Cardiac Pathways Corp., he worked at Baxter Healthcare. In each of these companies, he participated in the creation, development and launch of products. Mr. Sherman has authored more than ninety U.S. patents and has over one-hundred additional published applications. He earned a BS degree in Bioengineering from the University of California, San Diego. Mr. Sherman was selected as a director due to his history as a director of Motus GI Medical Technologies Ltd., our wholly owned subsidiary, and his leadership experience at other companies, including medical technology companies.

 

Shervin J. Korangy, Director

 

Mr. Korangy has served on our board of directors since March 2017. Mr. Korangy also serves as the President and Chief Executive Officer of BVI Medical, Inc., a leading global developer, manufacturer and marketer of specialized surgical devices for the ophthalmic marketplace. Prior to his appointment as CEO of BVI, he served as the Chief Financial Officer and Head of Strategy of BVI. From 2012 to 2017, Mr. Korangy served in various country General Management roles for Novartis Group AG (NYSE: NVS), a global healthcare company, where he worked with medical device, pharmaceutical and consumer health product segments. Prior to that, while part of Novartis Group AG from 2010 to 2012, Mr. Korangy was the Global Head of Corporate Finance, where he was responsible for global M&A, strategy, integrations, BD&L and portfolio planning. He served on the Novartis Finance Leadership Team and the Global Deal Committee. From 1996 to 2010, Mr. Korangy worked in the Private Equity and Restructuring Advisory divisions of the Blackstone Group (NYSE: BX), where he most recently was a Managing Director. Mr. Korangy is a current member of the Board of Directors (and Chairman of the strategy committee and member of the audit committee) of The Hain Celestial Group (NASDAQ: HAIN), a leading organic and natural products company. Mr. Korangy has also served on the Advisory Board of the McNulty Center for Leadership and Change Management at The Wharton School of the University of Pennsylvania, since January 2019. Mr. Korangy is a former member of the Board of Directors of Pelican Rouge, a consumer coffee manufacturer and vending business, Ultra Music, an electronic and dance music record label, Graham Packaging, a manufacturer and distributer of custom plastic containers for consumer product companies, Pinnacle Foods (NYSE: PF), a consumer packaged foods manufacturer and distributor and Bayview Financial, an asset manager and loan servicer. Mr. Korangy received his B.S. degree in economics at the Wharton School of the University of Pennsylvania. Mr. Korangy was selected as a director due to his board experience, his management experience with medical device, pharmaceutical and consumer health products, and his financial and accounting experience.

 

64
 

 

Gary J. Pruden, Director

 

Mr. Pruden has served on our board of directors since December 2017. Prior to joining us, from 1985 until 2017, Mr. Pruden held a number of senior commercial leadership positions across both the medical devices and pharmaceutical sectors of Johnson & Johnson (NYSE: JNJ). In April 2004, he became President of the Johnson & Johnson subsidiary, Janssen-Ortho Inc. in Canada. In January 2006, Mr. Pruden was appointed Worldwide President of Ethicon, Inc., a Johnson & Johnson subsidiary, and in 2009 became the Company Group Chairman of Ethicon, Inc. In 2012, he was named Worldwide Chairman of Johnson & Johnson’s Global Surgery Group and in 2015 he became Worldwide Chairman in the Medical Devices division. In April 2016, Mr. Pruden became a member of the Executive Committee at Johnson & Johnson where his official title was Executive Vice President, Worldwide Chairman, Medical Devices. Mr. Pruden also served in several capacities with the Advanced Medical Technology Association (AdvaMed), a medical device trade association, where he participated in negotiations with the FDA. While at AdvaMed Mr. Pruden served as a member of the Board of Directors, as Chair of the AdvaMed Regulatory Committee, and as a member of the AdvaMed Executive Committee. Mr Pruden serves as an independent board member for Olympus Corporation, (OTCMKTS: OCPNY) (and serves as a member of its compensation committee), Lantheus Holdings, Inc. (NASDAQ: LNTH) (and serves as a member of its Audit committee and the chair of its Compensation committee), OSSIO Inc, and Avisi Technologies Inc. Mr. Pruden received his B.S. degree in finance at Rider University, where he later served on the Board of Trustees from 2011 until 2015. Mr. Pruden was selected as a director due to his global management and regulatory experience with medical device and pharmaceutical products and his financial experience in leading a large business.

 

Sonja Nelson, Director

 

Ms. Nelson has served on our board of directors since June 2021. In June 2021, Ms. Nelson began serving as the Chief Financial Officer of Ambrx Biopharma, Inc, (NYSE: AMAM ) and beginning October 2022, as the company’s Chief Financial and Operating Officer. Prior to that, Ms. Nelson, served as the Senior Vice President, Finance, of ImmunityBio, Inc. (NASDAQ: IBRX), from March 2021 to June 2021. Ms. Nelson served as the Chief Financial Officer of NantKwest, Inc. from June 2018 to March 2021, at which time NantKwest, Inc. merged with ImmunityBio, Inc. (NASDAQ: IBRX). Ms. Nelson previously served as the Chief Accounting Officer of NantKwest, Inc. from May 2016 to June 2018 and as the VP/Corporate Controller of NantKwest, Inc. from November 2015 to May 2016. Ms. Nelson also served as a director of Inex Bio (a subsidiary of NantKwest, Inc., now merged with ImmunityBio, Inc. (NASDAQ: IBRX)) from October 2017 to June 2021. Prior to joining NantKwest, Inc., Ms. Nelson was Vice President and Corporate Controller at AltheaDx, Inc. from July 2014 through October 2015. Previously, Ms. Nelson was Senior Director and Controller at Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt plc) from May 2012 through June 2014. Prior to that, Ms. Nelson was Director, General Accounting at Cricket Communications, Inc. (acquired by AT&T, Inc.) from September 2008 through May 2012. Ms. Nelson began her career with KPMG LLP, holds a Bachelor’s degree in business administration with specialization in taxation and auditing from the University of Applied Sciences in Pforzheim, Germany, and is a Certified Public Accountant. Ms. Nelson was selected as a director due to her management experience with pharmaceutical and consumer health products, and her financial and accounting experience.

 

Family Relationships

 

There are no family relationships among any of the members of our board of directors or executive officers.

 

Code of Business Conduct and Ethics

 

We have adopted a written code of business conduct and ethics that applies to our employees, officers and directors. A current copy of our code is posted on the Corporate Governance section of our website, which is located at www.motusgi.com. We intend to disclose future amendments to certain provisions of our code of business conduct and ethics, or waivers of such provisions applicable to any principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, and our directors, on our website identified above or in filings with the SEC.

 

65
 

 

Committees of the Board of Directors

 

Our board of directors has established an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee. Our board of directors may establish other committees to facilitate the management of our business. The composition and functions of each committee are described below. Members serve on these committees until their resignation or until otherwise determined by our board of directors. Each of these committees operates under a charter that has been approved by our board of directors, which are available on our website.

 

Audit Committee. Our Audit Committee consists of Ms. Nelson, Mr. Pruden and Mr. Sherman, with Ms. Nelson serving as the Chairman of the Audit Committee. Our board of directors has determined that the three directors currently serving on our Audit Committee are independent within the meaning of the NASDAQ Marketplace Rules and Rule 10A-3 under the Exchange Act. In addition, our board of directors has determined that Ms. Nelson qualifies as an audit committee financial expert within the meaning of SEC regulations and The NASDAQ Marketplace Rules.

 

The Audit Committee oversees and monitors our financial reporting process and internal control system, reviews and evaluates the audit performed by our registered independent public accountants and reports to the board of directors any substantive issues found during the audit. The Audit Committee is directly responsible for the appointment, compensation and oversight of the work of our registered independent public accountants. The Audit Committee reviews and approves all transactions with affiliated parties.

 

Compensation Committee. Our Compensation Committee consists of Mr. Hochman, Mr. Pruden and Mr. Korangy, with Mr. Hochman serving as the Chairman of the Compensation Committee. Our board of directors has determined that the three directors currently serving on our Compensation Committee are independent under the listing standards, are “non-employee directors” as defined in rule 16b-3 promulgated under the Exchange Act and are “outside directors” as that term is defined in Section 162(m) of the Internal Revenue Code of 1986, as amended.

 

The Compensation Committee provides advice and makes recommendations to the board of directors in the areas of employee salaries, benefit programs and director compensation. The Compensation Committee also reviews and approves corporate goals and objectives relevant to the compensation of our President, Chief Executive Officer, and other officers and makes recommendations in that regard to the board of directors as a whole.

 

Nominating and Corporate Governance Committee. Our Nominating and Corporate Governance Committee consists of Mr. Sherman, Mr. Pruden, and Mr. Korangy, with Mr. Sherman serving as the Chairman of the Nominating and Corporate Governance Committee. The Nominating and Corporate Governance Committee nominates individuals to be elected to the board of directors by our stockholders. The Nominating and Corporate Governance Committee considers recommendations from stockholders if submitted in a timely manner in accordance with the procedures set forth in our bylaws and will apply the same criteria to all persons being considered. All members of the Nominating and Corporate Governance Committee are independent directors as defined under the NASDAQ listing standards.

 

ITEM 11. EXECUTIVE COMPENSATION

 

Summary Compensation Table

 

The following table shows the compensation awarded to or earned by our principal executive officer during the fiscal year ended December 31, 2022, our two other most highly compensated executive officers who were serving as executive officers as of December 31, 2022, and up to two additional individuals for whom disclosure would have been provided but for the fact that the individual was not serving as an executive officer as of December 31, 2022. The persons listed in the following table are referred to herein as the “named executive officers”.

 

66
 

 

Name and Principal Position  Year   Salary
($)		   Bonus
($)		   Stock
Awards
($) (2)		   Option
Awards
($) (1)		   All Other
Compensation
($)		   Total
($)		 
Timothy P. Moran   2022    475,000    -    79,398    79,398    49,803(3)   683,599 
Chief Executive Officer   2021    475,000    265,050    250,980    202,758    47,282(3)   1,241,070 
                                    
Mark Pomeranz   2022    385,000    -    43,102    43,092    44,311(3)   515,505 
President and Chief Operating Officer   2021    385,000    229,025    115,700    93,470    34,837(3)   858,032 
                                    
Andrew Taylor   2022    330,000    -    43,102    43,092    49,803(3)   465,997 
Chief Financial Officer   2021    310,000    115,320    106,800    86,280    42,332(3)   660,732 

 

(1) Amounts reflect the grant date fair value of option awards granted in 2022 and 2021 in accordance with Accounting Standards Codification Topic 718. For information regarding assumptions underlying the valuation of equity awards, see Note 11 to our Consolidated Financial Statements and the discussion under “Part II—Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operation” included in this report. These amounts do not correspond to the actual value that may be received by the named executive officers if the stock options are exercised.
(2) Amounts reflects the grant date fair value of stock awards granted in 2022 and 2021 computed in accordance with Accounting Standards Codification Topic 718. For information regarding assumptions underlying the valuation of equity awards, see Note 11 to our Consolidated Financial Statements.
(3) Amounts relate to corporate and health benefits and 401K employer match.

 

Narrative Disclosure to Summary Compensation Table

 

Employment Agreements with Our Named Executive Officers

 

We entered into an employment agreement with Mr. Moran, which became effective on October 1, 2018, on an at-will basis, which contains non-disclosure and invention assignment provisions. Under the terms of Mr. Moran’s employment agreement, he holds the position of Chief Executive Officer and receives a base salary of $475,000 annually (the “Base Salary”). In addition, Mr. Moran is eligible to receive an annual bonus payment (the “Performance Bonus”) in an amount equal to up to sixty percent (60%) of his then-Base Salary (the “Bonus Target”) if our board of directors determines that he has met the target objectives communicated to him. For the first twelve months of his employment (the period from October 1, 2018 through October 1, 2019), the payout range for the Performance Bonus is between fifty percent (50%) and two hundred percent (200%) of the Bonus Target if our board of directors determines the objectives have been achieved. Thereafter, subsequent payout parameters will be determined by our board of directors based upon parameters set by our board of directors and Mr. Moran for an overall executive bonus program using market data and analysis input from a third-party expert compensation firm.

 

In connection with his employment agreement, Mr. Moran was granted (i) an option, granted on November 8, 2018 to purchase 24,750 shares (the “Initial Option Grant”) of our Common Stock pursuant to the our 2016 Equity Incentive Plan (the “Plan”), at an exercise price equal to $75.60 per share and (ii) a restricted stock unit award, granted on February 13, 2019, for 8,250 shares of Common Stock pursuant to the Plan (the “Initial Restricted Stock Unit Award”). The Initial Option Grant vests in substantially equal quarterly installments over three years commencing from October 1, 2018, subject to Mr. Moran’s continued employment by us. The Initial Restricted Stock Unit Award vests in substantially equal quarterly installments over four years commencing from October 1, 2018, subject to Mr. Moran’s continued employment by us. The stock option grant agreement and restricted stock unit award agreements include terms and conditions set forth in our standard forms of such agreements under the Plan. In addition, pursuant to the terms of his employment agreement, Mr. Moran is eligible to receive, from time to time, equity awards under the Plan, or any other equity incentive plan we may adopt in the future, and the terms and conditions of such awards, if any, will be determined by our board of directors or Compensation Committee, in their discretion. Mr. Moran is also eligible to participate in any executive benefit plan or program we adopt. Further, Mr. Moran received employment buy-out payments (the “Employment Buy-Out Payments”) in the amount of $400,000 each on March 1, 2019, November 1, 2019, March 1, 2020 and November 1, 2020.

 

67
 

 

In the event of death, termination due to disability, termination by us for cause or by Mr. Moran without good reason, Mr. Moran will be entitled to: (i) the amount of his earned, but unpaid salary, prior to the effective date of termination; (ii) reimbursement for any expenses incurred through the effective date of termination; and (iii) any vested amount or benefit as of the effective date of termination. In addition, in the event of death or termination due to disability Mr. Moran will be entitled to the Employment Buy-Out Payments in accordance with the schedule described above. In the event of termination by us without cause or by Mr. Moran for good reason, Mr. Moran will be entitled to receive: (i) the amount of his earned, but unpaid salary, prior to the effective date of termination; (ii) reimbursement for any expenses incurred through the effective date of termination; (iii) any vested amount or benefit as of the effective date of termination; (iv) other than in the event of a termination within twelve months of a change in control, payment as severance twelve months of his Base Salary, or if Mr. Moran is terminated within twelve months of a change in control, payment as severance eighteen months of his Base Salary; (v) other than in the event of a termination within twelve months of a change in control, payment of our portion of the cost of COBRA coverage for twelve months, or if Mr. Moran is terminated within twelve months of a change in control, payment of our portion of the cost of COBRA coverage for eighteen months; (vi) any unpaid portion of the Employment Buy-Out Payments in accordance with the schedule described above; (vii) any earned but unpaid Performance Bonus that relates to the calendar year prior to the calendar year in which termination occurs; and (viii) other than in the event of a termination within twelve months of a change in control, accelerated vesting of any options that otherwise would have vested within twelve months of the termination date, or if Mr. Moran is terminated within twelve months of a change in control, accelerated vesting of all outstanding options.

 

On September 24, 2018, we entered into an amended and restated employment agreement with Mark Pomeranz, pursuant to which Mr. Pomeranz transitioned from his previous role as President and Chief Executive Officer, into the role of President and Chief Operating Officer as of October 1, 2018.

 

The amended and restated employment agreement with Mr. Pomeranz became effective on September 24, 2018, provides for employment on an at-will basis, and contains non-disclosure and invention assignment provisions. Under the terms of the amended and restated employment agreement, Mr. Pomeranz holds the position of President and Chief Operating Officer, and receives a base salary of $385,000 annually (the “Pomeranz Base Salary”). In addition, Mr. Pomeranz is eligible to receive (i) for the calendar year ending December 31, 2018, a bonus payment in an amount equal to up to thirty one and one quarter percent (31.25%) (the “2018 Bonus Target”) of his then base salary (the “2018 Bonus”) if our board of directors determines that he has met the target objectives communicated to him, with a payout range for the 2018 Bonus of between fifty percent (50%) and two hundred percent (200%) of the 2018 Bonus Target, and (ii) effective January 1, 2019 and thereafter an annual bonus payment (the “Pomeranz Performance Bonus”) in an amount equal to up to fifty percent (50%) of the Pomeranz Base Salary if our board of directors determines that he has met the target objectives communicated to him. Payout parameters for the Pomeranz Performance Bonus will be determined by our board of directors based upon parameters set by our board of directors and CEO for an overall executive bonus program using market data and analysis input from a third-party expert compensation firm. In May 2017, pursuant to his original employment agreement, Mr. Pomeranz received a grant of options to purchase up to 25,555 shares of our Common Stock pursuant to our Equity Incentive Plan with an exercise price of $100.00 per share, of which fifty-three percent (53%) were fully vested when issued, forty percent (40%) vest in a series of twelve (12) successive equal quarterly installments upon the completion of each successive calendar quarter of active service over the three (3) year period measured from the date of grant, as was determined by the Compensation Committee of our board of directors, and seven percent (7%) will not become fully vested until December 22, 2019. This option was repriced to $90.00 per share in September 2017. Pursuant to the terms of the amended and restated employment agreement, Mr. Pomeranz is also eligible to receive, from time to time, equity awards under our existing equity incentive plan, or any other equity incentive plan we may adopt in the future, and the terms and conditions of such awards, if any, will be determined by our board of directors or Compensation Committee, in their discretion. Mr. Pomeranz is also eligible to participate in any executive benefit plan or program we adopt.

 

In the event of termination for cause, or if Mr. Pomeranz terminates voluntarily, Mr. Pomeranz is entitled to: (i) his unpaid salary through and including the date of termination; (ii) any vested amount or benefit; and, (iii) reimbursement of business expenses. In the event of death, termination due to disability, termination without cause, or if Mr. Pomeranz terminates for good reason, Mr. Pomeranz will be entitled to: (i) his unpaid salary through and including the date of termination; (ii) any vested amount or benefit; (iii) reimbursement of business expenses; (iv) payment as severance twelve months of his base salary; (v) payment of the Company’s portion of the cost of COBRA coverage for twelve months; (vi) any earned but unpaid 2018 Bonus or Pomeranz Performance Bonus that relates to the calendar year prior to the calendar year in which termination occurs; and (vii) other than in the event of a termination within twelve months of a change in control, 25% of any unvested options will vest upon termination, or if Mr. Pomeranz is terminated within twelve months of a change in control, accelerated vesting of all outstanding options.

 

68
 

 

On March 26, 2019, we entered into an amended and restated employment agreement with Andrew Taylor, our Chief Financial Officer.

 

The amended and restated employment agreement with Mr. Taylor became effective on March 26, 2019, as subsequently amended on March 15, 2021, provides for employment on an at-will basis, and contains non-disclosure and invention assignment provisions. Under the terms of the amended and restated employment agreement, Mr. Taylor holds the position of Chief Financial Officer, and receives a base salary of $330,000 annually (the “Taylor Base Salary”). In addition, Mr. Taylor is eligible to receive, for any bonus period subsequent to December 31, 2019, an annual bonus payment (the “Taylor Performance Bonus”) in an amount equal to up to forty percent (40%) of the Taylor Base Salary if our board of directors determines that he has met the target objectives communicated to him. Payout parameters for the Taylor Performance Bonus will be determined by our board of directors based upon parameters set by our board of directors and CEO for an overall executive bonus program using market data and analysis input from a third-party expert compensation firm. In September 2017, pursuant to his original employment agreement, Mr. Taylor received a grant of options to purchase up to 12,000 shares of our Common Stock pursuant to our Equity Incentive Plan with an exercise price of $90.0 per share, which vests in a series of twelve (12) successive equal quarterly installments upon the completion of each successive calendar quarter of active service over the three (3) year period measured from the date of grant, as determined by the Compensation Committee of our board of directors. Pursuant to the terms of the amended and restated employment agreement, Mr. Taylor is also eligible to receive, from time to time, equity awards under our existing equity incentive plan, or any other equity incentive plan we may adopt in the future, and the terms and conditions of such awards, if any, will be determined by our board of directors or Compensation Committee, in their discretion. Mr. Taylor is also eligible to participate in any executive benefit plan or program we adopt.

 

In the event of termination for cause, or if Mr. Taylor terminates voluntarily, Mr. Taylor is entitled to: (i) his unpaid salary through and including the date of termination; (ii) any vested amount or benefit; and, (iii) reimbursement of business expenses. In the event of death, termination due to disability, termination without cause, or if Mr. Taylor terminates for good reason, Mr. Taylor will be entitled to: (i) his unpaid salary through and including the date of termination; (ii) any vested amount or benefit; (iii) reimbursement of business expenses; (iv) payment as severance twelve months of his base salary; (v) payment of the Company’s portion of the cost of COBRA coverage for twelve months; (vi) any earned but unpaid Taylor Performance Bonus that relates to the calendar year prior to the calendar year in which termination occurs; and (vii) other than in the event of a termination within twelve months of a change in control, 25% of any unvested options will vest upon termination, or if Mr. Taylor is terminated within twelve months of a change in control, accelerated vesting of all outstanding equity awards.

 

The employment agreements with Israeli employees of Motus GI Medical Technologies Ltd., our wholly owned subsidiary, contain standard provisions for a company in our industry regarding non-competition, confidentiality of information and assignment of inventions. The enforceability of covenants not to compete in Israel is subject to limitations. For example, Israeli courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy of a company’s confidential commercial information or its intellectual property.

 

69
 

 

Outstanding Equity Awards at Fiscal Year-End Table – 2022

 

The following table summarizes, for each of the named executive officers, the number of shares of our Common Stock underlying outstanding stock options held as of December 31, 2022.

 

   Option Awards  Stock Awards 
   Number of Securities Underlying Unexercised Options   Option Exercise   Option
Expiration		  Number of Shares or Units of Stock That Have Not   Market Value of Shares or Units of Stock That Have Not 
Name  Exercisable   Unexercisable   Price ($)   Date  Vested   Vested ($) 
                        
Timothy P. Moran (CEO)   24,749    -   $75.60(1)  November 8, 2028   9,970(9)   8,375 
    1,446    -   $86.40(2)  February 13, 2029          
    4,500    685   $43.20(3)  February 6, 2030          
    10,000    -   $23.40(4)  June 11, 2030          
    9,500    -   $14.80(5)  November 11, 2030          
    4,112    2,937   $35.60(11)  February 17, 2031          
    2,187    6,563    9.20(12)  February 10, 2032          
                             
Mark Pomeranz (COO)   3,361    -   $47.60(6)  April 2, 2024   5,220(10)   4,385 
    25,555    -   $90.00(7)  May 3, 2027          
    6,431    -   $86.40(2)  February 13, 2029          
    1,848    168   $43.20(3)  February 6, 2030          
    4,000    -   $23.40(4)  June 11, 2030          
    3,750    -   $14.80(5)  November 11,2030          
    1,893    1,356   $35.60(11)  February 17, 2031          
    1,187    3,562   $9.20(12)  February 10, 2032          
                             
Andrew Taylor (CFO)   11,999    -   $90.00(8)  September 29, 2027   5,089(10)   4,275 
    3,537    -   $86.40(2)  February 13, 2029          
    2,112    192   $43.20(3)  February 6, 2030          
    4,500    -   $23.40(4)  June 11, 2030          
    3,900    -   $14.80(5)  November 11, 2030          
    1,750    1,250    35.60(11)  February 17, 2031          
    1,185    3,564   $9.20(12)  February 10, 2032          

 

(1) Represents options to purchase shares of our Common Stock granted on November 8, 2018 with an exercise price of $75.60 per share. The shares underlying the option vest in a series of twelve (12) successive equal quarterly installments commencing on October 1, 2018 and continuing on the first day of each third month thereafter.
(2) Represents options to purchase shares of our Common Stock granted on February 13, 2019 with an exercise price of $86.40 per share. The shares underlying the option vest in a series of twelve (12) successive equal quarterly installments commencing on May 1, 2019 and continuing on the first day of each third month thereafter.
(3) Represents options to purchase shares of our Common Stock granted on February 6, 2020 with an exercise price of $43.20 per share. The shares underlying the option vest in a series of twelve (12) successive equal quarterly installments commencing on May 1, 2020 and continuing on the first day of each third month thereafter.
(4) Represents options to purchase shares of our Common Stock granted on June 11, 2020 with an exercise price of $23.40 per share. The shares underlying the option vest on the first anniversary of the date of grant.
(5) Represents options to purchase shares of our Common Stock granted on November 11, 2020 with an exercise price of $0.74 per share. The shares underlying the option vest on the first anniversary of the date of grant.
(6) Represents options to purchase shares of our Common Stock granted on April 2, 2014, under the Motus GI Medical Technologies LTD Employee Share Option Plan that were outstanding as of the Share Exchange Transaction, which were assumed by the 2016 Equity Incentive Plan (the “2016 Plan”) and continue in effect in accordance with their terms, on an adjusted basis to reflect the Share Exchange Transaction. 61% of the option was vested as of December 31, 2017, with the remaining 39% of the option vesting in full in November 2018.

 

70
 

 

(7) Represents options to purchase shares of our Common Stock granted on May 4, 2017, with an exercise price of $100.00 per share. Fifty-three percent (53%) of the option vested immediately upon grant, forty percent (40%) of the option vests in a series of twelve (12) successive equal quarterly installments commencing on May 4, 2017 and continuing on the first day of each third month thereafter, and the remaining seven percent (7%) of the option vests on December 22, 2019. This option was repriced to $90.00 per share in September 2017.
(8) Represents options to purchase shares of our Common Stock granted on September 29, 2017, with an exercise price of $90.00 per share. The shares underlying the option vest in a series of twelve (12) successive equal quarterly installments commencing on December 1, 2017 and continuing on the first day of each third month thereafter.
(9) Represents RSUs granted on October 1, 2018, February 13, 2019, February 6, 2020, and February 17, 2021. The shares underlying the RSUs granted on October 1, 2018 and February 13, 2019 vest in a series of sixteen (16) successive equal quarterly installments commencing on January 1, 2019 and May 1, 2019 and continuing on the first day of each third month thereafter. The shares underlying the RSUs granted on February 6, 2020 vest in a series of twelve (12) successive equal quarterly installments commencing on May 1, 2020 and continuing on the first day of each third month thereafter. The shares underlying the RSUs granted on February 17, 2021 vest in a series of twelve (12) successive equal quarterly installments commencing on May 1, 2021 and continuing on the first day of each third month thereafter.
(10) Represents RSUs granted on February 13, 2019, February 6, 2020, and February 17, 2021. The shares underlying the RSUs granted on February 13, 2019 vest in a series of sixteen (16) successive equal quarterly installments commencing on May 1, 2019 and continuing on the first day of each third month thereafter. The shares underlying the RSUs granted on February 6, 2020 vest in a series of twelve (12) successive equal quarterly installments commencing on May 1, 2020 and continuing on the first day of each third month thereafter. The shares underlying the RSUs granted on February 17, 2021 vest in a series of twelve (12) successive equal quarterly installments commencing on May 1, 2021 and continuing on the first day of each third month thereafter.
(11) Represents options to purchase shares of our Common Stock granted on February 17, 2021 with an exercise price of $5.608 per share. The shares underlying the option vest in a series of twelve (12) successive equal quarterly installments commencing on February 1, 2021 and continuing on the first day of each third month thereafter.
(12) Represents options to purchase shares of our Common Stock granted on February 10, 2022 with an exercise price of $9.20 per share. The shares underlying the option vest in a series of twelve (12) successive equal quarterly installments commencing on May 1, 2022 and continuing on the first day of each third month thereafter.

 

Director Compensation

 

The following table sets forth information concerning the compensation paid to certain of our non-employee directors during 2022.

 

Name 

Fees earned or

paid in cash

($)

  

Stock Awards

($)

  

Option Awards

($) (1)

  

Total

($)

 
David Hochman (2)   -    61,000(7)   22,685    83,685 
Darren Sherman (3)   -    43,450(7)   22,685    66,135 
Shervin Korangy (4)   -    39,600(7)   22,685    62,285 
Gary Pruden (5)   -    51,150(7)   22,685    73,835 
Sonja Nelson (6)   -    39,600(7)   22,685    62,285 

 

(1) Amounts reflect the aggregate grant date fair value of each stock option granted in 2022 in accordance with the Accounting Standards Codification Topic 718. For information regarding assumptions underlying the valuation of equity awards, see Note 11 to our Consolidated Financial Statements and the discussion under “Part II—Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operation” included in this report. These amounts do not correspond to the actual value that may be received by the directors if the stock options are exercised.
(2) The aggregate number of shares of Common Stock underlying stock options outstanding as of December 31, 2022 held by Mr. Hochman was 6,354.
(3) The aggregate number of shares of Common Stock underlying stock options outstanding as of December 31, 2022 held by Mr. Sherman was 4,526.
(4) The aggregate number of shares of Common Stock underlying stock options outstanding as of December 31, 2022 held by Mr. Korangy was 4,125.
(5) The aggregate number of shares of Common Stock underlying stock options outstanding as of December 31, 2022 held by Mr. Pruden was 5,328.
(6) The aggregate number of shares of Common Stock underlying stock options outstanding as of December 31, 2022 held by Ms. Nelson was 4,125.
(7) Represents the value of Common stock issued in lieu of cash compensation in 2022.

 

71
 

 

Non-Employee Director Compensation

 

Our board of directors approved a director compensation policy for our directors, effective January 1, 2022. This policy provides for the following cash compensation:

 

  ● each director is entitled to receive a quarterly fee of $7,150;
     
  ● the chairman of our board of directors will receive a quarterly fee of $6,450;
     
  ● the chair of the Audit Committee will receive a quarterly fee of $2,750;
     
  ● each chair of any other board of director committee will receive a quarterly fee of $1,650;
     
  ● each non-employee director sitting on more than two of our board of directors committees will receive an additional quarterly fee of $825;
     
  ● each non-chairperson member of the audit committee, the compensation committee and the nominating and corporate governance committee will receive annual fees of $2,062, $1,375 and $1,375, respectively.

 

Each non-employee director is also eligible to receive an annual option grant in an amount to be determined annually by our Compensation Committee in consultation with an independent compensation consultant, to purchase shares of our Common Stock under our existing equity incentive plan, or any other equity incentive plan we may adopt in the future, which shall vest in two equal annual installments, beginning on the first anniversary of the date of grant, and ending on the second anniversary of the date of grant.

 

Effective January 2022, our Board approved a temporary modification to the non-employee director compensation policy to permit payment of the entire 2022 fees in a single grant of our Common Stock, in lieu of cash compensation, for the quarters ending March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022 (the “2022 Fee Grant”). The 2022 Fee Grant was made to each non-employee director on January 5, 2022. We will also reimburse non-employee directors for reasonable expenses incurred in connection with attending board of director and committee meetings. In addition, effective January 2023, the non-management members of the Board agreed to defer their 2023 Board fees until a future date.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

Securities Authorized for Issuance Under Equity Compensation Plans

 

2016 Equity Incentive Plan

 

General

 

On December 14, 2016, our board of directors adopted our Motus GI Holdings, Inc. 2016 Equity Incentive Plan and 2016 Israeli Sub-Plan to the Motus GI Holdings, Inc. 2016 Equity Incentive Plan (the “2016 Plan”), subject to stockholder approval, which was received on December 20, 2016.

 

The general purpose of the 2016 Plan is to provide a means whereby eligible employees, officers, non-employee directors and other individual service providers develop a sense of proprietorship and personal involvement in our development and financial success, and to encourage them to devote their best efforts to our business, thereby advancing our interests and the interests of our stockholders. By means of the 2016 Plan, we seek to retain the services of such eligible persons and to provide incentives for such persons to exert maximum efforts for our success and the success of our subsidiaries.

 

72
 

 

The following table provides information with respect to our compensation plans under which equity compensation was authorized as of December 31, 2022.

 

   Number of securities
to be issued upon exercise of outstanding options, warrants and rights		   Weighted- average exercise price of outstanding options, warrants and rights   Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column a) 
Plan category  (a)   (b)   (c)(4) 
Equity compensation plans approved by security holders(1)   420,416(2)  $42.69(3)   15,165
Equity compensation plans not approved by security holders   -   $-    - 
Total   420,416   $42.69    15,165 

 

(1) The amounts shown in this row include securities under the 2016 Plan.
(2) Includes 400,137 shares of Common Stock issuable upon exercise of outstanding options and 20,278 shares of Common Stock issuable pursuant to outstanding restricted stock units
(3) The weighted average exercise price does not take into account the shares issuable pursuant to outstanding restricted stock units, which have no exercise price.
(4) In accordance with the “evergreen” provision in our 2016 Plan, an additional 279,586 shares were automatically made available for issuance on the first day of 2023, which represents 6% of the number of shares outstanding on December 31, 2022; these shares are excluded from this calculation.

 

Security Ownership of Certain Beneficial Owners and Management

 

The following table sets forth information regarding the beneficial ownership of our Common Stock as of the date of this report by:

 

  ● each of our stockholders who is known by us to beneficially own 5% or more of our Common Stock;
     
  ● each of our named executive officers;
     
  ● each of our directors; and
     
  ● all of our directors and current officers as a group.

 

Beneficial ownership is determined based on the rules and regulations of the SEC. A person has beneficial ownership of shares if such individual has the power to vote and/or dispose of shares. This power may be sole or shared and direct or indirect. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of our Common Stock that are subject to options or warrants held by that person and exercisable as of, or within 60 days of, February 14, 2023 are counted as outstanding. These shares, however, are not counted as outstanding for the purposes of computing the percentage ownership of any other person(s). Except as otherwise noted in the footnotes to the table, we believe that each person or entity named in the table has sole voting and investment power with respect to all shares of the Company’s Common Stock shown as beneficially owned by that person or entity (or shares such power with his or her spouse). Unless indicated below, the address of each individual listed below is c/o Motus GI Holdings, Inc., 1301 East Broward Boulevard, 3rd Floor, Ft. Lauderdale, FL 33301.

 

The percentage of the Common Stock beneficially owned by each person or entity named in the following table is based on 4,778,873 shares of Common Stock issued and outstanding as of February 14, 2023 plus any shares issuable upon exercise of options or warrants that are exercisable on or within 60 days after February 14, 2023 held by such person or entity.

 

73
 

 

Beneficial ownership representing less than 1% is denoted with an asterisk (*).

 

Name of beneficial owner  Amount and nature of beneficial ownership  

Percentage of

class

 
Officers and Directors          
Timothy P. Moran (1)   83,191   1.72%
Mark Pomeranz (2)   57,600    1.19%
David Hochman (3)   31,042    *
Darren Sherman (4)   20,620    * 
Sonja Nelson (5)   20,905    * 
Shervin Korangy (6)   18,634    * 
Andrew Taylor (7)   37,187    *
Gary Pruden (8)   21,531    * 
           
Directors and Officers as a Group (9 persons)   275,985    5.56%

 

1. Includes 58,495 shares of our Common Stock issuable upon the exercise of stock options that are exercisable within sixty days of February 14, 2023. Does not include 8,184 shares of our Common Stock issuable upon the exercise of stock options that are not exercisable within sixty days of February 14, 2023. Includes 21,529 shares of our Common Stock pursuant to restricted stock unit awards which have vested as of February 14, 2023, or which will be vested within sixty days of February 14, 2023. Does not include 8,189 shares of our Common Stock issuable upon the vesting of restricted stock units that will not vest within sixty days of February 14, 2023.
2. Includes 48,858 shares of our Common Stock issuable upon the exercise of stock options that are exercisable within sixty days of February 14, 2023. Does not include 4,253 shares of our Common Stock issuable upon the exercise of stock options that are not exercisable within sixty days of February 14, 2023. Includes 7,909 shares of our Common Stock pursuant to restricted stock unit awards which have vested as of February 14, 2023, or which will be vested within sixty days of February 14, 2023. Does not include 4,251 shares of our Common Stock issuable upon the vesting of restricted stock units that will not vest within sixty days of February 14, 2023.
3. Includes (i) 1,018 shares of our Common Stock held by NSH 2008 Family Trust, a family trust of which Mr. Hochman is a co-trustee and beneficiary and (ii) 5,500 shares of our Common Stock held by DPH 2008 Trust, a trust of which Mr. Hochman is a co-trustee and beneficiary. Includes 16,250 shares of our Common Stock issuable upon the exercise of stock options that are exercisable within sixty days of February 14, 2023. Includes (i) 45 shares of our Common Stock issuable upon the exercise of warrants, held directly by Mr. Hochman, that are exercisable within sixty days of February 14, 2023 and (ii) 189 shares of our Common Stock issuable upon the exercise of warrants, held by NSH 2008 Family Trust, a family trust of which Mr. Hochman is a co-trustee and beneficiary, that are exercisable within sixty days of February 14, 2023.
4. Includes 10,875 shares of our Common Stock issuable upon the exercise of stock options that are exercisable within sixty days of February 14, 2023. Includes 15 shares of our Common Stock issuable upon the exercise of warrants, held directly by Mr. Sherman, that are exercisable within sixty days of February 14, 2023.
5. Includes 3,750 shares of our Common Stock issuable upon the exercise of stock options that are exercisable withing sixty days of February 14, 2023. Does not include 1,250 shares of our Common Stock issuable upon the exercise of stock options that are not exercisable within sixty days of February 14, 2022.
6. Includes 9,125 shares of our Common Stock issuable upon the exercise of stock options that are exercisable within sixty days of February 14, 2023.
7. Includes 29,820 shares of our Common Stock issuable upon the exercise of stock options that are exercisable within sixty days of February 14, 2023. Does not include 4,169 shares of our Common Stock issuable upon the exercise of stock options that are not exercisable within sixty days of February 14, 2023. Does not include 4,167 shares of our Common Stock issuable upon the vesting of restricted stock units that will not vest within sixty days of February 14, 2023. Includes 7,066 shares of our Common Stock pursuant to restricted stock unit awards which have vested as of February 14, 2023, or which will be vested within sixty days of February 14, 2023.

 

74
 

 

8. Includes 8,375 shares of our Common Stock issuable upon the exercise of stock options that are exercisable within sixty days of February 14, 2023.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

Other than compensation arrangements for our named executive officers and directors, we describe below each transaction or series of similar transactions, since January 1, 2021 to which we were a party or will be a party, in which:

 

  ● the amounts involved exceeded or will exceed the lesser of (i) $120,000 or (ii) 1% of the average total assets of the Company at year end for the last two completed fiscal years; and
     
  ● any of our directors, executive officers, promoters or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest.

 

Compensation arrangements for our named executive officers and directors are described in Part III—Item 11—Executive Compensation.”

 

Royalty Payment Rights Certificates - Related Party Participation

 

Simultaneously with the closing of our IPO in February 2018, all 1,581,128 previously outstanding shares of our Series A Convertible Preferred Stock were converted, on a one-to-one basis, into an aggregate of 79,056 shares of our Common Stock. In connection with the conversion of the Series A Convertible Preferred Stock we issued Royalty Payment Rights Certificates (the “Royalty Payment Rights Certificates”) to each former holder of our Series A Convertible Preferred Stock, including certain of our directors and executive officers, and certain of our existing stockholders, including stockholders affiliated with certain of our directors including (i) a Royalty Payment Rights Certificate for 0.05% of the aggregate royalty amount payable to the holders of the Royalty Payment Rights Certificates to David Hochman, the Chairman of our board of directors, (ii) a Royalty Payment Rights Certificate for 0.05% of the aggregate royalty amount payable to the holders of the Royalty Payment Rights Certificates to Darren Sherman, a member of our board of directors, (iii) Royalty Payment Rights Certificate for an aggregate of 10.79% of the aggregate royalty amount payable to the holders of the Royalty Payment Rights Certificates to Ascent Biomedical Ventures II, L.P. and Ascent Biomedical Ventures Synecor, L.P., former beneficial owners of more than five percent of our Common Stock, (iv) a Royalty Payment Rights Certificate for 6.31% of the aggregate royalty amount payable to the holders of the Royalty Payment Rights Certificates to Orchestra Medical Ventures II, L.P., a former beneficial owner of more than five percent of our Common Stock, (v) a Royalty Payment Rights Certificate for 4.11% of the aggregate royalty amount payable to the holders of the Royalty Payment Rights Certificates to Orchestra MOTUS Co-Investment Partners, LLC, a former beneficial owner of more than five percent of our Common Stock, (vi) a Royalty Payment Rights Certificate for 4.00% of the aggregate royalty amount payable to the holders of the Royalty Payment Rights Certificates to Jacobs Investment Company LLC, an investment firm in which Gary Jacobs, a former member of our board of directors, who resigned as a member of our board of directors effective January 6, 2020, serves as Founder and Managing Director, and (vii) a Royalty Payment Rights Certificate for 16.22% of the aggregate royalty amount payable to the holders of the Royalty Payment Rights Certificates to Perceptive Life Sciences Master Fund Ltd., a beneficial owner of more than five percent of our Common Stock. Pursuant to the terms of the Royalty Payment Rights Certificates, if and when we generate sales of the Pure-Vu System, or if we receive any proceeds from the licensing of the Pure-Vu System, then we will pay to the holders of the Royalty Payment Rights Certificates (the “Holders”) the allocation of such royalty payment rights as listed on such Holders Royalty Payment Rights Certificate, a royalty (the “Royalty Amount”) equal to, in the aggregate, in royalty payments in any calendar year for all products:

 

The Company Commercializes Product Directly  

The Rights to Commercialize the Product is

Sublicensed by the Company to a third-party

3% of Net Sales*   5% of any Licensing Proceeds**

 

* Notwithstanding the foregoing, with respect to Net Sales based Royalty Amounts, (a) no Net Sales based Royalty Amount shall begin to accrue or become payable until we have first generated, in the aggregate, since inception, Net Sales equal to $20 million (the “Initial Net Sales Milestone”), and royalties shall only be computed on, and due with respect to, Net Sales generated in excess of the Initial Net Sales Milestone, and (b) the total Net Sales based Royalty Amount due and payable in any calendar year shall be subject to a cap per calendar year of $30 million. “Net Sales” is defined in the Royalty Payment Rights Certificates.
   
** Notwithstanding the foregoing, with respect to Licensing Proceeds based Royalty Amounts, (a) no Licensing Proceeds based Royalty Amount shall begin to accrue or become payable until we have first generated, in the aggregate, since inception, Licensing Proceeds equal to $3.5 million (the “Initial Licensing Proceeds Milestone”), and royalties shall only be computed on, and due with respect to, Licensing Proceeds in excess of the Initial Licensing Proceeds Milestone and (b) the total Licensing Proceeds based Royalty Amount due and payable in any calendar year shall be subject to a cap per calendar year of $30 million. “Licensing Proceeds” is defined in the Royalty Payment Rights Certificates.

 

75
 

 

The royalty will be payable up to the later of (i) the latest expiration date of our patents issued as of December 22, 2016, or (ii) the latest expiration date of any pending patents as of December 22, 2016 that have since been issued or may be issued in the future (which is currently March 2038). Following the expiration of all such patents, the Holders of the Royalty Payment Rights Certificates will no longer be entitled to any further royalties for any period following the latest to occur of such patent expiration.

 

Between December 12, 2019 and February 24, 2020, we consented to the transfer of Royalty Payment Rights Certificates representing an aggregate of 53.01% of the aggregate royalty amount payable to the holders of the Royalty Payment Rights Certificates from certain of our directors and certain of our existing stockholders, including stockholders affiliated with certain of our directors including (i) David Hochman, the Chairman of our board of directors, (ii) Darren Sherman, a member of our board of directors, (iii) Ascent Biomedical Ventures II, L.P. and Ascent Biomedical Ventures Synecor, L.P., former beneficial owners of more than five percent of our Common Stock, (iv) Orchestra Medical Ventures II, L.P., a former beneficial owner of more than five percent of our Common Stock, (v) Orchestra MOTUS Co-Investment Partners, LLC, a former beneficial owner of more than five percent of our Common Stock, (vi) Perceptive Life Sciences Master Fund Ltd., a beneficial owner of more than five percent of our Common Stock, and (vii) certain other holders of our Royalty Payment Rights Certificates to Orchestra BioMed, Inc., formerly a greater than 5% holder of our Common Stock and entity in which David Hochman, the Chairman of our board of directors, serves as the Chairman of the board of directors and as chief executive officer, and Darren Sherman, a member of our board of directors, serves as a director and as president and chief operating officer, pursuant to a private transaction between such parties.

 

License Agreement with Orchestra BioMed, Inc.

 

In January 2020, we entered into a license agreement (the “License Agreement”) with Orchestra BioMed, Inc., formerly a greater than 5% holder of our Common Stock and entity in which David Hochman, the Chairman of our board of directors, serves as the Chairman of the board of directors and as chief executive officer, and Darren Sherman, a member of our board of directors, serves as a director and as president and chief operating officer, pursuant to which we granted a license to Orchestra BioMed, Inc. for the use of portions of the office space not being used by us in our leased facility in Fort Lauderdale, Florida (the “Premises”), and a proportionate share of common areas of such Premises, which compromises approximately 35% of the Premises as of January 2020 and will expand incrementally to approximately 60 to 70% of the Premises by September 2024. In January 2020, Orchestra BioMed, Inc. paid us a one-time fee of $28.5 thousand, upon entering into the License Agreement and will continue to pay a monthly license fee to us until the expiration of the License Agreement in September 2024. Aggregate license fees will generally range from approximately $162 thousand to approximately $198 thousand in any given calendar year during the term of the License Agreement. In May 2022, the Company entered into an amendment to the Shared Space Agreement. Pursuant to the amendment, the area covered by the Shared Space Agreement was expanded to 95% of the premises and the aggregate license fees will generally range from approximately $212 thousand to approximately $270 thousand in any given calendar year during the term of the Shared Space Agreement until the termination of the lease in November 2024.

 

Indemnification Agreements

 

We have entered into indemnification agreements with all of our directors and named executive officers. These agreements require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. We also intend to enter into indemnification agreements with our future directors and executive officers.

 

76
 

 

Policies and Procedures for Related Party Transactions

 

Our board of directors has adopted a policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our Common Stock, any members of the immediate family of any of the foregoing persons and any firms, corporations or other entities in which any of the foregoing persons is employed or is a partner or principal or in a similar position or in which such person has a 5% or greater beneficial ownership interest (collectively “related parties”), are not permitted to enter into a transaction with us without the prior consent of our board of directors acting through the Audit Committee or, in certain circumstances, the chairman of the Audit Committee. Any request for us to enter into a transaction with a related party, in which the amount involved exceeds $100,000 and such related party would have a direct or indirect interest must first be presented to our Audit Committee, or in certain circumstances the chairman of our Audit Committee, for review, consideration and approval. In approving or rejecting any such proposal, our Audit Committee, or the chairman of our Audit Committee, is to consider the material facts of the transaction, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third-party under the same or similar circumstances, the extent of the benefits to us, the availability of other sources of comparable products or services and the extent of the related party’s interest in the transaction.

 

Director Independence

 

Our board of directors undertook a review of its composition, the composition of its committees and the independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that Mr. Hochman, Mr. Sherman, Dr. Nussbaum (who ceased being a director upon his death in September 2021), Mr. Korangy, Mr. Pruden and Ms. Nelson do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is “independent” as that term is defined under the Rules of the Nasdaq Market and the SEC.

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

 

Principal Accountant Fees and Services

 

The following table summarizes the fees paid for professional services rendered by EisnerAmper LLP, our independent registered public accounting firm, for each of the last two fiscal years:

 

Fee Category  2022   2021 
Audit Fees  $272,369  $246,421 
Audit-Related Fees  $-   $- 
Tax Fees  $27,800   $64,470 
All Other Fees  $-   $- 
Total Fees  $300,169   $310,891 

 

Audit Fees

 

“Audit fees” consist of approximately $207,000 and $182,000 in 2022 and 2021, respectively, of fees for professional services provided in connection with the audit of our annual audited financial statements and the review of our quarterly financial statements, and approximately $65,000 and $64,000 in 2022 and 2021, respectively, of fees for consents and comfort letters provided in connection with the offerings of our Common Stock.

 

Tax Fees

 

“Tax fees” consist of approximately $28,000 and $27,000, in 2022 and 2021, respectively, for services related to tax preparation and filing, and $0 and $38,000, in 2022 and 2021, respectively, for tax consulting services associated with tax preparation and filings and intercompany transfer pricing activities.

 

77
 

 

Procedures for Approval of Fees

 

The Audit Committee is responsible for appointing, setting compensation and overseeing the work of the independent auditors. The Audit Committee has established a policy regarding pre-approval of all auditing services and the terms thereof and non-audit services (other than non-audit services prohibited under Section 10A(g) of the Exchange Act or the applicable rules of the SEC or the Public Company Accounting Oversight Board) to be provided to us by the independent auditor. However, the pre-approval requirement may be waived with respect to the provision of non-audit services for us if the “de minimis” provisions of Section 10A(i)(1)(B) of the Exchange Act are satisfied.

 

The Audit Committee has considered whether the provision of Audit-Related Fees, Tax Fees, and all other fees as described above is compatible with maintaining EisnerAmper LLP’s independence and has determined that such services for fiscal year 2021 were compatible. All such services were approved by the Audit Committee pursuant to Rule 2-01 of Regulation S-X under the Exchange Act to the extent that rule was applicable.

 

The Audit Committee is responsible for reviewing and discussing the audited financial statements with management, discussing with the independent registered public accountants the matters required in AS 1301, receiving written disclosures from the independent registered public accountants required by the applicable requirements of the Public Company Accounting Oversight Board regarding the independent registered public accountants’ communications with the Audit Committee concerning independence and discussing with the independent registered public accountants their independence, and recommending to our board of directors that the audited financial statements be included in our annual report on Form 10-K.

 

78
 

 

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a) List of Documents filed as part of this Report

 

(1) Consolidated Financial Statements

 

The financial statements and related notes, together with the report of EisnerAmper LLP appear at pages F-1 through F-26 following the Exhibit List as required by “Part II—Item 8—Financial Statements and Supplementary Data” of this Form 10-K.

 

(2) Financial Statement Schedules.

 

Schedules are omitted because they are either not required, not applicable, or the information is otherwise included.

 

(3) Exhibits

 

The Company has filed with this report or incorporated by reference herein certain exhibits as specified below pursuant to Rule 12b-32 under the Exchange Act.

 

Exhibit       Incorporated by Reference   Filed
Number   Exhibit Description   Form   File No.   Exhibit   Filing Date   Herewith
2.1 +   Share Exchange Agreement, dated December 1, 2016   S-1   333-222441   2.1   1/5/2018    
                         
3.1   Certificate of Incorporation   S-1   333-222441   3.1   1/5/2018    
                         
3.2   Certificate of Amendment to the Certificate of Incorporation   S-1   333-222441   3.2   1/5/2018    
                         
3.3   Certificate of Amendment to the Certificate of Incorporation, dated August 13, 2020   8-K   001-38389   3.1   8/14/2020    
                         
3.4   Certificate of Amendment of Certificate of Incorporation of Motus GI Holdings, Inc. dated July 25, 2022   8-K   001-38389   3.1   7/26/2022    
                         
3.5   Bylaws, as amended   8-K   001-38389   3.1   11/14/2022    
                         
3.6   Certificate of Designations of Series A Convertible Preferred Stock   S-1   333-222441   3.4   1/5/2018    
                         
3.7   Certificate of Amendment of Certificate of Designations of Series A Convertible Preferred Stock   10-Q   001-38389   3.1   5/14/2018    
                         
4.1   Form of Common Stock Certificate   S-1   333-222441   4.1   1/5/2018    
                         
4.2   Form of Series A Convertible Preferred Stock Certificate   S-1   333-222441   4.2   1/5/2018    
                         
4.3   Form of Exchange Warrant   S-1   333-222441   4.3   1/5/2018    
                         
4.4   Form of Placement Agent Warrant   S-1   333-222441   4.4   1/5/2018    
                         
4.5   Form of Registration Rights Agreement   S-1   333-222441   4.5   1/5/2018    
                         
4.6   Form of May 2017 Consultant Warrant   S-1   333-222441   4.6   1/5/2018    
                         
4.7   Form of Placement Agent Royalty Payment Rights Certificate   S-1   333-222441   4.7   1/5/2018    

 

79
 

 

Exhibit       Incorporated by Reference   Filed
Number   Exhibit Description   Form   File No.   Exhibit   Filing Date   Herewith
4.8   Form of Amendment to Registration Rights Agreement   S-1   333-222441   4.8   1/5/2018    
                         
4.9   Form of Ten Percent Warrant   S-1   333-222441   4.9   1/5/2018    
                         
4.10   Form of Royalty Payment Rights Certificate   S-1/A   333-222441   4.10   1/31/2018    
                         
4.11   Form of June 2018 Consultant Warrant   10-Q   001-38389   4.1   8/13/2018    
                         
4.12   Form of May 2017 Additional Consultant Warrant   10-Q   001-38389   4.2   8/13/2018    
                         
4.13   Form of July 2018 Consultant Warrant   10-Q   001-38389   4.3   8/13/2018    
                         
4.14   Form of November 2018 Consultant Warrant   10-Q   001-38389   4.4   11/14/2018    
                         
4.15   Description of Registrants Securities   10-K    001-38389   4.15   3/16/2021    
                         
4.16   Form of Pre-Funded Warrant   8-K   001-38389   4.1   8/28/2020    
                         
4.17   Form of Common Warrant   8-K   001-38389   4.2   8/28/2020    
                         
4.18   Form of New Warrant   8-K   001-38389   4.1   1/21/2021    
                         
10.1   Placement Agency Agreement, dated December 1, 2016, between the Company and Placement Agent   S-1   333-222441   10.1   1/5/2018    
                         
10.2   Form of Subscription Agreement   S-1   333-222441   10.2   1/5/2018    
                         
10.3   Form of Voting Agreement, dated December 1, 2016, by and among the Company and the stockholders named therein   S-1   333-222441   10.3   1/5/2018    
                         
10.4 †   2016 Equity Incentive Plan and 2016 Israel Sub-Plan   S-1   333-222441   10.4   1/5/2018    
                         
10.5   Amendment to the Motus GI Holdings, Inc. 2016 Equity Incentive Plan, dated February 6, 2020   8-K   001-38389   10.1   8/14/2020    
                         
10.6 †   Form of Incentive Stock Option Agreement   S-1   333-222441   10.5   1/5/2018    
                         
10.7 †   Form of Non-Qualified Stock Option Agreement   S-1   333-222441   10.6   1/5/2018    
                         
10.8 †   Form of Restricted Stock Agreement   S-1   333-222441   10.7   1/5/2018    
                         
10.9 †   Form of Assumed Options to Israeli Employees and Directors Agreement   S-1   333-222441   10.8   1/5/2018    
                         
10.10   Form of Assumed Options to Israeli Non-Employees and Controlling Shareholders Agreement   S-1   333-222441   10.9   1/5/2018    
                         
10.11 †   Form of Israeli Option Grant to Israeli Employees and Directors Agreement   S-1   333-222441   10.10   1/5/2018    
                         
10.12   Form of Israeli Option Grant to Israeli Non-Employees and Controlling Shareholders Agreement   S-1   333-222441   10.11   1/5/2018    
                         
10.13 †   Employment Agreement, dated December 22, 2016, between the Company and Mark Pomeranz   S-1   333-222441   10.12   1/5/2018    

 

80
 

 

Exhibit       Incorporated by Reference   Filed
Number   Exhibit Description   Form   File No.   Exhibit   Filing Date   Herewith
10.14   Lease, dated April 13, 2017, between Company and Victoriana Building, LLC   S-1   333-222441   10.13   1/5/2018    
                         
10.15   Form of Subscription Agreement for Convertible Notes Offering   S-1   333-222441   10.14   1/5/2018    
                         
10.16   Finders Agreement, dated October 14, 2016, between the Company and Aegis Capital Corporation   S-1   333-222441   10.15   1/5/2018    
                         
10.17   Finders Agreement, dated December 22, 2016, between the Company and Aegis Capital Corporation   S-1   333-222441   10.16   1/5/2018    
                         
10.18 †   Form of Indemnification Agreement   S-1   333-222441   10.17   1/5/2018    
                         
10.19 †   Employment Agreement, dated August 16, 2017, between the Company and Andrew Taylor   S-1   333-222441   10.18   1/5/2018    
                         
10.20 #   Supply Agreement, dated September 1, 2017, between Motus GI Technologies Ltd. and Polyzen, Inc.   10-K   001-38389   10.20   3/29/2022    
                         
10.21 †   Amended and Restated Employment Agreement, effective September 24, 2018, between the Company and Mark Pomeranz   8-K   001-38389   10.2   9/25/2018    
                         
10.22 †   Employment Agreement, effective October 1, 2018, between the Company and Timothy P. Moran   8-K   001-38389   10.1   9/25/2018    
                         
10.23   Form of Restricted Stock Unit Award Agreement   10-K    001-38389   10.22   3/26/2019    
                         
10.24 †   Amended and Restated Employment Agreement, effective March 26, 2019, between the Company and Andrew Taylor   10-K    001-38389   10.23   3/26/2019    
                         
10.25 †   First Amendment to Amended and Restated Employment Agreement, dated March 15, 2021, between the Company and Andrew Taylor   10-K   001-38389    10.25    3/16/2021    
                         
10.26   Loan and Security Agreement, dated as of December 13, 2019 between Silicon Valley Bank and Motus GI Holdings, Inc.   8-K   001-38389   10.1   12/18/2019    
                         
10.27   Joinder and First Amendment to Loan and Security Agreement, dated as of February 7, 2020 between Silicon Valley Bank and Motus GI Holdings, Inc.   10-K   001-38389    10.25   3/30/2020    
                         
10.28   Second Amendment to Loan and Security Agreement, dated as of February 25, 2020 between Silicon Valley Bank and Motus GI Holdings, Inc.   10-K   001-38389   10.26   3/30/2020    

 

81
 

 

Exhibit       Incorporated by Reference   Filed
Number   Exhibit Description   Form   File No.   Exhibit   Filing Date   Herewith
10.29   Third Amendment to Loan and Security Agreement, dated as of January 4, 2021 between Silicon Valley Bank and Motus GI Holdings, Inc.   10-K   001-38389   10.25   3/16/2021    
                         
10.30   Deferral Agreement, dated as of April 10, 2020, effective as of April 2, 2020, by and between Silicon Valley Bank, Motus GI Holdings, Inc. and Motus GI, Inc.   8-K   001- 38389   10.1   4/13/2020    
                         
10.31   Placement Agency Agreement, dated August 28, 2020, by and between A.G.P./Alliance Global Partners and Motus GI Holdings, Inc.   8-K   001-38389   10.1   8/28/2020    
                         
10.32   Form of Securities Purchase Agreement, dated August 28, 2020, by and between Motus GI Holdings, Inc. and each Purchaser thereto   8-K   001-38389   10.2   8/28/2020    
                         
10.33   Form of Warrant Exercise Agreement, dated January 27, 2021, by and between Motus GI Holdings, Inc. and the Holder   8-K   001-38389   10.1   1/27/2021    
                         
10.34   Letter Agreement, dated January 27, 2021, by and between A.G.P./Alliance Global Partners and the Company   8-K   001-38389   10.2   1/27/2021    
                         
10.35   Loan Agreement, dated July 16, 2021, by and between Kreos Capital, Motus GI Holdings, Inc., Motus GI, LLC and Motus GI Medical Technologies, LTD.   8-K   001-38389   10.1   7/21/2021    
                         
10.36   Security Agreement, dated July 16, 2021 between Kreos Capital and Motus GI Holdings, Inc.   8-K   001-38389   10.2   7/21/2021    
                         
10.37   Security Agreement, dated July 16, 2021 between Kreos Capital and Motus GI, LLC.   8-K   001-38389   10.3   7/21/2021    
                         
10.38   Debenture – Fixed Charge dated July 16, 2021, between Kreos Capital and Motus GI Medical Technologies, LTD.   8-K   001-38389   10.4   7/21/2021    
                         
10.39   Debenture – Floating Charge dated as of July 16, 2021, between Kreos Capital and Motus GI, LLC.   8-K   001-38389   10.5   7/21/2021    
                         
10.40   US Intellectual property Security Agreement, dated July 16, 2021, between Kreos Capital and Motus GI Medical Technologies, LTD.   8-K   001-38389   10.6   7/21/2021    
                         
10.41 #   Master Supply Agreement, dated April 1, 2021, between J. Sterling Industries LLC and Motus GI Holdings, Inc.   10-K   001-38389   10.41   3/29/2022    

 

82
 

 

21.1   List of Subsidiaries of the Company   10-K   001-38389   21.1   3/16/2021    
                         
23.1   Consent of EisnerAmper LLP                   X
                         
31.1   Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)                   X
                         
31.2   Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)                   X
                         
32.1 **   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350                   X
                         
101.INS   Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).                   X
                         
101.SCH   Inline XBRL Taxonomy Extension Schema Document.                   X
                         
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.                   X
                         
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.                   X
                         
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.                   X
                         
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.                   X
                         
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibits 101)                    

 

+ As permitted by Item 601(b)(2) of Regulation S-K, certain schedules to this agreement have not been filed herewith. The company will furnish supplementally a copy of any omitted schedule to the SEC upon request.
† Indicates management contract or compensatory plan.
# Certain portions of this exhibit (indicated by “[***]”) have been omitted as we have determined (1) it is not material and (2) is the type that the Company treats as private or confidential.
** The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

 

ITEM 16. FORM 10-K SUMMARY

 

None.

 

83
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MOTUS GI HOLDINGS, INC.
     
Date: March 31, 2023 By: /s/ Timothy P. Moran
    Timothy P. Moran
    Chief Executive Officer
    (Principal Executive Officer)
     
Date: March 31, 2023 By: /s/ Andrew Taylor
    Andrew Taylor
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Timothy P. Moran  

President, Chief Executive Officer and Director

(Principal Executive Officer)

   March 31, 2023
Timothy P. Moran        
         
/s/ Andrew Taylor   Chief Financial Officer (Principal Financial and Accounting Officer)   March 31, 2023
Andrew Taylor        
         
/s/ David Hochman   Chairman of the Board   March 31, 2023
David Hochman        
         
/s/ Mark Pomeranz   President, Chief Operating Officer, and Director   March 31, 2023
Mark Pomeranz        
         
/s/ Darren Sherman   Director   March 31, 2023
Darren Sherman        
         
/s/ Sonja Nelson   Director   March 31, 2023
Sonja Nelson        
         
/s/ Shervin Korangy   Director   March 31, 2023
Shervin Korangy        
         
/s/ Gary Pruden   Director   March 31, 2023
Gary Pruden        

 

84
 

 

INDEX TO

CONSOLIDATED FINANCIAL STATEMENTS

 

Contents

 

    Page
Consolidated Financial Statements – December 31, 2022 and 2021:    
Report of Independent Registered Public Accounting Firm (PCAOB ID No. 274)   F-2
Consolidated Balance Sheets as of December 31, 2022 and 2021   F-3
Consolidated Statements of Comprehensive Loss for the years ended December 31, 2022 and 2021   F-4
Consolidated Statements of Changes in Shareholders’ Equity for the years ended December 31, 2022 and 2021   F-5
Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021   F-6
Notes to the Consolidated Financial Statements   F-7 - F-21

 

F-1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Shareholders of

Motus GI Holdings, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Motus GI Holdings, Inc. and Subsidiaries (the “Company”) as of December 31, 2022 and 2021, and the related consolidated statements of comprehensive loss, changes in shareholders’ equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of their operations and their cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company generated minimal revenues, experienced negative cash flows from operating activities and has incurred substantial operating losses that raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Contingent Royalty Obligation

 

As described in Note 4 to the consolidated financial statements, the Company estimates the fair value of its contingent royalty obligation using the discounted cash flow method. Management estimates the contingent royalty obligation primarily by estimating the future projected revenue of the Company, with other factors being growth rate, patent expiration assessments and a discount rate. The fair value of the contingent royalty obligation was approximately $1,212,000 as of December 31, 2022.

 

We identified the valuation of the contingent royalty obligation as a critical audit matter because the valuation inputs involve the application of significant judgement and estimation on the part of management, which led to a high degree of auditor subjectivity. We also applied significant judgment in performing our audit procedures and involved a valuation specialist to evaluate the reasonableness of management’s valuation model, as well as the inputs used within the model.

 

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. Our procedures included, among other things, (i) obtaining an understanding of management’s process and evaluating the design of controls related to the valuation of the contingent royalty obligation; (ii) assessing the reasonableness of management’s projected revenue by inquiring of management regarding its process for developing the projections and evaluating assumptions utilized for reasonableness; (iii) performing a sensitivity analysis of the assumptions in the calculation to evaluate the potential material effects of any changes in assumptions; and (iv) with the assistance of our valuation specialists, we (1) evaluated the reasonableness of management’s valuation methodology; (2) evaluated the reasonableness of the discount rate used by management by developing an independent weighted average cost of capital and compared it to the rate used by management; and (3) tested the mathematical accuracy of the discounted cash flow calculation.

 

/s/ EisnerAmper LLP

 

We have served as the Company’s auditor since 2018.

 

EISNERAMPER LLP

Philadelphia, Pennsylvania

March 31, 2023

 

F-2

 

 

Motus GI Holdings, Inc. and Subsidiaries

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

 

   2022   2021 
   December 31, 
   2022   2021 
Assets          
Current assets:          
Cash and cash equivalents  $14,042   $22,563 
Accounts receivable   59    109 
Inventory, current   488    496 
Prepaid expenses and other current assets   781    793 
Total current assets   15,370    23,961 
           
Fixed assets, net   1,325    1,428 
Inventory, non-current   

511

    - 
Right-of-use assets   428    687 
Other non-current assets   13    13 
Total assets  $17,647   $26,089 
           
Liabilities and Shareholders’ Equity          
Current liabilities:          
Accounts payable and accrued expenses  $1,969   $2,584 
Operating lease liabilities - current   245    307 
Other current liabilities   53    10 
Current portion of long-term debt, net of unamortized debt discount of $182 and $271, respectively   2,532    431 
Total current liabilities   4,799    3,332 
           
Contingent royalty obligation   1,212    1,760 
Operating lease liabilities - non-current   178    385 
Convertible note, net of unamortized debt discount of $108 and $166, respectively   3,892    3,834 
Long-term debt, net of unamortized debt discount of $135 and $317, respectively   4,589    7,121 
Total liabilities   14,670    16,432 
           
Commitments and contingent liabilities (Note 9)   -    - 
           
Shareholders’ equity          
Preferred stock $0.0001 par value; 10,000,000 shares authorized; zero shares issued and outstanding   -    - 
Common stock $0.0001 par value; 115,000,000 shares authorized; 4,659,769 and 2,416,021 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively   -    - 
Additional paid-in capital   144,328    132,411 
Accumulated deficit   (141,351)   (122,754)
Total shareholders’ equity   2,977    9,657 
Total liabilities and shareholders’ equity  $17,647   $26,089 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3

 

 

Motus GI Holdings, Inc. and Subsidiaries

Consolidated Statements of Comprehensive Loss

(In thousands, except share and per share amounts)

 

         
   Years Ended December 31, 
   2022   2021 
         
Revenue  $592   $391 
           
Operating expenses:          
Costs of revenue - sales   198    181 
Costs of revenue - impairment of inventory   598    443 
Research and development   5,611    5,341 
Sales and marketing   4,425    3,077 
General and administrative   7,611    9,273 
Total costs and expenses   18,443    18,315 
Operating loss   (17,851)   (17,924)
           
Gain (loss) on change in estimated fair value of contingent royalty obligation   548    (143)
Loss on extinguishment of debt   -    (237)
Finance expense, net   (1,252)   (717)
Other income   -    5 
Foreign currency loss   (42)   (17)
           
Net loss  $(18,597)  $(19,033)
Deemed dividends from warrant issuance   -    (6,145)
Net loss attributable to common shareholders  $(18,597)  $(25,178)
           
Basic and diluted loss per common share:          
Net loss attributable to common shareholders  $(5.74)  $(10.74)
Weighted average number of common shares outstanding, basic and diluted   3,237,952    2,344,759 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4

 

 

Motus GI Holdings, Inc. and Subsidiaries

Consolidated Statements of Changes in Shareholders’ Equity

(in thousands, except share and per share amounts)

 

   Shares   Amount   capital   deficit   equity 
   Common Stock  

Additional

paid-in

   Accumulated  

Total

shareholders’

 
   Shares   Amount   Capital   deficit   equity 
Balance at December 31, 2020   1,613,591    -    115,011    (103,721)   11,290 
Issuance of common shares upon public offering, net of offering costs of $74   67,043    -    1,826    -    1,826 
Issuance of common stock upon exercise of warrants, net of financing fees of $366   713,362    -    11,593    -    11,593 
Issuance of common stock for board of directors’ compensation   9,587    -    291    -    291 
Issuance of common shares upon vesting of restricted stock units   9,938    -    -    -    - 
Issuance of common stock to consultants   2,500    -    

53

         

53

 
Issuance of warrants associated with convertible note and long- term debt   -    -    165         165 
Share-based compensation   -    -    3,472    -    3,472 
Net loss   -             -    -    (19,033)   (19,033)
Balance at December 31, 2021   2,416,021    -    132,411    (122,754)   9,657 
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs of $368   2,195,106    -    9,884    -    9,884 
Issuance of common shares upon vesting of restricted stock units   26,230    -    -    -    - 
Fractional shares settled in cash pursuant to reverse stock split   (2,046)   -    (11)   -    (11)
Issuance of common stock for board of directors’ compensation   24,458    -    235    -    235 
Share-based compensation   -    -    1,809    -    1,809 
Net loss   -    -    -    (18,597)   (18,597)
Balance at December 31, 2022   4,659,769   $-   $144,328   $(141,351)  $2,977 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-5

 

 

Motus GI Holdings, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(In thousands, except share and per share amounts)

 

   2022   2021 
   Years Ended December 31, 
   2022   2021 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(18,597)  $(19,033)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   510    439 
Amortization of debt issuance costs   330    95 
(Gain) loss on change in estimated fair value of contingent royalty obligation   (548)   143 
Share-based compensation   1,809    3,472 
Issuance of common stock for board of directors’ compensation   235    235 
Issuance of common stock for consultants   -    53 
Loss on extinguishment of debt   -    237 
Impairment of inventory   598    443 
Impairment of fixed assets   46    - 
Amortization on operating lease right of use asset   327    262 
Changes in operating assets and liabilities:          
Accounts receivable   50    (74)
Inventory   (1,302)   (274)
Prepaid expenses and other current assets   12    (413)
Accounts payable and accrued expenses   (650)   303 
Operating lease liability   (330)   (260)
Other current and non-current liabilities   43    (50)
Net cash used in operating activities   (17,467)   (14,422)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of fixed assets   (224)   (470)
Net cash used in investing activities   (224)   (470)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from issuance of common shares   10,252    1,900 
Fractional shares paid in cash pursuant to reverse stock split   (11)   - 
Proceeds from exercise and purchase of warrants   -    11,959 
Borrowings under convertible note and long-term debt   -    12,000 
Repayment of debt   (703)   (8,220)
Payment of debt issuance costs   -    (563)
Equity financing fees   (368)   (440)
Net cash provided by financing activities   9,170    16,636 
           
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS   (8,521)   1,744 
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD   22,563    20,819 
CASH AND CASH EQUIVALENTS AT END OF PERIOD  $14,042   $22,563 
           
SUPPLEMENTAL CASH FLOW INFORMATION:          
CASH PAID FOR:          
Interest  $977   $640 
           
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:          
Common stock issued to settle accrued expenses for board of directors’ compensation  $-   $56 
Reclassification of inventory to fixed assets  $201   $140 
Reclassification of prepaid expenses to fixed assets  $4   $75 
Purchase of fixed assets in accounts payable and accrued expenses  $24   $4 
Warrants issued related to convertible note and long-term debt recorded as debt discount  $-   $165 
Accrued end of loan payment recorded as debt discount  $-   $140 
Operating lease liabilities arising from obtaining right-of-use assets  $66   $184 
Prepayment of lease obligation  $-   $17 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-6

 

 

Motus GI Holdings, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(In thousands, except share and per share amounts)

 

Note 1 – Description of Business

 

Motus GI Holdings, Inc. (the “Company”) was incorporated in Delaware, U.S.A. in September 2016. The Company and its subsidiaries, Motus GI Technologies, Ltd. and Motus GI, LLC, are collectively referred to as “Motus GI” or the “Company”.

 

The Company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the “FDA”) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (“GI”) endoscopy procedures. The Pure-Vu System has received a CE Mark in the EU for use in colonoscopy. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Through irrigation and evacuation of debris, the Pure-Vu System is designed to provide better-quality exams. The Company received 510(k) clearance in February 2022 from the FDA for the Pure-Vu EVS System and has commenced initial commercialization of this product. The Company does not expect to generate significant revenue from product sales until it further expands its commercialization efforts, which is subject to significant uncertainty.

 

Note 2 – Going Concern

 

To date, the Company has generated minimal revenues, experienced negative operating cash flows and has incurred substantial operating losses from its activities. Management expects the Company to continue to generate substantial operating losses and to continue to fund its operations primarily through utilization of its current financial resources, future product sales, and through the issuance of debt or equity, as well as through other strategic alternative transactions. Rising inflation and financial market volatility may adversely impact the Company’s ability to enter into, modify, and negotiate favorable terms and conditions relative to equity and debt financing initiatives. The uncertain financial markets, potential disruptions in supply chains, and changing priorities could also affect the Company’s ability to enter into key agreements. COVID-19 and government measures taken in response have also had an impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as certain medical services and supplies, have spiked, while demand for other goods and services have fallen. The future progression of the outbreak and its longer-term effects on the Company’s business and operations continue to evolve and are still uncertain. The Company and its third-party contract manufacturers, contract research organizations, and clinical sites may also face disruptions in procuring items that are essential to the Company’s research and development activities, including, for example, medical and laboratory supplies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts related to the outbreak in certain parts of the world. These disruptions may negatively impact the Company’s sales, its results of operations, financial condition, and liquidity into Q2 2023.

 

We have generated limited revenues to date from the sale of products. We have never been profitable and have incurred significant net losses each year since our inception, including a loss of $18.6 million for the year ended December 31, 2022, and we expect to continue to incur net operating losses for the foreseeable future. As of December 31, 2022, we had $14.0 million in cash and cash equivalents and an accumulated deficit of $141.4 million. We expect our current spend level to continue in connection with ongoing operating activities, including expenditures in R&D, sales and marketing, clinical affairs and manufacturing. As described above, we committed to a restructuring initiative designed to reduce our expenses and position us to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. In addition, in order to continue to operate as a standalone company, we would need additional financing to support our continuing operations. We also have significant debt under our Loan Agreement with Kreos which could negatively impact our ability to operate or consummate a strategic transaction.

 

In January 2023, we committed to a restructuring initiative designed to position us to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. If a strategic transaction is not completed, or if additional financing is not available, we may not be able to service our outstanding indebtedness and our payables and may have to file for bankruptcy protection or pursue a dissolution of the Company and liquidation of all of our remaining assets. In such an event, the amount of cash available for distribution to our stockholders, if any, will depend heavily on the timing of such decision, as with the passage of time the amount of cash available for distribution will be reduced as we continue to fund our operations and service our outstanding indebtedness. We cannot provide assurance as to the amount of cash that will be available to distribute to stockholders, if any, after paying our debts and other obligations and setting aside funds for reserves, nor as to the timing of any such distribution, if any.

 

Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.

 

Note 3 – Significant Accounting Policies and Basis of Presentation

 

A summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows:

 

Basis of presentation and use of estimates

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, of the Financial Accounting Standards Board (“FASB”).

 

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

F-7

 

 

Reverse Stock Split

 

On July 25, 2022, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-20. Shares of common stock underlying outstanding stock options and other equity instruments convertible into common stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.

 

Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split.

 

Functional currency and foreign currency translation

 

The functional currency of the Company, inclusive of foreign subsidiaries, is the U.S dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the consolidated statement of comprehensive loss as foreign currency (loss) gain, as appropriate.

 

Cash and cash equivalents

 

The Company considers all highly liquid investment securities with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Cash and cash equivalents include cash on-hand and highly-rated U.S. government backed money market fund investments.

 

Concentrations of Credit Risk and Off-balance Sheet Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company’s cash is held in accounts with financial institutions that management believes are creditworthy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.

 

Revenue recognition

 

Sales contracts executed for the second generation Pure-Vu System are accounted for in accordance with ASC Topic 606 - Revenue from Contracts with Customers (“ASC 606”) to depict the transfer of control to the Company’s customers in an amount reflecting the consideration to which the Company expects to be entitled to. The Pure-Vu System consists of a Workstation (a “Workstation”) and single use disposable sleeve (a “Disposable”).

 

ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases and collaboration arrangements. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when a performance obligation is satisfied.

 

Commercial placements of the second generation system include the Workstation, sale of the Disposables, and a service plan. The Workstation is operational without any significant customization and modification and the Disposables are specialized consumables that are readily available for purchase from the Company. Therefore, revenue from the sale of a Workstation is recognized after the customer commits to purchase the Workstation and the Workstation is delivered, which is when title is transferred. Disposables are identified as a separate performance obligation, and therefore, revenue from the sale of Disposables is recognized when the Disposables are delivered to the customer and title is transferred.

 

A free one-year service plan is included with the purchase of any second generation Pure-Vu Workstation. An extended service plan with varying support and maintenance of the Workstation is offered for sale after the free one-year service plan period. In the case of the free one-year service plan, a portion of the Workstation sales price is deferred and recognized ratably over the one-year service plan term based upon the relative standalone value. The standalone selling price of the Workstation is set at the beginning of the contract based on observable prices from standalone sales of the Workstation, however, at times, the Company has offered discounts from that price to certain customers. The standalone sales price of the one year service plan is based on the expected costs of replacement parts and direct costs to perform the service plus a standard margin, as set by the Company. The standard margin assumed is consistent with the margin expected in pricing the extended service plan. Revenue for the extended service plans is recognized ratably over the term of the service plan contract period.

 

At times, the Company may include a limited time free trial to potential customers to evaluate the Workstation for a period of up to 6 months and in certain instances extend the period to an aggregate of up to 11 months. The Company considers the 6-11 month usage period as a non-contiguous limited trial period because the total length of the free trial is still less than one year. In scenarios where the Company continues to provide the Workstation to a customer for a usage period of greater than one year, the arrangement falls outside of the scope of ASC 606, as described below. Management does not collect any upfront payments or deposits prior to commencing a free trial period. No revenue is recognized for the Workstation during the duration of a free trial, however, any Disposables purchased by the evaluator are recognized when delivered, as described above.

 

F-8

 

 

For contracts outside the scope of ASC 606, the Company determines income for proposed supply arrangements under 1) ASC 842 as it pertains to an embedded lease of the Workstation within a proposed supply arrangement and 2) ASC 606 for the sale of the sleeves within the proposed supply arrangement. The Company allocates the transaction price to the performance obligations within the proposed supply arrangements using the total estimated purchases method for both (i) arrangements that contain minimum purchase commitments and (ii) those arrangements that do not contain a minimum purchase commitment, but instead offer a volume discount for purchases that exceed a specified tier.

 

During the year ended December 31, 2022, the Company recognized revenue of $592, which consisted of $540 in accordance with ASC 606 and $52 in accordance with ASC 842. During the year ended December 31, 2021, the Company recognized revenue of $391, which consisted of $303 in accordance with ASC 606 and $88 in accordance with ASC 842.

 

During the year ended December 31, 2022, the Company recognized revenue at a point in time of $529 and recognized revenue over time of $63. During the year ended December 31, 2021, the Company recognized revenue at a point in time of $299 and recognized revenue over time of $92.

 

Contract Costs

 

Incremental commissions, if applicable, above a base commission level, are paid to sales representatives upon certain eligible sales, which are paid upon execution of the sales agreement. The guidance within ASC 606 provides a practical expedient if the amortization period of the assets that the entity otherwise would have recognized is one year or less. The Company chose to apply the available practical expedient as the commission paid on eligible sales orders relates to the period in which the sales order was fulfilled. For the years ending December 31, 2022 and 2021, incremental commissions paid on eligible sales orders were $96 and $35, respectively.

 

Accounts receivable and allowance for doubtful accounts

 

Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. The Company makes estimates for the allowance for doubtful accounts based upon its assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect customers’ ability to pay. As of December 31, 2022 and 2021, the allowance for doubtful accounts was $0.

 

Inventory

 

Inventory is stated at lower of cost and net realizable value using the weighted average cost method and is evaluated at least annually for impairment. The Company records an inventory reserve for losses associated with dated, expired, excess and obsolete items. Reserves and write-downs of inventory is based on management’s current knowledge with respect to inventory levels, planned production, and extension capabilities of materials on hand. A significant change in the timing or level of demand for the Company’s products compared to forecasted amounts may result in recording additional charges for excess and obsolete inventory in the future. The Company records charges for excess and obsolete inventory within cost of revenues. Inventories that exceed estimated realization for the next twelve months from balance sheet date based on future sales forecasts are classified as long-term assets.

 

Leases

 

The Company accounts for its leases in accordance with ASC 842, Leases, or ASC 842. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. The Company does not have financing leases.

 

Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.

 

The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty of renewal.

 

F-9

 

 

Fixed assets, net

 

Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated based on the straight-line method, at annual rates reflecting the estimated useful lives of the related assets, as follows:

 

 

Office equipment   5-15 years
Computers and software   3-5 years
Machinery   5-10 years
Lab and medical equipment   3-7 years
Leasehold improvements   Shorter of lease term or useful life

 

Share-based compensation

 

Employee and Non-Employee Share-Based Compensation

 

The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including employee stock options under the Company’s stock plans and equity awards issued to non-employees based on estimated fair values.

 

The accounting for awards issued to non-employees is similar to the accounting for employee awards, except that:

 

  ● the Company may elect on an award-by-award basis to use the contractual term as the expected term assumption in the option pricing model, and
     
  ● the cost of the grant is recognized in the same period(s) and in the same manner as if the grantor had paid cash.

 

ASC 718-10 requires companies to estimate the fair value of equity-based option awards on the date of grant using an option-pricing model. The fair value of the award is recognized as an expense on a straight-line basis over the requisite service periods in the Company’s consolidated statements of comprehensive loss. The Company recognizes share-based award forfeitures as they occur.

 

The Company estimates the fair value of granted option equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations of the Company.

 

Restricted Stock Units

 

The Company issues restricted stock units under its 2016 Equity Incentive Plan. The fair value of the restricted stock units is based on the closing stock price on the date of grant and is expensed as operating expense over the period during which the units vest. Each restricted stock unit entitles the grantee to one share of common stock to be received upon vesting up to four years after the grant date. Recipients of restricted stock units have no voting rights until the vesting of the award.

 

Basic and diluted net loss per share

 

Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive ordinary shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. Potentially dilutive common shares were excluded from the calculation of diluted loss per share for all periods presented due to their anti-dilutive effect due to losses in each period.

 

Net loss attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed preferred stock dividends declared, amortized or accumulated. The Company recorded a deemed dividend of $0 and $6,145 for the issuance of warrants during the years ended December 31, 2022 and 2021, respectively. The deemed dividend is added to the net loss in determining the net loss available to common stockholders.

 

F-10

 

 

Research and development expenses

 

Research and development expenses are charged to the consolidated statement of comprehensive loss as incurred.

 

Patent costs

 

Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are expensed as incurred.

 

Debt issuance costs

 

Debt issuance costs represent the costs associated with the issuance of a debt instrument and are amortized using the effective interest method over the life of the related debt instrument. The Company records debt issuance costs as a debt discount and is a reduction of the carrying amount of the debt liability.

 

Liabilities due to termination of employment agreements

 

Under Israeli employment laws, employees of Motus Ltd. are included under Article 14 of the Severance Compensation Act, 1963 (“Article 14”) for a portion of their salaries. According to Article 14, these employees are entitled to monthly deposits made by Motus Ltd. on their behalf with insurance companies.

 

Payments in accordance with Article 14 release Motus Ltd. from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company’s balance sheet, and there is no liability recorded as the Company does not have a future obligation to make any additional payments.

 

Income taxes

 

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company had a full valuation allowance against deferred tax assets.

 

The Company is subject to the provisions of ASC 740-10-25, Income Taxes (ASC 740). ASC 740 prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. On a quarterly basis, the Company undergoes a process to evaluate whether income tax accruals are in accordance with ASC 740 guidance on uncertain tax positions. There are currently no open Federal or State audits. The Company has not recorded any liability for uncertain tax positions at December 31, 2022 or December 31, 2021.

 

For the years ended December 31, 2022 and 2021, the Company recorded zero income tax expense. No tax benefit has been recorded in relation to the pre-tax loss for the years ended December 31, 2022 and 2021, due to a full valuation allowance to offset any deferred tax asset related to net operating loss carry forwards attributable to the losses.

 

F-11

 

 

Fair value of financial instrument

 

The Company accounts for financial instruments in accordance with ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”). ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:

 

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

 

Level 2 – Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data;

 

Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

 

There were no changes in the fair value hierarchy leveling during the years ended December 31, 2022 and 2021.

 

New Accounting Pronouncements- Recently Adopted

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options, which clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options due to a lack of explicit guidance in the FASB Codification. ASU 2021-04 provides guidance on modifications or exchanges of freestanding equity-classified written call options that are not within the scope of another Topic. Entities should treat a modification of the terms or conditions, or an exchange of a freestanding equity-classified written call option that remains equity-classified after modification or exchange, as an exchange of the original instrument for a new instrument. ASU 2021-04 provides further guidance on measuring the effect of such modifications or exchanges, and also provides guidance on the recognition of such modifications or exchanges on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021. The Company adopted this ASU on January 1, 2022, prospectively to modifications that occurred after the date of initial application. The adoption of this ASU did not result in a material impact to the consolidated financial statements and disclosures.

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements, or ASC 326. On January 1, 2023, the Company adopted ASC 326. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments. The adoption of ASC 326 did not have a material impact on the Company’s financial position or results of operations upon adoption.

 

Accounting Pronouncements- Not Yet Adopted

 

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting which provides optional expedients and exceptions for the accounting for contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. In January 2021, the FASB issued ASU 2021-01 to clarify the scope of certain optional expedients for derivatives that are affected by the discounting transition. In December 2022, the FASB issued ASU 2022-06 to defer the sunset date of Topic 848 from December 31, 2022, to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848. As of December 31, 2022, the Company is currently evaluating the impact of this guidance on its consolidated financial statements.

 

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This guidance simplifies the accounting for convertible instruments primarily by eliminating the existing cash conversion and beneficial conversion models within Subtopic 470-20, which will result in fewer embedded conversion options being accounted for separately from the debt host. The guidance also amends and simplifies the calculation of earnings per share relating to convertible instruments. This guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within that reporting period, using either a full or modified retrospective approach. As of December 31, 2022, the Company is currently evaluating the impact of the provisions of this guidance on its consolidated financial statements.

 

F-12

 

 

Note 4 – Fair Value Measurements

 

Liabilities measured and recorded at fair value on a recurring basis consisted of the following at December 31, 2022 and December 31, 2021:

 

 

   December 31, 2022 
   Level 1   Level 2   Level 3   Fair Value 
Liabilities                    
Contingent royalty obligation  $   -   $   -   $1,212   $1,212 

 

   December 31, 2021 
   Level 1   Level 2   Level 3   Fair Value 
Liabilities                    
Contingent royalty obligation  $   -   $   -   $1,760  $1,760 

 

Financial instruments with carrying values approximating fair value include cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, and certain other current liabilities, due to their short-term nature. Financial instruments with carrying values approximating fair value also include long-term debt and convertible notes which is based on a combined total of their face value and the amortization discount.

 

In estimating the fair value of the Company’s contingent royalty obligation (see Note 9), the Company used the discounted cash flow method as of December 31, 2022 and 2021. Based on the fair value hierarchy, the Company classified contingent royalty obligation within Level 3 because the valuation inputs are based on projected revenues discounted to a present value.

 

Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of a contingent royalty obligation, during the year ended December 31, 2022 was as follows:

 

 

   Fair Value
Measurements
of Contingent
Royalty
Obligation
(Level 3)		 
Balance at December 31, 2021  $1,760 
Change in estimated fair value of contingent royalty obligation   548 
Balance at December 31, 2022  $1,212 

 

The contingent royalty obligation is re-measured at each balance sheet date using several assumptions, including the following: 1) estimated sales growth, 2) length of product cycle, 3) patent life, 4) discount rate (23% as of December 31, 2022 and 21% as of December 31, 2021), and 5) rate of royalty payment (3% as of December 31, 2022 and December 31, 2021).

 

In accordance with ASC-820-10-50-2(g), the Company performed sensitivity analyses of the liability, which was classified as a Level 3 financial instrument. The contingent royalty obligation estimate may be significantly impacted by changes in assumptions used in these analyses. For example, the Company recalculated the fair value of the liability by applying a +/- 2% change to the input variable in the discounted cash flow model; the discount rate. A 2% decrease in the discount rate would increase the liability by approximately $126 and a 2% increase in the discount rate would decrease the liability by approximately $112.

 

F-13

 

 

Note 5 – Inventory

 

Inventory at December 31, 2022 and 2021 consisted of the following:

 

 

   2022   2021 
   December 31, 
   2022   2021 
Raw materials  $697   $569 
Work-in-process   155    - 
Finished goods   

548

    292 
Inventory reserve   (401)   (365)
Inventory, net   $999   $496 
Inventory, current  $488   $

496

 
Inventory, non-current 

$

511   $- 

 

For the years ended December 31, 2022 and 2021, an inventory impairment of $598 and $443, respectively, was recorded.

 

Note 6 – Fixed assets, net

 

Fixed assets, net, consists of the following:

 

   2022   2021 
   December 31, 
   2022   2021 
Office equipment  $171   $171 
Computers and software   321    305 
Machinery   1,049    807 
Lab and medical equipment   1,477    1,342 
Leasehold improvements   200    193 
Total   3,218    2,818 
Less accumulated depreciation and amortization   (1,893)   (1,390)
Fixed assets, net  $1,325   $1,428 

 

Depreciation and amortization expense for the years ended December 31, 2022 and 2021 was $510 and $439, respectively. The Company incurred a loss on the impairment of fixed assets in the amount of $46 and $0 for the years end December 31, 2022 and 2021, respectively.

 

Note 7 – Leases

 

The Company leases an office in Fort Lauderdale, Florida under an operating lease. The term expires November 2024. The annual base rent is subject to annual increases of 2.75%. As described within Note 10, the Company shares this space with a related party pursuant to the Shared Space Agreement, as defined below.

 

The Company leases an office in Israel under an operating lease. The term expired on December 31, 2022. The Company entered into a new tenancy contract with the facility for a period of twelve months from January 1, 2023 to December 31, 2023.

 

The Company leases vehicles under operating leases that expire at various dates through 2025.

 

Many of these leases provide for payment by the Company, as the lessee, of taxes, insurance premiums, costs of maintenance and other costs which are expensed as incurred. Certain operating leases include escalation clauses and some of which may include options to extend the leases for up to 3 years.

 

F-14

 

 

The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows:

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
Lease Cost          
Operating lease cost, net of related party license fee  $92   $139 
Variable lease cost   120    119 
Total lease cost  $212   $258 

 

   As of December 31, 
   2022   2021 
Assets          
Operating lease, right-of-use asset  $428   $687 
Liabilities          
Current          
Operating lease liabilities  $245   $307 
Non-current          
Operating lease liabilities, net of current portion   178    385 
Total lease liabilities  $423   $692 
           
Other information:          
Weighted average remaining lease term - operating leases   1.79 years    2.49 years 
Weighted-average discount rate - operating leases   7.36%   7.66%

 

The Company records operating lease payments to lease expense using the straight-line method. The Company’s lease expense was $212 and $258 for the years ended December 31, 2022 and 2021, respectively, included in general and administrative expenses, which is net of the related party license fee of $242 and $189 for the years ended December 31, 2022 and 2021, respectively (see Note 10).

 

Future minimum lease payments under non-cancellable operating leases as of December 31, 2022 were as follows:

 

Year Ended December 31,  Amount 
2023  $266 
2024   176 
2025   

7

 
Total future minimum lease payments   

449

 
Imputed interest   (26)
Total liability  $423 

 

The following table summarizes the cash paid for amounts included in the measurement of lease liabilities for the years ended December 31, 2022 and 2021:

 

   2022   2021 
   Years Ended December 31, 
   2022   2021 
Cash paid for amounts included in measurement of lease liabilities:  $(342)  $(324)
           

 

F-15

 

 

Note 8 – Convertible Note, Term Debt and Long-Term Debt

 

On July 16, 2021 (the “Effective Date”), the Company entered into a loan facility (the “Kreos Loan Agreement”) with Kreos Capital VI (Expert Fund) LP (the “Lender”). Under the Kreos Loan Agreement, the Lender will provide the Company with access to term loans in an aggregate principal amount of up to $12,000 (the “Loan”) in three tranches as follows: (a) on the Effective Date, a loan in the aggregate principal amount of $4,000 (the “Convertible Note”, or “Tranche A”), (b) on the Effective Date, a loan in the aggregate principal amount of $5,000 (“Tranche B”), and (c) available until December 31, 2021, a loan in the aggregate principal amount of $3,000 (“Tranche C”, together with Tranche B, the “Long-term Debt”). The Kreos Loan Agreement contains customary representations and warranties, indemnification provisions in favor of the Lender, events of default and affirmative and negative covenants, including, among others, covenants that limit or restrict the Company’s ability to, among other things, incur additional indebtedness, merge or consolidate, make acquisitions, pay dividends or other distributions or repurchase equity, make investments, dispose of assets and enter into certain transactions with affiliates, in each case subject to certain exceptions. Outstanding borrowings under the Loan are secured by a first priority security interest on substantially all of the personal property assets of the Company, including the Company’s material intellectual property and equity interests in its subsidiaries. There are no liquidity or financial covenants.

 

The Convertible Note and Tranche B were funded on the Effective Date. As of December 31, 2021, the Company drew down the full $3,000 aggregate principal amount of Tranche C.

 

The Convertible Note requires forty-eight monthly interest only payments at 7.75% per annum commencing after the Effective Date and thereafter full payment of the then outstanding principal balance of the Convertible Note on July 1, 2025. The Kreos Loan Agreement contains features that would permit the Lender to convert all or any portion of the outstanding principal balance of the Convertible Note at any time, pursuant to which the converted part of the Convertible Note will be converted into that number of shares of common stock of the Company to be issued to the Lender at a price per share equal to the conversion price, of $28 per share. Following the conversion of any portion of the outstanding principal balance of the Convertible Note, the principal balance of the Convertible Note remaining outstanding shall continue to bear interest at 7.75% per annum. The Tranche B loan requires interest only monthly payments commencing on the Effective Date until September 30, 2022 and, thereafter, thirty-three monthly payments of principal and interest accrued thereon until June 1, 2025. The Tranche C loan requires interest only monthly payments commencing on the date of the draw down until September 30, 2022 and, thereafter, thirty-two monthly payments of principal and interest accrued thereon until June 1, 2025.

 

In connection with the Kreos Loan Agreement, the Company also issued to the Lender a warrant (“Warrant”), dated July 16, 2021, to purchase up to 9,547 shares of the Company’s common stock, at an exercise price of $20.948 per share, payable in cash or on a cashless basis according to the formula set forth in the Warrant. The exercise price of the Warrant and the number of shares issuable upon exercise of the Warrant are subject to adjustments for stock splits, combinations, stock dividends or similar events. The Warrant is exercisable until the date that is ten years after the date of issuance. The Company concluded that the Warrant is indexed to its own stock and, accordingly is classified as equity. See note 11 for further discussion of the Warrant.

 

The Company treated Tranche A, Tranche B and Tranche C, and the Warrant as three separate freestanding financial instruments with the proceeds received in connection with the transaction allocated amongst the instruments based on relative fair value. The proceeds received in connection with the transaction allocated amongst the instruments based on relative fair value resulted in $165 being allocated to the Warrant and a corresponding amount recorded as a debt discount to the Convertible Note and Long-term Debt. The Company recorded an aggregate debt discount of $845 related to the Loan, inclusive of the debt discount of $165 in connection to the Warrant, which will be amortized to interest expense over the term of each respective tranche using the effective interest method. The Company also paid $540 in cash for debt issuance costs. Additionally, per the Kreos Loan Agreement, with respect to the Long-term Debt, there is an advance payment of $274 that is recorded at a debt discount. The advance payment represents the last month’s payment in relation to the Long-term Debt. There is also an end of loan payment of $140 which is included on the balance sheet as a liability within the Long-term Debt and also within the total aggregate debt discount of $845.

 

Subsequent to the issuance of the consolidated financial statements for the year ended December 31, 2021, the Company identified that the current portion of long-term debt was incorrectly classified as non-current on the balance sheet as of December 31, 2021. Management evaluated this misstatement and concluded it was not material to the financial statements and therefore, the Company elected to correct the current portion of long-term debt as of December 31, 2021 in these consolidated financial statements for comparative purposes.

 

F-16

 

 

For the year ended December 31, 2022, interest expense for the Loan was as follows:

 

   Year Ended December 31, 
   2022     2021 
Contractual interest expense  $1,001     $ 362 
Amortization of debt issuance costs   330       91 
Total interest expense  $1,331     $ 453 

 

Future principal payments under the Convertible Note as of December 31, 2022 are as follows:

 

Years Ending December 31,  Amount 
2023  $- 
2024   - 
2025   4,000 
Total future principal payments   4,000 
Less unamortized debt issuance costs   (108)
Total balance  $3,892

 

Future principal payments under the Term Debt as of December 31, 2022 are as follows:

 

Years Ending December 31,  Amount 
2023  $2,714 
2024   2,983 
2025   1,601 
Total future principal payments   7,298 
End of loan payments   140 
Less unamortized debt issuance costs of current portion of long-term debt   (182)
Less unamortized debt issuance costs of non-current portion long-term debt   

(135

)
Total balance  $7,121 

 

Note 9 – Commitments and Contingencies

 

Royalties to the IIA

 

The Company has received grants from the Government of the State of Israel through the Israeli National Authority for Technical Innovation (the “IIA”) for the financing of a portion of its research and development expenditures. The total amount that was received and recorded between the periods ending December 31, 2011 through 2016 was $1,332. No amounts were received during the years ended December 31, 2022 and 2021. The Company has a contingent obligation to the IIA for the total amount received along with the accumulated LIBOR interest to date in the amount of $1,426 and $1,419 as of December 31, 2022 and 2021, respectively. This obligation is repaid in the form of royalties on revenues generated in any fashion with a rate that is currently at 4% (which may be increased under certain circumstances). The Company may be obligated to pay up to 100% (which may be increased under certain circumstances) of the U.S. dollar-linked value of the grants received, plus interest at the rate of 12-month LIBOR.

 

Repayment of the grants is contingent upon the Company’s ongoing commercialization and generation of sales, which is subject to significant risk and uncertainty. The Company has no obligation to repay these grants if no significant sales are generated. The Company has recorded an immaterial expense for the years ended December 31, 2022 and 2021, and an immaterial liability at December 31, 2022 and 2021.

 

F-17

 

 

Royalty Payment Rights on Royalty Payment Rights Certificates

 

The Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”), establishing the rights and preferences of the holders of the Series A Convertible Preferred Stock, including certain directors and officers of the Company (the “Royalty Payment Rights”). As set forth in the Certificate of Designation, the Royalty Payment Rights initially entitled the holders in aggregate, to a royalty in an amount of:

 

  ● 3% of net sales subject to a maximum in any calendar year equal to the total dollar amount of Units closed on in the Company’s 2017 private placement (the “2017 Private Placement”); and
     
  ● 5% of licensing proceeds subject to a maximum in any calendar year equal to the total dollar amount of Units closed on in the 2017 Private Placement.

 

In addition, in connection with completion of the 2017 Private Placement, the Company issued the placement agent royalty payment rights certificates (the “Placement Agent Royalty Payment Rights Certificates”) which grants the placement agent, and its designees, the right to receive, in the aggregate, 10% of the amount of payments paid to the holders of the Series A Convertible Preferred Stock, or the holders of the Royalty Payment Rights Certificates (the “Royalty Payment Rights Certificates”), upon the conversion of the Series A Convertible Preferred Stock into shares of the Company’s common stock. The Placement Agent Royalty Payment Rights Certificates are on substantially similar terms as the Royalty Payment Rights of the Series A Convertible Preferred Stock.

 

The Royalty Payment Rights Certificate obligation and Placement Agent Royalty Payment Rights Certificate obligation (the “Contingent Royalty Obligation”) was recorded as a liability at fair value as “Contingent royalty obligation” in the consolidated balance sheets at December 31, 2022 and 2021 (see Contingent Royalty Obligation below). The fair value at inception was allocated to the royalty rights and the residual value was allocated to the preferred shares and recorded as equity.

 

The Company amended its Certificate of Designation to modify the Royalty Payment Rights when the Company consummated its Initial Public Offering (“IPO”) on February 16, 2018, at which time the Company converted the Series A Convertible Preferred Stock into shares of the Company’s common stock and issued the Royalty Payment Rights Certificates. Pursuant to the terms of the Royalty Payment Rights Certificates, if and when the Company generates sales of the current and potential future versions of the Pure-Vu System, including disposables, parts, and services, or if the Company receives any proceeds from the licensing of the current and potential future versions of the Pure-Vu System, then the Company will pay to the holders of the Royalty Payment Rights Certificates a royalty (the “Royalty Amount”) equal to, in the aggregate, in royalty payments in any calendar year for all products:

 

  ● 3% of Net Sales* for commercialized product directly; and
     
  ● 5% of any Licensing Proceeds** for rights to commercialize the product if sublicensed by the Company to a third-party.

 

* Notwithstanding the foregoing, with respect to Net Sales based Royalty Amounts, (a) no Net Sales based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Net Sales equal to $20,000 (the “Initial Net Sales Milestone”), and royalties shall only be computed on, and due with respect to, Net Sales generated in excess of the Initial Net Sales Milestone, and (b) the total Net Sales based Royalty Amount due and payable in any calendar year shall be subject to a royalty cap amount per calendar year of $30,000. “Net Sales” is defined in the Royalty Payment Rights Certificates. The Company has not reached the Initial Net Sales Milestone as of December 31, 2022.
   
** Notwithstanding the foregoing, with respect to Licensing Proceeds based Royalty Amounts, (a) no Licensing Proceeds based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Licensing Proceeds equal to $3,500 (the “Initial Licensing Proceeds Milestone”), and royalties shall only be computed on, and due with respect to, Licensing Proceeds in excess of the Initial Licensing Proceeds Milestone and (b) the total Licensing Proceeds based Royalty Amount due and payable in any calendar year shall be subject to a royalty cap amount per calendar year of $30,000. “Licensing” Proceeds is defined in the Certificate. The Company has not reached the Initial Licensing Proceeds Milestone as of December 31, 2022.

 

F-18

 

 

The Royalty Amount will be payable up to the later of (i) the latest expiration date of the Company’s patents issued as of December 22, 2016, or (ii) the latest expiration date of any pending patents as of December 22, 2016 that have since been issued or may be issued in the future (which is currently March 2039 jx). Following the expiration of all such patents, the holders of the Royalty Payment Rights Certificates and the holders of the Placement Agent Royalty Payment Rights Certificates will no longer be entitled to any further royalties for any period following the latest to occur of such patent expiration.

 

On February 16, 2018, the date of the closing of the IPO, (1) the amendment to the Certificate of Designation became effective, (2) all outstanding shares of Series A Convertible Preferred Stock were converted into shares of the Company’s common stock pursuant to a mandatory conversion, and (3) the Royalty Payment Rights Certificates were issued to the former holders of the Series A Convertible Preferred Stock.

 

Contingent Royalty Obligation

 

The contingent royalty obligation was recorded as a non-current liability at fair value in the consolidated balance sheets at December 31, 2022 and 2021 in the amount of $1,212 and $1,760, respectively. A gain on change in fair value of contingent royalty obligation of $548 for the year ended December 31, 2022 and a loss on change in fair value of contingent royalty obligation of $143 was recorded for the year ended December 31, 2021.

 

Other Commitments and Contingencies

 

The Company has a severance contingency for severance payments to its CEO, COO, and CFO in the aggregate of approximately $1,408, in the event that they are terminated without cause or leave due to good reason, as outlined in their employee agreements. Management estimates that the likelihood of payment is remote; therefore, no liability was reflected in these consolidated financial statements.

 

Manufacturing Component Purchase Obligations

 

The Company utilizes two outsourcing partners to manufacture its workstation and disposable portions of the Pure-Vu System, and to perform final assembly and testing of finished products. These outsourcing partners acquire components and build product based on demand information supplied by the Company. As of December 31, 2022, the Company expects to pay $41 under manufacturing-related supplier arrangements within the next year, substantially all of which is noncancelable.

 

Note 10 – Related Party Transactions

 

Shared Space Agreement

 

In January 2020, the Company entered into a license agreement (the “Shared Space Agreement”) with Orchestra BioMed, Inc. (OBIO), formerly a greater than 5% holder of the Company’s common stock and entity in which David Hochman, the Chairman of the Company’s board of directors, serves as the Chairman of the board of directors and Chief Executive Officer, and Darren Sherman, a member of the Company’s board of directors, serves as a director and as President and Chief Operating Officer. Pursuant to the Shared Space Agreement, the Company granted a license to OBIO for the use of portions of the office space not being used by the Company in the Company’s leased facility in Fort Lauderdale, Florida (the “Premises”), and a proportionate share of common areas of such Premises, which previously covered approximately 35% of the Premises and was to expand incrementally to approximately 60 to 70% of the Premises by September 2024. In May 2022, the Company entered into an amendment to the Shared Space Agreement. Pursuant to the amendment, the area covered by the Shared Space Agreement was expanded to 95% of the premises and the aggregate license fees will generally range from approximately $212 to approximately $270 in any given calendar year during the term of the Shared Space Agreement until the termination of the lease in November 2024. During the year ended December 31, 2022 and 2021, the Company recorded a license fee of $242 and $189, respectively, in relation to the Shared Space Agreement. This amount is netted with rent expense in general and administrative expenses.

 

Note 11 – Share-based compensation and Common Stock Issuance

 

The following table sets forth total non-cash share-based compensation for the issuance of common stock, options to purchase common stock, warrants to purchase common stock, and restricted stock unit awards by operating statement classification for the years ended December 31, 2022 and 2021:

 

   2022   2021 
  

Year ended December 31,

 
   2022   2021 
Research and development  $388   $575 
Sales and marketing   238    353 
General and administrative   1,183    2,544 
Total  $1,809   $3,472 

 

For the year ended December 31, 2022 and 2021, the Company recorded $1,145 and $2,270, respectively, for share-based compensation expense related to stock options.

 

As of December 31, 2022, unamortized share-based compensation for stock options was $964, with a weighted-average recognition period of 0.87 years.

 

For the year ended December 31, 2022 and 2021, the Company recorded $57 and $335, respectively, for share-based compensation expense related to warrants.

 

For the year ended December 31, 2022 and 2021, the Company recorded $607 and $867, respectively, for share-based compensation expense related to restricted stock units.

 

As of December 31, 2022, unamortized stock compensation for restricted stock units was $308, with a weighted-average recognition period of 0.81 years.

 

Stock option and warrant activity

 

In December 2016, the Company adopted the Motus GI Holdings, Inc. 2016 Equity Incentive Plan (the “2016 Plan”). Pursuant to the 2016 Plan, the Company’s board of directors may grant options to purchase shares of the Company’s common stock, stock appreciation rights, restricted stock, stock units, performance shares, performance units, incentive bonus awards, other cash-based awards and other stock-based awards to employees, officers, directors, consultants and advisors. Pursuant to the terms of an annual evergreen provision in the 2016 Plan, the number of shares of common stock available for issuance under the 2016 Plan shall increase annually by six percent (6%) of the total number of shares of common stock outstanding on December 31st of the preceding calendar year; provided, however, that the board of directors may act prior to the first day of any calendar year to provide that there shall be no increase such calendar year, or that the increase shall be a lesser number of shares of our common stock than would otherwise occur. On January 1, 2022, pursuant to an annual evergreen provision, the number of shares of common stock reserved for future grants was increased by 279,586 shares. Under the 2016 Plan, effective as of January 1, 2023, the maximum number of shares of the Company’s common stock authorized for issuance is 804,371. As of December 31, 2022, there were 15,165 shares of common stock available for future grant under the 2016 Plan.

 

A summary of the Company’s stock option and warrant activity is as follows:

 

   Options     Warrants 
  

Shares

Underlying

Options

  

Weighted

Average

Exercise Price

   Weighted Average Remaining Contractual Life (years)     Average Intrinsic Value    

Shares

Underlying

Warrants

  

Weighted

Average

Exercise Price

     Weighted Average Remaining Contractual Life (years)     Average Intrinsic Value 
Outstanding at December 31, 2020   251,419   $60.00     7.96     $ -      852,820   $37.20       5.78     $ - 
Granted   64,675   $32.80                    326,548   $41.40                 
Forfeited   (8,502)  $68.60                    (45,758)  $100.00                 
Exercised   (713,363)  $24.80                    -   $-                 
Outstanding at December 31, 2021   307,592   $54.10     7.45     $ -      420,247   $54.76       3.40     $ - 
Granted   102,997   $8.73                    6,000   $10.00                 
Expired   (6,597)  $64.24                    (26,986)  $101.13                 
Cancelled   -   $-                    (6,000)  $56.60                 
Forfeited   (3,855)  $11.48                    -   $-                 
Outstanding at December 31, 2022   400,137   $42.69     7.21     $ -      393,261   $50.86       2.66     $ - 
Exercisable at December 31, 2022   294,152   $52.77                    393,261   $50.86                 

 

The options granted during the years ended December 31, 2022 and 2021 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:

 

   For the year ended December 31, 
   2022   2021 
Expected term, in years    5.8    5.8 
Expected volatility    99.21%   106.24%
Risk-free interest rate     2.10%   0.77%
Dividend yield    -    - 

 

The grant date fair value for stock options issued during the years ended December 31, 2022 and 2021 were $8.62 and $26.4, respectively.

 

F-19

 

 

Restricted Stock Units

 

A summary of the Company’s restricted stock unit awards activity is as follows:

 

   Number of Shares  

Weighted Average

Grant Date

Fair Value

 
Nonvested at December 31, 2020   16,891   $62.00 
Granted   21,300    34.20 
Vested   (12,071)   48.40 
Nonvested at December 31, 2021   25,120   $44.77 
Granted   18,250    9.07 
Vested   (23,092)   39.53 
Nonvested at December 31, 2022   20,278   $18.62 

 

As of December 31, 2021, there were 3,138 vested and unissued restricted stock units. These restricted stock units were issued as common stock during the year ended December 31, 2022.

 

Issuance of Warrants to Purchase Common Stock

 

In February 2020, the Company entered into a services agreement whereby it agreed to issue warrants to purchase 6,000 shares of common stock of the Company. The warrants fully vested over a one-year period on a monthly basis and expire three years from the date of issuance and were exercisable at weighted average exercise price equal to $56.60 per share of common stock. In March 2022, the Company granted new warrants as a replacement to the vested warrants held by the service provider, for which all the share-based compensation expense had been recognized in prior fiscal periods. The issuance of new warrants concurrently with the cancellation of the existing warrants was treated as a modification. The Company agreed to issue replacement warrants to purchase 6,000 shares of common stock of the Company exercisable at a price equal to $10 per share of common stock. The fair value of the warrants were valued on the date of grant at $0.38 using the Black-Scholes option-pricing model with the following parameters: (1) risk-free interest rate of 0.91%; (2) expected life in years of 1.62; (3) expected stock volatility of 81.97%; and (4) expected dividend yield of 0%. The replacement warrants immediately vested upon issuance and expire three years from the date of issuance. As a result, the Company recognized $26 of share-based compensation for the year ended December 31, 2022, related to the incremental fair value which is equal to the excess of the fair value of the new warrants granted over the fair value of the original award on the cancellation date.

 

Issuance of Common Stock

 

On January 5, 2022, non-employee members of the Board of Directors were granted an aggregate of 24,458 shares of fully-vested common stock with a fair value of $9.60 per share of common stock, as compensation, in lieu of $235 of cash compensation, for service as directors for 2022. The Company recorded $235 and $177 in expense for director services during the year ended December 31, 2022 and 2021, respectively.

 

In March 2021, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”), under which we may offer and sell from time to time common shares having an aggregate offering price of up to $25.0 million. During the year ended December 31, 2022, we sold approximately 2.2 million shares of our common stock under this agreement, resulting in net cash proceeds of $9.9 million, after deducting issuance costs of $0.4 million. From January 1, 2023 to March 14, 2023, the Company issued and sold approximately 119,104 common shares of our common stock under this agreement, resulting in net cash proceeds of approximately $118.0 thousand, after deducting issuance costs $4.0 thousand.

 

Note 12 – Income Taxes

 

Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences. In accordance with ASC 740, “Income Taxes,” the Company recorded a valuation allowance to fully offset the gross deferred tax asset, because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December 31, 2022 and 2021.

 

As of December 31, 2022 and 2021, the Company had deferred tax assets of approximately $37,400 and $27,200, respectively, against which a full valuation allowance of $37,400 and $27,200, respectively had been recorded. The change in the valuation allowance for the year ended December 31, 2022 was an increase of $10,200. The increase in the valuation allowance for the year ended December 31, 2022 was mainly attributable to increases in net operating losses and non-deductible research expenses, which resulted in an increase in the deferred tax assets with a corresponding valuation allowance. Significant components of the Company’s deferred tax assets at December 31, 2022 and 2021 were as follows:

 

 

     2022   2021 
   December 31, 
   2022   2021 
Deferred tax assets:          
Net operating loss carryforwards – Federal and state  $14,614   $5,281 
Net operating loss carryforwards – Israel   18,813    19,354 
Share-based compensation   1,735    1,732 
Capitalized research and development   2,246    218 
Accrued liabilities and reserves   681    831 
Total deferred tax assets   38,089    27,416 
Deferred tax liabilities:          
Accelerated research and development expense   (548)   - 
Right of use asset   (109)   (158)
Other   (34)   (14)
Total deferred tax liabilities   (691)   (172)
Net deferred tax assets before valuation allowance   37,398    27,244 
Valuation allowance   (37,398)   (27,244)
Net deferred tax assets after valuation allowance  $-   $- 

 

F-20

 

 

A reconciliation of the federal statutory tax rate and the effective tax rates for the years ended December 31, 2022 and 2021 is as follows:

 

   For the Year Ended December 31, 
   2022   2021 
U.S. federal statutory tax rate   21.0%   21.0%
State income taxes, net of federal benefit   6.6    2.0 
U.S. vs. foreign tax rate differential   0.8    0.9 
Non-deductible expenses   (2.7)   (1.9)
Foreign exchange adjustments   (10.7)   2.5 
Change in valuation allowance   (15.0)   (24.5)
Effective tax rate   -%   -%

 

The Company had approximately $134,100 and $119,600 of gross net operating loss (“NOL”) carryforwards (federal, state and Israel) as of December 31, 2022 and 2021, respectively. Sections 382 and 383 of the Internal Revenue Code, and similar state regulations, contain provisions that may limit the NOL carryforwards available to be used to offset income in any given year upon the occurrence of certain events, including changes in the ownership interests of significant stockholders. In the event of a cumulative change in ownership in excess of 50% over a three-year period, the amount of the NOL carryforwards that the Company may utilize in any one year may be limited.

 

The Tax Cuts and Jobs Act of 2017 (TCJA) has modified the IRC 174 expenses related to research and development for the tax years beginning after December 31, 2021. Under the TCJA, the Company must now capitalize the expenditures related to research and development activities and amortize over five years for U.S. activities and 15 years for non-U.S. activities using a mid-year convention. Since this has been the Company’s policy since 2019, the current year capitalization of research and development costs in accordance with IRC 174 was $4,900,000 for a total accumulated gross amount of $8,800,000 as of December 31, 2022.

 

During the year ended December 31, 2021, the Company incurred an ownership change under Internal Revenue Code Section 382, resulting in an annual NOL utilization limitation of approximately $3,700. None of the Company’s NOL carryforwards or deferred tax assets were required to be reduced since the limitation did not preclude the Company from potentially utilizing all of its NOL carryforwards. Future significant ownership changes could cause a portion or all of the Company’s NOL carryforwards to expire before utilization, however.

 

A reconciliation of the Company’s NOLs for the years ended December 31, 2022 and 2021 is as follows:

 

 

     2022   2021 
   December 31, 
   2022   2021 
U.S. Federal NOL’s  $26,875   $18,420 
U.S. State NOL’s   25,464    17,009 
Israel NOL’s   81,794    84,148 
Total NOL’s  $134,133   $119,577 

 

The Company’s federal and state NOLs of $3,300 and $25,464, respectively, begin to expire after 2036 through 2042. The Company’s federal NOL of $23,575, generated since 2018, and the Israel NOL of $81,794 do not expire. A check the box election for Israel was made and accepted by the IRS as of January 1, 2019. As such, approximately $38,100 of Israeli NOLs are available for use in the U.S and have an indefinite life.

 

The Company follows guidance on accounting for uncertainty in income taxes which prescribes a minimum threshold a tax position is required to meet before being recognized in the financial statements. The Company does not have any liabilities as of December 31, 2022 and 2021 to account for potential income tax exposure. The Company is obligated to file income tax returns in the U.S. federal jurisdiction, several U.S. States and Israel. Since the Company had losses in the past, all prior years that generated net operating loss carry-forwards are open and subject to audit examination in relation to the net operating loss generated from those years.

 

Note 13 – Subsequent Events

 

In January 2023, the Company committed to a restructuring initiative designed to position the Company to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. The Company has engaged Lake Street Capital Markets LLC (“Lake Street Capital”) to advise the Company in this process. Potential strategic alternatives that may be considered by the Company are expected to include an acquisition, merger, reverse merger, other business combination, sale of assets, licensing and other strategic transactions. The restructuring initiative primarily includes the reduction of the Company’s workforce. The Company intends to continue to evaluate and identify other areas of its business to enhance efficiencies and improve processes, with a goal to further lower its operating expenses and capital needs. The Company expects to reduce its quarterly cash expenditures by approximately 35% by eliminating approximately 45% of its workforce during the first quarter of 2023. In connection with the restructuring, the Company expects to incur a non-recurring charge of approximately $1.0 to $2.0 million in the first quarter of 2023.

 

F-21

 

 GRAPHIC 2 form10-k_001.jpg begin 644 form10-k_001.jpg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form10-k_002.jpg begin 644 form10-k_002.jpg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form10-k_003.jpg begin 644 form10-k_003.jpg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end GRAPHIC 5 form10-k_004.jpg begin 644 form10-k_004.jpg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end GRAPHIC 6 form10-k_005.jpg begin 644 form10-k_005.jpg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form10-k_006.jpg begin 644 form10-k_006.jpg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form10-k_009.jpg begin 644 form10-k_009.jpg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end GRAPHIC 9 form10-k_010.jpg begin 644 form10-k_010.jpg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end GRAPHIC 10 image_001.jpg begin 644 image_001.jpg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b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ݵ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ǯ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end EX-23.1 11 ex23-1.htm

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statements of Motus GI Holdings, Inc. on Form S-3 (Nos. 333-230516, 333-254343 and 333-254346) and Form S-8 (Nos. 333-224003, 333-230506, 333-237476, 333-254344 and 333-263940) of our report dated March 31, 2023, on our audits of the financial statements as of December 31, 2022 and 2021 and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March 31, 2023. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern.

 

/s/ EisnerAmper LLP  
   
EISNERAMPER LLP  
Philadelphia, Pennsylvania  
March 31, 2023  

 

 

 EX-31.1 12 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT

TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Timothy P. Moran, certify that:

 

  1. I have reviewed this annual report on Form 10-K for the period ended December 31, 2022 of Motus GI Holdings, Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
    a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
       
    b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
       
    c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
       
    d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
       
  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
    a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
       
    b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  Date: March 31, 2023
   
  /s/ Timothy P. Moran
  Timothy P. Moran
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 EX-31.2 13 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT

TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Andrew Taylor, certify that:

 

  1. I have reviewed this annual report on Form 10-K for the period ended December 31, 2022 of Motus GI Holdings, Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
    a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
       
    b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
       
    c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
       
    d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
       
  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
    a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
       
    b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  Date: March 31, 2023
   
  /s/ Andrew Taylor
  Andrew Taylor
  Chief Financial Officer
  (Principal Financial Officer)

 

 

 EX-32.1 14 ex32-1.htm

 

Exhibit 32.1

 

Certification Pursuant to

18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

 

This Certification is being filed pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002. This Certification is included solely for the purposes of complying with the provisions of Section 906 of the Sarbanes-Oxley Act and is not intended to be used for any other purpose. In connection with the accompanying Annual Report on Form 10-K of Motus GI Holdings, Inc. for the year ended December 31, 2022 (the “Annual Report”), each of the undersigned hereby certifies in his capacity as an officer of Motus GI Holdings, Inc. (the “Company”) that to such officer’s knowledge:

 

(1) The Annual Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: March 31, 2023 By: /s/ Timothy P. Moran
    Timothy P. Moran
    Chief Executive Officer
    (Principal Executive Officer)

 

Dated: March 31, 2023 By: /s/ Andrew Taylor
    Andrew Taylor
    Chief Financial Officer
    (Principal Financial Officer)

 

This Certification is being furnished solely to accompany the Annual Report pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Motus GI Holdings, Inc. and will be retained by Motus GI Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 EX-101.SCH 15 mots-20221231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Significant Accounting Policies and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Fixed assets, net link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Convertible Note, Term Debt and Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Share-based compensation and Common Stock Issuance link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Significant Accounting Policies and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Significant Accounting Policies and Basis of Presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Fixed assets, net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Convertible Note, Term Debt and Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Share-based compensation and Common Stock Issuance (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Schedule of Fixed Assets are Stated at Cost Less Accumulated Depreciation (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Significant Accounting Policies and Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Schedule of Fair Value of Financial Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Fair Value Measurements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Inventory (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Schedule of Fixed Assets Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Fixed assets, net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Lease Cost and Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Future Minimum Lease Payments for Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule of Measurement of Lease Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Schedule of Interest Expense for Loan (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Schedule of Future Principal Payments (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Convertible Note, Term Debt and Long-Term Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Schedule of Stock-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Schedule of Stock option and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Schedule of Option Pricing Model Using Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Schedule of Restricted Stock Unit Awards Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Share-based compensation and Common Stock Issuance (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Schedule of Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Schedule of Reconciliation of NOL (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 16 mots-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 17 mots-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 18 mots-20221231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Timing of Transfer of Good or Service [Axis] Transferred at Point in Time [Member] Transferred over Time [Member] New Warrants [Member] Long-Lived Tangible Asset [Axis] Office Equipment [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Computers and Software [Member] Machinery [Member] Equipment [Member] Leasehold Improvements [Member] Product and Service [Axis] Contingent Royalty Obligation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Measurement Input Type [Axis] Measurement Input, Discount Rate [Member] Office [Member] Geographical [Axis] Fort Lauderdale [Member] ISRAEL Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Kreos Loan Agreement [Member] Financial Instrument [Axis] Tranche A [Member] Tranche B [Member] Tranche C [Member] Award Type [Axis] Warrant [Member] Long-Term Debt, Type [Axis] Convertible Debt [Member] Long-Term Debt [Member] Income Tax Authority [Axis] Israeli National Authority For Technical Innovation [Member] Royalty Payment Rights Certificates [Member] Sale of Stock [Axis] Private Placement [Member] Class of Stock [Axis] Series A Preferred Stock [Member] Royalty [Member] Shared Space Agreements [Member] Investment, Name [Axis] Orchestra Bio Med Inc [Member] Income Statement Location [Axis] Research and Development Expense [Member] Selling, General and Administrative Expenses [Member] General and Administrative Expense [Member] Derivative Instrument [Axis] Equity Option [Member] Restricted Stock Units (RSUs) [Member] Plan Name [Axis] 2016 Equity Incentive Plan [Member] Services Agreement [Member] Class of Warrant or Right [Axis] Warrants [Member] Replacement Warrants [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Dividend Rate [Member] Title of Individual [Axis] Non Employee [Member] Equity Distribution Agreement [Member] Federal [Member] State [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] Assets Current assets: Cash and cash equivalents Accounts receivable Inventory, current Prepaid expenses and other current assets Total current assets Fixed assets, net Inventory, non-current Right-of-use assets Other non-current assets Total assets Liabilities and Shareholders’ Equity Current liabilities: Accounts payable and accrued expenses Operating lease liabilities - current Other current liabilities Current portion of long-term debt, net of unamortized debt discount of $182 and $271, respectively Total current liabilities Contingent royalty obligation Operating lease liabilities - non-current Convertible note, net of unamortized debt discount of $108 and $166, respectively Long-term debt, net of unamortized debt discount of $135 and $317, respectively Total liabilities Commitments and contingent liabilities (Note 9) Shareholders’ equity Preferred stock $0.0001 par value; 10,000,000 shares authorized; zero shares issued and outstanding Common stock $0.0001 par value; 115,000,000 shares authorized; 4,659,769 and 2,416,021 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively Additional paid-in capital Accumulated deficit Total shareholders’ equity Total liabilities and shareholders’ equity Debt instrument, unamortized discount Convertible note, unamortized discount, non-current Debt instrument, unamortized discount, non-current Preferred stock par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses: Costs of revenue - sales Costs of revenue - impairment of inventory Research and development Sales and marketing General and administrative Total costs and expenses Operating loss Gain (loss) on change in estimated fair value of contingent royalty obligation Loss on extinguishment of debt Finance expense, net Other income Foreign currency loss Net loss Deemed dividends from warrant issuance Net loss attributable to common shareholders Basic and diluted loss per common share: Net loss attributable to common shareholders Weighted average number of common shares outstanding, basic and diluted Statement [Table] Statement [Line Items] Balance Beginning balance, shares Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs of $368 Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares Issuance of common stock upon exercise of warrants, net of financing fees of $366 Issuance of common stock upon exercise of warrants, shares Issuance of common stock for board of directors’ compensation Issuance of common stock for board of directors' compensation, shares Issuance of common shares upon vesting of restricted stock units Issuance of common shares upon vesting of restricted stock units, shares Fractional shares settled in cash pursuant to reverse stock split Fractional shares settled in cash pursuant to reverse stock split, shares Issuance of warrants associated with convertible note and long- term debt Share-based compensation Net loss Balance Ending balance, shares Proceeds from Issuance Initial Public Offering Financing fees Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Amortization of debt issuance costs (Gain) loss on change in estimated fair value of contingent royalty obligation Share-based compensation Issuance of common stock for board of directors’ compensation Issuance of common stock for consultants Loss on extinguishment of debt Impairment of inventory Impairment of fixed assets Amortization on operating lease right of use asset Changes in operating assets and liabilities: Accounts receivable Inventory Prepaid expenses and other current assets Accounts payable and accrued expenses Operating lease liability Other current and non-current liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of fixed assets Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common shares Fractional shares paid in cash pursuant to reverse stock split Proceeds from exercise and purchase of warrants Borrowings under convertible note and long-term debt Repayment of debt Payment of debt issuance costs Equity financing fees Net cash provided by financing activities NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS AT END OF PERIOD SUPPLEMENTAL CASH FLOW INFORMATION: CASH PAID FOR: Interest SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING ACTIVITIES: Common stock issued to settle accrued expenses for board of directors’ compensation Reclassification of inventory to fixed assets Reclassification of prepaid expenses to fixed assets Purchase of fixed assets in accounts payable and accrued expenses Warrants issued related to convertible note and long-term debt recorded as debt discount Accrued end of loan payment recorded as debt discount Operating lease liabilities arising from obtaining right-of-use assets Prepayment of lease obligation Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business Going Concern Accounting Policies [Abstract] Significant Accounting Policies and Basis of Presentation Fair Value Disclosures [Abstract] Fair Value Measurements Inventory Disclosure [Abstract] Inventory Property, Plant and Equipment [Abstract] Fixed assets, net Leases Leases Debt Disclosure [Abstract] Convertible Note, Term Debt and Long-Term Debt Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Related Party Transactions [Abstract] Related Party Transactions Share-Based Payment Arrangement [Abstract] Share-based compensation and Common Stock Issuance Income Tax Disclosure [Abstract] Income Taxes Subsequent Events [Abstract] Subsequent Events Basis of presentation and use of estimates Reverse Stock Split Functional currency and foreign currency translation Cash and cash equivalents Revenue recognition Contract Costs Accounts receivable and allowance for doubtful accounts Inventory Leases Fixed assets, net Share-based compensation Basic and diluted net loss per share Research and development expenses Patent costs Debt issuance costs Liabilities due to termination of employment agreements Income taxes Fair value of financial instrument New Accounting Pronouncements- Recently Adopted Accounting Pronouncements- Not Yet Adopted Schedule of Fixed Assets are Stated at Cost Less Accumulated Depreciation Schedule of Fair Value of Financial Assets and Liabilities Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation Schedule of Inventory Schedule of Fixed Assets Net Schedule of Lease Cost and Supplemental Balance Sheet Information Schedule of Future Minimum Lease Payments for Operating Leases Schedule of Measurement of Lease Liability Schedule of Interest Expense for Loan Schedule of Future Principal Payments Schedule of Stock-based Compensation Schedule of Stock option and Warrants Schedule of Option Pricing Model Using Weighted Average Assumptions Schedule of Restricted Stock Unit Awards Activity Schedule of Deferred Tax Assets Schedule of Effective Income Tax Rate Reconciliation Schedule of Reconciliation of NOL Net loss Accumulated deficit Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Useful lives Useful lies, description Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Operating Lease, Lease Income Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration] Revenue recognized Revenue recognized in accordance with ASC 606 Revenue recognized in accordance with ASC 842 Commissions paid Allowance for doubtful accounts [custom:DeemedDividend] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Contingent royalty obligation Balance at December 31, 2021 Change in estimated fair value of contingent royalty obligation Balance at December 31, 2022 Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Increase (decrease) in discount rate Royalty payment, percentage Fair value of the liability, description Raw materials Work-in-process Finished goods Inventory reserve Inventory, net Impairment of inventory Total Less accumulated depreciation and amortization Fixed assets, net Depreciation and amortization expense Schedule Of Lease Cost And Supplemental Balance Sheet Information Operating lease cost, net of related party license fee Variable lease cost Total lease cost Operating lease, right-of-use- asset Operating lease liabilities, current Operating lease liabilities, net of current portion Total lease liabilities Weighted average remaining lease term - operating leases Weighted-average discount rate - operating leases Schedule Of Future Minimum Lease Payments For Operating Leases 2023 2024 2025 Total future minimum lease payments Imputed interest Total liability Cash paid for amounts included in measurement of lease liabilities: Operating lease, description Operating lease expiration date Description of lease term option to extend Operating lease, expense License fees Contractual interest expense Amortization of debt issuance costs Total interest expense Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] 2023 2024 2025 Total future principal payments End of loan payments Less unamortized debt issuance costs of current portion of long-term debt Less unamortized debt issuance costs of non-current portion long-term debt Total balance Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Debt instrument, periodic payment, principal Debt instrument, interest rate Debt instrument, convertible, conversion price Warrant issued to purchase common shares Exercise price Fair value of warrant Advance payment Payments of debt issuance costs Advance payments for debt discount Long term debt Product Liability Contingency [Table] Product Liability Contingency [Line Items] Royalty received LIBOR interest rate Royalties percentage Description of royalty payment Net sales percentage Licensing percentage Percentage of payment amount Royalties income Proceeds from licensing based royalty amounts Contingent royalty obligation Gain on change in fair value of contingent royalty obligation Severance payments Manufacturing Costs Ownership percentage License fee Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total Offsetting Assets [Table] Offsetting Assets [Line Items] Shares underlying options, outstanding beginning Weighted average exercise price, outstanding beginning Weighted average remaining contractual life, outstanding Aggregate intrinsic value, outstanding beginning Shares Underlying Warrants, outstanding beginning Weighted Average Exercise Price, outstanding beginning Weighted Average Remaining Contractual Life, outstanding Aggregate Intrinsic Value, outstanding beginning Shares underlying options, granted Weighted average exercise price, granted Shares Underlying Warrants, granted Weighted Average Exercise Price, granted Shares underlying options, forfeited Weighted average exercise price, forfeited Shares Underlying Warrants, forfeited Weighted Average Exercise Price, forfeited Shares underlying options, exercised Weighted average exercise price, exercised Shares Underlying Warrants, exercised Weighted Average Exercise Price, exercised Shares underlying options, expired Weighted average exercise price, expired Shares Underlying Warrants, expired Weighted Average Exercise Price, expired Shares underlying options, cancelled Weighted average exercise price, cancelled Shares Underlying Warrants, cancelled Weighted Average Exercise Price, cancelled Shares underlying options, outstanding ending Weighted average exercise price, outstanding ending Aggregate intrinsic value, outstanding ending Shares Underlying Warrants, outstanding ending Weighted Average Exercise Price, outstanding ending Aggregate Intrinsic Value, outstanding ending Shares underlying options, exercisable Weighted average exercise price, exercisable Shares Underlying Warrants, exercisable Weighted Average Exercise Price, exercisable Expected term, in years Expected volatility Risk-free interest rate Dividend yield Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of Shares, nonvested beginning Aggregate weighted average grant date fair value, nonvested beginning Number of Shares, nonvested granted Aggregate weighted average grant date fair value, nonvested granted Number of Shares, nonvested vested Aggregate weighted average grant date fair value, nonvested vested Number of Shares, nonvested ending Aggregate weighted average grant date fair value, nonvested ending Share-based compensation expenses Stock based compensation for stock options Weighted-average recognition period Unamortization stock compensation Common stock percentage Common stock available for future grant Grant date fair value Vested and unissued restricted stock units Warrants to purchase of common stock Warrants exercise price Share Price Warrants and Rights Outstanding, Measurement Input Warrants and Rights Outstanding, Term Share based compnesation plan modification, incremental cost Share based compensation options, grants Fair value of common stock Cash compensation Expense for director services Aggregate of offering cost Number of common stock sold, shares Proceeds from common stock Proceeds from net of issuance costs Net operating loss carryforwards – Federal and state Net operating loss carryforwards – Israel Share-based compensation Capitalized research and development Accrued liabilities and reserves Total deferred tax assets Accelerated research and development expense Right of use asset Other Total deferred tax liabilities Net deferred tax assets before valuation allowance Valuation allowance Net deferred tax assets after valuation allowance U.S. federal statutory tax rate State income taxes, net of federal benefit U.S. vs. foreign tax rate differential Non-deductible expenses Foreign exchange adjustments Change in valuation allowance Effective tax rate U.S. Federal NOL’s U.S. State NOL’s Israel NOL’s Total NOL’s Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Deferred tax assets Deferred tax assets valuation allowance Valuation allowance Operating loss Research and development costs Accumulated gross amount Operating loss utilization limit Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Expire date, description Deferred Foreign Income Tax Expense (Benefit) [custom:DeferredForeignIncomeTaxExpenseBenefitAvailableUse] Subsequent Event [Table] Subsequent Event [Line Items] Non recurring charges Contingent royalty obligation. Convertible note noncurrent. Office [Member]. Fort Lauderdale [Member]. Schedule of lease cost and supplemental balance sheet information table text block. Costs of revenue impairment of inventory. Loss on changes in fair value of contingent royalty obligation. Finance income expense net Deemed dividends from warrant issuance. Schedule of measurement of lease liability table text block. Kreos Loan Agreement [Member] Tranche A [Member] Tranche B [Member] Tranche C [Member] Debt instrument unamortized discount current and non current. Issuance of common stock upon exercise of warrants. Issuance of common stock upon exercise of warrants, (shares). Loan payments. Israeli National Authority For Technical Innovation [Member]. London inter bank offered rate. Royalties on revenues, percentage Stock issued during period fractional shares settled in cash pursuant to reverse stock split value. Description of royalty payment. Royalty Payment Rights Certificates [Member]. Stock issued during period fractional shares settled in cash pursuant to reverse stock split shares. Percentage of payment amount. Royalties income Proceeds from licensing based royalty amounts Contingent royalty obligation non-current. Refers to amount of loss on change in fair value of contingent royalty obligation. Net sales percentage. Licensing percentage. Gain loss on change in estimated fair value of contingent royalty obligation. Impairment of inventory. Payments for equity financing fees. Cash paid for [Abstract] Common stock issued to settle accrued expenses for board of directors compensation. Purchase of fixed assets in prepaid expenses. Purchase of property and equipment in accounts payable and accrued expenses. Accrued end of loan payment recorded as debt discount. Prepayment of lease obligation. Issuance of common stock for board of directors compensation. Reverse stock split [Policy Text Block] Shared Space Agreements [Member]. Orchestra Bio Med Inc [Member]. Amount of license fees. Contract costs [Policy Text Block] Schedule of Fixed Assets are Stated at Cost Less Accumulated Depreciation [Table Text Block] Computers and Software [Member] Machinery [Member] Deemed dividend. New Warrants [Member] Debt Issuance Costs [Policy Text Block] Liabilities due to termination of employment agreements [Policy Text Block] New Accounting Pronouncements Not Yet Adopted [Policy Text Block] Receivables trade and other accounts receivable allowance for doubtful accounts [Policy Text Block] Capitalized research and development costs. Deferred tax liabilities right use of asset. Fair value portion of arrangements with third parties, of contingent royalty obligation. Contingent Royalty Obligation [Member] Information about increase decrease in discount rate. Percentage relating to royalty payment. Costs of revenue- Impairment of Inventory. Schedule of stockholders stock option and equity note warrants or rights text block. Share based compensation arrangement by share based payment award non option equity instruments exercisable. Share based compensation arrangements by share based payment award non options cancelled weighted average exercise price. Share based compensation arrangements by share based payment award non options outstanding weighted average exercisable. Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price. Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price. Share based compensation arrangements by share based payment award non options expired weighted average exercise price. Share based compensation arrangements by share based payment award non options feitures in period weighted average exercise price. Non Employee [Member]. Cash compensation. Services Agreement [Member]. Warrants [Member] Replacement Warrants [Member] Convertible debt unamortized discount noncurrent. Fractional shares paid in cash pursuant to reverse stock split. Non recurring charges. Federal [Member] State [Member] Expire date, description Deferred foreign income tax benefit available use. Deferred tax liabilities accelerated research and development expense. Inventory, current. 2016 Equity Incentive Plan [Member] Aggregate of offering costs. Equity Distribution Agreement [Member] Schedule Of Effective Income Tax Rate Reconciliation Net Operating Loss [Table Text Block] Unamortized debt issuance cost. Represents the share based compensation arrangement by share based payment award non options exercised in period weighted average exercise price. Operating loss carryforwards utilization limitation. Represents the share based compensation arrangement by share based payment award options cancelled in period. Represents the share based compensation arrangement by share based payment award options cancelled in period weighted average exercise price. Represents the share based compensation arrangement by share based payment award non options outstanding intrinsic value. Represents the share based compensation arrangement by share based payment award non option equity instruments cancelled. Assets, Current Assets [Default Label] Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Costs and Expenses Operating Income (Loss) LossOnChangesInFairValueOfContingentRoyaltyObligation Finance income expense net DeemedDividendsFromWarrantIssuance Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation Share-Based Payment Arrangement, Noncash Expense IssuanceOfCommonStockForBoardOfDirectorsCompensation Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities FractionalSharesPaidInCashPursuantToReverseStockSplit Repayments of Debt PaymentsForEquityFinancingFees Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Property, Plant and Equipment Disclosure [Text Block] Lessee, Operating Leases [Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Lessee, Leases [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Share-Based Payment Arrangement [Policy Text Block] ContingentRoyaltyObligationFairValueDisclosure Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Inventory Valuation Reserves Inventory, Net CostOfRevenueImpairmentOfInventory Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Lease, Cost Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Operating Lease, Payments Amortization of Debt Discount (Premium) Long-Term Debt, Maturity, Year One Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Three Long-Term Debt, Gross Unamortized Debt Issuance Expense UnamortizedDebtIssuanceCost Long-Term Debt ContingentRoyaltyObligationNonCurrent Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Deferred Tax Assets, Net of Valuation Allowance DeferredTaxLiabilitiesAcceleratedResearchAndDevelopmentExpense DeferredTaxLiabilitiesRightOfUseAsset Deferred Tax Liabilities, Other Deferred Tax Liabilities, Net Deferred Tax Assets, Net Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent EX-101.PRE 19 mots-20221231_pre.xml XBRL PRESENTATION FILE XML 20 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Mar. 27, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Current Fiscal Year End Date --12-31    
Entity File Number 001-38389    
Entity Registrant Name Motus GI Holdings, Inc.    
Entity Central Index Key 0001686850    
Entity Tax Identification Number 81-4042793    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 1301 East Broward Boulevard    
Entity Address, Address Line Two 3rd Floor    
Entity Address, City or Town Ft. Lauderdale    
Entity Address, State or Province FL    
Entity Address, Postal Zip Code 33301    
City Area Code (954)    
Local Phone Number 541-8000    
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Trading Symbol MOTS    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period true    
Entity Shell Company false    
Entity Public Float     $ 14.6
Entity Common Stock, Shares Outstanding   4,778,873  
Documents Incorporated by Reference [Text Block] None    
ICFR Auditor Attestation Flag false    
Auditor Firm ID 274    
Auditor Name EISNERAMPER LLP    
Auditor Location Philadelphia, Pennsylvania    
XML 21 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 14,042 $ 22,563
Accounts receivable 59 109
Inventory, current 488 496
Prepaid expenses and other current assets 781 793
Total current assets 15,370 23,961
Fixed assets, net 1,325 1,428
Inventory, non-current 511
Right-of-use assets 428 687
Other non-current assets 13 13
Total assets 17,647 26,089
Current liabilities:    
Accounts payable and accrued expenses 1,969 2,584
Operating lease liabilities - current 245 307
Other current liabilities 53 10
Current portion of long-term debt, net of unamortized debt discount of $182 and $271, respectively 2,532 431
Total current liabilities 4,799 3,332
Contingent royalty obligation 1,212 1,760
Operating lease liabilities - non-current 178 385
Convertible note, net of unamortized debt discount of $108 and $166, respectively 3,892 3,834
Long-term debt, net of unamortized debt discount of $135 and $317, respectively 4,589 7,121
Total liabilities 14,670 16,432
Commitments and contingent liabilities (Note 9)
Shareholders’ equity    
Preferred stock $0.0001 par value; 10,000,000 shares authorized; zero shares issued and outstanding
Common stock $0.0001 par value; 115,000,000 shares authorized; 4,659,769 and 2,416,021 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively
Additional paid-in capital 144,328 132,411
Accumulated deficit (141,351) (122,754)
Total shareholders’ equity 2,977 9,657
Total liabilities and shareholders’ equity $ 17,647 $ 26,089
XML 22 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Debt instrument, unamortized discount $ 182 $ 271
Convertible note, unamortized discount, non-current 108 166
Debt instrument, unamortized discount, non-current $ 135 $ 317
Preferred stock par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 115,000,000 115,000,000
Common stock, shares issued 4,659,769 2,416,021
Common stock, shares outstanding 4,659,769 2,416,021
XML 23 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]    
Revenue $ 592 $ 391
Operating expenses:    
Costs of revenue - sales 198 181
Costs of revenue - impairment of inventory 598 443
Research and development 5,611 5,341
Sales and marketing 4,425 3,077
General and administrative 7,611 9,273
Total costs and expenses 18,443 18,315
Operating loss (17,851) (17,924)
Gain (loss) on change in estimated fair value of contingent royalty obligation 548 (143)
Loss on extinguishment of debt (237)
Finance expense, net (1,252) (717)
Other income 5
Foreign currency loss (42) (17)
Net loss (18,597) (19,033)
Deemed dividends from warrant issuance (6,145)
Net loss attributable to common shareholders $ (18,597) $ (25,178)
Basic and diluted loss per common share:    
Net loss attributable to common shareholders $ (5.74) $ (10.74)
Weighted average number of common shares outstanding, basic and diluted 3,237,952 2,344,759
XML 24 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Changes in Shareholders' Equity - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2020 $ 115,011,000 $ (103,721,000) $ 11,290,000
Beginning balance, shares at Dec. 31, 2020 1,613,591      
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs of $368 1,826,000 1,826,000
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares 67,043      
Issuance of common stock upon exercise of warrants, net of financing fees of $366 11,593,000 11,593,000
Issuance of common stock upon exercise of warrants, shares 713,362      
Issuance of common stock for board of directors’ compensation 291,000 291,000
Issuance of common stock for board of directors' compensation, shares 9,587      
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units, shares 9,938      
Fractional shares settled in cash pursuant to reverse stock split 53   53
Fractional shares settled in cash pursuant to reverse stock split, shares 2,500      
Issuance of warrants associated with convertible note and long- term debt 165   165
Share-based compensation 3,472,000 3,472,000
Net loss (19,033,000) (19,033,000)
Balance at Dec. 31, 2021 132,411,000 (122,754,000) 9,657,000
Ending balance, shares at Dec. 31, 2021 2,416,021      
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs of $368 9,884,000 9,884,000
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares 2,195,106      
Issuance of common stock for board of directors’ compensation 235,000 235,000
Issuance of common stock for board of directors' compensation, shares 24,458      
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units, shares 26,230      
Fractional shares settled in cash pursuant to reverse stock split (11) (11)
Fractional shares settled in cash pursuant to reverse stock split, shares (2,046)      
Share-based compensation 1,809,000 1,809,000
Net loss (18,597,000) (18,597,000)
Balance at Dec. 31, 2022 $ 144,328,000 $ (141,351,000) $ 2,977,000
Ending balance, shares at Dec. 31, 2022 4,659,769      
XML 25 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Changes in Shareholders' Equity (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Financing fees $ 368  
Common Stock [Member]    
Proceeds from Issuance Initial Public Offering   $ 74
Financing fees   $ 366
XML 26 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (18,597) $ (19,033)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 510 439
Amortization of debt issuance costs 330 95
(Gain) loss on change in estimated fair value of contingent royalty obligation (548) 143
Share-based compensation 1,809 3,472
Issuance of common stock for board of directors’ compensation 235 235
Issuance of common stock for consultants 53
Loss on extinguishment of debt 237
Impairment of inventory 598 443
Impairment of fixed assets 46
Amortization on operating lease right of use asset 327 262
Changes in operating assets and liabilities:    
Accounts receivable 50 (74)
Inventory (1,302) (274)
Prepaid expenses and other current assets 12 (413)
Accounts payable and accrued expenses (650) 303
Operating lease liability (330) (260)
Other current and non-current liabilities 43 (50)
Net cash used in operating activities (17,467) (14,422)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of fixed assets (224) (470)
Net cash used in investing activities (224) (470)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common shares 10,252 1,900
Fractional shares paid in cash pursuant to reverse stock split (11)
Proceeds from exercise and purchase of warrants 11,959
Borrowings under convertible note and long-term debt 12,000
Repayment of debt (703) (8,220)
Payment of debt issuance costs (563)
Equity financing fees (368) (440)
Net cash provided by financing activities 9,170 16,636
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (8,521) 1,744
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 22,563 20,819
CASH AND CASH EQUIVALENTS AT END OF PERIOD 14,042 22,563
CASH PAID FOR:    
Interest 977 640
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:    
Common stock issued to settle accrued expenses for board of directors’ compensation 56
Reclassification of inventory to fixed assets 201 140
Reclassification of prepaid expenses to fixed assets 4 75
Purchase of fixed assets in accounts payable and accrued expenses 24 4
Warrants issued related to convertible note and long-term debt recorded as debt discount 165
Accrued end of loan payment recorded as debt discount 140
Operating lease liabilities arising from obtaining right-of-use assets 66 184
Prepayment of lease obligation $ 17
XML 27 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Description of Business
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business

Note 1 – Description of Business

 

Motus GI Holdings, Inc. (the “Company”) was incorporated in Delaware, U.S.A. in September 2016. The Company and its subsidiaries, Motus GI Technologies, Ltd. and Motus GI, LLC, are collectively referred to as “Motus GI” or the “Company”.

 

The Company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the “FDA”) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (“GI”) endoscopy procedures. The Pure-Vu System has received a CE Mark in the EU for use in colonoscopy. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Through irrigation and evacuation of debris, the Pure-Vu System is designed to provide better-quality exams. The Company received 510(k) clearance in February 2022 from the FDA for the Pure-Vu EVS System and has commenced initial commercialization of this product. The Company does not expect to generate significant revenue from product sales until it further expands its commercialization efforts, which is subject to significant uncertainty.

 
XML 28 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Going Concern
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

Note 2 – Going Concern

 

To date, the Company has generated minimal revenues, experienced negative operating cash flows and has incurred substantial operating losses from its activities. Management expects the Company to continue to generate substantial operating losses and to continue to fund its operations primarily through utilization of its current financial resources, future product sales, and through the issuance of debt or equity, as well as through other strategic alternative transactions. Rising inflation and financial market volatility may adversely impact the Company’s ability to enter into, modify, and negotiate favorable terms and conditions relative to equity and debt financing initiatives. The uncertain financial markets, potential disruptions in supply chains, and changing priorities could also affect the Company’s ability to enter into key agreements. COVID-19 and government measures taken in response have also had an impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as certain medical services and supplies, have spiked, while demand for other goods and services have fallen. The future progression of the outbreak and its longer-term effects on the Company’s business and operations continue to evolve and are still uncertain. The Company and its third-party contract manufacturers, contract research organizations, and clinical sites may also face disruptions in procuring items that are essential to the Company’s research and development activities, including, for example, medical and laboratory supplies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts related to the outbreak in certain parts of the world. These disruptions may negatively impact the Company’s sales, its results of operations, financial condition, and liquidity into Q2 2023.

 

We have generated limited revenues to date from the sale of products. We have never been profitable and have incurred significant net losses each year since our inception, including a loss of $18.6 million for the year ended December 31, 2022, and we expect to continue to incur net operating losses for the foreseeable future. As of December 31, 2022, we had $14.0 million in cash and cash equivalents and an accumulated deficit of $141.4 million. We expect our current spend level to continue in connection with ongoing operating activities, including expenditures in R&D, sales and marketing, clinical affairs and manufacturing. As described above, we committed to a restructuring initiative designed to reduce our expenses and position us to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. In addition, in order to continue to operate as a standalone company, we would need additional financing to support our continuing operations. We also have significant debt under our Loan Agreement with Kreos which could negatively impact our ability to operate or consummate a strategic transaction.

 

In January 2023, we committed to a restructuring initiative designed to position us to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. If a strategic transaction is not completed, or if additional financing is not available, we may not be able to service our outstanding indebtedness and our payables and may have to file for bankruptcy protection or pursue a dissolution of the Company and liquidation of all of our remaining assets. In such an event, the amount of cash available for distribution to our stockholders, if any, will depend heavily on the timing of such decision, as with the passage of time the amount of cash available for distribution will be reduced as we continue to fund our operations and service our outstanding indebtedness. We cannot provide assurance as to the amount of cash that will be available to distribute to stockholders, if any, after paying our debts and other obligations and setting aside funds for reserves, nor as to the timing of any such distribution, if any.

 

Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.

 
XML 29 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies and Basis of Presentation
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Significant Accounting Policies and Basis of Presentation

Note 3 – Significant Accounting Policies and Basis of Presentation

 

A summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows:

 

Basis of presentation and use of estimates

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, of the Financial Accounting Standards Board (“FASB”).

 

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

 

Reverse Stock Split

 

On July 25, 2022, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-20. Shares of common stock underlying outstanding stock options and other equity instruments convertible into common stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.

 

Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split.

 

Functional currency and foreign currency translation

 

The functional currency of the Company, inclusive of foreign subsidiaries, is the U.S dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the consolidated statement of comprehensive loss as foreign currency (loss) gain, as appropriate.

 

Cash and cash equivalents

 

The Company considers all highly liquid investment securities with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Cash and cash equivalents include cash on-hand and highly-rated U.S. government backed money market fund investments.

 

Concentrations of Credit Risk and Off-balance Sheet Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company’s cash is held in accounts with financial institutions that management believes are creditworthy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.

 

Revenue recognition

 

Sales contracts executed for the second generation Pure-Vu System are accounted for in accordance with ASC Topic 606 - Revenue from Contracts with Customers (“ASC 606”) to depict the transfer of control to the Company’s customers in an amount reflecting the consideration to which the Company expects to be entitled to. The Pure-Vu System consists of a Workstation (a “Workstation”) and single use disposable sleeve (a “Disposable”).

 

ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases and collaboration arrangements. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when a performance obligation is satisfied.

 

Commercial placements of the second generation system include the Workstation, sale of the Disposables, and a service plan. The Workstation is operational without any significant customization and modification and the Disposables are specialized consumables that are readily available for purchase from the Company. Therefore, revenue from the sale of a Workstation is recognized after the customer commits to purchase the Workstation and the Workstation is delivered, which is when title is transferred. Disposables are identified as a separate performance obligation, and therefore, revenue from the sale of Disposables is recognized when the Disposables are delivered to the customer and title is transferred.

 

A free one-year service plan is included with the purchase of any second generation Pure-Vu Workstation. An extended service plan with varying support and maintenance of the Workstation is offered for sale after the free one-year service plan period. In the case of the free one-year service plan, a portion of the Workstation sales price is deferred and recognized ratably over the one-year service plan term based upon the relative standalone value. The standalone selling price of the Workstation is set at the beginning of the contract based on observable prices from standalone sales of the Workstation, however, at times, the Company has offered discounts from that price to certain customers. The standalone sales price of the one year service plan is based on the expected costs of replacement parts and direct costs to perform the service plus a standard margin, as set by the Company. The standard margin assumed is consistent with the margin expected in pricing the extended service plan. Revenue for the extended service plans is recognized ratably over the term of the service plan contract period.

 

At times, the Company may include a limited time free trial to potential customers to evaluate the Workstation for a period of up to 6 months and in certain instances extend the period to an aggregate of up to 11 months. The Company considers the 6-11 month usage period as a non-contiguous limited trial period because the total length of the free trial is still less than one year. In scenarios where the Company continues to provide the Workstation to a customer for a usage period of greater than one year, the arrangement falls outside of the scope of ASC 606, as described below. Management does not collect any upfront payments or deposits prior to commencing a free trial period. No revenue is recognized for the Workstation during the duration of a free trial, however, any Disposables purchased by the evaluator are recognized when delivered, as described above.

 

 

For contracts outside the scope of ASC 606, the Company determines income for proposed supply arrangements under 1) ASC 842 as it pertains to an embedded lease of the Workstation within a proposed supply arrangement and 2) ASC 606 for the sale of the sleeves within the proposed supply arrangement. The Company allocates the transaction price to the performance obligations within the proposed supply arrangements using the total estimated purchases method for both (i) arrangements that contain minimum purchase commitments and (ii) those arrangements that do not contain a minimum purchase commitment, but instead offer a volume discount for purchases that exceed a specified tier.

 

During the year ended December 31, 2022, the Company recognized revenue of $592, which consisted of $540 in accordance with ASC 606 and $52 in accordance with ASC 842. During the year ended December 31, 2021, the Company recognized revenue of $391, which consisted of $303 in accordance with ASC 606 and $88 in accordance with ASC 842.

 

During the year ended December 31, 2022, the Company recognized revenue at a point in time of $529 and recognized revenue over time of $63. During the year ended December 31, 2021, the Company recognized revenue at a point in time of $299 and recognized revenue over time of $92.

 

Contract Costs

 

Incremental commissions, if applicable, above a base commission level, are paid to sales representatives upon certain eligible sales, which are paid upon execution of the sales agreement. The guidance within ASC 606 provides a practical expedient if the amortization period of the assets that the entity otherwise would have recognized is one year or less. The Company chose to apply the available practical expedient as the commission paid on eligible sales orders relates to the period in which the sales order was fulfilled. For the years ending December 31, 2022 and 2021, incremental commissions paid on eligible sales orders were $96 and $35, respectively.

 

Accounts receivable and allowance for doubtful accounts

 

Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. The Company makes estimates for the allowance for doubtful accounts based upon its assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect customers’ ability to pay. As of December 31, 2022 and 2021, the allowance for doubtful accounts was $0.

 

Inventory

 

Inventory is stated at lower of cost and net realizable value using the weighted average cost method and is evaluated at least annually for impairment. The Company records an inventory reserve for losses associated with dated, expired, excess and obsolete items. Reserves and write-downs of inventory is based on management’s current knowledge with respect to inventory levels, planned production, and extension capabilities of materials on hand. A significant change in the timing or level of demand for the Company’s products compared to forecasted amounts may result in recording additional charges for excess and obsolete inventory in the future. The Company records charges for excess and obsolete inventory within cost of revenues. Inventories that exceed estimated realization for the next twelve months from balance sheet date based on future sales forecasts are classified as long-term assets.

 

Leases

 

The Company accounts for its leases in accordance with ASC 842, Leases, or ASC 842. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. The Company does not have financing leases.

 

Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.

 

The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty of renewal.

 

 

Fixed assets, net

 

Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated based on the straight-line method, at annual rates reflecting the estimated useful lives of the related assets, as follows:

 

 

Office equipment   5-15 years
Computers and software   3-5 years
Machinery   5-10 years
Lab and medical equipment   3-7 years
Leasehold improvements   Shorter of lease term or useful life

 

Share-based compensation

 

Employee and Non-Employee Share-Based Compensation

 

The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including employee stock options under the Company’s stock plans and equity awards issued to non-employees based on estimated fair values.

 

The accounting for awards issued to non-employees is similar to the accounting for employee awards, except that:

 

  ● the Company may elect on an award-by-award basis to use the contractual term as the expected term assumption in the option pricing model, and
     
  ● the cost of the grant is recognized in the same period(s) and in the same manner as if the grantor had paid cash.

 

ASC 718-10 requires companies to estimate the fair value of equity-based option awards on the date of grant using an option-pricing model. The fair value of the award is recognized as an expense on a straight-line basis over the requisite service periods in the Company’s consolidated statements of comprehensive loss. The Company recognizes share-based award forfeitures as they occur.

 

The Company estimates the fair value of granted option equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations of the Company.

 

Restricted Stock Units

 

The Company issues restricted stock units under its 2016 Equity Incentive Plan. The fair value of the restricted stock units is based on the closing stock price on the date of grant and is expensed as operating expense over the period during which the units vest. Each restricted stock unit entitles the grantee to one share of common stock to be received upon vesting up to four years after the grant date. Recipients of restricted stock units have no voting rights until the vesting of the award.

 

Basic and diluted net loss per share

 

Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive ordinary shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. Potentially dilutive common shares were excluded from the calculation of diluted loss per share for all periods presented due to their anti-dilutive effect due to losses in each period.

 

Net loss attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed preferred stock dividends declared, amortized or accumulated. The Company recorded a deemed dividend of $0 and $6,145 for the issuance of warrants during the years ended December 31, 2022 and 2021, respectively. The deemed dividend is added to the net loss in determining the net loss available to common stockholders.

 

 

Research and development expenses

 

Research and development expenses are charged to the consolidated statement of comprehensive loss as incurred.

 

Patent costs

 

Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are expensed as incurred.

 

Debt issuance costs

 

Debt issuance costs represent the costs associated with the issuance of a debt instrument and are amortized using the effective interest method over the life of the related debt instrument. The Company records debt issuance costs as a debt discount and is a reduction of the carrying amount of the debt liability.

 

Liabilities due to termination of employment agreements

 

Under Israeli employment laws, employees of Motus Ltd. are included under Article 14 of the Severance Compensation Act, 1963 (“Article 14”) for a portion of their salaries. According to Article 14, these employees are entitled to monthly deposits made by Motus Ltd. on their behalf with insurance companies.

 

Payments in accordance with Article 14 release Motus Ltd. from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company’s balance sheet, and there is no liability recorded as the Company does not have a future obligation to make any additional payments.

 

Income taxes

 

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company had a full valuation allowance against deferred tax assets.

 

The Company is subject to the provisions of ASC 740-10-25, Income Taxes (ASC 740). ASC 740 prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. On a quarterly basis, the Company undergoes a process to evaluate whether income tax accruals are in accordance with ASC 740 guidance on uncertain tax positions. There are currently no open Federal or State audits. The Company has not recorded any liability for uncertain tax positions at December 31, 2022 or December 31, 2021.

 

For the years ended December 31, 2022 and 2021, the Company recorded zero income tax expense. No tax benefit has been recorded in relation to the pre-tax loss for the years ended December 31, 2022 and 2021, due to a full valuation allowance to offset any deferred tax asset related to net operating loss carry forwards attributable to the losses.

 

 

Fair value of financial instrument

 

The Company accounts for financial instruments in accordance with ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”). ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:

 

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

 

Level 2 – Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data;

 

Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

 

There were no changes in the fair value hierarchy leveling during the years ended December 31, 2022 and 2021.

 

New Accounting Pronouncements- Recently Adopted

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options, which clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options due to a lack of explicit guidance in the FASB Codification. ASU 2021-04 provides guidance on modifications or exchanges of freestanding equity-classified written call options that are not within the scope of another Topic. Entities should treat a modification of the terms or conditions, or an exchange of a freestanding equity-classified written call option that remains equity-classified after modification or exchange, as an exchange of the original instrument for a new instrument. ASU 2021-04 provides further guidance on measuring the effect of such modifications or exchanges, and also provides guidance on the recognition of such modifications or exchanges on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021. The Company adopted this ASU on January 1, 2022, prospectively to modifications that occurred after the date of initial application. The adoption of this ASU did not result in a material impact to the consolidated financial statements and disclosures.

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements, or ASC 326. On January 1, 2023, the Company adopted ASC 326. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments. The adoption of ASC 326 did not have a material impact on the Company’s financial position or results of operations upon adoption.

 

Accounting Pronouncements- Not Yet Adopted

 

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting which provides optional expedients and exceptions for the accounting for contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. In January 2021, the FASB issued ASU 2021-01 to clarify the scope of certain optional expedients for derivatives that are affected by the discounting transition. In December 2022, the FASB issued ASU 2022-06 to defer the sunset date of Topic 848 from December 31, 2022, to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848. As of December 31, 2022, the Company is currently evaluating the impact of this guidance on its consolidated financial statements.

 

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This guidance simplifies the accounting for convertible instruments primarily by eliminating the existing cash conversion and beneficial conversion models within Subtopic 470-20, which will result in fewer embedded conversion options being accounted for separately from the debt host. The guidance also amends and simplifies the calculation of earnings per share relating to convertible instruments. This guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within that reporting period, using either a full or modified retrospective approach. As of December 31, 2022, the Company is currently evaluating the impact of the provisions of this guidance on its consolidated financial statements.

 

 
XML 30 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 4 – Fair Value Measurements

 

Liabilities measured and recorded at fair value on a recurring basis consisted of the following at December 31, 2022 and December 31, 2021:

 

 

   December 31, 2022 
   Level 1   Level 2   Level 3   Fair Value 
Liabilities                    
Contingent royalty obligation  $   -   $   -   $1,212   $1,212 

 

   December 31, 2021 
   Level 1   Level 2   Level 3   Fair Value 
Liabilities                    
Contingent royalty obligation  $   -   $   -   $1,760  $1,760 

 

Financial instruments with carrying values approximating fair value include cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, and certain other current liabilities, due to their short-term nature. Financial instruments with carrying values approximating fair value also include long-term debt and convertible notes which is based on a combined total of their face value and the amortization discount.

 

In estimating the fair value of the Company’s contingent royalty obligation (see Note 9), the Company used the discounted cash flow method as of December 31, 2022 and 2021. Based on the fair value hierarchy, the Company classified contingent royalty obligation within Level 3 because the valuation inputs are based on projected revenues discounted to a present value.

 

Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of a contingent royalty obligation, during the year ended December 31, 2022 was as follows:

 

 

   Fair Value
Measurements
of Contingent
Royalty
Obligation
(Level 3)		 
Balance at December 31, 2021  $1,760 
Change in estimated fair value of contingent royalty obligation   548 
Balance at December 31, 2022  $1,212 

 

The contingent royalty obligation is re-measured at each balance sheet date using several assumptions, including the following: 1) estimated sales growth, 2) length of product cycle, 3) patent life, 4) discount rate (23% as of December 31, 2022 and 21% as of December 31, 2021), and 5) rate of royalty payment (3% as of December 31, 2022 and December 31, 2021).

 

In accordance with ASC-820-10-50-2(g), the Company performed sensitivity analyses of the liability, which was classified as a Level 3 financial instrument. The contingent royalty obligation estimate may be significantly impacted by changes in assumptions used in these analyses. For example, the Company recalculated the fair value of the liability by applying a +/- 2% change to the input variable in the discounted cash flow model; the discount rate. A 2% decrease in the discount rate would increase the liability by approximately $126 and a 2% increase in the discount rate would decrease the liability by approximately $112.

 

 
XML 31 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Inventory
 12 Months Ended
Dec. 31, 2022
Inventory Disclosure [Abstract]  
Inventory

Note 5 – Inventory

 

Inventory at December 31, 2022 and 2021 consisted of the following:

 

 

   2022   2021 
   December 31, 
   2022   2021 
Raw materials  $697   $569 
Work-in-process   155    - 
Finished goods   

548

    292 
Inventory reserve   (401)   (365)
Inventory, net   $999   $496 
Inventory, current  $488   $

496

 
Inventory, non-current 

$

511   $- 

 

For the years ended December 31, 2022 and 2021, an inventory impairment of $598 and $443, respectively, was recorded.

 
XML 32 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Fixed assets, net
 12 Months Ended
Dec. 31, 2022
Property, Plant and Equipment [Abstract]  
Fixed assets, net

Note 6 – Fixed assets, net

 

Fixed assets, net, consists of the following:

 

   2022   2021 
   December 31, 
   2022   2021 
Office equipment  $171   $171 
Computers and software   321    305 
Machinery   1,049    807 
Lab and medical equipment   1,477    1,342 
Leasehold improvements   200    193 
Total   3,218    2,818 
Less accumulated depreciation and amortization   (1,893)   (1,390)
Fixed assets, net  $1,325   $1,428 

 

Depreciation and amortization expense for the years ended December 31, 2022 and 2021 was $510 and $439, respectively. The Company incurred a loss on the impairment of fixed assets in the amount of $46 and $0 for the years end December 31, 2022 and 2021, respectively.

 
XML 33 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Leases
 12 Months Ended
Dec. 31, 2022
Leases  
Leases

Note 7 – Leases

 

The Company leases an office in Fort Lauderdale, Florida under an operating lease. The term expires November 2024. The annual base rent is subject to annual increases of 2.75%. As described within Note 10, the Company shares this space with a related party pursuant to the Shared Space Agreement, as defined below.

 

The Company leases an office in Israel under an operating lease. The term expired on December 31, 2022. The Company entered into a new tenancy contract with the facility for a period of twelve months from January 1, 2023 to December 31, 2023.

 

The Company leases vehicles under operating leases that expire at various dates through 2025.

 

Many of these leases provide for payment by the Company, as the lessee, of taxes, insurance premiums, costs of maintenance and other costs which are expensed as incurred. Certain operating leases include escalation clauses and some of which may include options to extend the leases for up to 3 years.

 

 

The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows:

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
Lease Cost          
Operating lease cost, net of related party license fee  $92   $139 
Variable lease cost   120    119 
Total lease cost  $212   $258 

 

   As of December 31, 
   2022   2021 
Assets          
Operating lease, right-of-use asset  $428   $687 
Liabilities          
Current          
Operating lease liabilities  $245   $307 
Non-current          
Operating lease liabilities, net of current portion   178    385 
Total lease liabilities  $423   $692 
           
Other information:          
Weighted average remaining lease term - operating leases   1.79 years    2.49 years 
Weighted-average discount rate - operating leases   7.36%   7.66%

 

The Company records operating lease payments to lease expense using the straight-line method. The Company’s lease expense was $212 and $258 for the years ended December 31, 2022 and 2021, respectively, included in general and administrative expenses, which is net of the related party license fee of $242 and $189 for the years ended December 31, 2022 and 2021, respectively (see Note 10).

 

Future minimum lease payments under non-cancellable operating leases as of December 31, 2022 were as follows:

 

Year Ended December 31,  Amount 
2023  $266 
2024   176 
2025   

7

 
Total future minimum lease payments   

449

 
Imputed interest   (26)
Total liability  $423 

 

The following table summarizes the cash paid for amounts included in the measurement of lease liabilities for the years ended December 31, 2022 and 2021:

 

   2022   2021 
   Years Ended December 31, 
   2022   2021 
Cash paid for amounts included in measurement of lease liabilities:  $(342)  $(324)
           

 

 
XML 34 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Convertible Note, Term Debt and Long-Term Debt
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Convertible Note, Term Debt and Long-Term Debt

Note 8 – Convertible Note, Term Debt and Long-Term Debt

 

On July 16, 2021 (the “Effective Date”), the Company entered into a loan facility (the “Kreos Loan Agreement”) with Kreos Capital VI (Expert Fund) LP (the “Lender”). Under the Kreos Loan Agreement, the Lender will provide the Company with access to term loans in an aggregate principal amount of up to $12,000 (the “Loan”) in three tranches as follows: (a) on the Effective Date, a loan in the aggregate principal amount of $4,000 (the “Convertible Note”, or “Tranche A”), (b) on the Effective Date, a loan in the aggregate principal amount of $5,000 (“Tranche B”), and (c) available until December 31, 2021, a loan in the aggregate principal amount of $3,000 (“Tranche C”, together with Tranche B, the “Long-term Debt”). The Kreos Loan Agreement contains customary representations and warranties, indemnification provisions in favor of the Lender, events of default and affirmative and negative covenants, including, among others, covenants that limit or restrict the Company’s ability to, among other things, incur additional indebtedness, merge or consolidate, make acquisitions, pay dividends or other distributions or repurchase equity, make investments, dispose of assets and enter into certain transactions with affiliates, in each case subject to certain exceptions. Outstanding borrowings under the Loan are secured by a first priority security interest on substantially all of the personal property assets of the Company, including the Company’s material intellectual property and equity interests in its subsidiaries. There are no liquidity or financial covenants.

 

The Convertible Note and Tranche B were funded on the Effective Date. As of December 31, 2021, the Company drew down the full $3,000 aggregate principal amount of Tranche C.

 

The Convertible Note requires forty-eight monthly interest only payments at 7.75% per annum commencing after the Effective Date and thereafter full payment of the then outstanding principal balance of the Convertible Note on July 1, 2025. The Kreos Loan Agreement contains features that would permit the Lender to convert all or any portion of the outstanding principal balance of the Convertible Note at any time, pursuant to which the converted part of the Convertible Note will be converted into that number of shares of common stock of the Company to be issued to the Lender at a price per share equal to the conversion price, of $28 per share. Following the conversion of any portion of the outstanding principal balance of the Convertible Note, the principal balance of the Convertible Note remaining outstanding shall continue to bear interest at 7.75% per annum. The Tranche B loan requires interest only monthly payments commencing on the Effective Date until September 30, 2022 and, thereafter, thirty-three monthly payments of principal and interest accrued thereon until June 1, 2025. The Tranche C loan requires interest only monthly payments commencing on the date of the draw down until September 30, 2022 and, thereafter, thirty-two monthly payments of principal and interest accrued thereon until June 1, 2025.

 

In connection with the Kreos Loan Agreement, the Company also issued to the Lender a warrant (“Warrant”), dated July 16, 2021, to purchase up to 9,547 shares of the Company’s common stock, at an exercise price of $20.948 per share, payable in cash or on a cashless basis according to the formula set forth in the Warrant. The exercise price of the Warrant and the number of shares issuable upon exercise of the Warrant are subject to adjustments for stock splits, combinations, stock dividends or similar events. The Warrant is exercisable until the date that is ten years after the date of issuance. The Company concluded that the Warrant is indexed to its own stock and, accordingly is classified as equity. See note 11 for further discussion of the Warrant.

 

The Company treated Tranche A, Tranche B and Tranche C, and the Warrant as three separate freestanding financial instruments with the proceeds received in connection with the transaction allocated amongst the instruments based on relative fair value. The proceeds received in connection with the transaction allocated amongst the instruments based on relative fair value resulted in $165 being allocated to the Warrant and a corresponding amount recorded as a debt discount to the Convertible Note and Long-term Debt. The Company recorded an aggregate debt discount of $845 related to the Loan, inclusive of the debt discount of $165 in connection to the Warrant, which will be amortized to interest expense over the term of each respective tranche using the effective interest method. The Company also paid $540 in cash for debt issuance costs. Additionally, per the Kreos Loan Agreement, with respect to the Long-term Debt, there is an advance payment of $274 that is recorded at a debt discount. The advance payment represents the last month’s payment in relation to the Long-term Debt. There is also an end of loan payment of $140 which is included on the balance sheet as a liability within the Long-term Debt and also within the total aggregate debt discount of $845.

 

Subsequent to the issuance of the consolidated financial statements for the year ended December 31, 2021, the Company identified that the current portion of long-term debt was incorrectly classified as non-current on the balance sheet as of December 31, 2021. Management evaluated this misstatement and concluded it was not material to the financial statements and therefore, the Company elected to correct the current portion of long-term debt as of December 31, 2021 in these consolidated financial statements for comparative purposes.

 

 

For the year ended December 31, 2022, interest expense for the Loan was as follows:

 

   Year Ended December 31, 
   2022     2021 
Contractual interest expense  $1,001     $ 362 
Amortization of debt issuance costs   330       91 
Total interest expense  $1,331     $ 453 

 

Future principal payments under the Convertible Note as of December 31, 2022 are as follows:

 

Years Ending December 31,  Amount 
2023  $- 
2024   - 
2025   4,000 
Total future principal payments   4,000 
Less unamortized debt issuance costs   (108)
Total balance  $3,892

 

Future principal payments under the Term Debt as of December 31, 2022 are as follows:

 

Years Ending December 31,  Amount 
2023  $2,714 
2024   2,983 
2025   1,601 
Total future principal payments   7,298 
End of loan payments   140 
Less unamortized debt issuance costs of current portion of long-term debt   (182)
Less unamortized debt issuance costs of non-current portion long-term debt   

(135

)
Total balance  $7,121 

 
XML 35 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 9 – Commitments and Contingencies

 

Royalties to the IIA

 

The Company has received grants from the Government of the State of Israel through the Israeli National Authority for Technical Innovation (the “IIA”) for the financing of a portion of its research and development expenditures. The total amount that was received and recorded between the periods ending December 31, 2011 through 2016 was $1,332. No amounts were received during the years ended December 31, 2022 and 2021. The Company has a contingent obligation to the IIA for the total amount received along with the accumulated LIBOR interest to date in the amount of $1,426 and $1,419 as of December 31, 2022 and 2021, respectively. This obligation is repaid in the form of royalties on revenues generated in any fashion with a rate that is currently at 4% (which may be increased under certain circumstances). The Company may be obligated to pay up to 100% (which may be increased under certain circumstances) of the U.S. dollar-linked value of the grants received, plus interest at the rate of 12-month LIBOR.

 

Repayment of the grants is contingent upon the Company’s ongoing commercialization and generation of sales, which is subject to significant risk and uncertainty. The Company has no obligation to repay these grants if no significant sales are generated. The Company has recorded an immaterial expense for the years ended December 31, 2022 and 2021, and an immaterial liability at December 31, 2022 and 2021.

 

 

Royalty Payment Rights on Royalty Payment Rights Certificates

 

The Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”), establishing the rights and preferences of the holders of the Series A Convertible Preferred Stock, including certain directors and officers of the Company (the “Royalty Payment Rights”). As set forth in the Certificate of Designation, the Royalty Payment Rights initially entitled the holders in aggregate, to a royalty in an amount of:

 

  ● 3% of net sales subject to a maximum in any calendar year equal to the total dollar amount of Units closed on in the Company’s 2017 private placement (the “2017 Private Placement”); and
     
  ● 5% of licensing proceeds subject to a maximum in any calendar year equal to the total dollar amount of Units closed on in the 2017 Private Placement.

 

In addition, in connection with completion of the 2017 Private Placement, the Company issued the placement agent royalty payment rights certificates (the “Placement Agent Royalty Payment Rights Certificates”) which grants the placement agent, and its designees, the right to receive, in the aggregate, 10% of the amount of payments paid to the holders of the Series A Convertible Preferred Stock, or the holders of the Royalty Payment Rights Certificates (the “Royalty Payment Rights Certificates”), upon the conversion of the Series A Convertible Preferred Stock into shares of the Company’s common stock. The Placement Agent Royalty Payment Rights Certificates are on substantially similar terms as the Royalty Payment Rights of the Series A Convertible Preferred Stock.

 

The Royalty Payment Rights Certificate obligation and Placement Agent Royalty Payment Rights Certificate obligation (the “Contingent Royalty Obligation”) was recorded as a liability at fair value as “Contingent royalty obligation” in the consolidated balance sheets at December 31, 2022 and 2021 (see Contingent Royalty Obligation below). The fair value at inception was allocated to the royalty rights and the residual value was allocated to the preferred shares and recorded as equity.

 

The Company amended its Certificate of Designation to modify the Royalty Payment Rights when the Company consummated its Initial Public Offering (“IPO”) on February 16, 2018, at which time the Company converted the Series A Convertible Preferred Stock into shares of the Company’s common stock and issued the Royalty Payment Rights Certificates. Pursuant to the terms of the Royalty Payment Rights Certificates, if and when the Company generates sales of the current and potential future versions of the Pure-Vu System, including disposables, parts, and services, or if the Company receives any proceeds from the licensing of the current and potential future versions of the Pure-Vu System, then the Company will pay to the holders of the Royalty Payment Rights Certificates a royalty (the “Royalty Amount”) equal to, in the aggregate, in royalty payments in any calendar year for all products:

 

  ● 3% of Net Sales* for commercialized product directly; and
     
  ● 5% of any Licensing Proceeds** for rights to commercialize the product if sublicensed by the Company to a third-party.

 

* Notwithstanding the foregoing, with respect to Net Sales based Royalty Amounts, (a) no Net Sales based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Net Sales equal to $20,000 (the “Initial Net Sales Milestone”), and royalties shall only be computed on, and due with respect to, Net Sales generated in excess of the Initial Net Sales Milestone, and (b) the total Net Sales based Royalty Amount due and payable in any calendar year shall be subject to a royalty cap amount per calendar year of $30,000. “Net Sales” is defined in the Royalty Payment Rights Certificates. The Company has not reached the Initial Net Sales Milestone as of December 31, 2022.
   
** Notwithstanding the foregoing, with respect to Licensing Proceeds based Royalty Amounts, (a) no Licensing Proceeds based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Licensing Proceeds equal to $3,500 (the “Initial Licensing Proceeds Milestone”), and royalties shall only be computed on, and due with respect to, Licensing Proceeds in excess of the Initial Licensing Proceeds Milestone and (b) the total Licensing Proceeds based Royalty Amount due and payable in any calendar year shall be subject to a royalty cap amount per calendar year of $30,000. “Licensing” Proceeds is defined in the Certificate. The Company has not reached the Initial Licensing Proceeds Milestone as of December 31, 2022.

 

 

The Royalty Amount will be payable up to the later of (i) the latest expiration date of the Company’s patents issued as of December 22, 2016, or (ii) the latest expiration date of any pending patents as of December 22, 2016 that have since been issued or may be issued in the future (which is currently March 2039 jx). Following the expiration of all such patents, the holders of the Royalty Payment Rights Certificates and the holders of the Placement Agent Royalty Payment Rights Certificates will no longer be entitled to any further royalties for any period following the latest to occur of such patent expiration.

 

On February 16, 2018, the date of the closing of the IPO, (1) the amendment to the Certificate of Designation became effective, (2) all outstanding shares of Series A Convertible Preferred Stock were converted into shares of the Company’s common stock pursuant to a mandatory conversion, and (3) the Royalty Payment Rights Certificates were issued to the former holders of the Series A Convertible Preferred Stock.

 

Contingent Royalty Obligation

 

The contingent royalty obligation was recorded as a non-current liability at fair value in the consolidated balance sheets at December 31, 2022 and 2021 in the amount of $1,212 and $1,760, respectively. A gain on change in fair value of contingent royalty obligation of $548 for the year ended December 31, 2022 and a loss on change in fair value of contingent royalty obligation of $143 was recorded for the year ended December 31, 2021.

 

Other Commitments and Contingencies

 

The Company has a severance contingency for severance payments to its CEO, COO, and CFO in the aggregate of approximately $1,408, in the event that they are terminated without cause or leave due to good reason, as outlined in their employee agreements. Management estimates that the likelihood of payment is remote; therefore, no liability was reflected in these consolidated financial statements.

 

Manufacturing Component Purchase Obligations

 

The Company utilizes two outsourcing partners to manufacture its workstation and disposable portions of the Pure-Vu System, and to perform final assembly and testing of finished products. These outsourcing partners acquire components and build product based on demand information supplied by the Company. As of December 31, 2022, the Company expects to pay $41 under manufacturing-related supplier arrangements within the next year, substantially all of which is noncancelable.

 
XML 36 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions
 12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
Related Party Transactions

Note 10 – Related Party Transactions

 

Shared Space Agreement

 

In January 2020, the Company entered into a license agreement (the “Shared Space Agreement”) with Orchestra BioMed, Inc. (OBIO), formerly a greater than 5% holder of the Company’s common stock and entity in which David Hochman, the Chairman of the Company’s board of directors, serves as the Chairman of the board of directors and Chief Executive Officer, and Darren Sherman, a member of the Company’s board of directors, serves as a director and as President and Chief Operating Officer. Pursuant to the Shared Space Agreement, the Company granted a license to OBIO for the use of portions of the office space not being used by the Company in the Company’s leased facility in Fort Lauderdale, Florida (the “Premises”), and a proportionate share of common areas of such Premises, which previously covered approximately 35% of the Premises and was to expand incrementally to approximately 60 to 70% of the Premises by September 2024. In May 2022, the Company entered into an amendment to the Shared Space Agreement. Pursuant to the amendment, the area covered by the Shared Space Agreement was expanded to 95% of the premises and the aggregate license fees will generally range from approximately $212 to approximately $270 in any given calendar year during the term of the Shared Space Agreement until the termination of the lease in November 2024. During the year ended December 31, 2022 and 2021, the Company recorded a license fee of $242 and $189, respectively, in relation to the Shared Space Agreement. This amount is netted with rent expense in general and administrative expenses.

 
XML 37 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Share-based compensation and Common Stock Issuance
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Share-based compensation and Common Stock Issuance

Note 11 – Share-based compensation and Common Stock Issuance

 

The following table sets forth total non-cash share-based compensation for the issuance of common stock, options to purchase common stock, warrants to purchase common stock, and restricted stock unit awards by operating statement classification for the years ended December 31, 2022 and 2021:

 

   2022   2021 
  

Year ended December 31,

 
   2022   2021 
Research and development  $388   $575 
Sales and marketing   238    353 
General and administrative   1,183    2,544 
Total  $1,809   $3,472 

 

For the year ended December 31, 2022 and 2021, the Company recorded $1,145 and $2,270, respectively, for share-based compensation expense related to stock options.

 

As of December 31, 2022, unamortized share-based compensation for stock options was $964, with a weighted-average recognition period of 0.87 years.

 

For the year ended December 31, 2022 and 2021, the Company recorded $57 and $335, respectively, for share-based compensation expense related to warrants.

 

For the year ended December 31, 2022 and 2021, the Company recorded $607 and $867, respectively, for share-based compensation expense related to restricted stock units.

 

As of December 31, 2022, unamortized stock compensation for restricted stock units was $308, with a weighted-average recognition period of 0.81 years.

 

Stock option and warrant activity

 

In December 2016, the Company adopted the Motus GI Holdings, Inc. 2016 Equity Incentive Plan (the “2016 Plan”). Pursuant to the 2016 Plan, the Company’s board of directors may grant options to purchase shares of the Company’s common stock, stock appreciation rights, restricted stock, stock units, performance shares, performance units, incentive bonus awards, other cash-based awards and other stock-based awards to employees, officers, directors, consultants and advisors. Pursuant to the terms of an annual evergreen provision in the 2016 Plan, the number of shares of common stock available for issuance under the 2016 Plan shall increase annually by six percent (6%) of the total number of shares of common stock outstanding on December 31st of the preceding calendar year; provided, however, that the board of directors may act prior to the first day of any calendar year to provide that there shall be no increase such calendar year, or that the increase shall be a lesser number of shares of our common stock than would otherwise occur. On January 1, 2022, pursuant to an annual evergreen provision, the number of shares of common stock reserved for future grants was increased by 279,586 shares. Under the 2016 Plan, effective as of January 1, 2023, the maximum number of shares of the Company’s common stock authorized for issuance is 804,371. As of December 31, 2022, there were 15,165 shares of common stock available for future grant under the 2016 Plan.

 

A summary of the Company’s stock option and warrant activity is as follows:

 

   Options     Warrants 
  

Shares

Underlying

Options

  

Weighted

Average

Exercise Price

   Weighted Average Remaining Contractual Life (years)     Average Intrinsic Value    

Shares

Underlying

Warrants

  

Weighted

Average

Exercise Price

     Weighted Average Remaining Contractual Life (years)     Average Intrinsic Value 
Outstanding at December 31, 2020   251,419   $60.00     7.96     $ -      852,820   $37.20       5.78     $ - 
Granted   64,675   $32.80                    326,548   $41.40                 
Forfeited   (8,502)  $68.60                    (45,758)  $100.00                 
Exercised   (713,363)  $24.80                    -   $-                 
Outstanding at December 31, 2021   307,592   $54.10     7.45     $ -      420,247   $54.76       3.40     $ - 
Granted   102,997   $8.73                    6,000   $10.00                 
Expired   (6,597)  $64.24                    (26,986)  $101.13                 
Cancelled   -   $-                    (6,000)  $56.60                 
Forfeited   (3,855)  $11.48                    -   $-                 
Outstanding at December 31, 2022   400,137   $42.69     7.21     $ -      393,261   $50.86       2.66     $ - 
Exercisable at December 31, 2022   294,152   $52.77                    393,261   $50.86                 

 

The options granted during the years ended December 31, 2022 and 2021 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:

 

   For the year ended December 31, 
   2022   2021 
Expected term, in years    5.8    5.8 
Expected volatility    99.21%   106.24%
Risk-free interest rate     2.10%   0.77%
Dividend yield    -    - 

 

The grant date fair value for stock options issued during the years ended December 31, 2022 and 2021 were $8.62 and $26.4, respectively.

 

 

Restricted Stock Units

 

A summary of the Company’s restricted stock unit awards activity is as follows:

 

   Number of Shares  

Weighted Average

Grant Date

Fair Value

 
Nonvested at December 31, 2020   16,891   $62.00 
Granted   21,300    34.20 
Vested   (12,071)   48.40 
Nonvested at December 31, 2021   25,120   $44.77 
Granted   18,250    9.07 
Vested   (23,092)   39.53 
Nonvested at December 31, 2022   20,278   $18.62 

 

As of December 31, 2021, there were 3,138 vested and unissued restricted stock units. These restricted stock units were issued as common stock during the year ended December 31, 2022.

 

Issuance of Warrants to Purchase Common Stock

 

In February 2020, the Company entered into a services agreement whereby it agreed to issue warrants to purchase 6,000 shares of common stock of the Company. The warrants fully vested over a one-year period on a monthly basis and expire three years from the date of issuance and were exercisable at weighted average exercise price equal to $56.60 per share of common stock. In March 2022, the Company granted new warrants as a replacement to the vested warrants held by the service provider, for which all the share-based compensation expense had been recognized in prior fiscal periods. The issuance of new warrants concurrently with the cancellation of the existing warrants was treated as a modification. The Company agreed to issue replacement warrants to purchase 6,000 shares of common stock of the Company exercisable at a price equal to $10 per share of common stock. The fair value of the warrants were valued on the date of grant at $0.38 using the Black-Scholes option-pricing model with the following parameters: (1) risk-free interest rate of 0.91%; (2) expected life in years of 1.62; (3) expected stock volatility of 81.97%; and (4) expected dividend yield of 0%. The replacement warrants immediately vested upon issuance and expire three years from the date of issuance. As a result, the Company recognized $26 of share-based compensation for the year ended December 31, 2022, related to the incremental fair value which is equal to the excess of the fair value of the new warrants granted over the fair value of the original award on the cancellation date.

 

Issuance of Common Stock

 

On January 5, 2022, non-employee members of the Board of Directors were granted an aggregate of 24,458 shares of fully-vested common stock with a fair value of $9.60 per share of common stock, as compensation, in lieu of $235 of cash compensation, for service as directors for 2022. The Company recorded $235 and $177 in expense for director services during the year ended December 31, 2022 and 2021, respectively.

 

In March 2021, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”), under which we may offer and sell from time to time common shares having an aggregate offering price of up to $25.0 million. During the year ended December 31, 2022, we sold approximately 2.2 million shares of our common stock under this agreement, resulting in net cash proceeds of $9.9 million, after deducting issuance costs of $0.4 million. From January 1, 2023 to March 14, 2023, the Company issued and sold approximately 119,104 common shares of our common stock under this agreement, resulting in net cash proceeds of approximately $118.0 thousand, after deducting issuance costs $4.0 thousand.

 
XML 38 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes

Note 12 – Income Taxes

 

Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences. In accordance with ASC 740, “Income Taxes,” the Company recorded a valuation allowance to fully offset the gross deferred tax asset, because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December 31, 2022 and 2021.

 

As of December 31, 2022 and 2021, the Company had deferred tax assets of approximately $37,400 and $27,200, respectively, against which a full valuation allowance of $37,400 and $27,200, respectively had been recorded. The change in the valuation allowance for the year ended December 31, 2022 was an increase of $10,200. The increase in the valuation allowance for the year ended December 31, 2022 was mainly attributable to increases in net operating losses and non-deductible research expenses, which resulted in an increase in the deferred tax assets with a corresponding valuation allowance. Significant components of the Company’s deferred tax assets at December 31, 2022 and 2021 were as follows:

 

 

     2022   2021 
   December 31, 
   2022   2021 
Deferred tax assets:          
Net operating loss carryforwards – Federal and state  $14,614   $5,281 
Net operating loss carryforwards – Israel   18,813    19,354 
Share-based compensation   1,735    1,732 
Capitalized research and development   2,246    218 
Accrued liabilities and reserves   681    831 
Total deferred tax assets   38,089    27,416 
Deferred tax liabilities:          
Accelerated research and development expense   (548)   - 
Right of use asset   (109)   (158)
Other   (34)   (14)
Total deferred tax liabilities   (691)   (172)
Net deferred tax assets before valuation allowance   37,398    27,244 
Valuation allowance   (37,398)   (27,244)
Net deferred tax assets after valuation allowance  $-   $- 

 

 

A reconciliation of the federal statutory tax rate and the effective tax rates for the years ended December 31, 2022 and 2021 is as follows:

 

   For the Year Ended December 31, 
   2022   2021 
U.S. federal statutory tax rate   21.0%   21.0%
State income taxes, net of federal benefit   6.6    2.0 
U.S. vs. foreign tax rate differential   0.8    0.9 
Non-deductible expenses   (2.7)   (1.9)
Foreign exchange adjustments   (10.7)   2.5 
Change in valuation allowance   (15.0)   (24.5)
Effective tax rate   -%   -%

 

The Company had approximately $134,100 and $119,600 of gross net operating loss (“NOL”) carryforwards (federal, state and Israel) as of December 31, 2022 and 2021, respectively. Sections 382 and 383 of the Internal Revenue Code, and similar state regulations, contain provisions that may limit the NOL carryforwards available to be used to offset income in any given year upon the occurrence of certain events, including changes in the ownership interests of significant stockholders. In the event of a cumulative change in ownership in excess of 50% over a three-year period, the amount of the NOL carryforwards that the Company may utilize in any one year may be limited.

 

The Tax Cuts and Jobs Act of 2017 (TCJA) has modified the IRC 174 expenses related to research and development for the tax years beginning after December 31, 2021. Under the TCJA, the Company must now capitalize the expenditures related to research and development activities and amortize over five years for U.S. activities and 15 years for non-U.S. activities using a mid-year convention. Since this has been the Company’s policy since 2019, the current year capitalization of research and development costs in accordance with IRC 174 was $4,900,000 for a total accumulated gross amount of $8,800,000 as of December 31, 2022.

 

During the year ended December 31, 2021, the Company incurred an ownership change under Internal Revenue Code Section 382, resulting in an annual NOL utilization limitation of approximately $3,700. None of the Company’s NOL carryforwards or deferred tax assets were required to be reduced since the limitation did not preclude the Company from potentially utilizing all of its NOL carryforwards. Future significant ownership changes could cause a portion or all of the Company’s NOL carryforwards to expire before utilization, however.

 

A reconciliation of the Company’s NOLs for the years ended December 31, 2022 and 2021 is as follows:

 

 

     2022   2021 
   December 31, 
   2022   2021 
U.S. Federal NOL’s  $26,875   $18,420 
U.S. State NOL’s   25,464    17,009 
Israel NOL’s   81,794    84,148 
Total NOL’s  $134,133   $119,577 

 

The Company’s federal and state NOLs of $3,300 and $25,464, respectively, begin to expire after 2036 through 2042. The Company’s federal NOL of $23,575, generated since 2018, and the Israel NOL of $81,794 do not expire. A check the box election for Israel was made and accepted by the IRS as of January 1, 2019. As such, approximately $38,100 of Israeli NOLs are available for use in the U.S and have an indefinite life.

 

The Company follows guidance on accounting for uncertainty in income taxes which prescribes a minimum threshold a tax position is required to meet before being recognized in the financial statements. The Company does not have any liabilities as of December 31, 2022 and 2021 to account for potential income tax exposure. The Company is obligated to file income tax returns in the U.S. federal jurisdiction, several U.S. States and Israel. Since the Company had losses in the past, all prior years that generated net operating loss carry-forwards are open and subject to audit examination in relation to the net operating loss generated from those years.

 
XML 39 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events
 12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events

Note 13 – Subsequent Events

 

In January 2023, the Company committed to a restructuring initiative designed to position the Company to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. The Company has engaged Lake Street Capital Markets LLC (“Lake Street Capital”) to advise the Company in this process. Potential strategic alternatives that may be considered by the Company are expected to include an acquisition, merger, reverse merger, other business combination, sale of assets, licensing and other strategic transactions. The restructuring initiative primarily includes the reduction of the Company’s workforce. The Company intends to continue to evaluate and identify other areas of its business to enhance efficiencies and improve processes, with a goal to further lower its operating expenses and capital needs. The Company expects to reduce its quarterly cash expenditures by approximately 35% by eliminating approximately 45% of its workforce during the first quarter of 2023. In connection with the restructuring, the Company expects to incur a non-recurring charge of approximately $1.0 to $2.0 million in the first quarter of 2023.
XML 40 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies and Basis of Presentation (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis of presentation and use of estimates

Basis of presentation and use of estimates

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, of the Financial Accounting Standards Board (“FASB”).

 

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

 
Reverse Stock Split

Reverse Stock Split

 

On July 25, 2022, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-20. Shares of common stock underlying outstanding stock options and other equity instruments convertible into common stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.

 

Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split.

 
Functional currency and foreign currency translation

Functional currency and foreign currency translation

 

The functional currency of the Company, inclusive of foreign subsidiaries, is the U.S dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the consolidated statement of comprehensive loss as foreign currency (loss) gain, as appropriate.

 
Cash and cash equivalents

Cash and cash equivalents

 

The Company considers all highly liquid investment securities with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Cash and cash equivalents include cash on-hand and highly-rated U.S. government backed money market fund investments.

 

Concentrations of Credit Risk and Off-balance Sheet Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company’s cash is held in accounts with financial institutions that management believes are creditworthy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.

 
Revenue recognition

Revenue recognition

 

Sales contracts executed for the second generation Pure-Vu System are accounted for in accordance with ASC Topic 606 - Revenue from Contracts with Customers (“ASC 606”) to depict the transfer of control to the Company’s customers in an amount reflecting the consideration to which the Company expects to be entitled to. The Pure-Vu System consists of a Workstation (a “Workstation”) and single use disposable sleeve (a “Disposable”).

 

ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases and collaboration arrangements. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when a performance obligation is satisfied.

 

Commercial placements of the second generation system include the Workstation, sale of the Disposables, and a service plan. The Workstation is operational without any significant customization and modification and the Disposables are specialized consumables that are readily available for purchase from the Company. Therefore, revenue from the sale of a Workstation is recognized after the customer commits to purchase the Workstation and the Workstation is delivered, which is when title is transferred. Disposables are identified as a separate performance obligation, and therefore, revenue from the sale of Disposables is recognized when the Disposables are delivered to the customer and title is transferred.

 

A free one-year service plan is included with the purchase of any second generation Pure-Vu Workstation. An extended service plan with varying support and maintenance of the Workstation is offered for sale after the free one-year service plan period. In the case of the free one-year service plan, a portion of the Workstation sales price is deferred and recognized ratably over the one-year service plan term based upon the relative standalone value. The standalone selling price of the Workstation is set at the beginning of the contract based on observable prices from standalone sales of the Workstation, however, at times, the Company has offered discounts from that price to certain customers. The standalone sales price of the one year service plan is based on the expected costs of replacement parts and direct costs to perform the service plus a standard margin, as set by the Company. The standard margin assumed is consistent with the margin expected in pricing the extended service plan. Revenue for the extended service plans is recognized ratably over the term of the service plan contract period.

 

At times, the Company may include a limited time free trial to potential customers to evaluate the Workstation for a period of up to 6 months and in certain instances extend the period to an aggregate of up to 11 months. The Company considers the 6-11 month usage period as a non-contiguous limited trial period because the total length of the free trial is still less than one year. In scenarios where the Company continues to provide the Workstation to a customer for a usage period of greater than one year, the arrangement falls outside of the scope of ASC 606, as described below. Management does not collect any upfront payments or deposits prior to commencing a free trial period. No revenue is recognized for the Workstation during the duration of a free trial, however, any Disposables purchased by the evaluator are recognized when delivered, as described above.

 

 

For contracts outside the scope of ASC 606, the Company determines income for proposed supply arrangements under 1) ASC 842 as it pertains to an embedded lease of the Workstation within a proposed supply arrangement and 2) ASC 606 for the sale of the sleeves within the proposed supply arrangement. The Company allocates the transaction price to the performance obligations within the proposed supply arrangements using the total estimated purchases method for both (i) arrangements that contain minimum purchase commitments and (ii) those arrangements that do not contain a minimum purchase commitment, but instead offer a volume discount for purchases that exceed a specified tier.

 

During the year ended December 31, 2022, the Company recognized revenue of $592, which consisted of $540 in accordance with ASC 606 and $52 in accordance with ASC 842. During the year ended December 31, 2021, the Company recognized revenue of $391, which consisted of $303 in accordance with ASC 606 and $88 in accordance with ASC 842.

 

During the year ended December 31, 2022, the Company recognized revenue at a point in time of $529 and recognized revenue over time of $63. During the year ended December 31, 2021, the Company recognized revenue at a point in time of $299 and recognized revenue over time of $92.

 
Contract Costs

Contract Costs

 

Incremental commissions, if applicable, above a base commission level, are paid to sales representatives upon certain eligible sales, which are paid upon execution of the sales agreement. The guidance within ASC 606 provides a practical expedient if the amortization period of the assets that the entity otherwise would have recognized is one year or less. The Company chose to apply the available practical expedient as the commission paid on eligible sales orders relates to the period in which the sales order was fulfilled. For the years ending December 31, 2022 and 2021, incremental commissions paid on eligible sales orders were $96 and $35, respectively.

 
Accounts receivable and allowance for doubtful accounts

Accounts receivable and allowance for doubtful accounts

 

Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. The Company makes estimates for the allowance for doubtful accounts based upon its assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect customers’ ability to pay. As of December 31, 2022 and 2021, the allowance for doubtful accounts was $0.

 
Inventory

Inventory

 

Inventory is stated at lower of cost and net realizable value using the weighted average cost method and is evaluated at least annually for impairment. The Company records an inventory reserve for losses associated with dated, expired, excess and obsolete items. Reserves and write-downs of inventory is based on management’s current knowledge with respect to inventory levels, planned production, and extension capabilities of materials on hand. A significant change in the timing or level of demand for the Company’s products compared to forecasted amounts may result in recording additional charges for excess and obsolete inventory in the future. The Company records charges for excess and obsolete inventory within cost of revenues. Inventories that exceed estimated realization for the next twelve months from balance sheet date based on future sales forecasts are classified as long-term assets.

 
Leases

Leases

 

The Company accounts for its leases in accordance with ASC 842, Leases, or ASC 842. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. The Company does not have financing leases.

 

Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.

 

The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty of renewal.

 

 
Fixed assets, net

Fixed assets, net

 

Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated based on the straight-line method, at annual rates reflecting the estimated useful lives of the related assets, as follows:

 

 

Office equipment   5-15 years
Computers and software   3-5 years
Machinery   5-10 years
Lab and medical equipment   3-7 years
Leasehold improvements   Shorter of lease term or useful life

 
Share-based compensation

Share-based compensation

 

Employee and Non-Employee Share-Based Compensation

 

The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including employee stock options under the Company’s stock plans and equity awards issued to non-employees based on estimated fair values.

 

The accounting for awards issued to non-employees is similar to the accounting for employee awards, except that:

 

  ● the Company may elect on an award-by-award basis to use the contractual term as the expected term assumption in the option pricing model, and
     
  ● the cost of the grant is recognized in the same period(s) and in the same manner as if the grantor had paid cash.

 

ASC 718-10 requires companies to estimate the fair value of equity-based option awards on the date of grant using an option-pricing model. The fair value of the award is recognized as an expense on a straight-line basis over the requisite service periods in the Company’s consolidated statements of comprehensive loss. The Company recognizes share-based award forfeitures as they occur.

 

The Company estimates the fair value of granted option equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations of the Company.

 

Restricted Stock Units

 

The Company issues restricted stock units under its 2016 Equity Incentive Plan. The fair value of the restricted stock units is based on the closing stock price on the date of grant and is expensed as operating expense over the period during which the units vest. Each restricted stock unit entitles the grantee to one share of common stock to be received upon vesting up to four years after the grant date. Recipients of restricted stock units have no voting rights until the vesting of the award.

 
Basic and diluted net loss per share

Basic and diluted net loss per share

 

Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive ordinary shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. Potentially dilutive common shares were excluded from the calculation of diluted loss per share for all periods presented due to their anti-dilutive effect due to losses in each period.

 

Net loss attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed preferred stock dividends declared, amortized or accumulated. The Company recorded a deemed dividend of $0 and $6,145 for the issuance of warrants during the years ended December 31, 2022 and 2021, respectively. The deemed dividend is added to the net loss in determining the net loss available to common stockholders.

 

 
Research and development expenses

Research and development expenses

 

Research and development expenses are charged to the consolidated statement of comprehensive loss as incurred.

 
Patent costs

Patent costs

 

Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are expensed as incurred.

 
Debt issuance costs

Debt issuance costs

 

Debt issuance costs represent the costs associated with the issuance of a debt instrument and are amortized using the effective interest method over the life of the related debt instrument. The Company records debt issuance costs as a debt discount and is a reduction of the carrying amount of the debt liability.

 
Liabilities due to termination of employment agreements

Liabilities due to termination of employment agreements

 

Under Israeli employment laws, employees of Motus Ltd. are included under Article 14 of the Severance Compensation Act, 1963 (“Article 14”) for a portion of their salaries. According to Article 14, these employees are entitled to monthly deposits made by Motus Ltd. on their behalf with insurance companies.

 

Payments in accordance with Article 14 release Motus Ltd. from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company’s balance sheet, and there is no liability recorded as the Company does not have a future obligation to make any additional payments.

 
Income taxes

Income taxes

 

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company had a full valuation allowance against deferred tax assets.

 

The Company is subject to the provisions of ASC 740-10-25, Income Taxes (ASC 740). ASC 740 prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. On a quarterly basis, the Company undergoes a process to evaluate whether income tax accruals are in accordance with ASC 740 guidance on uncertain tax positions. There are currently no open Federal or State audits. The Company has not recorded any liability for uncertain tax positions at December 31, 2022 or December 31, 2021.

 

For the years ended December 31, 2022 and 2021, the Company recorded zero income tax expense. No tax benefit has been recorded in relation to the pre-tax loss for the years ended December 31, 2022 and 2021, due to a full valuation allowance to offset any deferred tax asset related to net operating loss carry forwards attributable to the losses.

 

 
Fair value of financial instrument

Fair value of financial instrument

 

The Company accounts for financial instruments in accordance with ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”). ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:

 

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

 

Level 2 – Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data;

 

Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

 

There were no changes in the fair value hierarchy leveling during the years ended December 31, 2022 and 2021.

 
New Accounting Pronouncements- Recently Adopted

New Accounting Pronouncements- Recently Adopted

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options, which clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options due to a lack of explicit guidance in the FASB Codification. ASU 2021-04 provides guidance on modifications or exchanges of freestanding equity-classified written call options that are not within the scope of another Topic. Entities should treat a modification of the terms or conditions, or an exchange of a freestanding equity-classified written call option that remains equity-classified after modification or exchange, as an exchange of the original instrument for a new instrument. ASU 2021-04 provides further guidance on measuring the effect of such modifications or exchanges, and also provides guidance on the recognition of such modifications or exchanges on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021. The Company adopted this ASU on January 1, 2022, prospectively to modifications that occurred after the date of initial application. The adoption of this ASU did not result in a material impact to the consolidated financial statements and disclosures.

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements, or ASC 326. On January 1, 2023, the Company adopted ASC 326. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments. The adoption of ASC 326 did not have a material impact on the Company’s financial position or results of operations upon adoption.

 
Accounting Pronouncements- Not Yet Adopted

Accounting Pronouncements- Not Yet Adopted

 

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting which provides optional expedients and exceptions for the accounting for contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. In January 2021, the FASB issued ASU 2021-01 to clarify the scope of certain optional expedients for derivatives that are affected by the discounting transition. In December 2022, the FASB issued ASU 2022-06 to defer the sunset date of Topic 848 from December 31, 2022, to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848. As of December 31, 2022, the Company is currently evaluating the impact of this guidance on its consolidated financial statements.

 

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This guidance simplifies the accounting for convertible instruments primarily by eliminating the existing cash conversion and beneficial conversion models within Subtopic 470-20, which will result in fewer embedded conversion options being accounted for separately from the debt host. The guidance also amends and simplifies the calculation of earnings per share relating to convertible instruments. This guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within that reporting period, using either a full or modified retrospective approach. As of December 31, 2022, the Company is currently evaluating the impact of the provisions of this guidance on its consolidated financial statements.
XML 41 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies and Basis of Presentation (Tables)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Schedule of Fixed Assets are Stated at Cost Less Accumulated Depreciation

Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated based on the straight-line method, at annual rates reflecting the estimated useful lives of the related assets, as follows:

 

 

Office equipment   5-15 years
Computers and software   3-5 years
Machinery   5-10 years
Lab and medical equipment   3-7 years
Leasehold improvements   Shorter of lease term or useful life
XML 42 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Financial Assets and Liabilities

Liabilities measured and recorded at fair value on a recurring basis consisted of the following at December 31, 2022 and December 31, 2021:

 

 

   December 31, 2022 
   Level 1   Level 2   Level 3   Fair Value 
Liabilities                    
Contingent royalty obligation  $   -   $   -   $1,212   $1,212 

 

   December 31, 2021 
   Level 1   Level 2   Level 3   Fair Value 
Liabilities                    
Contingent royalty obligation  $   -   $   -   $1,760  $1,760 
Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation

Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of a contingent royalty obligation, during the year ended December 31, 2022 was as follows:

 

 

   Fair Value
Measurements
of Contingent
Royalty
Obligation
(Level 3)		 
Balance at December 31, 2021  $1,760 
Change in estimated fair value of contingent royalty obligation   548 
Balance at December 31, 2022  $1,212 
XML 43 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Inventory (Tables)
 12 Months Ended
Dec. 31, 2022
Inventory Disclosure [Abstract]  
Schedule of Inventory

Inventory at December 31, 2022 and 2021 consisted of the following:

 

 

   2022   2021 
   December 31, 
   2022   2021 
Raw materials  $697   $569 
Work-in-process   155    - 
Finished goods   

548

    292 
Inventory reserve   (401)   (365)
Inventory, net   $999   $496 
Inventory, current  $488   $

496

 
Inventory, non-current 

$

511   $- 
XML 44 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Fixed assets, net (Tables)
 12 Months Ended
Dec. 31, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Fixed Assets Net

Fixed assets, net, consists of the following:

 

   2022   2021 
   December 31, 
   2022   2021 
Office equipment  $171   $171 
Computers and software   321    305 
Machinery   1,049    807 
Lab and medical equipment   1,477    1,342 
Leasehold improvements   200    193 
Total   3,218    2,818 
Less accumulated depreciation and amortization   (1,893)   (1,390)
Fixed assets, net  $1,325   $1,428 
XML 45 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2022
Leases  
Schedule of Lease Cost and Supplemental Balance Sheet Information

The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows:

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
Lease Cost          
Operating lease cost, net of related party license fee  $92   $139 
Variable lease cost   120    119 
Total lease cost  $212   $258 

 

   As of December 31, 
   2022   2021 
Assets          
Operating lease, right-of-use asset  $428   $687 
Liabilities          
Current          
Operating lease liabilities  $245   $307 
Non-current          
Operating lease liabilities, net of current portion   178    385 
Total lease liabilities  $423   $692 
           
Other information:          
Weighted average remaining lease term - operating leases   1.79 years    2.49 years 
Weighted-average discount rate - operating leases   7.36%   7.66%
Schedule of Future Minimum Lease Payments for Operating Leases

Future minimum lease payments under non-cancellable operating leases as of December 31, 2022 were as follows:

 

Year Ended December 31,  Amount 
2023  $266 
2024   176 
2025   

7

 
Total future minimum lease payments   

449

 
Imputed interest   (26)
Total liability  $423 
Schedule of Measurement of Lease Liability

The following table summarizes the cash paid for amounts included in the measurement of lease liabilities for the years ended December 31, 2022 and 2021:

 

   2022   2021 
   Years Ended December 31, 
   2022   2021 
Cash paid for amounts included in measurement of lease liabilities:  $(342)  $(324)
           
XML 46 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Convertible Note, Term Debt and Long-Term Debt (Tables)
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Schedule of Interest Expense for Loan

For the year ended December 31, 2022, interest expense for the Loan was as follows:

 

   Year Ended December 31, 
   2022     2021 
Contractual interest expense  $1,001     $ 362 
Amortization of debt issuance costs   330       91 
Total interest expense  $1,331     $ 453 
Schedule of Future Principal Payments

Future principal payments under the Convertible Note as of December 31, 2022 are as follows:

 

Years Ending December 31,  Amount 
2023  $- 
2024   - 
2025   4,000 
Total future principal payments   4,000 
Less unamortized debt issuance costs   (108)
Total balance  $3,892

 

Future principal payments under the Term Debt as of December 31, 2022 are as follows:

 

Years Ending December 31,  Amount 
2023  $2,714 
2024   2,983 
2025   1,601 
Total future principal payments   7,298 
End of loan payments   140 
Less unamortized debt issuance costs of current portion of long-term debt   (182)
Less unamortized debt issuance costs of non-current portion long-term debt   

(135

)
Total balance  $7,121 
XML 47 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Share-based compensation and Common Stock Issuance (Tables)
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-based Compensation

The following table sets forth total non-cash share-based compensation for the issuance of common stock, options to purchase common stock, warrants to purchase common stock, and restricted stock unit awards by operating statement classification for the years ended December 31, 2022 and 2021:

 

   2022   2021 
  

Year ended December 31,

 
   2022   2021 
Research and development  $388   $575 
Sales and marketing   238    353 
General and administrative   1,183    2,544 
Total  $1,809   $3,472 
Schedule of Stock option and Warrants

A summary of the Company’s stock option and warrant activity is as follows:

 

   Options     Warrants 
  

Shares

Underlying

Options

  

Weighted

Average

Exercise Price

   Weighted Average Remaining Contractual Life (years)     Average Intrinsic Value    

Shares

Underlying

Warrants

  

Weighted

Average

Exercise Price

     Weighted Average Remaining Contractual Life (years)     Average Intrinsic Value 
Outstanding at December 31, 2020   251,419   $60.00     7.96     $ -      852,820   $37.20       5.78     $ - 
Granted   64,675   $32.80                    326,548   $41.40                 
Forfeited   (8,502)  $68.60                    (45,758)  $100.00                 
Exercised   (713,363)  $24.80                    -   $-                 
Outstanding at December 31, 2021   307,592   $54.10     7.45     $ -      420,247   $54.76       3.40     $ - 
Granted   102,997   $8.73                    6,000   $10.00                 
Expired   (6,597)  $64.24                    (26,986)  $101.13                 
Cancelled   -   $-                    (6,000)  $56.60                 
Forfeited   (3,855)  $11.48                    -   $-                 
Outstanding at December 31, 2022   400,137   $42.69     7.21     $ -      393,261   $50.86       2.66     $ - 
Exercisable at December 31, 2022   294,152   $52.77                    393,261   $50.86                 
Schedule of Option Pricing Model Using Weighted Average Assumptions

The options granted during the years ended December 31, 2022 and 2021 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:

 

   For the year ended December 31, 
   2022   2021 
Expected term, in years    5.8    5.8 
Expected volatility    99.21%   106.24%
Risk-free interest rate     2.10%   0.77%
Dividend yield    -    - 
Schedule of Restricted Stock Unit Awards Activity

A summary of the Company’s restricted stock unit awards activity is as follows:

 

   Number of Shares  

Weighted Average

Grant Date

Fair Value

 
Nonvested at December 31, 2020   16,891   $62.00 
Granted   21,300    34.20 
Vested   (12,071)   48.40 
Nonvested at December 31, 2021   25,120   $44.77 
Granted   18,250    9.07 
Vested   (23,092)   39.53 
Nonvested at December 31, 2022   20,278   $18.62 
XML 48 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of Deferred Tax Assets

 

     2022   2021 
   December 31, 
   2022   2021 
Deferred tax assets:          
Net operating loss carryforwards – Federal and state  $14,614   $5,281 
Net operating loss carryforwards – Israel   18,813    19,354 
Share-based compensation   1,735    1,732 
Capitalized research and development   2,246    218 
Accrued liabilities and reserves   681    831 
Total deferred tax assets   38,089    27,416 
Deferred tax liabilities:          
Accelerated research and development expense   (548)   - 
Right of use asset   (109)   (158)
Other   (34)   (14)
Total deferred tax liabilities   (691)   (172)
Net deferred tax assets before valuation allowance   37,398    27,244 
Valuation allowance   (37,398)   (27,244)
Net deferred tax assets after valuation allowance  $-   $- 
Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of the federal statutory tax rate and the effective tax rates for the years ended December 31, 2022 and 2021 is as follows:

 

   For the Year Ended December 31, 
   2022   2021 
U.S. federal statutory tax rate   21.0%   21.0%
State income taxes, net of federal benefit   6.6    2.0 
U.S. vs. foreign tax rate differential   0.8    0.9 
Non-deductible expenses   (2.7)   (1.9)
Foreign exchange adjustments   (10.7)   2.5 
Change in valuation allowance   (15.0)   (24.5)
Effective tax rate   -%   -%
Schedule of Reconciliation of NOL

A reconciliation of the Company’s NOLs for the years ended December 31, 2022 and 2021 is as follows:

 

 

     2022   2021 
   December 31, 
   2022   2021 
U.S. Federal NOL’s  $26,875   $18,420 
U.S. State NOL’s   25,464    17,009 
Israel NOL’s   81,794    84,148 
Total NOL’s  $134,133   $119,577 
XML 49 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Going Concern (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Net loss $ 18,597 $ 19,033
Cash and cash equivalents 14,042 22,563
Accumulated deficit $ 141,351 $ 122,754
XML 50 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Fixed Assets are Stated at Cost Less Accumulated Depreciation (Details)
 12 Months Ended
Dec. 31, 2022
Office Equipment [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Useful lives 5 years
Office Equipment [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Useful lives 15 years
Computers and Software [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Useful lives 3 years
Computers and Software [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Useful lives 5 years
Machinery [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Useful lives 5 years
Machinery [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Useful lives 10 years
Equipment [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Useful lives 3 years
Equipment [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Useful lives 7 years
Leasehold Improvements [Member]  
Property, Plant and Equipment [Line Items]  
Useful lies, description Shorter of lease term or useful life
XML 51 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies and Basis of Presentation (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]    
Operating Lease, Lease Income $ 52 $ 88
Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration] Revenue recognized Revenue recognized
Revenue recognized $ 592 $ 391
Revenue recognized in accordance with ASC 606 540 303
Revenue recognized in accordance with ASC 842 52 88
Commissions paid 96 35
Allowance for doubtful accounts 0 0
New Warrants [Member]    
Disaggregation of Revenue [Line Items]    
[custom:DeemedDividend] 0 6,145
Transferred at Point in Time [Member]    
Disaggregation of Revenue [Line Items]    
Revenue recognized 529 299
Transferred over Time [Member]    
Disaggregation of Revenue [Line Items]    
Revenue recognized $ 63 $ 92
XML 52 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Fair Value of Financial Assets and Liabilities (Details) - Contingent Royalty Obligation [Member] - Fair Value, Recurring [Member] - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent royalty obligation $ 1,212  
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent royalty obligation
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent royalty obligation
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent royalty obligation $ 1,212 $ 1,760
XML 53 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation (Details) - Fair Value, Inputs, Level 3 [Member]
$ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Balance at December 31, 2021 $ 1,760
Change in estimated fair value of contingent royalty obligation 548
Balance at December 31, 2022 $ 1,212
XML 54 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements (Details Narrative)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value of the liability, description the Company recalculated the fair value of the liability by applying a +/- 2% change to the input variable in the discounted cash flow model; the discount rate. A 2% decrease in the discount rate would increase the liability by approximately $126 and a 2% increase in the discount rate would decrease the liability by approximately $112.  
Measurement Input, Discount Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Increase (decrease) in discount rate 23.00% 21.00%
Royalty payment, percentage 3.00% 3.00%
XML 55 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Inventory (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Raw materials $ 697 $ 569
Work-in-process 155
Finished goods 548 292
Inventory reserve (401) (365)
Inventory, net 999 496
Inventory, current 488 496
Inventory, non-current $ 511
XML 56 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Inventory (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Impairment of inventory $ 598 $ 443
XML 57 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Fixed Assets Net (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Total $ 3,218 $ 2,818
Less accumulated depreciation and amortization (1,893) (1,390)
Fixed assets, net 1,325 1,428
Office Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total 171 171
Computers and Software [Member]    
Property, Plant and Equipment [Line Items]    
Total 321 305
Machinery [Member]    
Property, Plant and Equipment [Line Items]    
Total 1,049 807
Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total 1,477 1,342
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Total $ 200 $ 193
XML 58 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Fixed assets, net (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Abstract]    
Depreciation and amortization expense $ 510 $ 439
Impairment of fixed assets $ 46
XML 59 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Lease Cost and Supplemental Balance Sheet Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Leases    
Operating lease cost, net of related party license fee $ 92 $ 139
Variable lease cost 120 119
Total lease cost 212 258
Operating lease, right-of-use- asset 428 687
Operating lease liabilities, current 245 307
Operating lease liabilities, net of current portion 178 385
Total lease liabilities $ 423 $ 692
Weighted average remaining lease term - operating leases 1 year 9 months 14 days 2 years 5 months 26 days
Weighted-average discount rate - operating leases 7.36% 7.66%
XML 60 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Future Minimum Lease Payments for Operating Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Leases    
2023 $ 266  
2024 176  
2025 7  
Total future minimum lease payments 449  
Imputed interest (26)  
Total liability $ 423 $ 692
XML 61 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Measurement of Lease Liability (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Leases    
Cash paid for amounts included in measurement of lease liabilities: $ (342) $ (324)
XML 62 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Description of lease term option to extend Certain operating leases include escalation clauses and some of which may include options to extend the leases for up to 3 years.  
Operating lease, expense $ 212 $ 258
License fees $ 242 $ 189
Office [Member] | Fort Lauderdale [Member]    
Property, Plant and Equipment [Line Items]    
Operating lease, description The term expires November 2024. The annual base rent is subject to annual increases of 2.75%.  
Office [Member] | ISRAEL    
Property, Plant and Equipment [Line Items]    
Operating lease, description The term expired on December 31, 2022. The Company entered into a new tenancy contract with the facility for a period of twelve months from January 1, 2023 to December 31, 2023.  
Operating lease expiration date Dec. 31, 2022  
XML 63 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Interest Expense for Loan (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
Debt Disclosure [Abstract]  
Contractual interest expense $ 1,001
Amortization of debt issuance costs 330
Total interest expense $ 1,331
XML 64 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Future Principal Payments (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
Long-Term Debt [Member]  
Debt Instrument [Line Items]  
2023 $ 2,714
2024 2,983
2025 1,601
Total future principal payments 7,298
End of loan payments 140
Less unamortized debt issuance costs of current portion of long-term debt (182)
Less unamortized debt issuance costs of non-current portion long-term debt (135)
Total balance 7,121
Convertible Debt [Member]  
Debt Instrument [Line Items]  
2023
2024
2025 4,000
Total future principal payments 4,000
Less unamortized debt issuance costs of current portion of long-term debt (108)
Total balance $ 3,892
XML 65 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Convertible Note, Term Debt and Long-Term Debt (Details Narrative) - USD ($)
 12 Months Ended
Jul. 16, 2021
Dec. 31, 2022
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payments of debt issuance costs   $ 563,000
Long term debt   $ 2,532,000 431,000
Tranche C [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Debt instrument, periodic payment, principal $ 3,000,000   3,000,000
Kreos Loan Agreement [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Debt instrument, periodic payment, principal $ 12,000,000    
Debt instrument, interest rate   7.75%  
Debt instrument, convertible, conversion price   $ 28  
Warrant issued to purchase common shares 9,547    
Exercise price $ 20.948    
Fair value of warrant   $ 165  
Advance payment   845,000 $ 845,000
Payments of debt issuance costs   540,000  
Advance payments for debt discount   274,000  
Long term debt   140,000  
Kreos Loan Agreement [Member] | Warrant [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Advance payment   $ 165,000  
Kreos Loan Agreement [Member] | Tranche A [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Debt instrument, periodic payment, principal $ 4,000,000    
Kreos Loan Agreement [Member] | Tranche B [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Debt instrument, periodic payment, principal $ 5,000,000    
XML 66 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended 60 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2016
Product Liability Contingency [Line Items]      
Royalty received $ 30,000   $ 1,332
LIBOR interest rate $ 1,426 $ 1,419  
Royalties percentage 4.00%    
Net sales percentage 3.00%    
Licensing percentage 5.00%    
Contingent royalty obligation $ 1,212 1,760  
Gain on change in fair value of contingent royalty obligation 548 143  
Severance payments 1,408    
Manufacturing Costs 41    
Royalty [Member]      
Product Liability Contingency [Line Items]      
Royalties income 20,000    
Proceeds from licensing based royalty amounts $ 3,500    
Series A Preferred Stock [Member]      
Product Liability Contingency [Line Items]      
Percentage of payment amount 10.00%    
Private Placement [Member]      
Product Liability Contingency [Line Items]      
Net sales percentage 3.00%    
Licensing percentage 5.00%    
Royalty Payment Rights Certificates [Member]      
Product Liability Contingency [Line Items]      
Description of royalty payment the Royalty Payment Rights initially entitled the holders in aggregate, to a royalty in an amount of:    
Israeli National Authority For Technical Innovation [Member]      
Product Liability Contingency [Line Items]      
Royalty received $ 0 $ 0  
XML 67 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Jan. 31, 2020
License fee $ 242 $ 189  
Minimum [Member]      
License fee 212    
Maximum [Member]      
License fee $ 270    
Shared Space Agreements [Member] | Orchestra Bio Med Inc [Member]      
Ownership percentage     5.00%
XML 68 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Stock-based Compensation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total $ 1,809 $ 3,472
Research and Development Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total 388 575
Selling, General and Administrative Expenses [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total 238 353
General and Administrative Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total $ 1,183 $ 2,544
XML 69 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Stock option and Warrants (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Offsetting Assets [Line Items]      
Shares underlying options, forfeited (26)    
Warrant [Member]      
Offsetting Assets [Line Items]      
Shares Underlying Warrants, outstanding beginning 420,247 852,820  
Weighted Average Exercise Price, outstanding beginning $ 54.76 $ 37.20  
Weighted Average Remaining Contractual Life, outstanding 2 years 7 months 28 days 3 years 4 months 24 days 5 years 9 months 10 days
Aggregate Intrinsic Value, outstanding beginning  
Shares Underlying Warrants, granted 6,000 326,548  
Weighted Average Exercise Price, granted $ 10.00 $ 41.40  
Shares Underlying Warrants, forfeited (45,758)  
Weighted Average Exercise Price, forfeited $ 100.00  
Shares Underlying Warrants, exercised    
Weighted Average Exercise Price, exercised    
Shares Underlying Warrants, expired (26,986)    
Weighted Average Exercise Price, expired $ 101.13    
Shares Underlying Warrants, cancelled (6,000)    
Weighted Average Exercise Price, cancelled $ 56.60    
Shares Underlying Warrants, outstanding ending 393,261 420,247 852,820
Weighted Average Exercise Price, outstanding ending $ 50.86 $ 54.76 $ 37.20
Aggregate Intrinsic Value, outstanding ending
Shares Underlying Warrants, exercisable 393,261    
Weighted Average Exercise Price, exercisable $ 50.86    
Equity Option [Member]      
Offsetting Assets [Line Items]      
Shares underlying options, outstanding beginning 307,592 251,419  
Weighted average exercise price, outstanding beginning $ 54.10 $ 60.00  
Weighted average remaining contractual life, outstanding 7 years 2 months 15 days 7 years 5 months 12 days 7 years 11 months 15 days
Aggregate intrinsic value, outstanding beginning  
Shares underlying options, granted 102,997 64,675  
Weighted average exercise price, granted $ 8.73 $ 32.80  
Shares underlying options, forfeited (3,855) (8,502)  
Weighted average exercise price, forfeited $ 11.48 $ 68.60  
Shares underlying options, exercised   (713,363)  
Weighted average exercise price, exercised   $ 24.80  
Shares underlying options, expired (6,597)    
Weighted average exercise price, expired $ 64.24    
Shares underlying options, cancelled    
Weighted average exercise price, cancelled    
Shares underlying options, outstanding ending 400,137 307,592 251,419
Weighted average exercise price, outstanding ending $ 42.69 $ 54.10 $ 60.00
Aggregate intrinsic value, outstanding ending
Shares underlying options, exercisable 294,152    
Weighted average exercise price, exercisable $ 52.77    
XML 70 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Option Pricing Model Using Weighted Average Assumptions (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]    
Expected term, in years 5 years 9 months 18 days 5 years 9 months 18 days
Expected volatility 99.21% 106.24%
Risk-free interest rate 2.10% 0.77%
Dividend yield
XML 71 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Restricted Stock Unit Awards Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of Shares, nonvested beginning 25,120 16,891
Aggregate weighted average grant date fair value, nonvested beginning $ 44.77 $ 62.00
Number of Shares, nonvested granted 18,250 21,300
Aggregate weighted average grant date fair value, nonvested granted $ 9.07 $ 34.20
Number of Shares, nonvested vested (23,092) (12,071)
Aggregate weighted average grant date fair value, nonvested vested $ 39.53 $ 48.40
Number of Shares, nonvested ending 20,278 25,120
Aggregate weighted average grant date fair value, nonvested ending $ 18.62 $ 44.77
XML 72 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Share-based compensation and Common Stock Issuance (Details Narrative)
 1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended
Jan. 05, 2022
USD ($)
$ / shares
shares
Mar. 31, 2021
USD ($)
Dec. 31, 2016
Mar. 14, 2023
USD ($)
shares
Mar. 31, 2021
USD ($)
Dec. 31, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Jan. 01, 2022
shares
Feb. 29, 2020
$ / shares
shares
Feb. 06, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Grant date fair value | $ / shares           $ 8.62 $ 26.4      
Share based compnesation plan modification, incremental cost | shares           26        
Proceeds from common stock           $ 10,252,000 $ 1,900,000      
Non Employee [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Share based compensation options, grants | shares 24,458                  
Fair value of common stock | $ / shares $ 9.60                  
Cash compensation $ 235                  
Expense for director services           $ 235 177      
Services Agreement [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Warrants exercise price | $ / shares                 $ 10  
Services Agreement [Member] | Warrants [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Warrants to purchase of common stock | shares                 6,000  
Warrants exercise price | $ / shares                 $ 56.60  
Services Agreement [Member] | Replacement Warrants [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Warrants to purchase of common stock | shares                 6,000  
Equity Distribution Agreement [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Number of common stock sold, shares | shares       119,104   2,200,000        
Proceeds from common stock       $ 118,000.0   $ 9,900,000        
Proceeds from net of issuance costs       $ 4,000.0 $ 400,000          
Maximum [Member] | Equity Distribution Agreement [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Aggregate of offering cost   $ 25,000,000.0                
2016 Equity Incentive Plan [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Common stock available for future grant | shares           15,165   279,586    
2016 Equity Incentive Plan [Member] | Maximum [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Common stock available for future grant | shares               804,371    
Restricted Stock Units (RSUs) [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Share-based compensation expenses           $ 607,000 $ 867,000      
Weighted-average recognition period           9 months 21 days        
Unamortization stock compensation           $ 308,000        
Vested and unissued restricted stock units | shares             3,138      
Warrant [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Share-based compensation expenses           57,000 $ 335,000      
Share Price | $ / shares                 $ 0.38  
Warrants and Rights Outstanding, Term                 1 year 7 months 13 days  
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Warrants and Rights Outstanding, Measurement Input                 0.91  
Warrant [Member] | Measurement Input, Price Volatility [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Warrants and Rights Outstanding, Measurement Input                   81.97
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Warrants and Rights Outstanding, Measurement Input                   0
Common Stock [Member] | 2016 Equity Incentive Plan [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Common stock percentage     6.00%              
Equity Option [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Share-based compensation expenses           1,145,000 $ 2,270,000      
Stock based compensation for stock options           $ 964,000        
Weighted-average recognition period           10 months 13 days        
Share based compnesation plan modification, incremental cost | shares           3,855 8,502      
Share based compensation options, grants | shares           102,997 64,675      
XML 73 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Deferred Tax Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Net operating loss carryforwards – Federal and state $ 14,614 $ 5,281
Net operating loss carryforwards – Israel 18,813 19,354
Share-based compensation 1,735 1,732
Capitalized research and development 2,246 218
Accrued liabilities and reserves 681 831
Total deferred tax assets 38,089 27,416
Accelerated research and development expense (548)
Right of use asset (109) (158)
Other (34) (14)
Total deferred tax liabilities (691) (172)
Net deferred tax assets before valuation allowance 37,398 27,244
Valuation allowance (37,398) (27,244)
Net deferred tax assets after valuation allowance
XML 74 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Effective Income Tax Rate Reconciliation (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
U.S. federal statutory tax rate 21.00% 21.00%
State income taxes, net of federal benefit 6.60% 2.00%
U.S. vs. foreign tax rate differential 0.80% 0.90%
Non-deductible expenses (2.70%) (1.90%)
Foreign exchange adjustments (10.70%) 2.50%
Change in valuation allowance 15.00% 24.50%
Effective tax rate
XML 75 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Reconciliation of NOL (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
U.S. Federal NOL’s $ 26,875 $ 18,420
U.S. State NOL’s 25,464 17,009
Israel NOL’s 81,794 84,148
Total NOL’s $ 134,133 $ 119,577
XML 76 R57.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2018
Operating Loss Carryforwards [Line Items]      
Deferred tax assets $ 37,398,000 $ 27,244,000  
Deferred tax assets valuation allowance 37,398,000 27,244,000  
Valuation allowance 10,200,000    
Operating loss 134,100,000 119,600,000  
Research and development costs 4,900,000    
Accumulated gross amount 8,800,000    
Operating loss utilization limit   3,700,000  
Deferred Federal Income Tax Expense (Benefit) 26,875,000 18,420,000  
Deferred State and Local Income Tax Expense (Benefit) $ 25,464,000 17,009,000  
Expire date, description begin to expire after 2036 through 2042    
Deferred Foreign Income Tax Expense (Benefit) $ 81,794,000 84,148,000  
ISRAEL      
Operating Loss Carryforwards [Line Items]      
Deferred Foreign Income Tax Expense (Benefit) 81,794,000    
[custom:DeferredForeignIncomeTaxExpenseBenefitAvailableUse] 38,100,000    
Federal [Member]      
Operating Loss Carryforwards [Line Items]      
Deferred Federal Income Tax Expense (Benefit) $ 3,300,000   $ 23,575,000,000
State [Member]      
Operating Loss Carryforwards [Line Items]      
Deferred State and Local Income Tax Expense (Benefit)   $ 25,464,000  
XML 77 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events (Details Narrative) - Subsequent Event [Member]
$ in Millions
 3 Months Ended
Mar. 31, 2023
USD ($)
Minimum [Member]  
Subsequent Event [Line Items]  
Non recurring charges $ 1.0
Maximum [Member]  
Subsequent Event [Line Items]  
Non recurring charges $ 2.0
XML 78 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001686850 2022-01-01 2022-12-31 0001686850 2022-06-30 0001686850 2023-03-27 0001686850 2022-12-31 0001686850 2021-12-31 0001686850 2021-01-01 2021-12-31 0001686850 us-gaap:CommonStockMember 2020-12-31 0001686850 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001686850 us-gaap:RetainedEarningsMember 2020-12-31 0001686850 2020-12-31 0001686850 us-gaap:CommonStockMember 2021-12-31 0001686850 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001686850 us-gaap:RetainedEarningsMember 2021-12-31 0001686850 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001686850 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001686850 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001686850 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001686850 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001686850 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001686850 us-gaap:CommonStockMember 2022-12-31 0001686850 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001686850 us-gaap:RetainedEarningsMember 2022-12-31 0001686850 us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-12-31 0001686850 us-gaap:TransferredOverTimeMember 2022-01-01 2022-12-31 0001686850 us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-12-31 0001686850 us-gaap:TransferredOverTimeMember 2021-01-01 2021-12-31 0001686850 mots:NewWarrantsMember 2022-01-01 2022-12-31 0001686850 mots:NewWarrantsMember 2021-01-01 2021-12-31 0001686850 srt:MinimumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-12-31 0001686850 srt:MaximumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-12-31 0001686850 srt:MinimumMember mots:ComputersAndSoftwareMember 2022-01-01 2022-12-31 0001686850 srt:MaximumMember mots:ComputersAndSoftwareMember 2022-01-01 2022-12-31 0001686850 srt:MinimumMember mots:MachineryMember 2022-01-01 2022-12-31 0001686850 srt:MaximumMember mots:MachineryMember 2022-01-01 2022-12-31 0001686850 srt:MinimumMember us-gaap:EquipmentMember 2022-01-01 2022-12-31 0001686850 srt:MaximumMember us-gaap:EquipmentMember 2022-01-01 2022-12-31 0001686850 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0001686850 mots:ContingentRoyaltyObligationMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001686850 mots:ContingentRoyaltyObligationMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001686850 mots:ContingentRoyaltyObligationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001686850 mots:ContingentRoyaltyObligationMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001686850 mots:ContingentRoyaltyObligationMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001686850 mots:ContingentRoyaltyObligationMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001686850 mots:ContingentRoyaltyObligationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001686850 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001686850 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-12-31 0001686850 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001686850 us-gaap:MeasurementInputDiscountRateMember 2022-01-01 2022-12-31 0001686850 us-gaap:MeasurementInputDiscountRateMember 2021-01-01 2021-12-31 0001686850 us-gaap:OfficeEquipmentMember 2022-12-31 0001686850 us-gaap:OfficeEquipmentMember 2021-12-31 0001686850 mots:ComputersAndSoftwareMember 2022-12-31 0001686850 mots:ComputersAndSoftwareMember 2021-12-31 0001686850 mots:MachineryMember 2022-12-31 0001686850 mots:MachineryMember 2021-12-31 0001686850 us-gaap:EquipmentMember 2022-12-31 0001686850 us-gaap:EquipmentMember 2021-12-31 0001686850 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001686850 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001686850 mots:FortLauderdaleMember mots:OfficeMember 2022-01-01 2022-12-31 0001686850 country:IL mots:OfficeMember 2022-01-01 2022-12-31 0001686850 mots:KreosLoanAgreementMember 2021-07-15 2021-07-16 0001686850 mots:TrancheAMember mots:KreosLoanAgreementMember 2021-07-15 2021-07-16 0001686850 mots:TrancheBMember mots:KreosLoanAgreementMember 2021-07-15 2021-07-16 0001686850 mots:TrancheCMember 2021-07-15 2021-07-16 0001686850 mots:TrancheCMember 2021-01-01 2021-12-31 0001686850 mots:KreosLoanAgreementMember 2022-01-01 2022-12-31 0001686850 mots:KreosLoanAgreementMember 2022-12-31 0001686850 mots:KreosLoanAgreementMember 2021-07-16 0001686850 us-gaap:WarrantMember mots:KreosLoanAgreementMember 2022-12-31 0001686850 mots:KreosLoanAgreementMember 2021-12-31 0001686850 us-gaap:ConvertibleDebtMember 2022-12-31 0001686850 us-gaap:LongTermDebtMember 2022-12-31 0001686850 2011-12-31 2016-12-31 0001686850 mots:IsraeliNationalAuthorityForTechnicalInnovationMember 2022-01-01 2022-12-31 0001686850 mots:IsraeliNationalAuthorityForTechnicalInnovationMember 2021-01-01 2021-12-31 0001686850 mots:RoyaltyPaymentRightsCertificatesMember 2022-01-01 2022-12-31 0001686850 us-gaap:PrivatePlacementMember 2022-01-01 2022-12-31 0001686850 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-12-31 0001686850 us-gaap:RoyaltyMember 2022-01-01 2022-12-31 0001686850 mots:OrchestraBioMedIncMember mots:SharedSpaceAgreementsMember 2020-01-31 0001686850 srt:MinimumMember 2022-01-01 2022-12-31 0001686850 srt:MaximumMember 2022-01-01 2022-12-31 0001686850 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001686850 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001686850 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0001686850 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001686850 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001686850 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001686850 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001686850 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001686850 us-gaap:StockOptionMember 2022-12-31 0001686850 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001686850 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001686850 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001686850 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001686850 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001686850 mots:TwoThousandSixteenEquityIncentivePlanMember us-gaap:CommonStockMember 2016-12-01 2016-12-31 0001686850 mots:TwoThousandSixteenEquityIncentivePlanMember 2022-01-01 0001686850 srt:MaximumMember mots:TwoThousandSixteenEquityIncentivePlanMember 2022-01-01 0001686850 mots:TwoThousandSixteenEquityIncentivePlanMember 2022-12-31 0001686850 mots:WarrantsMember mots:ServicesAgreementMember 2020-02-29 0001686850 mots:ReplacementWarrantsMember mots:ServicesAgreementMember 2020-02-29 0001686850 mots:ServicesAgreementMember 2020-02-29 0001686850 us-gaap:WarrantMember 2020-02-29 0001686850 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2020-02-29 0001686850 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2020-02-06 0001686850 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2020-02-06 0001686850 mots:NonEmployeeMember 2022-01-04 2022-01-05 0001686850 mots:NonEmployeeMember 2022-01-05 0001686850 mots:NonEmployeeMember 2022-01-01 2022-12-31 0001686850 mots:NonEmployeeMember 2021-01-01 2021-12-31 0001686850 srt:MaximumMember mots:EquityDistributionAgreementMember 2021-03-01 2021-03-31 0001686850 mots:EquityDistributionAgreementMember 2022-01-01 2022-12-31 0001686850 mots:EquityDistributionAgreementMember 2021-01-01 2021-03-31 0001686850 mots:EquityDistributionAgreementMember 2023-01-01 2023-03-14 0001686850 us-gaap:StockOptionMember 2020-12-31 0001686850 us-gaap:StockOptionMember 2020-01-01 2020-12-31 0001686850 us-gaap:WarrantMember 2020-12-31 0001686850 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001686850 us-gaap:StockOptionMember 2021-12-31 0001686850 us-gaap:WarrantMember 2021-12-31 0001686850 us-gaap:WarrantMember 2022-12-31 0001686850 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001686850 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001686850 mots:FederalMember 2022-01-01 2022-12-31 0001686850 mots:StateMember 2021-01-01 2021-12-31 0001686850 mots:FederalMember 2018-01-01 2018-12-31 0001686850 country:IL 2022-01-01 2022-12-31 0001686850 srt:MinimumMember us-gaap:SubsequentEventMember 2023-01-01 2023-03-31 0001686850 srt:MaximumMember us-gaap:SubsequentEventMember 2023-01-01 2023-03-31 iso4217:USD shares iso4217:USD shares pure 0001686850 false FY http://fasb.org/us-gaap/2022#Revenues http://fasb.org/us-gaap/2022#Revenues 10-K true 2022-12-31 --12-31 2022 false 001-38389 Motus GI Holdings, Inc. DE 81-4042793 1301 East Broward Boulevard 3rd Floor Ft. Lauderdale FL 33301 (954) 541-8000 Common Stock, par value $0.0001 per share MOTS NASDAQ No No Yes Yes Non-accelerated Filer true true true false false 14600000 4778873 None 274 EISNERAMPER LLP Philadelphia, Pennsylvania 14042000 22563000 59000 109000 488000 496000 781000 793000 15370000 23961000 1325000 1428000 511000 428000 687000 13000 13000 17647000 26089000 1969000 2584000 245000 307000 53000 10000 182000 271000 2532000 431000 4799000 3332000 1212000 1760000 178000 385000 108000 166000 3892000 3834000 135000 317000 4589000 7121000 14670000 16432000 0.0001 0.0001 10000000 10000000 0 0 0 0 0.0001 0.0001 115000000 115000000 4659769 4659769 2416021 2416021 144328000 132411000 -141351000 -122754000 2977000 9657000 17647000 26089000 592000 391000 198000 181000 598000 443000 5611000 5341000 4425000 3077000 7611000 9273000 18443000 18315000 -17851000 -17924000 -548000 143000 -237000 1252000 717000 5000 -42000 -17000 -18597000 -19033000 6145000 -18597000 -25178000 -5.74 -10.74 3237952 2344759 1613591 115011000 -103721000 11290000 74000 67043 1826000 1826000 366000 713362 11593000 11593000 9587 291000 291000 9938 2500 53 53 165 165 3472000 3472000 -19033000 -19033000 2416021 132411000 -122754000 9657000 2416021 132411000 -122754000 9657000 368000 2195106 9884000 9884000 26230 -2046 -11 -11 24458 235000 235000 1809000 1809000 -18597000 -18597000 4659769 144328000 -141351000 2977000 4659769 144328000 -141351000 2977000 -18597000 -19033000 510000 439000 330000 95000 548000 -143000 1809000 3472000 235000 235000 53000 -237000 598000 443000 46000 327000 262000 -50000 74000 1302000 274000 -12000 413000 -650000 303000 -330000 -260000 43000 -50000 -17467000 -14422000 224000 470000 -224000 -470000 10252000 1900000 11000 11959000 12000000 703000 8220000 563000 368000 440000 9170000 16636000 -8521000 1744000 22563000 20819000 14042000 22563000 977000 640000 56000 201000 140000 4000 75000 24000 4000 165000 140000 66000 184000 17000 <p id="xdx_805_eus-gaap--NatureOfOperations_zuMoW7lMKl63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_820_z5irFm0SEbIl">Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motus GI Holdings, Inc. (the “Company”) was incorporated in Delaware, U.S.A. in September 2016. The Company and its subsidiaries, Motus GI Technologies, Ltd. and Motus GI, LLC, are collectively referred to as “Motus GI” or the “Company”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the “FDA”) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (“GI”) endoscopy procedures. The Pure-Vu System has received a CE Mark in the EU for use in colonoscopy. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Through irrigation and evacuation of debris, the Pure-Vu System is designed to provide better-quality exams. The Company received 510(k) clearance in February 2022 from the FDA for the Pure-Vu EVS System and has commenced initial commercialization of this product. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not expect to generate significant revenue from product sales until it further expands its commercialization efforts, which is subject to significant uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_807_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zkL4rA69uKM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – <span id="xdx_82B_zxu0OPcGczPc">Going Concern</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To date, the Company has generated minimal revenues, experienced negative operating cash flows and has incurred substantial operating losses from its activities. Management expects the Company to continue to generate substantial operating losses and to continue to fund its operations primarily through utilization of its current financial resources, future product sales, and through the issuance of debt or equity, as well as through other strategic alternative transactions. Rising inflation and financial market volatility may adversely impact the Company’s ability to enter into, modify, and negotiate favorable terms and conditions relative to equity and debt financing initiatives. The uncertain financial markets, potential disruptions in supply chains, and changing priorities could also affect the Company’s ability to enter into key agreements. COVID-19 and government measures taken in response have also had an impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as certain medical services and supplies, have spiked, while demand for other goods and services have fallen. The future progression of the outbreak and its longer-term effects on the Company’s business and operations continue to evolve and are still uncertain. The Company and its third-party contract manufacturers, contract research organizations, and clinical sites may also face disruptions in procuring items that are essential to the Company’s research and development activities, including, for example, medical and laboratory supplies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts related to the outbreak in certain parts of the world. These disruptions may negatively impact the Company’s sales, its results of operations, financial condition, and liquidity into Q2 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have generated limited revenues to date from the sale of products. We have never been profitable and have incurred significant net losses each year since our inception, including a loss of $<span id="xdx_900_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20221231_zyArylYVfqW1" title="Net loss">18.6</span> million for the year ended December 31, 2022, and we expect to continue to incur net operating losses for the foreseeable future. As of December 31, 2022, we had $<span id="xdx_90D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_z0VNvxyYwu9d" title="Cash and cash equivalents">14.0</span> million in cash and cash equivalents and an accumulated deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20221231_zUmMDuNaPmla" title="Accumulated deficit">141.4</span> million. We expect our current spend level to continue in connection with ongoing operating activities, including expenditures in R&amp;D, sales and marketing, clinical affairs and manufacturing. As described above, <span style="background-color: white">we committed to a restructuring initiative designed to reduce our expenses and position us to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. </span>In addition, in order to continue to operate as a standalone company, we would need additional financing to support our continuing operations. We also have significant debt under our Loan Agreement with Kreos which could negatively impact our ability to operate or consummate a strategic transaction.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2023, we committed to a restructuring initiative designed to position us to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. If a strategic transaction is not completed, or if additional financing is not available, we may not be able to service our outstanding indebtedness and our payables and may have to file for bankruptcy protection or pursue a dissolution of the Company and liquidation of all of our remaining assets. In such an event, the amount of cash available for distribution to our stockholders, if any, will depend heavily on the timing of such decision, as with the passage of time the amount of cash available for distribution will be reduced as we continue to fund our operations and service our outstanding indebtedness. We cannot provide assurance as to the amount of cash that will be available to distribute to stockholders, if any, after paying our debts and other obligations and setting aside funds for reserves, nor as to the timing of any such distribution, if any.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -18600000 14000000.0 -141400000 <p id="xdx_801_eus-gaap--SignificantAccountingPoliciesTextBlock_zyh9C2kZ2cj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 – <span id="xdx_821_zcO1KOF6MhLl">Significant Accounting Policies and Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--UseOfEstimates_zLCh00ujSol8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z4H5ycMaeLac">Basis of presentation and use of estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, of the Financial Accounting Standards Board (“FASB”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84C_ecustom--ReverseStockSplitPolicyTextBlock_z6lmvbE1bInd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86E_z2Tx3b7GamMe">Reverse Stock Split</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On July 25, 2022, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-20. Shares of common stock underlying outstanding stock options and other equity instruments convertible into common stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z7raguP8yY1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zOoJzwU2Cesa">Functional currency and foreign currency translation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The functional currency of the Company, inclusive of foreign subsidiaries, is the U.S dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the consolidated statement of comprehensive loss as foreign currency (loss) gain, as appropriate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zntZNXcDPTkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zN3pn1Di6E4j">Cash and cash equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investment securities with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Cash and cash equivalents include cash on-hand and highly-rated U.S. government backed money market fund investments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations of Credit Risk and Off-balance Sheet Risk</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company’s cash is held in accounts with financial institutions that management believes are creditworthy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--RevenueRecognitionPolicyTextBlock_z8FKDnnxv904" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zm4cyTtsOkld">Revenue recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales contracts executed for the second generation Pure-Vu System are accounted for in accordance with ASC Topic 606 - Revenue from Contracts with Customers (“ASC 606”) to depict the transfer of control to the Company’s customers in an amount reflecting the consideration to which the Company expects to be entitled to. The Pure-Vu System consists of a Workstation (a “Workstation”) and single use disposable sleeve (a “Disposable”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases and collaboration arrangements. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when a performance obligation is satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercial placements of the second generation system include the Workstation, sale of the Disposables, and a service plan. The Workstation is operational without any significant customization and modification and the Disposables are specialized consumables that are readily available for purchase from the Company. Therefore, revenue from the sale of a Workstation is recognized after the customer commits to purchase the Workstation and the Workstation is delivered, which is when title is transferred. Disposables are identified as a separate performance obligation, and therefore, revenue from the sale of Disposables is recognized when the Disposables are delivered to the customer and title is transferred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A free one-year service plan is included with the purchase of any second generation Pure-Vu Workstation. An extended service plan with varying support and maintenance of the Workstation is offered for sale after the free one-year service plan period. In the case of the free one-year service plan, a portion of the Workstation sales price is deferred and recognized ratably over the one-year service plan term based upon the relative standalone value. The standalone selling price of the Workstation is set at the beginning of the contract based on observable prices from standalone sales of the Workstation, however, at times, the Company has offered discounts from that price to certain customers. The standalone sales price of the one year service plan is based on the expected costs of replacement parts and direct costs to perform the service plus a standard margin, as set by the Company. The standard margin assumed is consistent with the margin expected in pricing the extended service plan. Revenue for the extended service plans is recognized ratably over the term of the service plan contract period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At times, the Company may include a limited time free trial to potential customers to evaluate the Workstation for a period of up to 6 months and in certain instances extend the period to an aggregate of up to 11 months. The Company considers the 6-11 month usage period as a non-contiguous limited trial period because the total length of the free trial is still less than one year. In scenarios where the Company continues to provide the Workstation to a customer for a usage period of greater than one year, the arrangement falls outside of the scope of ASC 606, as described below. Management does not collect any upfront payments or deposits prior to commencing a free trial period. No revenue is recognized for the Workstation during the duration of a free trial, however, any Disposables purchased by the evaluator are recognized when delivered, as described above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For contracts outside the scope of ASC 606, the Company determines income for proposed supply arrangements under 1) ASC 842 as it pertains to an embedded lease of the Workstation within a proposed supply arrangement and 2) ASC 606 for the sale of the sleeves within the proposed supply arrangement. The Company allocates the transaction price to the performance obligations within the proposed supply arrangements using the total estimated purchases method for both (i) arrangements that contain minimum purchase commitments and (ii) those arrangements that do not contain a minimum purchase commitment, but instead offer a volume discount for purchases that exceed a specified tier.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company recognized <span><span id="xdx_906_eus-gaap--OperatingLeaseIncomeComprehensiveIncomeExtensibleList_iP1us-gaap--OperatingLeaseLeaseIncome_dxL_c20220101__20221231_zymbM0dMziKd" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2022%23Revenues"><span id="xdx_90A_eus-gaap--OperatingLeaseIncomeComprehensiveIncomeExtensibleList_iP1us-gaap--OperatingLeaseLeaseIncome_dxL_c20210101__20211231_zJi2UXTVlv3b" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2022%23Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0540"><span style="-sec-ix-hidden: xdx2ixbrl0541">revenue</span></span></span></span></span> of $<span id="xdx_906_eus-gaap--Revenues_pn3n3_c20220101__20221231_zGOGhgbGgNEl" title="Revenue recognized">592</span>, which consisted of $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231_zfZDY5ENkf3h" title="Revenue recognized in accordance with ASC 606">540</span> in accordance with ASC 606 and $<span id="xdx_905_eus-gaap--OperatingLeaseLeaseIncome_pn3n3_c20220101__20221231_zHpVTHf0Thie" title="Revenue recognized in accordance with ASC 842">52</span> in accordance with ASC 842. During the year ended December 31, 2021, the Company recognized revenue of $<span id="xdx_90B_eus-gaap--Revenues_pn3n3_c20210101__20211231_zALMsNOups9d" title="Revenue recognized">391</span>, which consisted of $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231_ztN1GF0UrQ2j" title="Revenue recognized in accordance with ASC 606">303</span> in accordance with ASC 606 and $<span id="xdx_90A_eus-gaap--OperatingLeaseLeaseIncome_pn3n3_c20210101__20211231_zlRYlFwV9qkf" title="Revenue recognized in accordance with ASC 842">88</span> in accordance with ASC 842.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company recognized revenue at a point in time of $<span id="xdx_909_eus-gaap--Revenues_pn3n3_c20220101__20221231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zjjuGzjMlLJ4" title="Revenue recognized">529</span> and recognized revenue over time of $<span id="xdx_905_eus-gaap--Revenues_pn3n3_c20220101__20221231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_z0us3Wbqwpm9" title="Revenue recognized">63</span>. During the year ended December 31, 2021, the Company recognized revenue at a point in time of $<span id="xdx_90A_eus-gaap--Revenues_pn3n3_c20210101__20211231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zpz6BEfAwh4l" title="Revenue recognized">299</span> and recognized revenue over time of $<span id="xdx_90B_eus-gaap--Revenues_pn3n3_c20210101__20211231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_z9zbyh3T9tWc" title="Revenue recognized">92</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_ecustom--ContractCostsPolicyTextBlock_zfsRjRUszYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zAIxb9jVwee6">Contract Costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incremental commissions, if applicable, above a base commission level, are paid to sales representatives upon certain eligible sales, which are paid upon execution of the sales agreement. The guidance within ASC 606 provides a practical expedient if the amortization period of the assets that the entity otherwise would have recognized is one year or less. The Company chose to apply the available practical expedient as the commission paid on eligible sales orders relates to the period in which the sales order was fulfilled. For the years ending December 31, 2022 and 2021, incremental commissions paid on eligible sales orders were $<span id="xdx_903_eus-gaap--PaymentsForCommissions_pn3n3_c20220101__20221231_zTr7jNpbyUz7" title="Commissions paid">96</span> and $<span id="xdx_909_eus-gaap--PaymentsForCommissions_pn3n3_c20210101__20211231_zOdiyx6Gheb" title="Commissions paid">35</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock_z0466q2TvTRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zGqd9PWmA5fd">Accounts receivable and allowance for doubtful accounts</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. The Company makes estimates for the allowance for doubtful accounts based upon its assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect customers’ ability to pay. As of December 31, 2022 and 2021, the allowance for doubtful accounts was $<span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20221231_zgVWEsmwVNdh" title="Allowance for doubtful accounts"><span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20211231_zCH3zIOIo9D7" title="Allowance for doubtful accounts">0</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--InventoryPolicyTextBlock_zgWmv1Ei2COg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zH66gkAITbk1">Inventory</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is stated at lower of cost and net realizable value using the weighted average cost method and is evaluated at least annually for impairment. The Company records an inventory reserve for losses associated with dated, expired, excess and obsolete items. Reserves and write-downs of inventory is based on management’s current knowledge with respect to inventory levels, planned production, and extension capabilities of materials on hand. A significant change in the timing or level of demand for the Company’s products compared to forecasted amounts may result in recording additional charges for excess and obsolete inventory in the future. The Company records charges for excess and obsolete inventory within cost of revenues. </span>Inventories that exceed estimated realization for the next twelve months from balance sheet date based on future sales forecasts are classified as long-term assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_zsKVirHCTOu9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zoGV94ZEtkX1">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its leases in accordance with ASC 842, Leases, or ASC 842. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. The Company does not have financing leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty of renewal.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_844_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zE808h7XJDml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zhCV8wo7ABNb">Fixed assets, net</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_ecustom--ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationTableTextBlock_zXkF5tpJQ1al" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated based on the straight-line method, at annual rates reflecting the estimated useful lives of the related assets, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zjuLzjZjjeDc" style="display: none">Schedule of Fixed Assets are Stated at Cost Less Accumulated Depreciation</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zD6CXy1b6FWg" title="Useful lives">5</span>-<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_z4KylAwiRFej" title="Useful lives">15</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and software</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_zUXEgP7RCrk9" title="Useful lives">3</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_zXlPJc5u1FRa" title="Useful lives">5</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember__srt--RangeAxis__srt--MinimumMember_zSOKlNcb3dRe" title="Useful lives">5</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember__srt--RangeAxis__srt--MaximumMember_zw0QPWvfSyTd" title="Useful lives">10</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab and medical equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zLBfGkZz5EKl" title="Useful lives">3</span>-<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zb2WWAgpYHu" title="Useful lives">7</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z1BfMwvf60M5" title="Useful lies, description">Shorter of lease term or useful life</span></span></td></tr> </table> <p id="xdx_8AD_zPYAZAH4N8H1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zUMQ5vZaS6yh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zFrXh7DeP9l6">Share-based compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employee and Non-Employee Share-Based Compensation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including employee stock options under the Company’s stock plans and equity awards issued to non-employees based on estimated fair values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting for awards issued to non-employees is similar to the accounting for employee awards, except that:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company may elect on an award-by-award basis to use the contractual term as the expected term assumption in the option pricing model, and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of the grant is recognized in the same period(s) and in the same manner as if the grantor had paid cash.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 718-10 requires companies to estimate the fair value of equity-based option awards on the date of grant using an option-pricing model. The fair value of the award is recognized as an expense on a straight-line basis over the requisite service periods in the Company’s consolidated statements of comprehensive loss. The Company recognizes share-based award forfeitures as they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimates the fair value of granted option equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted Stock Units</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issues restricted stock units under its 2016 Equity Incentive Plan. The fair value of the restricted stock units is based on the closing stock price on the date of grant and is expensed as operating expense over the period during which the units vest. Each restricted stock unit entitles the grantee to one share of common stock to be received upon vesting up to four years after the grant date. Recipients of restricted stock units have no voting rights until the vesting of the award.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_z2EKLwsTAdh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zn0tOfC3lV69">Basic and diluted net loss per share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive ordinary shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. Potentially dilutive common shares were excluded from the calculation of diluted loss per share for all periods presented due to their anti-dilutive effect due to losses in each period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Net loss attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed preferred stock dividends declared, amortized or accumulated. The Company recorded a deemed dividend of $<span id="xdx_902_ecustom--DeemedDividend_pn3n3_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_zJgVXgYuX5Ag">0 and $</span></span><span id="xdx_90C_ecustom--DeemedDividend_pn3n3_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_zwu7bk0AGJS2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">6,145 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">for the issuance of warrants during the years ended December 31, 2022 and 2021, respectively. The deemed dividend is added to the net loss in determining the net loss available to common stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zfPWK74tmy7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zFAfEOMM9L7h">Research and development expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses are charged to the consolidated statement of comprehensive loss as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z3Hm4nil6Hk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zpXTLgkUu1Le">Patent costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--DebtIssuanceCostsPolicyTextBlock_zUaBje62XnLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zzfoajlTCIR7">Debt issuance costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt issuance costs represent the costs associated with the issuance of a debt instrument and are amortized using the effective interest method over the life of the related debt instrument. The Company records debt issuance costs as a debt discount and is a reduction of the carrying amount of the debt liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_ecustom--LiabilitiesDueToTerminationOfEmploymentAgreementsPolicyTextBlock_zY50hiZQlak8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z2oArlxpp1Tl">Liabilities due to termination of employment agreements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Israeli employment laws, employees of Motus Ltd. are included under Article 14 of the Severance Compensation Act, 1963 (“Article 14”) for a portion of their salaries. According to Article 14, these employees are entitled to monthly deposits made by Motus Ltd. on their behalf with insurance companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments in accordance with Article 14 release Motus Ltd. from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company’s balance sheet, and there is no liability recorded as the Company does not have a future obligation to make any additional payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zgHpWgejytI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income taxes</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company had a full valuation allowance against deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company is subject to the provisions of ASC 740-10-25, Income Taxes (ASC 740). ASC 740 prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. On a quarterly basis, the Company undergoes a process to evaluate whether income tax accruals are in accordance with ASC 740 guidance on uncertain tax positions. There are currently no open Federal or State audits. The Company has not recorded any liability for uncertain tax positions at December 31, 2022 or December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2022 and 2021, the Company recorded zero income tax expense. No tax benefit has been recorded in relation to the pre-tax loss for the years ended December 31, 2022 and 2021, due to a full valuation allowance to offset any deferred tax asset related to net operating loss carry forwards attributable to the losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zRKxPystD9b4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_ze6ngebLPsxb">Fair value of financial instrument</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for financial instruments in accordance with ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”). ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no changes in the fair value hierarchy leveling during the years ended December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zL195aNJx5S3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zUoJqWYfrTW9">New Accounting Pronouncements- Recently Adopted</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50)</i>, <i>Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options</i>, which clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options due to a lack of explicit guidance in the FASB Codification. ASU 2021-04 provides guidance on modifications or exchanges of freestanding equity-classified written call options that are not within the scope of another Topic. Entities should treat a modification of the terms or conditions, or an exchange of a freestanding equity-classified written call option that remains equity-classified after modification or exchange, as an exchange of the original instrument for a new instrument. ASU 2021-04 provides further guidance on measuring the effect of such modifications or exchanges, and also provides guidance on the recognition of such modifications or exchanges on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021. The Company adopted this ASU on January 1, 2022, prospectively to modifications that occurred after the date of initial application. The adoption of this ASU did not result in a material impact to the consolidated financial statements and disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements</i>, or ASC 326. On January 1, 2023, the Company adopted ASC 326. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, <i>Financial Instruments-Overall</i>, applied on an instrument-by-instrument basis for eligible instruments. The adoption of ASC 326 did not have a material impact on the Company’s financial position or results of operations upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_ecustom--NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zGlqRnmmq5j2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zgDuGY0w1Pv6">Accounting Pronouncements- Not Yet Adopted</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020, the FASB issued ASU No. 2020-04, <i>Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i> which provides optional expedients and exceptions for the accounting for contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. In January 2021, the FASB issued ASU 2021-01 to clarify the scope of certain optional expedients for derivatives that are affected by the discounting transition. In December 2022, the FASB issued ASU 2022-06 to defer the sunset date of Topic 848 from December 31, 2022, to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848. As of December 31, 2022, the Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU No. 2020-06, <i>Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. </i>This guidance simplifies the accounting for convertible instruments primarily by eliminating the existing cash conversion and beneficial conversion models within Subtopic 470-20, which will result in fewer embedded conversion options being accounted for separately from the debt host. The guidance also amends and simplifies the calculation of earnings per share relating to convertible instruments. This guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within that reporting period, using either a full or modified retrospective approach. As of December 31, 2022, the Company is currently evaluating the impact of the provisions of this guidance on its consolidated financial statements.</span></p> <p id="xdx_858_zrFMAmGLlOQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_848_eus-gaap--UseOfEstimates_zLCh00ujSol8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z4H5ycMaeLac">Basis of presentation and use of estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, of the Financial Accounting Standards Board (“FASB”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84C_ecustom--ReverseStockSplitPolicyTextBlock_z6lmvbE1bInd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86E_z2Tx3b7GamMe">Reverse Stock Split</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On July 25, 2022, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-20. Shares of common stock underlying outstanding stock options and other equity instruments convertible into common stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z7raguP8yY1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zOoJzwU2Cesa">Functional currency and foreign currency translation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The functional currency of the Company, inclusive of foreign subsidiaries, is the U.S dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the consolidated statement of comprehensive loss as foreign currency (loss) gain, as appropriate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zntZNXcDPTkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zN3pn1Di6E4j">Cash and cash equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investment securities with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Cash and cash equivalents include cash on-hand and highly-rated U.S. government backed money market fund investments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations of Credit Risk and Off-balance Sheet Risk</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company’s cash is held in accounts with financial institutions that management believes are creditworthy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--RevenueRecognitionPolicyTextBlock_z8FKDnnxv904" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zm4cyTtsOkld">Revenue recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales contracts executed for the second generation Pure-Vu System are accounted for in accordance with ASC Topic 606 - Revenue from Contracts with Customers (“ASC 606”) to depict the transfer of control to the Company’s customers in an amount reflecting the consideration to which the Company expects to be entitled to. The Pure-Vu System consists of a Workstation (a “Workstation”) and single use disposable sleeve (a “Disposable”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases and collaboration arrangements. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when a performance obligation is satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercial placements of the second generation system include the Workstation, sale of the Disposables, and a service plan. The Workstation is operational without any significant customization and modification and the Disposables are specialized consumables that are readily available for purchase from the Company. Therefore, revenue from the sale of a Workstation is recognized after the customer commits to purchase the Workstation and the Workstation is delivered, which is when title is transferred. Disposables are identified as a separate performance obligation, and therefore, revenue from the sale of Disposables is recognized when the Disposables are delivered to the customer and title is transferred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A free one-year service plan is included with the purchase of any second generation Pure-Vu Workstation. An extended service plan with varying support and maintenance of the Workstation is offered for sale after the free one-year service plan period. In the case of the free one-year service plan, a portion of the Workstation sales price is deferred and recognized ratably over the one-year service plan term based upon the relative standalone value. The standalone selling price of the Workstation is set at the beginning of the contract based on observable prices from standalone sales of the Workstation, however, at times, the Company has offered discounts from that price to certain customers. The standalone sales price of the one year service plan is based on the expected costs of replacement parts and direct costs to perform the service plus a standard margin, as set by the Company. The standard margin assumed is consistent with the margin expected in pricing the extended service plan. Revenue for the extended service plans is recognized ratably over the term of the service plan contract period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At times, the Company may include a limited time free trial to potential customers to evaluate the Workstation for a period of up to 6 months and in certain instances extend the period to an aggregate of up to 11 months. The Company considers the 6-11 month usage period as a non-contiguous limited trial period because the total length of the free trial is still less than one year. In scenarios where the Company continues to provide the Workstation to a customer for a usage period of greater than one year, the arrangement falls outside of the scope of ASC 606, as described below. Management does not collect any upfront payments or deposits prior to commencing a free trial period. No revenue is recognized for the Workstation during the duration of a free trial, however, any Disposables purchased by the evaluator are recognized when delivered, as described above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For contracts outside the scope of ASC 606, the Company determines income for proposed supply arrangements under 1) ASC 842 as it pertains to an embedded lease of the Workstation within a proposed supply arrangement and 2) ASC 606 for the sale of the sleeves within the proposed supply arrangement. The Company allocates the transaction price to the performance obligations within the proposed supply arrangements using the total estimated purchases method for both (i) arrangements that contain minimum purchase commitments and (ii) those arrangements that do not contain a minimum purchase commitment, but instead offer a volume discount for purchases that exceed a specified tier.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company recognized <span><span id="xdx_906_eus-gaap--OperatingLeaseIncomeComprehensiveIncomeExtensibleList_iP1us-gaap--OperatingLeaseLeaseIncome_dxL_c20220101__20221231_zymbM0dMziKd" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2022%23Revenues"><span id="xdx_90A_eus-gaap--OperatingLeaseIncomeComprehensiveIncomeExtensibleList_iP1us-gaap--OperatingLeaseLeaseIncome_dxL_c20210101__20211231_zJi2UXTVlv3b" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2022%23Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0540"><span style="-sec-ix-hidden: xdx2ixbrl0541">revenue</span></span></span></span></span> of $<span id="xdx_906_eus-gaap--Revenues_pn3n3_c20220101__20221231_zGOGhgbGgNEl" title="Revenue recognized">592</span>, which consisted of $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231_zfZDY5ENkf3h" title="Revenue recognized in accordance with ASC 606">540</span> in accordance with ASC 606 and $<span id="xdx_905_eus-gaap--OperatingLeaseLeaseIncome_pn3n3_c20220101__20221231_zHpVTHf0Thie" title="Revenue recognized in accordance with ASC 842">52</span> in accordance with ASC 842. During the year ended December 31, 2021, the Company recognized revenue of $<span id="xdx_90B_eus-gaap--Revenues_pn3n3_c20210101__20211231_zALMsNOups9d" title="Revenue recognized">391</span>, which consisted of $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231_ztN1GF0UrQ2j" title="Revenue recognized in accordance with ASC 606">303</span> in accordance with ASC 606 and $<span id="xdx_90A_eus-gaap--OperatingLeaseLeaseIncome_pn3n3_c20210101__20211231_zlRYlFwV9qkf" title="Revenue recognized in accordance with ASC 842">88</span> in accordance with ASC 842.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company recognized revenue at a point in time of $<span id="xdx_909_eus-gaap--Revenues_pn3n3_c20220101__20221231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zjjuGzjMlLJ4" title="Revenue recognized">529</span> and recognized revenue over time of $<span id="xdx_905_eus-gaap--Revenues_pn3n3_c20220101__20221231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_z0us3Wbqwpm9" title="Revenue recognized">63</span>. During the year ended December 31, 2021, the Company recognized revenue at a point in time of $<span id="xdx_90A_eus-gaap--Revenues_pn3n3_c20210101__20211231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zpz6BEfAwh4l" title="Revenue recognized">299</span> and recognized revenue over time of $<span id="xdx_90B_eus-gaap--Revenues_pn3n3_c20210101__20211231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_z9zbyh3T9tWc" title="Revenue recognized">92</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 592000 540000 52000 391000 303000 88000 529000 63000 299000 92000 <p id="xdx_844_ecustom--ContractCostsPolicyTextBlock_zfsRjRUszYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zAIxb9jVwee6">Contract Costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incremental commissions, if applicable, above a base commission level, are paid to sales representatives upon certain eligible sales, which are paid upon execution of the sales agreement. The guidance within ASC 606 provides a practical expedient if the amortization period of the assets that the entity otherwise would have recognized is one year or less. The Company chose to apply the available practical expedient as the commission paid on eligible sales orders relates to the period in which the sales order was fulfilled. For the years ending December 31, 2022 and 2021, incremental commissions paid on eligible sales orders were $<span id="xdx_903_eus-gaap--PaymentsForCommissions_pn3n3_c20220101__20221231_zTr7jNpbyUz7" title="Commissions paid">96</span> and $<span id="xdx_909_eus-gaap--PaymentsForCommissions_pn3n3_c20210101__20211231_zOdiyx6Gheb" title="Commissions paid">35</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 96000 35000 <p id="xdx_841_ecustom--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock_z0466q2TvTRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zGqd9PWmA5fd">Accounts receivable and allowance for doubtful accounts</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. The Company makes estimates for the allowance for doubtful accounts based upon its assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect customers’ ability to pay. As of December 31, 2022 and 2021, the allowance for doubtful accounts was $<span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20221231_zgVWEsmwVNdh" title="Allowance for doubtful accounts"><span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20211231_zCH3zIOIo9D7" title="Allowance for doubtful accounts">0</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_845_eus-gaap--InventoryPolicyTextBlock_zgWmv1Ei2COg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zH66gkAITbk1">Inventory</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is stated at lower of cost and net realizable value using the weighted average cost method and is evaluated at least annually for impairment. The Company records an inventory reserve for losses associated with dated, expired, excess and obsolete items. Reserves and write-downs of inventory is based on management’s current knowledge with respect to inventory levels, planned production, and extension capabilities of materials on hand. A significant change in the timing or level of demand for the Company’s products compared to forecasted amounts may result in recording additional charges for excess and obsolete inventory in the future. The Company records charges for excess and obsolete inventory within cost of revenues. </span>Inventories that exceed estimated realization for the next twelve months from balance sheet date based on future sales forecasts are classified as long-term assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_zsKVirHCTOu9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zoGV94ZEtkX1">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its leases in accordance with ASC 842, Leases, or ASC 842. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. The Company does not have financing leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty of renewal.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_844_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zE808h7XJDml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zhCV8wo7ABNb">Fixed assets, net</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_ecustom--ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationTableTextBlock_zXkF5tpJQ1al" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated based on the straight-line method, at annual rates reflecting the estimated useful lives of the related assets, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zjuLzjZjjeDc" style="display: none">Schedule of Fixed Assets are Stated at Cost Less Accumulated Depreciation</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zD6CXy1b6FWg" title="Useful lives">5</span>-<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_z4KylAwiRFej" title="Useful lives">15</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and software</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_zUXEgP7RCrk9" title="Useful lives">3</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_zXlPJc5u1FRa" title="Useful lives">5</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember__srt--RangeAxis__srt--MinimumMember_zSOKlNcb3dRe" title="Useful lives">5</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember__srt--RangeAxis__srt--MaximumMember_zw0QPWvfSyTd" title="Useful lives">10</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab and medical equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zLBfGkZz5EKl" title="Useful lives">3</span>-<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zb2WWAgpYHu" title="Useful lives">7</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z1BfMwvf60M5" title="Useful lies, description">Shorter of lease term or useful life</span></span></td></tr> </table> <p id="xdx_8AD_zPYAZAH4N8H1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_ecustom--ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationTableTextBlock_zXkF5tpJQ1al" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated based on the straight-line method, at annual rates reflecting the estimated useful lives of the related assets, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zjuLzjZjjeDc" style="display: none">Schedule of Fixed Assets are Stated at Cost Less Accumulated Depreciation</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zD6CXy1b6FWg" title="Useful lives">5</span>-<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_z4KylAwiRFej" title="Useful lives">15</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and software</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndSoftwareMember__srt--RangeAxis__srt--MinimumMember_zUXEgP7RCrk9" title="Useful lives">3</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndSoftwareMember__srt--RangeAxis__srt--MaximumMember_zXlPJc5u1FRa" title="Useful lives">5</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember__srt--RangeAxis__srt--MinimumMember_zSOKlNcb3dRe" title="Useful lives">5</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember__srt--RangeAxis__srt--MaximumMember_zw0QPWvfSyTd" title="Useful lives">10</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab and medical equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zLBfGkZz5EKl" title="Useful lives">3</span>-<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zb2WWAgpYHu" title="Useful lives">7</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z1BfMwvf60M5" title="Useful lies, description">Shorter of lease term or useful life</span></span></td></tr> </table> P5Y P15Y P3Y P5Y P5Y P10Y P3Y P7Y Shorter of lease term or useful life <p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zUMQ5vZaS6yh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zFrXh7DeP9l6">Share-based compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employee and Non-Employee Share-Based Compensation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including employee stock options under the Company’s stock plans and equity awards issued to non-employees based on estimated fair values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting for awards issued to non-employees is similar to the accounting for employee awards, except that:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company may elect on an award-by-award basis to use the contractual term as the expected term assumption in the option pricing model, and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of the grant is recognized in the same period(s) and in the same manner as if the grantor had paid cash.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 718-10 requires companies to estimate the fair value of equity-based option awards on the date of grant using an option-pricing model. The fair value of the award is recognized as an expense on a straight-line basis over the requisite service periods in the Company’s consolidated statements of comprehensive loss. The Company recognizes share-based award forfeitures as they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimates the fair value of granted option equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted Stock Units</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issues restricted stock units under its 2016 Equity Incentive Plan. The fair value of the restricted stock units is based on the closing stock price on the date of grant and is expensed as operating expense over the period during which the units vest. Each restricted stock unit entitles the grantee to one share of common stock to be received upon vesting up to four years after the grant date. Recipients of restricted stock units have no voting rights until the vesting of the award.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_z2EKLwsTAdh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zn0tOfC3lV69">Basic and diluted net loss per share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive ordinary shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. Potentially dilutive common shares were excluded from the calculation of diluted loss per share for all periods presented due to their anti-dilutive effect due to losses in each period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Net loss attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed preferred stock dividends declared, amortized or accumulated. The Company recorded a deemed dividend of $<span id="xdx_902_ecustom--DeemedDividend_pn3n3_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_zJgVXgYuX5Ag">0 and $</span></span><span id="xdx_90C_ecustom--DeemedDividend_pn3n3_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_zwu7bk0AGJS2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">6,145 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">for the issuance of warrants during the years ended December 31, 2022 and 2021, respectively. The deemed dividend is added to the net loss in determining the net loss available to common stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0 6145000 <p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zfPWK74tmy7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zFAfEOMM9L7h">Research and development expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses are charged to the consolidated statement of comprehensive loss as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z3Hm4nil6Hk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zpXTLgkUu1Le">Patent costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--DebtIssuanceCostsPolicyTextBlock_zUaBje62XnLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zzfoajlTCIR7">Debt issuance costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt issuance costs represent the costs associated with the issuance of a debt instrument and are amortized using the effective interest method over the life of the related debt instrument. The Company records debt issuance costs as a debt discount and is a reduction of the carrying amount of the debt liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_ecustom--LiabilitiesDueToTerminationOfEmploymentAgreementsPolicyTextBlock_zY50hiZQlak8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z2oArlxpp1Tl">Liabilities due to termination of employment agreements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Israeli employment laws, employees of Motus Ltd. are included under Article 14 of the Severance Compensation Act, 1963 (“Article 14”) for a portion of their salaries. According to Article 14, these employees are entitled to monthly deposits made by Motus Ltd. on their behalf with insurance companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments in accordance with Article 14 release Motus Ltd. from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company’s balance sheet, and there is no liability recorded as the Company does not have a future obligation to make any additional payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zgHpWgejytI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income taxes</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company had a full valuation allowance against deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company is subject to the provisions of ASC 740-10-25, Income Taxes (ASC 740). ASC 740 prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. On a quarterly basis, the Company undergoes a process to evaluate whether income tax accruals are in accordance with ASC 740 guidance on uncertain tax positions. There are currently no open Federal or State audits. The Company has not recorded any liability for uncertain tax positions at December 31, 2022 or December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2022 and 2021, the Company recorded zero income tax expense. No tax benefit has been recorded in relation to the pre-tax loss for the years ended December 31, 2022 and 2021, due to a full valuation allowance to offset any deferred tax asset related to net operating loss carry forwards attributable to the losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zRKxPystD9b4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_ze6ngebLPsxb">Fair value of financial instrument</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for financial instruments in accordance with ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”). ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no changes in the fair value hierarchy leveling during the years ended December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zL195aNJx5S3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zUoJqWYfrTW9">New Accounting Pronouncements- Recently Adopted</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50)</i>, <i>Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options</i>, which clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options due to a lack of explicit guidance in the FASB Codification. ASU 2021-04 provides guidance on modifications or exchanges of freestanding equity-classified written call options that are not within the scope of another Topic. Entities should treat a modification of the terms or conditions, or an exchange of a freestanding equity-classified written call option that remains equity-classified after modification or exchange, as an exchange of the original instrument for a new instrument. ASU 2021-04 provides further guidance on measuring the effect of such modifications or exchanges, and also provides guidance on the recognition of such modifications or exchanges on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021. The Company adopted this ASU on January 1, 2022, prospectively to modifications that occurred after the date of initial application. The adoption of this ASU did not result in a material impact to the consolidated financial statements and disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements</i>, or ASC 326. On January 1, 2023, the Company adopted ASC 326. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, <i>Financial Instruments-Overall</i>, applied on an instrument-by-instrument basis for eligible instruments. The adoption of ASC 326 did not have a material impact on the Company’s financial position or results of operations upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_ecustom--NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zGlqRnmmq5j2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zgDuGY0w1Pv6">Accounting Pronouncements- Not Yet Adopted</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020, the FASB issued ASU No. 2020-04, <i>Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i> which provides optional expedients and exceptions for the accounting for contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. In January 2021, the FASB issued ASU 2021-01 to clarify the scope of certain optional expedients for derivatives that are affected by the discounting transition. In December 2022, the FASB issued ASU 2022-06 to defer the sunset date of Topic 848 from December 31, 2022, to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848. As of December 31, 2022, the Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU No. 2020-06, <i>Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. </i>This guidance simplifies the accounting for convertible instruments primarily by eliminating the existing cash conversion and beneficial conversion models within Subtopic 470-20, which will result in fewer embedded conversion options being accounted for separately from the debt host. The guidance also amends and simplifies the calculation of earnings per share relating to convertible instruments. This guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within that reporting period, using either a full or modified retrospective approach. As of December 31, 2022, the Company is currently evaluating the impact of the provisions of this guidance on its consolidated financial statements.</span></p> <p id="xdx_801_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zsls2Nt1NRWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 – <span id="xdx_826_zuheNrbF2Ms5">Fair Value Measurements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zgO1nkaUqWDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities measured and recorded at fair value on a recurring basis consisted of the following at December 31, 2022 and December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zK7FrlwWImzd" style="display: none">Schedule of Fair Value of Financial Assets and Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent royalty obligation</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pdn3_c20221231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zF1tKAPEoKVf" style="text-align: right" title="Contingent royalty obligation">   <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0627">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pdn3_c20221231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zEOdvB6qbICf" style="text-align: right" title="Contingent royalty obligation">   <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pn3n3_c20221231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcpL6Q0sYcPf" style="text-align: right" title="Contingent royalty obligation">1,212</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pn3n3_c20221231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0tuCjGHg4k4" style="text-align: right" title="Contingent royalty obligation">1,212</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent royalty obligation</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pdn3_c20211231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zhbExhV1FbEk" style="text-align: right" title="Contingent royalty obligation">   <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0635">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pdn3_c20211231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdQKUkt0S7Ve" style="text-align: right" title="Contingent royalty obligation">   <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0637">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pn3n3_c20211231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXAqaxFaHTr" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Contingent royalty obligation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,760</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pn3n3_c20211231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzpBcgaR4zGl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Contingent royalty obligation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,760</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zMOhN6PrEX3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments with carrying values approximating fair value include cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, and certain other current liabilities, due to their short-term nature. Financial instruments with carrying values approximating fair value also include long-term debt and convertible notes which is based on a combined total of their face value and the amortization discount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In estimating the fair value of the Company’s contingent royalty obligation (see Note 9), the Company used the discounted cash flow method as of December 31, 2022 and 2021. Based on the fair value hierarchy, the Company classified contingent royalty obligation within Level 3 because the valuation inputs are based on projected revenues discounted to a present value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_zXSGWDJVm6ak" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of a contingent royalty obligation, during the year ended December 31, 2022 was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zIRWcJeyOsza" style="display: none">Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z898AOw3f5Mh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value<br/> Measurements<br/> of Contingent<br/> Royalty<br/> Obligation<br/> (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_zYcmpeNQGh3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,760</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_z8UeJ8s6pg4k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in estimated fair value of contingent royalty obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">548</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_zu4y48u1Myq7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,212</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zQ9IzNvpRBk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contingent royalty obligation is re-measured at each balance sheet date using several assumptions, including the following: 1) estimated sales growth, 2) length of product cycle, 3) patent life, 4) discount rate (<span id="xdx_906_ecustom--IncreaseDecreaseInDiscountRate_pid_dp_uPure_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zxS64b6dpyw2" title="Increase (decrease) in discount rate">23</span>% as of December 31, 2022 and <span id="xdx_90E_ecustom--IncreaseDecreaseInDiscountRate_pid_dp_uPure_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_z5GGXU6lPU8k" title="Increase (decrease) in discount rate">21%</span> as of December 31, 2021), and 5) rate of royalty payment (<span id="xdx_90C_ecustom--RoyaltyPaymentDicountPercentage_pid_dp_uPure_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zigrAA9Jj1ai" title="Royalty payment, percentage"><span id="xdx_902_ecustom--RoyaltyPaymentDicountPercentage_pid_dp_uPure_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_z3u2GBFFcsDl" title="Royalty payment, percentage">3%</span></span> as of December 31, 2022 and December 31, 2021).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC-820-10-50-2(g), the Company performed sensitivity analyses of the liability, which was classified as a Level 3 financial instrument. The contingent royalty obligation estimate may be significantly impacted by changes in assumptions used in these analyses. For example, <span id="xdx_908_eus-gaap--ServicingLiabilityAtFairValueDescriptionOfOtherChangesInFairValue_c20220101__20221231_zs7mlcr9htF3" title="Fair value of the liability, description">the Company recalculated the fair value of the liability by applying a +/- 2% change to the input variable in the discounted cash flow model; the discount rate. A 2% decrease in the discount rate would increase the liability by approximately $126 and a 2% increase in the discount rate would decrease the liability by approximately $112.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89B_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zgO1nkaUqWDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities measured and recorded at fair value on a recurring basis consisted of the following at December 31, 2022 and December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zK7FrlwWImzd" style="display: none">Schedule of Fair Value of Financial Assets and Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent royalty obligation</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pdn3_c20221231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zF1tKAPEoKVf" style="text-align: right" title="Contingent royalty obligation">   <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0627">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pdn3_c20221231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zEOdvB6qbICf" style="text-align: right" title="Contingent royalty obligation">   <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pn3n3_c20221231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcpL6Q0sYcPf" style="text-align: right" title="Contingent royalty obligation">1,212</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pn3n3_c20221231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0tuCjGHg4k4" style="text-align: right" title="Contingent royalty obligation">1,212</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent royalty obligation</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pdn3_c20211231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zhbExhV1FbEk" style="text-align: right" title="Contingent royalty obligation">   <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0635">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pdn3_c20211231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdQKUkt0S7Ve" style="text-align: right" title="Contingent royalty obligation">   <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0637">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pn3n3_c20211231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXAqaxFaHTr" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Contingent royalty obligation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,760</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--ContingentRoyaltyObligationFairValueDisclosure_iI_pn3n3_c20211231__srt--ProductOrServiceAxis__custom--ContingentRoyaltyObligationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzpBcgaR4zGl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Contingent royalty obligation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,760</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> 1212000 1212000 1760000 1760000 <p id="xdx_89D_eus-gaap--ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_zXSGWDJVm6ak" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of a contingent royalty obligation, during the year ended December 31, 2022 was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zIRWcJeyOsza" style="display: none">Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z898AOw3f5Mh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value<br/> Measurements<br/> of Contingent<br/> Royalty<br/> Obligation<br/> (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_zYcmpeNQGh3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,760</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_z8UeJ8s6pg4k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in estimated fair value of contingent royalty obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">548</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_zu4y48u1Myq7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,212</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1760000 548000 1212000 0.23 0.21 0.03 0.03 the Company recalculated the fair value of the liability by applying a +/- 2% change to the input variable in the discounted cash flow model; the discount rate. A 2% decrease in the discount rate would increase the liability by approximately $126 and a 2% increase in the discount rate would decrease the liability by approximately $112. <p id="xdx_800_eus-gaap--InventoryDisclosureTextBlock_ziuyrEpZVCZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 – <span id="xdx_829_zMZafld1Rx5h">Inventory</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zySW9wzDOo4c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory at December 31, 2022 and 2021 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zkqf00GJ1u5b" style="display: none">Schedule of Inventory</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zTYMZHLEbbT6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20211231_zpDsdgC4R7a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzQIo_zxXxb8aHxXIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">697</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">569</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzQIo_zlHC52FW3wgf" style="vertical-align: bottom; background-color: White"> <td>Work-in-process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">155</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0669">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzQIo_zhILwq63kHJ" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">548</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InventoryValuationReserves_iNI_pn3n3_di_msINzQIo_zFF4GJXrdWnd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Inventory reserve</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(401</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(365</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--InventoryNet_iTI_pn3n3_mtINzQIo_zYK4IzBRexVe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Inventory, net </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">999</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">496</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--InventoryCurrent_iI_pn3n3_zdScKU8wj3ta" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Inventory, current</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">488</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">496</p></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryNoncurrent_iI_pn3n3_zOo49l8BX7u3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Inventory, non-current</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"><p style="margin: 0">$</p></td><td style="border-bottom: Black 2.5pt double; text-align: right">511</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zWGmamUbURO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2022 and 2021, an inventory impairment of $<span id="xdx_906_ecustom--CostOfRevenueImpairmentOfInventory_pn3n3_c20220101__20221231_zga3pgkt47Ma" title="Impairment of inventory">598 and $<span id="xdx_904_ecustom--CostOfRevenueImpairmentOfInventory_pn3n3_c20210101__20211231_zFPj35d3SRTk" title="Impairment of inventory">443</span>, respectively, was recorded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zySW9wzDOo4c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory at December 31, 2022 and 2021 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zkqf00GJ1u5b" style="display: none">Schedule of Inventory</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zTYMZHLEbbT6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20211231_zpDsdgC4R7a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzQIo_zxXxb8aHxXIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">697</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">569</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzQIo_zlHC52FW3wgf" style="vertical-align: bottom; background-color: White"> <td>Work-in-process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">155</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0669">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzQIo_zhILwq63kHJ" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">548</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InventoryValuationReserves_iNI_pn3n3_di_msINzQIo_zFF4GJXrdWnd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Inventory reserve</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(401</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(365</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--InventoryNet_iTI_pn3n3_mtINzQIo_zYK4IzBRexVe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Inventory, net </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">999</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">496</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--InventoryCurrent_iI_pn3n3_zdScKU8wj3ta" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Inventory, current</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">488</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">496</p></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryNoncurrent_iI_pn3n3_zOo49l8BX7u3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Inventory, non-current</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"><p style="margin: 0">$</p></td><td style="border-bottom: Black 2.5pt double; text-align: right">511</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 697000 569000 155000 548000 292000 401000 365000 999000 496000 488000 496000 511000 598000 443000 <p id="xdx_801_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zoLo9zVviGmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 – <span id="xdx_828_zmITDWxiMkp8">Fixed assets, net</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zUUdbVIcC0pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed assets, net, consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zCvXaFwvVXXb" style="display: none">Schedule of Fixed Assets Net</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_zKh6YfKDJJ2j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20211231_zx3MA0FNd8Sg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zWc4r8hH5TYb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">171</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">171</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndSoftwareMember_zMQ1U0tzbG2l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computers and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">321</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">305</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember_ziusvSOORKIk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Machinery</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">807</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zDP8nlBUh8ob" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab and medical equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,477</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zDxPs6LvEoa5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">193</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzI8P_zkfV540zbvw9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,218</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,818</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzI8P_zAV7uDSagvMe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,893</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,390</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzI8P_zv8tDjNEjdMl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Fixed assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,325</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_z6G6UKxy8N3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation and amortization expense for the years ended December 31, 2022 and 2021 was $<span id="xdx_905_eus-gaap--DepreciationAndAmortization_pn3n3_c20220101__20221231_zXh5ymHrM6Xb" title="Depreciation and amortization expense">510</span> and $<span id="xdx_90F_eus-gaap--DepreciationAndAmortization_pn3n3_c20210101__20211231_zAKOYKZgiTI2" title="Depreciation and amortization expense">439</span>, respectively. The Company incurred a loss on the impairment of fixed assets in the amount of $<span id="xdx_908_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pn3n3_c20220101__20221231_zTU6A1sdv4J6" title="Impairment of fixed assets">46</span> and $<span id="xdx_904_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pn3n3_dxL_c20210101__20211231_zmY8Df6RIa0i" title="Impairment of fixed assets::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0724">0</span></span> for the years end December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zUUdbVIcC0pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed assets, net, consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zCvXaFwvVXXb" style="display: none">Schedule of Fixed Assets Net</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_zKh6YfKDJJ2j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20211231_zx3MA0FNd8Sg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zWc4r8hH5TYb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">171</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">171</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndSoftwareMember_zMQ1U0tzbG2l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computers and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">321</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">305</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember_ziusvSOORKIk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Machinery</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">807</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zDP8nlBUh8ob" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab and medical equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,477</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zDxPs6LvEoa5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">193</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzI8P_zkfV540zbvw9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,218</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,818</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzI8P_zAV7uDSagvMe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,893</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,390</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzI8P_zv8tDjNEjdMl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Fixed assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,325</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 171000 171000 321000 305000 1049000 807000 1477000 1342000 200000 193000 3218000 2818000 1893000 1390000 1325000 1428000 510000 439000 46000 <p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_z9xV7ztBlFUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – <span id="xdx_826_zZ5GNFW4ioTj">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases an office in Fort Lauderdale, Florida under an operating lease. <span id="xdx_907_eus-gaap--LesseeOperatingLeaseDescription_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeMember__srt--StatementGeographicalAxis__custom--FortLauderdaleMember_zkArT2bOSdg2" title="Operating lease, description">The term expires November 2024. The annual base rent is subject to annual increases of 2.75%.</span> As described within Note 10, the Company shares this space with a related party pursuant to the Shared Space Agreement, as defined below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases an office in Israel under an operating lease. <span id="xdx_905_eus-gaap--LesseeOperatingLeaseDescription_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeMember__srt--StatementGeographicalAxis__country--IL_zSiB97fAFbMl" title="Operating lease, description">The term expired on <span id="xdx_902_eus-gaap--LeaseExpirationDate1_dd_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeMember__srt--StatementGeographicalAxis__country--IL_zlWwmiSjc5Bh" title="Operating lease expiration date">December 31, 2022</span>. The Company entered into a new tenancy contract with the facility for a period of twelve months from January 1, 2023 to December 31, 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases vehicles under operating leases that expire at various dates through 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many of these leases provide for payment by the Company, as the lessee, of taxes, insurance premiums, costs of maintenance and other costs which are expensed as incurred. <span id="xdx_906_eus-gaap--LesseeOperatingLeaseOptionToExtend_pid_c20220101__20221231_zafh36IflAT1" title="Description of lease term option to extend">Certain operating leases include escalation clauses and some of which may include options to extend the leases for up to 3 years.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_ecustom--ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationTableTextBlock_z4oUZWemsQkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zySNF4qDTk9k" style="display: none">Schedule of Lease Cost and Supplemental Balance Sheet Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20221231_zyonjEkPNDAc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20210101__20211231_zfCJr2SX2D1k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Lease Cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_pn3n3_maLCzGIV_zt9OKIx4b2V5" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Operating lease cost, net of related party license fee</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">92</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">139</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--VariableLeaseCost_pn3n3_zi1WCrngzlh7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Variable lease cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">120</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LeaseCost_iT_pn3n3_zlgY4wAA3Ni4" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">258</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Operating lease, right-of-use asset</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20221231_zXorCGWtm7sc" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Operating lease, right-of-use- asset">428</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20211231_zdpuJhS9NiOc" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Operating lease, right-of-use- asset">687</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20221231_zt7pMMItgkei" style="text-align: right" title="Operating lease liabilities, current">245</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityCurrent_c20211231_pn3n3" style="text-align: right" title="Operating lease liabilities, current">307</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Non-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20221231_zvreaENBfBr7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating lease liabilities, net of current portion">178</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20211231_z2O4RVxub6l3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating lease liabilities, net of current portion">385</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20221231_zUudTwwebUQ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities">423</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities">692</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Other information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average remaining lease term - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_pid_dtY_c20221231_zUapZEypk3Wc" title="Weighted average remaining lease term - operating leases">1.79</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_pid_dtY_c20211231_z9j4NcBOszO1" title="Weighted average remaining lease term - operating leases">2.49</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_z8OYX4wk1Ot4" title="Weighted-average discount rate - operating leases">7.36</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231_zJLPnh2p81Jf" title="Weighted-average discount rate - operating leases">7.66</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A5_zJiXF7A07cag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records operating lease payments to lease expense using the straight-line method. The Company’s lease expense was $<span id="xdx_90D_eus-gaap--OperatingLeaseExpense_pn3n3_c20220101__20221231_zABo6oAxLH9k" title="Operating lease, expense">212</span> and $<span id="xdx_905_eus-gaap--OperatingLeaseExpense_pn3n3_c20210101__20211231_z6TA5mG0N2Ea" title="Operating lease, expense">258</span> for the years ended December 31, 2022 and 2021, respectively, included in general and administrative expenses, which is net of the related party license fee of $<span id="xdx_90C_eus-gaap--DirectTaxesAndLicensesCosts_pn3n3_c20220101__20221231_z3c9FEl04Y6j" title="License fees">242</span> and $<span id="xdx_902_eus-gaap--DirectTaxesAndLicensesCosts_pn3n3_c20210101__20211231_zFytMWMMvdOd" title="License fees">189</span> for the years ended December 31, 2022 and 2021, respectively (see Note 10).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z8hOafYHO5e1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease payments under non-cancellable operating leases as of December 31, 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zTzzK00RgXuf" style="display: none">Schedule of Future Minimum Lease Payments for Operating Leases</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year Ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20221231_zm8xrpDWAPri" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzK2b_zypolz8Yz1qk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">266</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzK2b_zsxylF6dVIQ4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">176</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzK2b_z4BI0P7Iw7q3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0">7</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzK2b_zSedHGet6rW4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Total future minimum lease payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><p style="margin: 0">449</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zySFCvISVVt" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_znJ7fL8WN1R8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">423</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zhR99SlyWIwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_ecustom--ScheduleofMeasurementofLeaseLiabilityTableTextBlock_zAu1BMJZ8pf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the cash paid for amounts included in the measurement of lease liabilities for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zPF2JMw0IdI1" style="display: none">Schedule of Measurement of Lease Liability</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20220101__20221231_zifeMmCztINa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20211231_zuX56iTR3uq3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeasePayments_iN_pn3n3_di_z8PlgrgvtrPk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Cash paid for amounts included in measurement of lease liabilities:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(342</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(324</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A6_zLU8oX1WR6ql" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> The term expires November 2024. The annual base rent is subject to annual increases of 2.75%. The term expired on December 31, 2022. The Company entered into a new tenancy contract with the facility for a period of twelve months from January 1, 2023 to December 31, 2023. 2022-12-31 Certain operating leases include escalation clauses and some of which may include options to extend the leases for up to 3 years. <p id="xdx_899_ecustom--ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationTableTextBlock_z4oUZWemsQkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zySNF4qDTk9k" style="display: none">Schedule of Lease Cost and Supplemental Balance Sheet Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20221231_zyonjEkPNDAc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20210101__20211231_zfCJr2SX2D1k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Lease Cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_pn3n3_maLCzGIV_zt9OKIx4b2V5" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Operating lease cost, net of related party license fee</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">92</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">139</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--VariableLeaseCost_pn3n3_zi1WCrngzlh7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Variable lease cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">120</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LeaseCost_iT_pn3n3_zlgY4wAA3Ni4" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">258</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Operating lease, right-of-use asset</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20221231_zXorCGWtm7sc" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Operating lease, right-of-use- asset">428</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20211231_zdpuJhS9NiOc" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Operating lease, right-of-use- asset">687</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20221231_zt7pMMItgkei" style="text-align: right" title="Operating lease liabilities, current">245</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityCurrent_c20211231_pn3n3" style="text-align: right" title="Operating lease liabilities, current">307</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Non-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20221231_zvreaENBfBr7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating lease liabilities, net of current portion">178</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20211231_z2O4RVxub6l3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating lease liabilities, net of current portion">385</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20221231_zUudTwwebUQ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities">423</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities">692</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Other information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average remaining lease term - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_pid_dtY_c20221231_zUapZEypk3Wc" title="Weighted average remaining lease term - operating leases">1.79</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_pid_dtY_c20211231_z9j4NcBOszO1" title="Weighted average remaining lease term - operating leases">2.49</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_z8OYX4wk1Ot4" title="Weighted-average discount rate - operating leases">7.36</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231_zJLPnh2p81Jf" title="Weighted-average discount rate - operating leases">7.66</span></td><td style="text-align: left">%</td></tr> </table> 92000 139000 120000 119000 212000 258000 428000 687000 245000 307000 178000 385000 423000 692000 P1Y9M14D P2Y5M26D 0.0736 0.0766 212000 258000 242000 189000 <p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z8hOafYHO5e1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease payments under non-cancellable operating leases as of December 31, 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zTzzK00RgXuf" style="display: none">Schedule of Future Minimum Lease Payments for Operating Leases</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year Ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20221231_zm8xrpDWAPri" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzK2b_zypolz8Yz1qk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">266</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzK2b_zsxylF6dVIQ4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">176</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzK2b_z4BI0P7Iw7q3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0">7</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzK2b_zSedHGet6rW4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Total future minimum lease payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><p style="margin: 0">449</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zySFCvISVVt" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_znJ7fL8WN1R8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">423</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 266000 176000 7000 449000 26000 423000 <p id="xdx_891_ecustom--ScheduleofMeasurementofLeaseLiabilityTableTextBlock_zAu1BMJZ8pf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the cash paid for amounts included in the measurement of lease liabilities for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zPF2JMw0IdI1" style="display: none">Schedule of Measurement of Lease Liability</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20220101__20221231_zifeMmCztINa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20211231_zuX56iTR3uq3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeasePayments_iN_pn3n3_di_z8PlgrgvtrPk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Cash paid for amounts included in measurement of lease liabilities:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(342</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(324</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> 342000 324000 <p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_zCWwPWrtsdhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_82C_z6Wi1Ar2QUX3">Convertible Note, Term Debt and Long-Term Debt</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 16, 2021 (the “Effective Date”), the Company entered into a loan facility (the “Kreos Loan Agreement”) with Kreos Capital VI (Expert Fund) LP (the “Lender”). Under the Kreos Loan Agreement, the Lender will provide the Company with access to term loans in an aggregate principal amount of up to $<span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn3n3_c20210715__20210716__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember_zvctYAOtB3Gj">12,000</span> (the “Loan”) in three tranches as follows: (a) on the Effective Date, a loan in the aggregate principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn3n3_c20210715__20210716__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember__us-gaap--FinancialInstrumentAxis__custom--TrancheAMember_zw8jgClqQFo4">4,000</span> (the “Convertible Note”, or “Tranche A”), (b) on the Effective Date, a loan in the aggregate principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn3n3_c20210715__20210716__us-gaap--FinancialInstrumentAxis__custom--TrancheBMember__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember_zru6C4RL5YSf">5,000</span> (“Tranche B”), and (c) available until December 31, 2021, a loan in the aggregate principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn3n3_c20210715__20210716__us-gaap--FinancialInstrumentAxis__custom--TrancheCMember_zPQJ9VBZFUee" title="Debt instrument, periodic payment, principal">3,000</span> (“Tranche C”, together with Tranche B, the “Long-term Debt”). The Kreos Loan Agreement contains customary representations and warranties, indemnification provisions in favor of the Lender, events of default and affirmative and negative covenants, including, among others, covenants that limit or restrict the Company’s ability to, among other things, incur additional indebtedness, merge or consolidate, make acquisitions, pay dividends or other distributions or repurchase equity, make investments, dispose of assets and enter into certain transactions with affiliates, in each case subject to certain exceptions. Outstanding borrowings under the Loan are secured by a first priority security interest on substantially all of the personal property assets of the Company, including the Company’s material intellectual property and equity interests in its subsidiaries. There are no liquidity or financial covenants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Convertible Note and Tranche B were funded on the Effective Date. As of December 31, 2021</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, the Company drew down the full $<span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn3n3_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--TrancheCMember_zWIobtVMS8v9" title="Debt instrument, periodic payment, principal">3,000</span> aggregate principal amount of Tranche C.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Convertible Note requires forty-eight monthly interest only payments at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember_zddynfdrgBPi" title="Debt instrument, interest rate">7.75%</span> per annum commencing after the Effective Date and thereafter full payment of the then outstanding principal balance of the Convertible Note on July 1, 2025. The Kreos Loan Agreement contains features that would permit the Lender to convert all or any portion of the outstanding principal balance of the Convertible Note at any time, pursuant to which the converted part of the Convertible Note will be converted into that number of shares of common stock of the Company to be issued to the Lender at a price per share equal to the conversion price, of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember_zg8J93eitmIh" title="Debt instrument, convertible, conversion price">28</span> per share. Following the conversion of any portion of the outstanding principal balance of the Convertible Note, the principal balance of the Convertible Note remaining outstanding shall continue to bear interest at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember_z712iKwAsT4k" title="Debt instrument, interest rate">7.75</span>% per annum. The Tranche B loan requires interest only monthly payments commencing on the Effective Date until September 30, 2022 and, thereafter, thirty-three monthly payments of principal and interest accrued thereon until June 1, 2025. The Tranche C loan requires interest only monthly payments commencing on the date of the draw down until September 30, 2022 and, thereafter, thirty-two monthly payments of principal and interest accrued thereon until June 1, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In connection with the Kreos Loan Agreement, the Company also issued to the Lender a warrant (“Warrant”), dated July 16, 2021, to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210716__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember_zLyNrOhKYBw6" title="Warrant issued to purchase common shares">9,547</span> shares of the Company’s common stock, at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210716__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember_z0mOTBeSCM37" title="Exercise price">20.948</span> per share, payable in cash or on a cashless basis according to the formula set forth in the Warrant. The exercise price of the Warrant and the number of shares issuable upon exercise of the Warrant are subject to adjustments for stock splits, combinations, stock dividends or similar events. The Warrant is exercisable until the date that is ten years after the date of issuance. The Company concluded that the Warrant is indexed to its own stock and, accordingly is classified as equity. See note 11 for further discussion of the Warrant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company treated Tranche A, Tranche B and Tranche C, and the Warrant as three separate freestanding financial instruments with the proceeds received in connection with the transaction allocated amongst the instruments based on relative fair value. The proceeds received in connection with the transaction allocated amongst the instruments based on relative fair value resulted in $<span title="Warrant issued to purchase common shares"><span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember_zIh1TRU8VhB5" title="Fair value of warrant">165</span></span> being allocated to the Warrant and a corresponding amount recorded as a debt discount to the Convertible Note and Long-term Debt. The Company recorded an aggregate debt discount of $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20221231__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember_zHowCrWzwtz7" title="Debt discount">845</span> related to the Loan, inclusive of the debt discount of $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember_z8Axj2Z2j5Jj" title="Debt discount">165</span> in connection to the Warrant, which will be amortized to interest expense over the term of each respective tranche using the effective interest method. The Company also paid $<span id="xdx_90D_eus-gaap--PaymentsOfDebtIssuanceCosts_pn3n3_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember_zq1MhDkom126" title="Payments of debt issuance costs">540</span> in cash for debt issuance costs. Additionally, per the Kreos Loan Agreement, with respect to the Long-term Debt, there is an advance payment of $<span id="xdx_904_ecustom--DebtInstrumentUnamortizedDiscountCurrentAndNonCurrent_iI_pn3n3_c20221231__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember_zj0d6JJneWC6" title="Advance payments for debt discount">274</span> that is recorded at a debt discount. The advance payment represents the last month’s payment in relation to the Long-term Debt.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> There is also an end of loan payment of $<span id="xdx_907_eus-gaap--LongTermDebtCurrent_iI_pn3n3_c20221231__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember_zHTnow2XQ7m6" title="Long term debt">140</span> which is included on the balance sheet as a liability within the Long-term Debt and also within the total aggregate debt discount of $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20221231__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember_zHyOgUhLh323" title="Advance payment"><span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20211231__us-gaap--TypeOfArrangementAxis__custom--KreosLoanAgreementMember_zOnQUPHbpW4k" title="Advance payment">845</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to the issuance of the consolidated financial statements for the year ended December 31, 2021, the Company identified that the current portion of long-term debt was incorrectly classified as non-current on the balance sheet as of December 31, 2021. Management evaluated this misstatement and concluded it was not material to the financial statements and therefore, the Company elected to correct the current portion of long-term debt as of December 31, 2021 in these consolidated financial statements for comparative purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--InterestAndOtherIncomeTableTextBlock_zgPJbVTmeOWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For the year ended December 31, 2022, interest expense for the Loan was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zdxgKQ1wJ3Pi" style="display: none">Schedule of Interest Expense for Loan</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Year Ended December 31,</b></td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2021</b></td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Contractual interest expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--InterestExpenseOther_pn3n3_c20220101__20221231_zEP3LxPBh5d5" title="Contractual interest expense">1,001</span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">362</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Amortization of debt issuance costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20220101__20221231_zfP8YmOO3aJh" title="Amortization of debt issuance costs">330</span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">91</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total interest expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--InterestExpense_pn3n3_c20220101__20221231_zwabHj1QDE8g" title="Total interest expense">1,331</span></td> <td> </td> <td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">453</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zVmkuFyu5VIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zEpSnETZRUFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future principal payments under the Convertible Note as of December 31, 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zTRPUJ99F5t9" style="display: none">Schedule of Future Principal Payments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Years Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221231_zhRCBSm1rGNg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_maDICAzUQw_zmywts5NMkD" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_maDICAzUQw_zrqG3Tju2xe2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0845">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_maDICAzUQw_zUf6MdCxylOh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 80%; text-align: left">2025</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">4,000</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_mtDICAzUQw_maLTDz4Wx_zSkWkW9XIoV3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total future principal payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--LoanPayments_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_maLTDz4Wx_zAwun4t2WDZk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">End of loan payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">140</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--UnamortizedDebtIssuanceExpense_iNI_pn3n3_di_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_msLTDz4Wx_zPf2IOSYboga" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less unamortized debt issuance costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(108</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--UnamortizedDebtIssuanceCost_iNI_pn3n3_di_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_msLTDz4Wx_zt5PA5cQZf97" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less unamortized debt issuance costs of non-current portion long-term debt</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><p style="margin: 0"/></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebt_iTI_pn3n3_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_mtLTDz4Wx_zDaRjuhXiJDb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,892</td><td style="padding-bottom: 2.5pt; text-align: left"/></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future principal payments under the Term Debt as of December 31, 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Years Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20221231_zZLIIuk9tXg7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_maDICAz5Ei_z99XsTTRq9Rc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,714</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_maDICAz5Ei_z1soBFo3sOzj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,983</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_maDICAz5Ei_zL4c3s9dbxj7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,601</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_mtDICAz5Ei_maLTDzNrl_zcotxICOMQI5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total future principal payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,298</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--LoanPayments_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_maLTDzNrl_zYzsPeoC60k3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">End of loan payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">140</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--UnamortizedDebtIssuanceExpense_iNI_pn3n3_di_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_msLTDzNrl_z0rlCL48D8Oj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less unamortized debt issuance costs of current portion of long-term debt</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">(182</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_ecustom--UnamortizedDebtIssuanceCost_iNI_pn3n3_di_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_msLTDzNrl_z38qfp5H15tc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less unamortized debt issuance costs of non-current portion long-term debt</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0">(135</p></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--LongTermDebt_iTI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_mtLTDzNrl_zODRRAHQhQHl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,121</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zlhGMEbM8uv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 12000000 4000000 5000000 3000000 3000000 0.0775 28 0.0775 9547 20.948 165 845000 165000 540000 274000 140000 845000 845000 <p id="xdx_898_eus-gaap--InterestAndOtherIncomeTableTextBlock_zgPJbVTmeOWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For the year ended December 31, 2022, interest expense for the Loan was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zdxgKQ1wJ3Pi" style="display: none">Schedule of Interest Expense for Loan</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Year Ended December 31,</b></td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2021</b></td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Contractual interest expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--InterestExpenseOther_pn3n3_c20220101__20221231_zEP3LxPBh5d5" title="Contractual interest expense">1,001</span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">362</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Amortization of debt issuance costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20220101__20221231_zfP8YmOO3aJh" title="Amortization of debt issuance costs">330</span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">91</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total interest expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--InterestExpense_pn3n3_c20220101__20221231_zwabHj1QDE8g" title="Total interest expense">1,331</span></td> <td> </td> <td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">453</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1001000 330000 1331000 <p id="xdx_89E_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zEpSnETZRUFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future principal payments under the Convertible Note as of December 31, 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zTRPUJ99F5t9" style="display: none">Schedule of Future Principal Payments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Years Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221231_zhRCBSm1rGNg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_maDICAzUQw_zmywts5NMkD" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_maDICAzUQw_zrqG3Tju2xe2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0845">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_maDICAzUQw_zUf6MdCxylOh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 80%; text-align: left">2025</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">4,000</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_mtDICAzUQw_maLTDz4Wx_zSkWkW9XIoV3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total future principal payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--LoanPayments_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_maLTDz4Wx_zAwun4t2WDZk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">End of loan payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">140</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--UnamortizedDebtIssuanceExpense_iNI_pn3n3_di_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_msLTDz4Wx_zPf2IOSYboga" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less unamortized debt issuance costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(108</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--UnamortizedDebtIssuanceCost_iNI_pn3n3_di_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_msLTDz4Wx_zt5PA5cQZf97" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less unamortized debt issuance costs of non-current portion long-term debt</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><p style="margin: 0"/></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebt_iTI_pn3n3_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_mtLTDz4Wx_zDaRjuhXiJDb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,892</td><td style="padding-bottom: 2.5pt; text-align: left"/></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future principal payments under the Term Debt as of December 31, 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Years Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20221231_zZLIIuk9tXg7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_maDICAz5Ei_z99XsTTRq9Rc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,714</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_maDICAz5Ei_z1soBFo3sOzj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,983</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_maDICAz5Ei_zL4c3s9dbxj7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,601</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_mtDICAz5Ei_maLTDzNrl_zcotxICOMQI5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total future principal payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,298</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--LoanPayments_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_maLTDzNrl_zYzsPeoC60k3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">End of loan payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">140</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--UnamortizedDebtIssuanceExpense_iNI_pn3n3_di_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_msLTDzNrl_z0rlCL48D8Oj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less unamortized debt issuance costs of current portion of long-term debt</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">(182</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_ecustom--UnamortizedDebtIssuanceCost_iNI_pn3n3_di_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_msLTDzNrl_z38qfp5H15tc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less unamortized debt issuance costs of non-current portion long-term debt</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0">(135</p></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--LongTermDebt_iTI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--LongTermDebtMember_mtLTDzNrl_zODRRAHQhQHl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,121</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4000000 4000000 140000 108000 3892000 2714000 2983000 1601000 7298000 140000 182000 135000 7121000 <p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zPMs558aLGSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_828_zSlTSri8Yozg">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Royalties to the IIA</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has received grants from the Government of the State of Israel through the Israeli National Authority for Technical Innovation (the “IIA”) for the financing of a portion of its research and development expenditures. The total amount that was received and recorded between the periods ending December 31, 2011 through 2016 was $<span id="xdx_903_eus-gaap--ProceedsFromRoyaltiesReceived_pn3n3_c20111231__20161231_z7CtuNYgCfS8" title="Royalty received">1,332</span>. <span id="xdx_90B_eus-gaap--ProceedsFromRoyaltiesReceived_pn3n3_do_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--IsraeliNationalAuthorityForTechnicalInnovationMember_zS7RFPFLpLM3" title="Royalty received"><span id="xdx_907_eus-gaap--ProceedsFromRoyaltiesReceived_pn3n3_do_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--IsraeliNationalAuthorityForTechnicalInnovationMember_zaZGXLzwmxhf" title="Royalty received">No</span></span> amounts were received during the years ended December 31, 2022 and 2021. The Company has a contingent obligation to the IIA for the total amount received along with the accumulated LIBOR interest to date in the amount of $<span id="xdx_905_ecustom--LondonInterbankOfferedRate_iI_pn3n3_c20221231_zwUXEn5iTtNi" title="LIBOR interest rate">1,426</span> and $<span id="xdx_905_ecustom--LondonInterbankOfferedRate_iI_pn3n3_c20211231_zdEKRtaeuIq9" title="LIBOR interest rate">1,419</span> as of December 31, 2022 and 2021, respectively. This obligation is repaid in the form of royalties on revenues generated in any fashion with a rate that is currently at <span id="xdx_90F_ecustom--RoyaltiesPercentage_c20220101__20221231_zkUzJsGGl4Xd" title="Royalties percentage">4%</span> (which may be increased under certain circumstances). The Company may be obligated to pay up to 100% (which may be increased under certain circumstances) of the U.S. dollar-linked value of the grants received, plus interest at the rate of 12-month LIBOR.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment of the grants is contingent upon the Company’s ongoing commercialization and generation of sales, which is subject to significant risk and uncertainty. The Company has no obligation to repay these grants if no significant sales are generated. The Company has recorded an immaterial expense for the years ended December 31, 2022 and 2021, and an immaterial liability at December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Royalty Payment Rights on Royalty Payment Rights Certificates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”), establishing the rights and preferences of the holders of the Series A Convertible Preferred Stock, including certain directors and officers of the Company (the “Royalty Payment Rights”). As set forth in the Certificate of Designation, <span id="xdx_90C_ecustom--DescriptionOfRoyaltyPayment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--RoyaltyPaymentRightsCertificatesMember_z5yzfXpRNBI3" title="Description of royalty payment">the Royalty Payment Rights initially entitled the holders in aggregate, to a royalty in an amount of:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--NetSalesPercentage_pid_uPure_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zr7oY4xblXh3" title="Net sales percentage">3%</span> of net sales subject to a maximum in any calendar year equal to the total dollar amount of Units closed on in the Company’s 2017 private placement (the “2017 Private Placement”); and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--LicensingPercentage_pid_uPure_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZbC6ouV532c" title="Licensing percentage">5%</span> of licensing proceeds subject to a maximum in any calendar year equal to the total dollar amount of Units closed on in the 2017 Private Placement.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, in connection with completion of the 2017 Private Placement, the Company issued the placement agent royalty payment rights certificates (the “Placement Agent Royalty Payment Rights Certificates”) which grants the placement agent, and its designees, the right to receive, in the aggregate, <span id="xdx_901_ecustom--PercentageOfPaymentAmount_pid_dp_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zghccGEsait" title="Percentage of payment amount">10%</span> of the amount of payments paid to the holders of the Series A Convertible Preferred Stock, or the holders of the Royalty Payment Rights Certificates (the “Royalty Payment Rights Certificates”), upon the conversion of the Series A Convertible Preferred Stock into shares of the Company’s common stock. The Placement Agent Royalty Payment Rights Certificates are on substantially similar terms as the Royalty Payment Rights of the Series A Convertible Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Royalty Payment Rights Certificate obligation and Placement Agent Royalty Payment Rights Certificate obligation (the “Contingent Royalty Obligation”) was recorded as a liability at fair value as “Contingent royalty obligation” in the consolidated balance sheets at December 31, 2022 and 2021 (see Contingent Royalty Obligation below). The fair value at inception was allocated to the royalty rights and the residual value was allocated to the preferred shares and recorded as equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company amended its Certificate of Designation to modify the Royalty Payment Rights when the Company consummated its Initial Public Offering (“IPO”) on February 16, 2018, at which time the Company converted the Series A Convertible Preferred Stock into shares of the Company’s common stock and issued the Royalty Payment Rights Certificates. Pursuant to the terms of the Royalty Payment Rights Certificates, if and when the Company generates sales of the current and potential future versions of the Pure-Vu System, including disposables, parts, and services, or if the Company receives any proceeds from the licensing of the current and potential future versions of the Pure-Vu System, then the Company will pay to the holders of the Royalty Payment Rights Certificates a royalty (the “Royalty Amount”) equal to, in the aggregate, in royalty payments in any calendar year for all products:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--NetSalesPercentage_pid_uPure_c20220101__20221231_zL9oo09crA11" title="Net sales percentage">3%</span> of Net Sales* for commercialized product directly; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--LicensingPercentage_pid_uPure_c20220101__20221231_zWmXZDi5bjGj" title="Licensing percentage">5%</span> of any Licensing Proceeds** for rights to commercialize the product if sublicensed by the Company to a third-party.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the foregoing, with respect to Net Sales based Royalty Amounts, (a) no Net Sales based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Net Sales equal to $<span id="xdx_909_ecustom--RoyaltyIncomeNet_pn3n3_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zn75c2nrB3if" title="Royalties income">20,000</span> (the “Initial Net Sales Milestone”), and royalties shall only be computed on, and due with respect to, Net Sales generated in excess of the Initial Net Sales Milestone, and (b) the total Net Sales based Royalty Amount due and payable in any calendar year shall be subject to a royalty cap amount per calendar year of $<span id="xdx_903_eus-gaap--ProceedsFromRoyaltiesReceived_pn3n3_c20220101__20221231_zWWZvCZkU1tg" title="Royalties received">30,000</span>. “Net Sales” is defined in the Royalty Payment Rights Certificates. The Company has not reached the Initial Net Sales Milestone as of December 31, 2022.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the foregoing, with respect to Licensing Proceeds based Royalty Amounts, (a) no Licensing Proceeds based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Licensing Proceeds equal to $<span id="xdx_90D_ecustom--ProceedsFromLicensingBasedRoyaltyAmounts_pn3n3_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--RoyaltyMember_z91XVlOVRAD5" title="Proceeds from licensing based royalty amounts">3,500</span> (the “Initial Licensing Proceeds Milestone”), and royalties shall only be computed on, and due with respect to, Licensing Proceeds in excess of the Initial Licensing Proceeds Milestone and (b) the total Licensing Proceeds based Royalty Amount due and payable in any calendar year shall be subject to a royalty cap amount per calendar year of $<span id="xdx_90E_eus-gaap--ProceedsFromRoyaltiesReceived_pn3n3_c20220101__20221231_zZvI5LNxjmf6" title="Royalty received">30,000</span>. “Licensing” Proceeds is defined in the Certificate. The Company has not reached the Initial Licensing Proceeds Milestone as of December 31, 2022.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Royalty Amount will be payable up to the later of (i) the latest expiration date of the Company’s patents issued as of December 22, 2016, or (ii) the latest expiration date of any pending patents as of December 22, 2016 that have since been issued or may be issued in the future (which is currently March 2039 jx). Following the expiration of all such patents, the holders of the Royalty Payment Rights Certificates and the holders of the Placement Agent Royalty Payment Rights Certificates will no longer be entitled to any further royalties for any period following the latest to occur of such patent expiration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 16, 2018, the date of the closing of the IPO, (1) the amendment to the Certificate of Designation became effective, (2) all outstanding shares of Series A Convertible Preferred Stock were converted into shares of the Company’s common stock pursuant to a mandatory conversion, and (3) the Royalty Payment Rights Certificates were issued to the former holders of the Series A Convertible Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contingent Royalty Obligation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contingent royalty obligation was recorded as a non-current liability at fair value in the consolidated balance sheets at December 31, 2022 and 2021 in the amount of $<span id="xdx_901_ecustom--ContingentRoyaltyObligationNonCurrent_iI_pn3n3_c20221231_zXeGc2kYFvf9" title="Contingent royalty obligation">1,212</span> and $<span id="xdx_90D_ecustom--ContingentRoyaltyObligationNonCurrent_iI_pn3n3_c20211231_z7O66pCMal68" title="Contingent royalty obligation">1,760</span>, respectively. A gain on change in fair value of contingent royalty obligation of $<span id="xdx_905_ecustom--LossOnChangeInFairValueOfContingentRoyaltyObligation_pn3n3_c20220101__20221231_zuYdqUOpMb9a" title="Gain on change in fair value of contingent royalty obligation">548</span> for the year ended December 31, 2022 and a loss on change in fair value of contingent royalty obligation of $<span id="xdx_906_ecustom--LossOnChangeInFairValueOfContingentRoyaltyObligation_pn3n3_c20210101__20211231_zw6SqyPQEwzf" title="Gain on change in fair value of contingent royalty obligation">143</span> was recorded for the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Commitments and Contingencies</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has a severance contingency for severance payments to its CEO, COO, and CFO in the aggregate of approximately $<span id="xdx_904_eus-gaap--SeveranceCosts1_pn3n3_c20220101__20221231_zJ4Nugc1n4nk" title="Severance payments">1,408</span>, in the event that they are terminated without cause or leave due to good reason, as outlined in their employee agreements. Management estimates that the likelihood of payment is remote; therefore, no liability was reflected in these consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing Component Purchase Obligations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilizes two outsourcing partners to manufacture its workstation and disposable portions of the Pure-Vu System, and to perform final assembly and testing of finished products. These outsourcing partners acquire components and build product based on demand information supplied by the Company. As of December 31, 2022, the Company expects to pay $<span id="xdx_90D_eus-gaap--ManufacturingCosts_pn3n3_c20220101__20221231_zPA46HAMutNa" title="Manufacturing Costs">41</span> under manufacturing-related supplier arrangements within the next year, substantially all of which is noncancelable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 1332000 0 0 1426000 1419000 0.04 the Royalty Payment Rights initially entitled the holders in aggregate, to a royalty in an amount of: 0.03 0.05 0.10 0.03 0.05 20000000 30000000 3500000 30000000 1212000 1760000 548000 143000 1408000 41000 <p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zLmovw32khB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 – <span id="xdx_82B_zBxLoh8z5keb">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shared Space Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In January 2020, the Company entered into a license agreement (the “Shared Space Agreement”) with Orchestra BioMed, Inc. (OBIO), formerly a greater than <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_c20200131__us-gaap--TypeOfArrangementAxis__custom--SharedSpaceAgreementsMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OrchestraBioMedIncMember_zJLrkM347r37" title="Ownership percentage">5%</span> holder of the Company’s common stock and entity in which David Hochman, the Chairman of the Company’s board of directors, serves as the Chairman of the board of directors and Chief Executive Officer, and Darren Sherman, a member of the Company’s board of directors, serves as a director and as President and Chief Operating Officer. Pursuant to the Shared Space Agreement, the Company granted a license to OBIO for the use of portions of the office space not being used by the Company in the Company’s leased facility in Fort Lauderdale, Florida (the “Premises”), and a proportionate share of common areas of such Premises, which previously covered approximately 35% of the Premises and was to expand incrementally to approximately 60 to 70% of the Premises by September 2024. In May 2022, the Company entered into an amendment to the Shared Space Agreement. Pursuant to the amendment, the area covered by the Shared Space Agreement was expanded to 95% of the premises and the aggregate license fees will generally range from approximately $<span id="xdx_907_ecustom--LicenseFees_pn3n3_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zJ8SLHhUmuo9" title="License fee">212</span> to approximately $<span id="xdx_900_ecustom--LicenseFees_pn3n3_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zTplX3A8azt2" title="License fee">270</span> in any given calendar year during the term of the Shared Space Agreement until the termination of the lease in November 2024. During the year ended December 31, 2022 and 2021, the Company recorded a license fee of $<span id="xdx_901_ecustom--LicenseFees_pn3n3_c20220101__20221231_z5rDJoR88aM7" title="License fee">242</span> and $<span id="xdx_90E_ecustom--LicenseFees_pn3n3_c20210101__20211231_zrbtkA4vCDgg" title="License fee">189</span>, respectively, in relation to the Shared Space Agreement. This amount is netted with rent expense in general and administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0.05 212000 270000 242000 189000 <p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zdo8sUiNFxIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – <span id="xdx_826_zA4GkjA5kym">Share-based compensation and Common Stock Issuance</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zq8HhPxrQzil" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth total non-cash share-based compensation for the issuance of common stock, options to purchase common stock, warrants to purchase common stock, and restricted stock unit awards by operating statement classification for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zc2QEQ8KGObl" style="display: none">Schedule of Stock-based Compensation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20220101__20221231_zdqIDMP9epZ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20210101__20211231_zWQ9KFFsVtKg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended December 31,</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zZRggdRE02Eh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">388</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">575</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z9b7RdI2uZP2" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">353</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zj18wNpaUd47" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,183</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,544</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_pn3n3_zQwLfC4VK2P2" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,809</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,472</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zgwBwtTh9iqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2022 and 2021, the Company recorded $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ze0wEu8HCfBi" title="Share-based compensation expenses">1,145</span> and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztQp5y66u38l" title="Share-based compensation expenses">2,270</span>, respectively, for share-based compensation expense related to stock options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, unamortized share-based compensation for stock options was $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zc1RpprzSOS8" title="Stock based compensation for stock options">964</span>, with a weighted-average recognition period of <span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zv7LBW8ANzY2" title="Weighted-average recognition period">0.87</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2022 and 2021, the Company recorded $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPaFrYuwBcc3" title="Allocated stock based compensation">57 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqz4oKJSL6l7" title="Allocated stock based compensation">335</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively, for share-based compensation expense related to warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2022 and 2021, the Company recorded $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_za6xIADygUll" title="Share-based compensation expenses">607</span> and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrQMUqTvXDh8" title="Share-based compensation expenses">867</span>, respectively, for share-based compensation expense related to restricted stock units.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, unamortized stock compensation for restricted stock units was $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pn3n3_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvtM4YFqO5cd" title="Unamortization stock compensation">308</span>, with a weighted-average recognition period of <span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdWHnSweIp86" title="Weighted-average recognition period">0.81</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock option and warrant activity</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2016, the Company adopted the Motus GI Holdings, Inc. 2016 Equity Incentive Plan (the “2016 Plan”). Pursuant to the 2016 Plan, the Company’s board of directors may grant options to purchase shares of the Company’s common stock, stock appreciation rights, restricted stock, stock units, performance shares, performance units, incentive bonus awards, other cash-based awards and other stock-based awards to employees, officers, directors, consultants and advisors. Pursuant to the terms of an annual evergreen provision in the 2016 Plan, the number of shares of common stock available for issuance under the 2016 Plan shall increase annually by six percent (<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20161201__20161231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenEquityIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN9eMJ4hdzW4" title="Common stock percentage">6%</span>) of the total number of shares of common stock outstanding on December 31st of the preceding calendar year; provided, however, that the board of directors may act prior to the first day of any calendar year to provide that there shall be no increase such calendar year, or that the increase shall be a lesser number of shares of our common stock than would otherwise occur. On January 1, 2022, pursuant to an annual evergreen provision, the number of shares of common stock reserved for future grants was increased by <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220101__us-gaap--PlanNameAxis__custom--TwoThousandSixteenEquityIncentivePlanMember_zKFKI2bMxH4a" title="Number of shares of common stock reserved for future grants">279,586</span> shares. Under the 2016 Plan, effective as of January 1, 2023, the maximum number of shares of the Company’s common stock authorized for issuance is <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220101__us-gaap--PlanNameAxis__custom--TwoThousandSixteenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zSwMWOujOvKk">804,371</span>. As of December 31, 2022, there were <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenEquityIncentivePlanMember_zL7vnSWY5eN" title="Common stock available for future grant">15,165</span> shares of common stock available for future grant under the 2016 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_89C_ecustom--ScheduleOfStockholdersStockOptionAndEquityNoteWarrantsOrRightsTextBlock_zCu81AqBhFmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s stock option and warrant activity is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zRm6L5lQJkZ8" style="display: none">Schedule of Stock option and Warrants</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Options</b></td> <td style="border-right: Black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Warrants</b></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Remaining Contractual Life (years)</b></span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Intrinsic Value</b></span></td> <td style="border-right: Black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Remaining Contractual Life (years)</b></span></td> <td style="padding-bottom: 1.5pt"> </td> <td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Intrinsic Value</b></span></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Outstanding at December 31, 2020</td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJ03sQ0UNznk" style="text-align: right; width: 4%" title="Shares underlying options, outstanding beginning">251,419</td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbNgxOdZKT6b" style="text-align: right; width: 4%" title="Weighted average exercise price, outstanding beginning">60.00</td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqoN8yJzVWd9" title="Weighted average remaining contractual life, outstanding beginning">7.96</span></span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpcucSf61Sg3" style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right" title="Aggregate intrinsic value, outstanding beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0984">-</span></span></td> <td style="border-right: Black 1.5pt solid; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXcxl9TCWuw2" style="text-align: right; width: 4%" title="Shares Underlying Warrants, Outstanding beginning">852,820</td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6PomaZJtty6" style="text-align: right; width: 4%" title="Weighted Average Exercise Price, Outstanding beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37.20</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhQ5VkyG82Fh" title="Weighted average remaining contractual life, outstanding beginning">5.78</span></span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyGfKzEVTUjh" style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right" title="Aggregate Intrinsic Value, outstanding beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0992">-</span></span></td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zb8W0t2J8ULa" style="text-align: right" title="Shares underlying options, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64,675</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWwtguOr39Z4" style="text-align: right" title="Weighted average exercise price, granted">32.80</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zulanlkoBSHh" style="text-align: right" title="Shares Underlying Warrants, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">326,548</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYYNuaJbLmLj" style="text-align: right" title="Weighted Average Exercise Price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41.40</span></td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9rHFMt7GTl7" style="text-align: right" title="Shares underlying options, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,502</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeQiZoODiLA6" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68.60</span></td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4PKYkupTsej" style="text-align: right" title="Shares Underlying Warrants, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(45,758</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYsFkP5CeR7j" style="text-align: right" title="Weighted Average Exercise Price, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.00</span></td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHQeXKvFllTh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares underlying options, exercised">(713,363</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzd993PvevL8" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, exercised">24.80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zacnFusq3SZ" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Underlying Warrants, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7ydadLaV4o5" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1016">-</span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeKyQrjYE6N1" style="text-align: right" title="Shares underlying options, outstanding beginning">307,592</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhdWeSBwZ5a" style="text-align: right" title="Weighted average exercise price, outstanding beginning">54.10</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziUTjLkgL7F5" title="Weighted average remaining contractual life, outstanding beginning">7.45</span></span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2Zjcd2zx5j8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, outstanding beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zALqvspjYkn1" style="text-align: right" title="Shares Underlying Warrants, outstanding beginning">420,247</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEL87Lq8dsnk" style="text-align: right" title="Weighted Average Exercise Price, outstanding beginning">54.76</td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyGzQ3xwQ6Of" title="Weighted average remaining contractual life, outstanding beginning">3.40</span></span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFkiIz9CrrH6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, outstanding beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1032">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbWLGq923JQ1" style="text-align: right" title="Shares underlying options, granted">102,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5Gjy78W8697" style="text-align: right" title="Weighted average exercise price, granted">8.73</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9dmsjFuP089" style="text-align: right" title="Shares Underlying Warrants, granted">6,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaYGwOx6H7Kf" style="text-align: right" title="Weighted Average Exercise Price, granted">10.00</td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEBXdMj804yb" style="text-align: right" title="Shares underlying options, expired">(6,597</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zed7GriFr8Fe" style="text-align: right" title="Weighted average exercise price, expired">64.24</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zax493bDNOKe" style="text-align: right" title="Shares Underlying Warrants, expired">(26,986</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExpiredPrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvlOe6IA6Uaj" style="text-align: right" title="Weighted Average Exercise Price, expired">101.13</td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_iN_pid_di_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFVjZ7g029D" style="text-align: right" title="Shares underlying options, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4W2VDsWKoPg" style="text-align: right" title="Weighted average exercise price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zibzepmt4hg9" style="text-align: right" title="Shares Underlying Warrants, cancelled">(6,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsCancelledWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOsKlVDSfaE4" style="text-align: right" title="Weighted Average Exercise Price, cancelled">56.60</td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqOgrZKrjk5l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares underlying options, forfeited">(3,855</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zytYDgQaNSkk" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, forfeited">11.48</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUduKMtKB6xa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Underlying Warrants, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY9xOzhuFpG7" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1064">-</span></td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkAdh7HcVhmk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares underlying options, outstanding ending">400,137</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zX42jQzXkvTb" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, outstanding ending">42.69</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span title="Weighted average remaining contractual life, outstanding beginning"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNX42z1hp45k" title="Weighted average remaining contractual life, outstanding">7.21</span></span></span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z83KBHern8F7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, outstanding ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcMgfGottW09" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Underlying Warrants, outstanding ending">393,261</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze5SJ0dCBZuf" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, outstanding ending">50.86</td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYlSaIgHMRba" title="Weighted Average Remaining Contractual Life, outstanding">2.66</span></span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyDVVeG1RxL" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, outstanding ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAubrx65Rfve" style="text-align: right" title="Shares underlying options, exercisable">294,152</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRa1gsWI5ndc" style="text-align: right" title="Weighted average exercise price, exercisable">52.77</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znfhmccYdu02" style="text-align: right" title="Shares Underlying Warrants, exercisable">393,261</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisable_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjVoUoTfOcZ6" style="text-align: right" title="Weighted Average Exercise Price, exercisable">50.86</td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_zpB7ggJrDZud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zD9rzj2kBI35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options granted during the years ended December 31, 2022 and 2021 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zaRUVW3HtFoa" style="display: none">Schedule of Option Pricing Model Using Weighted Average Assumptions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected term, in years </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zV7KSy8BcfWc" title="Expected term, in years">5.8</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_ztKLwhD4Aerg" title="Expected term, in years">5.8</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231_zgcosjAtciuj" title="Expected volatility">99.21</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231_zHtkIyeS0ER4" title="Expected volatility">106.24</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_zfJ0RqbTsnr3" style="text-align: right" title="Risk-free interest rate"><span style="font-size: 10pt"> 2.10</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231_zYr9uaHsNgi2" style="text-align: right" title="Risk-free interest rate">0.77</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20221231_zdgj2MeFgUOi" style="text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1104">-</span></td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20211231_zEZ3PARTgMwc" style="font-size: 12pt; text-align: right" title="Dividend yield"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1106">-</span></span></td><td style="font-size: 12pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zjorLKK9ifE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The grant date fair value for stock options issued during the years ended December 31, 2022 and 2021 were $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zgMDh7t73K2f" title="Grant date fair value">8.62</span> and $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_zLrxAAjOo5z" title="Grant date fair value">26.4</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted Stock Units</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zFsnjr2ga8vc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s restricted stock unit awards activity is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_z35aprcW8Sna" style="display: none">Schedule of Restricted Stock Unit Awards Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant Date</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Nonvested at December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkEeXAiiiB7g" style="text-align: right" title="Number of Shares, nonvested beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,891</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zH9d9n1F6jq7" style="text-align: right" title="Aggregate weighted average grant date fair value, nonvested beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62.00</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znY3B5qonuyg" style="text-align: right" title="Number of Shares, nonvested granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,300</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVd0RT0GKPNh" style="text-align: right" title="Aggregate weighted average grant date fair value, nonvested granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.20</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z77F8clldbwk" style="text-align: right" title="Number of Shares, nonvested vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,071</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRmUV1cQWsCc" style="text-align: right" title="Aggregate weighted average grant date fair value, nonvested vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48.40</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Nonvested at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvJjAqpC2tDj" style="width: 16%; text-align: right" title="Number of Shares, nonvested beginning">25,120</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpdqysB10uB3" style="width: 16%; text-align: right" title="Aggregate weighted average grant date fair value, nonvested beginning">44.77</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zS9dovNvsVH9" style="text-align: right" title="Number of Shares, nonvested granted">18,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMJxX5otHZX8" style="text-align: right" title="Aggregate weighted average grant date fair value, nonvested granted">9.07</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2QG72KTq873" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, nonvested vested">(23,092</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYxuQqMNrlg5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate weighted average grant date fair value, nonvested vested">39.53</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Nonvested at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPfFBCozvGNk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, nonvested ending">20,278</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z21LhbIstGV6" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate weighted average grant date fair value, nonvested ending">18.62</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_z7ImvAkN1Bye" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, there were <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXjuVPhhyxNg" title="Vested and unissued restricted stock units">3,138</span> vested and unissued restricted stock units. These restricted stock units were issued as common stock during the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance of Warrants to Purchase Common Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2020, the Company entered into a services agreement whereby it agreed to issue warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200229__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zoeSj7EGFJK2" title="Class of Warrant or Right, Number of Securities Called by Each Warrant or Right">6,000</span> shares of common stock of the Company. The warrants fully vested over a one-year period on a monthly basis and expire three years from the date of issuance and were exercisable at weighted average exercise price equal to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200229__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zF3cQul7z4Af" title="Warrants exercise price">56.60</span> per share of common stock. In March 2022, the Company granted new warrants as a replacement to the vested warrants held by the service provider, for which all the share-based compensation expense had been recognized in prior fiscal periods. The issuance of new warrants concurrently with the cancellation of the existing warrants was treated as a modification. The Company agreed to issue replacement warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200229__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ReplacementWarrantsMember_ziRcC9aniaH1" title="Warrants to purchase of common stock">6,000</span> shares of common stock of the Company exercisable at a price equal to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200229__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_zONzihig7zw7" title="Warrants exercise price">10</span> per share of common stock. The fair value of the warrants were valued on the date of grant at $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20200229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvH1aYgzgvJb">0.38</span> using the Black-Scholes option-pricing model with the following parameters: (1) risk-free interest rate of <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20200229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zkBf2czvS0g8">0.91</span>%; (2) expected life in years of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20200229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zc0nhyzpf6w7">1.62</span>; (3) expected stock volatility of <span><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20200206__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zFUEOw1LzmTj">81.97</span>%</span>; and (4) expected dividend yield of <span><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20200206__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zxd5vjlV77Qf">0</span>%</span>. The replacement warrants immediately vested upon issuance and expire three years from the date of issuance. As a result, the Company recognized $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20220101__20221231_zCGGrQioUPtc" title="Share based compnesation plan modification, incremental cost">26</span> of share-based compensation for the year ended December 31, 2022, related to the incremental fair value which is equal to the excess of the fair value of the new warrants granted over the fair value of the original award on the cancellation date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance of Common Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 5, 2022, non-employee members of the Board of Directors were granted an aggregate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_uShares_c20220104__20220105__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zaJ9bHFKyYe8" title="Share based compensation options, grants">24,458</span> shares of fully-vested common stock with a fair value of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20220105__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zHYp0EkJ43e" title="Fair value of common stock">9.60</span> per share of common stock, as compensation, in lieu of $<span id="xdx_900_ecustom--CashCompensation_iI_c20220105__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zbOnQjGo9Fx7" title="Cash compensation">235</span> of cash compensation, for service as directors for 2022. The Company recorded $<span id="xdx_908_eus-gaap--OfficersCompensation_c20220101__20221231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zw7kOHN1Ftgg" title="Expense for director services">235</span> and $<span title="Cash compensation"><span id="xdx_908_eus-gaap--OfficersCompensation_c20210101__20211231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zIDqRLSdARTa" title="Expense for director services">177</span></span> in expense for director services during the year ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In March 2021, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Oppenheimer &amp; Co. Inc. (“Oppenheimer”), under which we may offer and sell from time to time common shares having an aggregate offering price of up to $<span id="xdx_905_ecustom--AggregateOfOfferingCost_pn5n6_c20210301__20210331__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember__srt--RangeAxis__srt--MaximumMember_zh8Rta5IOUr6" title="Aggregate of offering cost">25.0</span> million. During the year ended December 31, 2022, we sold approximately <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zm40YVpDoSk6" title="Number of common stock sold, shares">2.2</span> million shares of our common stock under this agreement, resulting in net cash proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zghWQ4mGMc9c" title="Proceeds from common stock">9.9</span> million, after deducting issuance costs of $<span id="xdx_904_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_pn5n6_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zekSAffS3X96" title="Proceeds from net of issuance costs">0.4</span> million. From January 1, 2023 to March 14, 2023, the Company issued and sold approximately <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20230314__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zvCXBNuPTDD6" title="Number of common stock sold, shares">119,104</span> common shares of our common stock under this agreement, resulting in net cash proceeds of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20230101__20230314__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zxBBerttX9v5" title="Proceeds from common stock">118.0</span> thousand, after deducting issuance costs $<span id="xdx_901_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_pn3n3_c20230101__20230314__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zMVIhoUhWvqg" title="Proceeds from net of issuance costs">4.0</span> thousand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zq8HhPxrQzil" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth total non-cash share-based compensation for the issuance of common stock, options to purchase common stock, warrants to purchase common stock, and restricted stock unit awards by operating statement classification for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zc2QEQ8KGObl" style="display: none">Schedule of Stock-based Compensation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20220101__20221231_zdqIDMP9epZ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20210101__20211231_zWQ9KFFsVtKg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended December 31,</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zZRggdRE02Eh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">388</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">575</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z9b7RdI2uZP2" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">353</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zj18wNpaUd47" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,183</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,544</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_pn3n3_zQwLfC4VK2P2" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,809</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,472</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 388000 575000 238000 353000 1183000 2544000 1809000 3472000 1145000 2270000 964000 P0Y10M13D 57000 335000 607000 867000 308000 P0Y9M21D 0.06 279586 804371 15165 <p id="xdx_89C_ecustom--ScheduleOfStockholdersStockOptionAndEquityNoteWarrantsOrRightsTextBlock_zCu81AqBhFmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s stock option and warrant activity is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zRm6L5lQJkZ8" style="display: none">Schedule of Stock option and Warrants</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Options</b></td> <td style="border-right: Black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Warrants</b></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Remaining Contractual Life (years)</b></span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Intrinsic Value</b></span></td> <td style="border-right: Black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Remaining Contractual Life (years)</b></span></td> <td style="padding-bottom: 1.5pt"> </td> <td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Intrinsic Value</b></span></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Outstanding at December 31, 2020</td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJ03sQ0UNznk" style="text-align: right; width: 4%" title="Shares underlying options, outstanding beginning">251,419</td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbNgxOdZKT6b" style="text-align: right; width: 4%" title="Weighted average exercise price, outstanding beginning">60.00</td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqoN8yJzVWd9" title="Weighted average remaining contractual life, outstanding beginning">7.96</span></span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpcucSf61Sg3" style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right" title="Aggregate intrinsic value, outstanding beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0984">-</span></span></td> <td style="border-right: Black 1.5pt solid; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXcxl9TCWuw2" style="text-align: right; width: 4%" title="Shares Underlying Warrants, Outstanding beginning">852,820</td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6PomaZJtty6" style="text-align: right; width: 4%" title="Weighted Average Exercise Price, Outstanding beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37.20</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhQ5VkyG82Fh" title="Weighted average remaining contractual life, outstanding beginning">5.78</span></span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyGfKzEVTUjh" style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right" title="Aggregate Intrinsic Value, outstanding beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0992">-</span></span></td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zb8W0t2J8ULa" style="text-align: right" title="Shares underlying options, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64,675</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWwtguOr39Z4" style="text-align: right" title="Weighted average exercise price, granted">32.80</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zulanlkoBSHh" style="text-align: right" title="Shares Underlying Warrants, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">326,548</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYYNuaJbLmLj" style="text-align: right" title="Weighted Average Exercise Price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41.40</span></td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9rHFMt7GTl7" style="text-align: right" title="Shares underlying options, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,502</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeQiZoODiLA6" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68.60</span></td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4PKYkupTsej" style="text-align: right" title="Shares Underlying Warrants, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(45,758</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYsFkP5CeR7j" style="text-align: right" title="Weighted Average Exercise Price, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.00</span></td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHQeXKvFllTh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares underlying options, exercised">(713,363</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzd993PvevL8" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, exercised">24.80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zacnFusq3SZ" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Underlying Warrants, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7ydadLaV4o5" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1016">-</span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeKyQrjYE6N1" style="text-align: right" title="Shares underlying options, outstanding beginning">307,592</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhdWeSBwZ5a" style="text-align: right" title="Weighted average exercise price, outstanding beginning">54.10</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziUTjLkgL7F5" title="Weighted average remaining contractual life, outstanding beginning">7.45</span></span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2Zjcd2zx5j8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, outstanding beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zALqvspjYkn1" style="text-align: right" title="Shares Underlying Warrants, outstanding beginning">420,247</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEL87Lq8dsnk" style="text-align: right" title="Weighted Average Exercise Price, outstanding beginning">54.76</td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyGzQ3xwQ6Of" title="Weighted average remaining contractual life, outstanding beginning">3.40</span></span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFkiIz9CrrH6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, outstanding beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1032">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbWLGq923JQ1" style="text-align: right" title="Shares underlying options, granted">102,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5Gjy78W8697" style="text-align: right" title="Weighted average exercise price, granted">8.73</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9dmsjFuP089" style="text-align: right" title="Shares Underlying Warrants, granted">6,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaYGwOx6H7Kf" style="text-align: right" title="Weighted Average Exercise Price, granted">10.00</td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEBXdMj804yb" style="text-align: right" title="Shares underlying options, expired">(6,597</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zed7GriFr8Fe" style="text-align: right" title="Weighted average exercise price, expired">64.24</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zax493bDNOKe" style="text-align: right" title="Shares Underlying Warrants, expired">(26,986</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExpiredPrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvlOe6IA6Uaj" style="text-align: right" title="Weighted Average Exercise Price, expired">101.13</td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_iN_pid_di_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFVjZ7g029D" style="text-align: right" title="Shares underlying options, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4W2VDsWKoPg" style="text-align: right" title="Weighted average exercise price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zibzepmt4hg9" style="text-align: right" title="Shares Underlying Warrants, cancelled">(6,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsCancelledWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOsKlVDSfaE4" style="text-align: right" title="Weighted Average Exercise Price, cancelled">56.60</td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqOgrZKrjk5l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares underlying options, forfeited">(3,855</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zytYDgQaNSkk" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, forfeited">11.48</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUduKMtKB6xa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Underlying Warrants, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY9xOzhuFpG7" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1064">-</span></td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkAdh7HcVhmk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares underlying options, outstanding ending">400,137</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zX42jQzXkvTb" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, outstanding ending">42.69</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span title="Weighted average remaining contractual life, outstanding beginning"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNX42z1hp45k" title="Weighted average remaining contractual life, outstanding">7.21</span></span></span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z83KBHern8F7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, outstanding ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcMgfGottW09" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Underlying Warrants, outstanding ending">393,261</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze5SJ0dCBZuf" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, outstanding ending">50.86</td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYlSaIgHMRba" title="Weighted Average Remaining Contractual Life, outstanding">2.66</span></span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyDVVeG1RxL" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, outstanding ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAubrx65Rfve" style="text-align: right" title="Shares underlying options, exercisable">294,152</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRa1gsWI5ndc" style="text-align: right" title="Weighted average exercise price, exercisable">52.77</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-right: Black 1.5pt solid"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znfhmccYdu02" style="text-align: right" title="Shares Underlying Warrants, exercisable">393,261</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisable_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjVoUoTfOcZ6" style="text-align: right" title="Weighted Average Exercise Price, exercisable">50.86</td> <td> </td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"> </td></tr> </table> 251419 60.00 P7Y11M15D 852820 37.20 P5Y9M10D 64675 32.80 326548 41.40 8502 68.60 -45758 100.00 713363 24.80 307592 54.10 P7Y5M12D 420247 54.76 P3Y4M24D 102997 8.73 6000 10.00 6597 64.24 26986 101.13 6000 56.60 3855 11.48 400137 42.69 P7Y2M15D 393261 50.86 P2Y7M28D 294152 52.77 393261 50.86 <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zD9rzj2kBI35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options granted during the years ended December 31, 2022 and 2021 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zaRUVW3HtFoa" style="display: none">Schedule of Option Pricing Model Using Weighted Average Assumptions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected term, in years </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zV7KSy8BcfWc" title="Expected term, in years">5.8</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_ztKLwhD4Aerg" title="Expected term, in years">5.8</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231_zgcosjAtciuj" title="Expected volatility">99.21</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231_zHtkIyeS0ER4" title="Expected volatility">106.24</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_zfJ0RqbTsnr3" style="text-align: right" title="Risk-free interest rate"><span style="font-size: 10pt"> 2.10</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231_zYr9uaHsNgi2" style="text-align: right" title="Risk-free interest rate">0.77</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20221231_zdgj2MeFgUOi" style="text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1104">-</span></td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20211231_zEZ3PARTgMwc" style="font-size: 12pt; text-align: right" title="Dividend yield"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1106">-</span></span></td><td style="font-size: 12pt; text-align: left"> </td></tr> </table> P5Y9M18D P5Y9M18D 0.9921 1.0624 0.0210 0.0077 8.62 26.4 <p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zFsnjr2ga8vc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s restricted stock unit awards activity is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_z35aprcW8Sna" style="display: none">Schedule of Restricted Stock Unit Awards Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant Date</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Nonvested at December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkEeXAiiiB7g" style="text-align: right" title="Number of Shares, nonvested beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,891</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zH9d9n1F6jq7" style="text-align: right" title="Aggregate weighted average grant date fair value, nonvested beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62.00</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znY3B5qonuyg" style="text-align: right" title="Number of Shares, nonvested granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,300</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVd0RT0GKPNh" style="text-align: right" title="Aggregate weighted average grant date fair value, nonvested granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.20</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z77F8clldbwk" style="text-align: right" title="Number of Shares, nonvested vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,071</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRmUV1cQWsCc" style="text-align: right" title="Aggregate weighted average grant date fair value, nonvested vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48.40</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Nonvested at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvJjAqpC2tDj" style="width: 16%; text-align: right" title="Number of Shares, nonvested beginning">25,120</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpdqysB10uB3" style="width: 16%; text-align: right" title="Aggregate weighted average grant date fair value, nonvested beginning">44.77</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zS9dovNvsVH9" style="text-align: right" title="Number of Shares, nonvested granted">18,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMJxX5otHZX8" style="text-align: right" title="Aggregate weighted average grant date fair value, nonvested granted">9.07</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2QG72KTq873" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, nonvested vested">(23,092</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYxuQqMNrlg5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate weighted average grant date fair value, nonvested vested">39.53</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Nonvested at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPfFBCozvGNk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, nonvested ending">20,278</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z21LhbIstGV6" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate weighted average grant date fair value, nonvested ending">18.62</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 16891 62.00 21300 34.20 12071 48.40 25120 44.77 18250 9.07 23092 39.53 20278 18.62 3138 6000 56.60 6000 10 0.38 0.91 P1Y7M13D 81.97 0 26 24458 9.60 235 235 177 25000000.0 2200000 9900000 400000 119104 118000.0 4000.0 <p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zeoiR2mx07z" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12 – <span id="xdx_829_zhuDu0tV4ur">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences. In accordance with ASC 740, “Income Taxes,” the Company recorded a valuation allowance to fully offset the gross deferred tax asset, because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022 and 2021, the Company had deferred tax assets of approximately $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsGross_iI_pn5n3_c20221231_ziEijNcdPYN4" title="Deferred tax assets">37,400</span> and $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsGross_iI_pn5n3_c20211231_z5YzovrPRVQ9" title="Deferred tax assets">27,200</span>, respectively, against which a full valuation allowance of $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n3_c20221231_zobvW0U7bth4" title="Deferred tax assets valuation allowance">37,400</span> and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n3_c20211231_zjRnG2Qg7xo9" title="Deferred tax assets valuation allowance">27,200</span>, respectively had been recorded. The change in the valuation allowance for the year ended December 31, 2022 was an increase of $<span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20220101__20221231_zjEXfGWVez43" title="Valuation allowance">10,200</span>. The increase in the valuation allowance for the year ended December 31, 2022 was mainly attributable to increases in net operating losses and non-deductible research expenses, which resulted in an increase in the deferred tax assets with a corresponding valuation allowance. Significant components of the Company’s deferred tax assets at December 31, 2022 and 2021 were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zu5mjDDUxs8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zKZYUkdrfrL4" style="display: none">Schedule of Deferred Tax Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_493_20221231_zhdFKJv0RHmd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20211231_zLwM8Lr2WmUa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Deferred tax assets:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTANzQ80_ziEvdPUjr0qh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net operating loss carryforwards – Federal and state</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">14,614</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,281</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_maDTANzQ80_zsKLl7kMAhHd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net operating loss carryforwards – Israel</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,813</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,354</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzQ80_zFKEnDXpP8Pi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,735</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,732</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredTaxAssetDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_maDTANzQ80_z8RDg3NkXl81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Capitalized research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,246</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">218</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTANzQ80_zmYtvMBDBfE6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued liabilities and reserves</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">681</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">831</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzQ80_zAawbJO0BtXh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,089</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,416</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxLiabilitiesAcceleratedResearchAndDevelopmentExpense_iNI_di_maDTLzDM3_zGkOdB0Pw4Ff" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accelerated research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(548</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDTLzDM3_z3dHJWdB2Cu" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right of use asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(109</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(158</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesOther_iNI_di_maDTLzDM3_zzSOHFnjlK2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(34</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLzDM3_zSqTGSLoHSAc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(691</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(172</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iI_maDTALNzl6E_zR3GsGI30Xn" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net deferred tax assets before valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,398</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,244</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzl6E_zZtEXw2rFSFk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37,398</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,244</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzl6E_zs8AIIGDh2D7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets after valuation allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1233">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zX87KwzSgLBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zFcUeUkKelCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the federal statutory tax rate and the effective tax rates for the years ended December 31, 2022 and 2021 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zYtKeUBLP2O4" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">U.S. federal statutory tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_znFZJJJgKqB3" title="U.S. federal statutory tax rate">21.0</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231_zcqC20V41mc1" title="U.S. federal statutory tax rate">21.0</span></td><td style="width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pip0_dp_uPure_c20220101__20221231_zW7ggQNlwxkh" style="text-align: right" title="State income taxes, net of federal benefit">6.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pip0_dp_uPure_c20210101__20211231_zTDFcVV75oZ4" style="text-align: right" title="State income taxes, net of federal benefit">2.0</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">U.S. vs. foreign tax rate differential</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_c20220101__20221231_zsDsJySpBxD1" style="text-align: right" title="U.S. vs. foreign tax rate differential">0.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_c20210101__20211231_zYb1raGhknNi" style="text-align: right" title="U.S. vs. foreign tax rate differential">0.9</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_pid_dpi_uPure_c20220101__20221231_zueRXIVxE9M1" title="Non-deductible expenses">(2.7</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_pid_dpi_uPure_c20210101__20211231_zYgoeWy3GESh" title="Non-deductible expenses">(1.9</span></td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Foreign exchange adjustments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_c20220101__20221231_zLRFq8Tdz5f3" style="text-align: right" title="Foreign exchange adjustments">(10.7</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_c20210101__20211231_zviTyAbfL0f8" style="text-align: right" title="Foreign exchange adjustments">2.5</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_c20220101__20221231_zCw5cOFO2Bik" title="Change in valuation allowance">15.0</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_c20210101__20211231_ztuNqjQJqPxl" title="Change in valuation allowance">24.5</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zUcGXbj7MLBk" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective tax rate"><span style="-sec-ix-hidden: xdx2ixbrl1262">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231_zcTxihv9n6Q5" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1264">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td> </tr> </table> <p id="xdx_8A7_z6ruWfGYQRl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had approximately $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20221231_z19izDYD28C5" title="Operating loss carryforwards">134,100</span> and $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20211231_z7NCmwQnkwof" title="Operating loss">119,600</span> of gross net operating loss (“NOL”) carryforwards (federal, state and Israel) as of December 31, 2022 and 2021, respectively. Sections 382 and 383 of the Internal Revenue Code, and similar state regulations, contain provisions that may limit the NOL carryforwards available to be used to offset income in any given year upon the occurrence of certain events, including changes in the ownership interests of significant stockholders. In the event of a cumulative change in ownership in excess of 50% over a three-year period, the amount of the NOL carryforwards that the Company may utilize in any one year may be limited.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Tax Cuts and Jobs Act of 2017 (TCJA) has modified the IRC 174 expenses related to research and development for the tax years beginning after December 31, 2021. Under the TCJA, the Company must now capitalize the expenditures related to research and development activities and amortize over five years for U.S. activities and 15 years for non-U.S. activities using a mid-year convention. Since this has been the Company’s policy since 2019, the current year capitalization of research and development costs in accordance with IRC 174 was $<span id="xdx_90C_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20220101__20221231_zr1O4hzqSyRh" title="Research and development costs">4,900,000</span> for a total accumulated gross amount of $<span id="xdx_900_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_c20220101__20221231_zJVEJxbEjfdi" title="Accumulated gross amount">8,800,000</span> as of December 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company incurred an ownership change under Internal Revenue Code Section 382, resulting in an annual NOL utilization limitation of approximately $<span id="xdx_90F_ecustom--OperatingLossCarryforwardsUtilizationLimitation_iI_pn3n3_c20211231_zk2uUAkYaEue" title="Operating loss utilization limit">3,700</span>. None of the Company’s NOL carryforwards or deferred tax assets were required to be reduced since the limitation did not preclude the Company from potentially utilizing all of its NOL carryforwards. Future significant ownership changes could cause a portion or all of the Company’s NOL carryforwards to expire before utilization, however.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_ecustom--ScheduleOfEffectiveIncomeTaxRateReconciliationNetOperatingLossTableTextBlock_zoai31uKXGHk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the Company’s NOLs for the years ended December 31, 2022 and 2021 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zENxZofOfSE8" style="display: none">Schedule of Reconciliation of NOL</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td id="xdx_49E_20220101__20221231_z4pvVMvjUmCd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20210101__20211231_z23UmfbZWLA2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDFSALz5Kw_z9YAVrEIZNX1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">U.S. Federal NOL’s</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">26,875</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">18,420</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDFSALz5Kw_zqrqLVvmSFb8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">U.S. State NOL’s</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">25,464</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,009</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_pn3n3_maDFSALz5Kw_zCSqXJlyKhQ1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Israel NOL’s</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81,794</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">84,148</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_pn3n3_mtDFSALz5Kw_zMdXA2v6i9ga" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total NOL’s</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">134,133</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">119,577</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_z5Lwnh5szv4c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company’s federal and state NOLs of $<span id="xdx_900_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zT5BlxSOulMh">3,300 </span>and $<span id="xdx_909_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--StateMember_zP2zBsh0rEZb">25,464</span>, respectively, <span id="xdx_90F_ecustom--ExpireDateDescription_c20220101__20221231_zwmwTnGiCHEh">begin to expire after 2036 through 2042</span>. The Company’s federal NOL of $<span id="xdx_909_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn5n6_c20180101__20181231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zLwJAXKjeIqe">23,575</span>, generated since 2018, and the Israel NOL of $<span id="xdx_90A_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_pn3n3_c20220101__20221231__srt--StatementGeographicalAxis__country--IL_zm8ltC3FpRp">81,794 </span>do not expire. A check the box election for Israel was made and accepted by the IRS as of January 1, 2019. As such, approximately $<span id="xdx_907_ecustom--DeferredForeignIncomeTaxExpenseBenefitAvailableUse_pn3n3_c20220101__20221231__srt--StatementGeographicalAxis__country--IL_zPclKjWAGiSb">38,100</span> of Israeli NOLs are available for use in the U.S and have an indefinite life.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows guidance on accounting for uncertainty in income taxes which prescribes a minimum threshold a tax position is required to meet before being recognized in the financial statements. The Company does not have any liabilities as of December 31, 2022 and 2021 to account for potential income tax exposure. The Company is obligated to file income tax returns in the U.S. federal jurisdiction, several U.S. States and Israel. Since the Company had losses in the past, all prior years that generated net operating loss carry-forwards are open and subject to audit examination in relation to the net operating loss generated from those years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 37400000 27200000 37400000 27200000 10200000 <p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zu5mjDDUxs8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zKZYUkdrfrL4" style="display: none">Schedule of Deferred Tax Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_493_20221231_zhdFKJv0RHmd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20211231_zLwM8Lr2WmUa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Deferred tax assets:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTANzQ80_ziEvdPUjr0qh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net operating loss carryforwards – Federal and state</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">14,614</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,281</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_maDTANzQ80_zsKLl7kMAhHd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net operating loss carryforwards – Israel</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,813</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,354</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzQ80_zFKEnDXpP8Pi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,735</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,732</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredTaxAssetDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_maDTANzQ80_z8RDg3NkXl81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Capitalized research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,246</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">218</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTANzQ80_zmYtvMBDBfE6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued liabilities and reserves</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">681</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">831</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzQ80_zAawbJO0BtXh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,089</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,416</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxLiabilitiesAcceleratedResearchAndDevelopmentExpense_iNI_di_maDTLzDM3_zGkOdB0Pw4Ff" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accelerated research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(548</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDTLzDM3_z3dHJWdB2Cu" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right of use asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(109</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(158</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesOther_iNI_di_maDTLzDM3_zzSOHFnjlK2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(34</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLzDM3_zSqTGSLoHSAc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(691</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(172</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iI_maDTALNzl6E_zR3GsGI30Xn" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net deferred tax assets before valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,398</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,244</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzl6E_zZtEXw2rFSFk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37,398</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,244</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzl6E_zs8AIIGDh2D7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets after valuation allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1233">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 14614000 5281000 18813000 19354000 1735000 1732000 2246000 218000 681000 831000 38089000 27416000 548000 109000 158000 34000 14000 691000 172000 37398000 27244000 37398000 27244000 <p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zFcUeUkKelCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the federal statutory tax rate and the effective tax rates for the years ended December 31, 2022 and 2021 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zYtKeUBLP2O4" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">U.S. federal statutory tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_znFZJJJgKqB3" title="U.S. federal statutory tax rate">21.0</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231_zcqC20V41mc1" title="U.S. federal statutory tax rate">21.0</span></td><td style="width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pip0_dp_uPure_c20220101__20221231_zW7ggQNlwxkh" style="text-align: right" title="State income taxes, net of federal benefit">6.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pip0_dp_uPure_c20210101__20211231_zTDFcVV75oZ4" style="text-align: right" title="State income taxes, net of federal benefit">2.0</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">U.S. vs. foreign tax rate differential</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_c20220101__20221231_zsDsJySpBxD1" style="text-align: right" title="U.S. vs. foreign tax rate differential">0.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_c20210101__20211231_zYb1raGhknNi" style="text-align: right" title="U.S. vs. foreign tax rate differential">0.9</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_pid_dpi_uPure_c20220101__20221231_zueRXIVxE9M1" title="Non-deductible expenses">(2.7</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_pid_dpi_uPure_c20210101__20211231_zYgoeWy3GESh" title="Non-deductible expenses">(1.9</span></td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Foreign exchange adjustments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_c20220101__20221231_zLRFq8Tdz5f3" style="text-align: right" title="Foreign exchange adjustments">(10.7</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_c20210101__20211231_zviTyAbfL0f8" style="text-align: right" title="Foreign exchange adjustments">2.5</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_c20220101__20221231_zCw5cOFO2Bik" title="Change in valuation allowance">15.0</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_c20210101__20211231_ztuNqjQJqPxl" title="Change in valuation allowance">24.5</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zUcGXbj7MLBk" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective tax rate"><span style="-sec-ix-hidden: xdx2ixbrl1262">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231_zcTxihv9n6Q5" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1264">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td> </tr> </table> 0.210 0.210 0.066 0.020 0.008 0.009 0.027 0.019 -0.107 0.025 -0.150 -0.245 134100000 119600000 4900000 8800000 3700000 <p id="xdx_89D_ecustom--ScheduleOfEffectiveIncomeTaxRateReconciliationNetOperatingLossTableTextBlock_zoai31uKXGHk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the Company’s NOLs for the years ended December 31, 2022 and 2021 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zENxZofOfSE8" style="display: none">Schedule of Reconciliation of NOL</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td id="xdx_49E_20220101__20221231_z4pvVMvjUmCd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20210101__20211231_z23UmfbZWLA2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDFSALz5Kw_z9YAVrEIZNX1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">U.S. Federal NOL’s</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">26,875</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">18,420</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDFSALz5Kw_zqrqLVvmSFb8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">U.S. State NOL’s</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">25,464</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,009</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_pn3n3_maDFSALz5Kw_zCSqXJlyKhQ1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Israel NOL’s</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81,794</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">84,148</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_pn3n3_mtDFSALz5Kw_zMdXA2v6i9ga" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total NOL’s</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">134,133</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">119,577</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 26875000 18420000 25464000 17009000 81794000 84148000 134133000 119577000 3300000 25464000 begin to expire after 2036 through 2042 23575000000 81794000 38100000 <p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zEALJ5gKKkJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13 – <span id="xdx_824_zUUN3dPhDGWf">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In January <span style="background-color: white">2023</span>, the Company committed to a restructuring initiative designed to position the Company to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. <span style="background-color: white">The Company has engaged Lake Street Capital Markets LLC (“Lake Street Capital”) to advise the Company in this process. Potential strategic alternatives that may be considered by the Company are expected to include an acquisition, merger, reverse merger, other business combination, sale of assets, licensing and other strategic </span> <span style="background-color: white">transactions. The</span> restructuring initiative primarily includes the reduction of the Company’s workforce. The Company intends to continue to evaluate and identify other areas of its business to enhance efficiencies and improve processes, with a goal to further lower its operating expenses and capital needs. The Company expects to reduce its quarterly cash expenditures by approximately 35% by eliminating approximately 45% of its workforce during the first quarter of 2023. In connection with the restructuring, the Company expects to incur a non-recurring charge of approximately $<span id="xdx_90F_ecustom--NonrecurringCharges_pn5n6_c20230101__20230331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zaufcD2kEEh6" title="Non recurring charges">1.0</span> to $<span id="xdx_903_ecustom--NonrecurringCharges_pn5n6_c20230101__20230331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zTCRNn44gmY3" title="Non recurring charges">2.0</span> million in the first quarter of 2023.</span></p> 1000000.0 2000000.0 EXCEL 79 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

&PO=V]R:W-H965T M&UL4$L! A0# M% @ 8H%_5D:TYM7) @ &P< !D ("!L=L 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 8H%_5KJU M3&,I P ) \ !D ("!4^< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 8H%_5G43S?O/ @ Z0@ !D M ("!4/$ 'AL+W=O&PO M=V]R:W-H965TCV !X;"]W;W)K&UL4$L! A0#% @ 8H%_5A5(3RF8 @ C08 !D ("! M^OH 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 8H%_5LJ.-/)L @ T@4 !D ("!E00! 'AL+W=O&PO=V]R:W-H965T@( ,8% 9 " @:4+ 0!X M;"]W;W)K&UL4$L! A0#% @ 8H%_5GWO62YI M P 'PT !D ("!5@X! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 8H%_5A.T@^4E P >@P !D M ("!]!T! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 8H%_5MF!8FK= @ 1 @ !D ("!SRP! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M8H%_5DW-EC7J P T@T !D ("!P$,! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 8H%_5IKMH38P!0 M5QX !D ("!<4X! 'AL+W=O Y@-W4" N!P &0 @('8 M4P$ >&PO=V]R:W-H965T7!E&UL4$L%!@ !" $( !1( "9D $ 0 $! end XML 80 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 81 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 82 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 131 362 1 false 54 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://motusgi.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://motusgi.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://motusgi.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://motusgi.com/role/StatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Shareholders' Equity Sheet http://motusgi.com/role/StatementsOfChangesInShareholdersEquity Consolidated Statements of Changes in Shareholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Parenthetical) Sheet http://motusgi.com/role/StatementsOfChangesInShareholdersEquityParenthetical Consolidated Statements of Changes in Shareholders' Equity (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Cash Flows Sheet http://motusgi.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 00000008 - Disclosure - Description of Business Sheet http://motusgi.com/role/DescriptionOfBusiness Description of Business Notes 8 false false R9.htm 00000009 - Disclosure - Going Concern Sheet http://motusgi.com/role/GoingConcern Going Concern Notes 9 false false R10.htm 00000010 - Disclosure - Significant Accounting Policies and Basis of Presentation Sheet http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentation Significant Accounting Policies and Basis of Presentation Notes 10 false false R11.htm 00000011 - Disclosure - Fair Value Measurements Sheet http://motusgi.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 00000012 - Disclosure - Inventory Sheet http://motusgi.com/role/Inventory Inventory Notes 12 false false R13.htm 00000013 - Disclosure - Fixed assets, net Sheet http://motusgi.com/role/FixedAssetsNet Fixed assets, net Notes 13 false false R14.htm 00000014 - Disclosure - Leases Sheet http://motusgi.com/role/Leases Leases Notes 14 false false R15.htm 00000015 - Disclosure - Convertible Note, Term Debt and Long-Term Debt Sheet http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebt Convertible Note, Term Debt and Long-Term Debt Notes 15 false false R16.htm 00000016 - Disclosure - Commitments and Contingencies Sheet http://motusgi.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 00000017 - Disclosure - Related Party Transactions Sheet http://motusgi.com/role/RelatedPartyTransactions Related Party Transactions Notes 17 false false R18.htm 00000018 - Disclosure - Share-based compensation and Common Stock Issuance Sheet http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuance Share-based compensation and Common Stock Issuance Notes 18 false false R19.htm 00000019 - Disclosure - Income Taxes Sheet http://motusgi.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 00000020 - Disclosure - Subsequent Events Sheet http://motusgi.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 00000021 - Disclosure - Significant Accounting Policies and Basis of Presentation (Policies) Sheet http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies Significant Accounting Policies and Basis of Presentation (Policies) Policies http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentation 21 false false R22.htm 00000022 - Disclosure - Significant Accounting Policies and Basis of Presentation (Tables) Sheet http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationTables Significant Accounting Policies and Basis of Presentation (Tables) Tables http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentation 22 false false R23.htm 00000023 - Disclosure - Fair Value Measurements (Tables) Sheet http://motusgi.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://motusgi.com/role/FairValueMeasurements 23 false false R24.htm 00000024 - Disclosure - Inventory (Tables) Sheet http://motusgi.com/role/InventoryTables Inventory (Tables) Tables http://motusgi.com/role/Inventory 24 false false R25.htm 00000025 - Disclosure - Fixed assets, net (Tables) Sheet http://motusgi.com/role/FixedAssetsNetTables Fixed assets, net (Tables) Tables http://motusgi.com/role/FixedAssetsNet 25 false false R26.htm 00000026 - Disclosure - Leases (Tables) Sheet http://motusgi.com/role/LeasesTables Leases (Tables) Tables http://motusgi.com/role/Leases 26 false false R27.htm 00000027 - Disclosure - Convertible Note, Term Debt and Long-Term Debt (Tables) Sheet http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtTables Convertible Note, Term Debt and Long-Term Debt (Tables) Tables http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebt 27 false false R28.htm 00000028 - Disclosure - Share-based compensation and Common Stock Issuance (Tables) Sheet http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceTables Share-based compensation and Common Stock Issuance (Tables) Tables http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuance 28 false false R29.htm 00000029 - Disclosure - Income Taxes (Tables) Sheet http://motusgi.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://motusgi.com/role/IncomeTaxes 29 false false R30.htm 00000030 - Disclosure - Going Concern (Details Narrative) Sheet http://motusgi.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://motusgi.com/role/GoingConcern 30 false false R31.htm 00000031 - Disclosure - Schedule of Fixed Assets are Stated at Cost Less Accumulated Depreciation (Details) Sheet http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails Schedule of Fixed Assets are Stated at Cost Less Accumulated Depreciation (Details) Details 31 false false R32.htm 00000032 - Disclosure - Significant Accounting Policies and Basis of Presentation (Details Narrative) Sheet http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative Significant Accounting Policies and Basis of Presentation (Details Narrative) Details http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationTables 32 false false R33.htm 00000033 - Disclosure - Schedule of Fair Value of Financial Assets and Liabilities (Details) Sheet http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails Schedule of Fair Value of Financial Assets and Liabilities (Details) Details 33 false false R34.htm 00000034 - Disclosure - Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation (Details) Sheet http://motusgi.com/role/ScheduleOfEstimatedFairValueOfLevel3ContingentRoyaltyObligationDetails Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation (Details) Details 34 false false R35.htm 00000035 - Disclosure - Fair Value Measurements (Details Narrative) Sheet http://motusgi.com/role/FairValueMeasurementsDetailsNarrative Fair Value Measurements (Details Narrative) Details http://motusgi.com/role/FairValueMeasurementsTables 35 false false R36.htm 00000036 - Disclosure - Schedule of Inventory (Details) Sheet http://motusgi.com/role/ScheduleOfInventoryDetails Schedule of Inventory (Details) Details 36 false false R37.htm 00000037 - Disclosure - Inventory (Details Narrative) Sheet http://motusgi.com/role/InventoryDetailsNarrative Inventory (Details Narrative) Details http://motusgi.com/role/InventoryTables 37 false false R38.htm 00000038 - Disclosure - Schedule of Fixed Assets Net (Details) Sheet http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails Schedule of Fixed Assets Net (Details) Details 38 false false R39.htm 00000039 - Disclosure - Fixed assets, net (Details Narrative) Sheet http://motusgi.com/role/FixedAssetsNetDetailsNarrative Fixed assets, net (Details Narrative) Details http://motusgi.com/role/FixedAssetsNetTables 39 false false R40.htm 00000040 - Disclosure - Schedule of Lease Cost and Supplemental Balance Sheet Information (Details) Sheet http://motusgi.com/role/ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationDetails Schedule of Lease Cost and Supplemental Balance Sheet Information (Details) Details 40 false false R41.htm 00000041 - Disclosure - Schedule of Future Minimum Lease Payments for Operating Leases (Details) Sheet http://motusgi.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails Schedule of Future Minimum Lease Payments for Operating Leases (Details) Details 41 false false R42.htm 00000042 - Disclosure - Schedule of Measurement of Lease Liability (Details) Sheet http://motusgi.com/role/ScheduleOfMeasurementOfLeaseLiabilityDetails Schedule of Measurement of Lease Liability (Details) Details 42 false false R43.htm 00000043 - Disclosure - Leases (Details Narrative) Sheet http://motusgi.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://motusgi.com/role/LeasesTables 43 false false R44.htm 00000044 - Disclosure - Schedule of Interest Expense for Loan (Details) Sheet http://motusgi.com/role/ScheduleOfInterestExpenseForLoanDetails Schedule of Interest Expense for Loan (Details) Details 44 false false R45.htm 00000045 - Disclosure - Schedule of Future Principal Payments (Details) Sheet http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails Schedule of Future Principal Payments (Details) Details 45 false false R46.htm 00000046 - Disclosure - Convertible Note, Term Debt and Long-Term Debt (Details Narrative) Sheet http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative Convertible Note, Term Debt and Long-Term Debt (Details Narrative) Details http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtTables 46 false false R47.htm 00000047 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://motusgi.com/role/CommitmentsAndContingencies 47 false false R48.htm 00000048 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://motusgi.com/role/RelatedPartyTransactions 48 false false R49.htm 00000049 - Disclosure - Schedule of Stock-based Compensation (Details) Sheet http://motusgi.com/role/ScheduleOfStock-basedCompensationDetails Schedule of Stock-based Compensation (Details) Details 49 false false R50.htm 00000050 - Disclosure - Schedule of Stock option and Warrants (Details) Sheet http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails Schedule of Stock option and Warrants (Details) Details 50 false false R51.htm 00000051 - Disclosure - Schedule of Option Pricing Model Using Weighted Average Assumptions (Details) Sheet http://motusgi.com/role/ScheduleOfOptionPricingModelUsingWeightedAverageAssumptionsDetails Schedule of Option Pricing Model Using Weighted Average Assumptions (Details) Details 51 false false R52.htm 00000052 - Disclosure - Schedule of Restricted Stock Unit Awards Activity (Details) Sheet http://motusgi.com/role/ScheduleOfRestrictedStockUnitAwardsActivityDetails Schedule of Restricted Stock Unit Awards Activity (Details) Details 52 false false R53.htm 00000053 - Disclosure - Share-based compensation and Common Stock Issuance (Details Narrative) Sheet http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative Share-based compensation and Common Stock Issuance (Details Narrative) Details http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceTables 53 false false R54.htm 00000054 - Disclosure - Schedule of Deferred Tax Assets (Details) Sheet http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails Schedule of Deferred Tax Assets (Details) Details 54 false false R55.htm 00000055 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://motusgi.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails Schedule of Effective Income Tax Rate Reconciliation (Details) Details 55 false false R56.htm 00000056 - Disclosure - Schedule of Reconciliation of NOL (Details) Sheet http://motusgi.com/role/ScheduleOfReconciliationOfNolDetails Schedule of Reconciliation of NOL (Details) Details 56 false false R57.htm 00000057 - Disclosure - Income Taxes (Details Narrative) Sheet http://motusgi.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://motusgi.com/role/IncomeTaxesTables 57 false false R58.htm 00000058 - Disclosure - Subsequent Events (Details Narrative) Sheet http://motusgi.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://motusgi.com/role/SubsequentEvents 58 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 14484 form10-k.htm ex23-1.htm ex31-1.htm ex31-2.htm ex32-1.htm mots-20221231.xsd mots-20221231_cal.xml mots-20221231_def.xml mots-20221231_lab.xml mots-20221231_pre.xml form10-k_001.jpg form10-k_002.jpg form10-k_003.jpg form10-k_004.jpg form10-k_005.jpg form10-k_006.jpg form10-k_009.jpg form10-k_010.jpg image_001.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 85 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 23, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 570, "http://xbrl.sec.gov/dei/2022": 39 }, "contextCount": 131, "dts": { "calculationLink": { "local": [ "mots-20221231_cal.xml" ] }, "definitionLink": { "local": [ "mots-20221231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "mots-20221231_lab.xml" ] }, "presentationLink": { "local": [ "mots-20221231_pre.xml" ] }, "schema": { "local": [ "mots-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 542, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 64, "http://motusgi.com/20221231": 22, "http://xbrl.sec.gov/dei/2022": 3, "total": 89 }, "keyCustom": 73, "keyStandard": 289, "memberCustom": 22, "memberStandard": 31, "nsprefix": "mots", "nsuri": "http://motusgi.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://motusgi.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Significant Accounting Policies and Basis of Presentation", "menuCat": "Notes", "order": "10", "role": "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentation", "shortName": "Significant Accounting Policies and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "11", "role": "http://motusgi.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Inventory", "menuCat": "Notes", "order": "12", "role": "http://motusgi.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Fixed assets, net", "menuCat": "Notes", "order": "13", "role": "http://motusgi.com/role/FixedAssetsNet", "shortName": "Fixed assets, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Leases", "menuCat": "Notes", "order": "14", "role": "http://motusgi.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Convertible Note, Term Debt and Long-Term Debt", "menuCat": "Notes", "order": "15", "role": "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebt", "shortName": "Convertible Note, Term Debt and Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "16", "role": "http://motusgi.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "17", "role": "http://motusgi.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Share-based compensation and Common Stock Issuance", "menuCat": "Notes", "order": "18", "role": "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuance", "shortName": "Share-based compensation and Common Stock Issuance", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "19", "role": "http://motusgi.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://motusgi.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "20", "role": "http://motusgi.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Significant Accounting Policies and Basis of Presentation (Policies)", "menuCat": "Policies", "order": "21", "role": "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies", "shortName": "Significant Accounting Policies and Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "mots:ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Significant Accounting Policies and Basis of Presentation (Tables)", "menuCat": "Tables", "order": "22", "role": "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationTables", "shortName": "Significant Accounting Policies and Basis of Presentation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "mots:ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "23", "role": "http://motusgi.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Inventory (Tables)", "menuCat": "Tables", "order": "24", "role": "http://motusgi.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Fixed assets, net (Tables)", "menuCat": "Tables", "order": "25", "role": "http://motusgi.com/role/FixedAssetsNetTables", "shortName": "Fixed assets, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "mots:ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "26", "role": "http://motusgi.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "mots:ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InterestAndOtherIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Convertible Note, Term Debt and Long-Term Debt (Tables)", "menuCat": "Tables", "order": "27", "role": "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtTables", "shortName": "Convertible Note, Term Debt and Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InterestAndOtherIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Share-based compensation and Common Stock Issuance (Tables)", "menuCat": "Tables", "order": "28", "role": "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceTables", "shortName": "Share-based compensation and Common Stock Issuance (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "29", "role": "http://motusgi.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://motusgi.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Going Concern (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://motusgi.com/role/GoingConcernDetailsNarrative", "shortName": "Going Concern (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "mots:ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Schedule of Fixed Assets are Stated at Cost Less Accumulated Depreciation (Details)", "menuCat": "Details", "order": "31", "role": "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails", "shortName": "Schedule of Fixed Assets are Stated at Cost Less Accumulated Depreciation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "mots:ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Significant Accounting Policies and Basis of Presentation (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative", "shortName": "Significant Accounting Policies and Basis of Presentation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_custom_ContingentRoyaltyObligationMember_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "mots:ContingentRoyaltyObligationFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Schedule of Fair Value of Financial Assets and Liabilities (Details)", "menuCat": "Details", "order": "33", "role": "http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails", "shortName": "Schedule of Fair Value of Financial Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_custom_ContingentRoyaltyObligationMember_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "mots:ContingentRoyaltyObligationFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation (Details)", "menuCat": "Details", "order": "34", "role": "http://motusgi.com/role/ScheduleOfEstimatedFairValueOfLevel3ContingentRoyaltyObligationDetails", "shortName": "Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ServicingLiabilityAtFairValueDescriptionOfOtherChangesInFairValue", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Fair Value Measurements (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://motusgi.com/role/FairValueMeasurementsDetailsNarrative", "shortName": "Fair Value Measurements (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ServicingLiabilityAtFairValueDescriptionOfOtherChangesInFairValue", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Schedule of Inventory (Details)", "menuCat": "Details", "order": "36", "role": "http://motusgi.com/role/ScheduleOfInventoryDetails", "shortName": "Schedule of Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "mots:CostOfRevenueImpairmentOfInventory", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Inventory (Details Narrative)", "menuCat": "Details", "order": "37", "role": "http://motusgi.com/role/InventoryDetailsNarrative", "shortName": "Inventory (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "mots:CostOfRevenueImpairmentOfInventory", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Schedule of Fixed Assets Net (Details)", "menuCat": "Details", "order": "38", "role": "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails", "shortName": "Schedule of Fixed Assets Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Fixed assets, net (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://motusgi.com/role/FixedAssetsNetDetailsNarrative", "shortName": "Fixed assets, net (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://motusgi.com/role/StatementsOfComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "mots:ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Schedule of Lease Cost and Supplemental Balance Sheet Information (Details)", "menuCat": "Details", "order": "40", "role": "http://motusgi.com/role/ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationDetails", "shortName": "Schedule of Lease Cost and Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "mots:ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Schedule of Future Minimum Lease Payments for Operating Leases (Details)", "menuCat": "Details", "order": "41", "role": "http://motusgi.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails", "shortName": "Schedule of Future Minimum Lease Payments for Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "mots:ScheduleofMeasurementofLeaseLiabilityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Schedule of Measurement of Lease Liability (Details)", "menuCat": "Details", "order": "42", "role": "http://motusgi.com/role/ScheduleOfMeasurementOfLeaseLiabilityDetails", "shortName": "Schedule of Measurement of Lease Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "mots:ScheduleofMeasurementofLeaseLiabilityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Leases (Details Narrative)", "menuCat": "Details", "order": "43", "role": "http://motusgi.com/role/LeasesDetailsNarrative", "shortName": "Leases (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:InterestAndOtherIncomeTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseOther", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Schedule of Interest Expense for Loan (Details)", "menuCat": "Details", "order": "44", "role": "http://motusgi.com/role/ScheduleOfInterestExpenseForLoanDetails", "shortName": "Schedule of Interest Expense for Loan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:InterestAndOtherIncomeTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseOther", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_us-gaap_LongTermDebtMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Schedule of Future Principal Payments (Details)", "menuCat": "Details", "order": "45", "role": "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails", "shortName": "Schedule of Future Principal Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_us-gaap_LongTermDebtMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsOfDebtIssuanceCosts", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Convertible Note, Term Debt and Long-Term Debt (Details Narrative)", "menuCat": "Details", "order": "46", "role": "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative", "shortName": "Convertible Note, Term Debt and Long-Term Debt (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-07-152021-07-16_custom_TrancheCMember", "decimals": "-3", "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromRoyaltiesReceived", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Commitments and Contingencies (Details Narrative)", "menuCat": "Details", "order": "47", "role": "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromRoyaltiesReceived", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "mots:LicenseFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Related Party Transactions (Details Narrative)", "menuCat": "Details", "order": "48", "role": "http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "mots:LicenseFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Schedule of Stock-based Compensation (Details)", "menuCat": "Details", "order": "49", "role": "http://motusgi.com/role/ScheduleOfStock-basedCompensationDetails", "shortName": "Schedule of Stock-based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Changes in Shareholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity", "shortName": "Consolidated Statements of Changes in Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - Schedule of Stock option and Warrants (Details)", "menuCat": "Details", "order": "50", "role": "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails", "shortName": "Schedule of Stock option and Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "mots:ScheduleOfStockholdersStockOptionAndEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_WarrantMember", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - Schedule of Option Pricing Model Using Weighted Average Assumptions (Details)", "menuCat": "Details", "order": "51", "role": "http://motusgi.com/role/ScheduleOfOptionPricingModelUsingWeightedAverageAssumptionsDetails", "shortName": "Schedule of Option Pricing Model Using Weighted Average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - Schedule of Restricted Stock Unit Awards Activity (Details)", "menuCat": "Details", "order": "52", "role": "http://motusgi.com/role/ScheduleOfRestrictedStockUnitAwardsActivityDetails", "shortName": "Schedule of Restricted Stock Unit Awards Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - Share-based compensation and Common Stock Issuance (Details Narrative)", "menuCat": "Details", "order": "53", "role": "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative", "shortName": "Share-based compensation and Common Stock Issuance (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - Schedule of Deferred Tax Assets (Details)", "menuCat": "Details", "order": "54", "role": "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails", "shortName": "Schedule of Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)", "menuCat": "Details", "order": "55", "role": "http://motusgi.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "mots:ScheduleOfEffectiveIncomeTaxRateReconciliationNetOperatingLossTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - Schedule of Reconciliation of NOL (Details)", "menuCat": "Details", "order": "56", "role": "http://motusgi.com/role/ScheduleOfReconciliationOfNolDetails", "shortName": "Schedule of Reconciliation of NOL (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mots:ScheduleOfEffectiveIncomeTaxRateReconciliationNetOperatingLossTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - Income Taxes (Details Narrative)", "menuCat": "Details", "order": "57", "role": "http://motusgi.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2023-01-012023-03-31_us-gaap_SubsequentEventMember_srt_MinimumMember", "decimals": "-5", "first": true, "lang": null, "name": "mots:NonrecurringCharges", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - Subsequent Events (Details Narrative)", "menuCat": "Details", "order": "58", "role": "http://motusgi.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2023-01-012023-03-31_us-gaap_SubsequentEventMember_srt_MinimumMember", "decimals": "-5", "first": true, "lang": null, "name": "mots:NonrecurringCharges", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)", "menuCat": "Statements", "order": "6", "role": "http://motusgi.com/role/StatementsOfChangesInShareholdersEquityParenthetical", "shortName": "Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://motusgi.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AmortizationOfFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Description of Business", "menuCat": "Notes", "order": "8", "role": "http://motusgi.com/role/DescriptionOfBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Going Concern", "menuCat": "Notes", "order": "9", "role": "http://motusgi.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 54, "tag": { "country_IL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ISRAEL" } } }, "localname": "IL", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative", "http://motusgi.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r548", "r550", "r551" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r548", "r550", "r551" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r548", "r550", "r551" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r548", "r550", "r551" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r548", "r550", "r551" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://motusgi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "mots_AccruedEndOfLoanPaymentRecordedAsDebtDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued end of loan payment recorded as debt discount.", "label": "Accrued end of loan payment recorded as debt discount" } } }, "localname": "AccruedEndOfLoanPaymentRecordedAsDebtDiscount", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mots_AggregateOfOfferingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate of offering costs.", "label": "Aggregate of offering cost" } } }, "localname": "AggregateOfOfferingCost", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mots_CashCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash compensation.", "label": "Cash compensation" } } }, "localname": "CashCompensation", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mots_CashPaidForAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash paid for [Abstract]", "label": "CASH PAID FOR:" } } }, "localname": "CashPaidForAbstract", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "mots_CommonStockIssuedToSettleAccruedExpensesForBoardOfDirectorsCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued to settle accrued expenses for board of directors compensation.", "label": "Common stock issued to settle accrued expenses for board of directors\u2019 compensation" } } }, "localname": "CommonStockIssuedToSettleAccruedExpensesForBoardOfDirectorsCompensation", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mots_ComputersAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computers and Software [Member]", "label": "Computers and Software [Member]" } } }, "localname": "ComputersAndSoftwareMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails", "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails" ], "xbrltype": "domainItemType" }, "mots_ContingentRoyaltyObligation": { "auth_ref": [], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent royalty obligation.", "label": "Contingent royalty obligation" } } }, "localname": "ContingentRoyaltyObligation", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "mots_ContingentRoyaltyObligationFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of arrangements with third parties, of contingent royalty obligation.", "label": "ContingentRoyaltyObligationFairValueDisclosure", "verboseLabel": "Contingent royalty obligation" } } }, "localname": "ContingentRoyaltyObligationFairValueDisclosure", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mots_ContingentRoyaltyObligationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Royalty Obligation [Member]", "label": "Contingent Royalty Obligation [Member]" } } }, "localname": "ContingentRoyaltyObligationMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "mots_ContingentRoyaltyObligationNonCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent royalty obligation non-current.", "label": "ContingentRoyaltyObligationNonCurrent", "verboseLabel": "Contingent royalty obligation" } } }, "localname": "ContingentRoyaltyObligationNonCurrent", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mots_ContractCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract costs [Policy Text Block]", "label": "Contract Costs" } } }, "localname": "ContractCostsPolicyTextBlock", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "mots_ConvertibleDebtUnamortizedDiscountNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Convertible debt unamortized discount noncurrent.", "label": "Convertible note, unamortized discount, non-current" } } }, "localname": "ConvertibleDebtUnamortizedDiscountNoncurrent", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "mots_ConvertibleNoteNoncurrent": { "auth_ref": [], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible note noncurrent.", "label": "Convertible note, net of unamortized debt discount of $108 and $166, respectively" } } }, "localname": "ConvertibleNoteNoncurrent", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "mots_CostOfRevenueImpairmentOfInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs of revenue- Impairment of Inventory.", "label": "CostOfRevenueImpairmentOfInventory", "verboseLabel": "Impairment of inventory" } } }, "localname": "CostOfRevenueImpairmentOfInventory", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/InventoryDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mots_CostsOfRevenueImpairmentOfInventory": { "auth_ref": [], "calculation": { "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs of revenue impairment of inventory.", "label": "Costs of revenue - impairment of inventory" } } }, "localname": "CostsOfRevenueImpairmentOfInventory", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "mots_DebtInstrumentUnamortizedDiscountCurrentAndNonCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument unamortized discount current and non current.", "label": "Advance payments for debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrentAndNonCurrent", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mots_DebtIssuanceCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Issuance Costs [Policy Text Block]", "label": "Debt issuance costs" } } }, "localname": "DebtIssuanceCostsPolicyTextBlock", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "mots_DeemedDividend": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deemed dividend.", "label": "[custom:DeemedDividend]" } } }, "localname": "DeemedDividend", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mots_DeemedDividendsFromWarrantIssuance": { "auth_ref": [], "calculation": { "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deemed dividends from warrant issuance.", "label": "DeemedDividendsFromWarrantIssuance", "negatedLabel": "Deemed dividends from warrant issuance" } } }, "localname": "DeemedDividendsFromWarrantIssuance", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "mots_DeferredForeignIncomeTaxExpenseBenefitAvailableUse": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred foreign income tax benefit available use.", "label": "[custom:DeferredForeignIncomeTaxExpenseBenefitAvailableUse]" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefitAvailableUse", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mots_DeferredTaxAssetDeferredExpenseCapitalizedResearchAndDevelopmentCosts": { "auth_ref": [], "calculation": { "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Capitalized research and development costs.", "label": "Capitalized research and development" } } }, "localname": "DeferredTaxAssetDeferredExpenseCapitalizedResearchAndDevelopmentCosts", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mots_DeferredTaxLiabilitiesAcceleratedResearchAndDevelopmentExpense": { "auth_ref": [], "calculation": { "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities accelerated research and development expense.", "label": "DeferredTaxLiabilitiesAcceleratedResearchAndDevelopmentExpense", "negatedLabel": "Accelerated research and development expense" } } }, "localname": "DeferredTaxLiabilitiesAcceleratedResearchAndDevelopmentExpense", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mots_DeferredTaxLiabilitiesRightOfUseAsset": { "auth_ref": [], "calculation": { "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities right use of asset.", "label": "DeferredTaxLiabilitiesRightOfUseAsset", "negatedLabel": "Right of use asset" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAsset", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mots_DescriptionOfRoyaltyPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of royalty payment.", "label": "Description of royalty payment" } } }, "localname": "DescriptionOfRoyaltyPayment", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "mots_DisclosureLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases", "terseLabel": "Schedule Of Future Minimum Lease Payments For Operating Leases", "verboseLabel": "Schedule Of Lease Cost And Supplemental Balance Sheet Information" } } }, "localname": "DisclosureLeasesAbstract", "nsuri": "http://motusgi.com/20221231", "xbrltype": "stringItemType" }, "mots_EquityDistributionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Distribution Agreement [Member]", "label": "Equity Distribution Agreement [Member]" } } }, "localname": "EquityDistributionAgreementMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_ExpireDateDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expire date, description", "label": "Expire date, description" } } }, "localname": "ExpireDateDescription", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "mots_FederalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal [Member]", "label": "Federal [Member]" } } }, "localname": "FederalMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_FinanceIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance income expense net", "label": "Finance income expense net", "negatedLabel": "Finance expense, net" } } }, "localname": "FinanceIncomeExpenseNet", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "mots_FortLauderdaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fort Lauderdale [Member].", "label": "Fort Lauderdale [Member]" } } }, "localname": "FortLauderdaleMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_FractionalSharesPaidInCashPursuantToReverseStockSplit": { "auth_ref": [], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fractional shares paid in cash pursuant to reverse stock split.", "label": "FractionalSharesPaidInCashPursuantToReverseStockSplit", "negatedLabel": "Fractional shares paid in cash pursuant to reverse stock split" } } }, "localname": "FractionalSharesPaidInCashPursuantToReverseStockSplit", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mots_GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation": { "auth_ref": [], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain loss on change in estimated fair value of contingent royalty obligation.", "label": "GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation", "negatedLabel": "(Gain) loss on change in estimated fair value of contingent royalty obligation" } } }, "localname": "GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mots_ImpairmentOfInventory": { "auth_ref": [], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impairment of inventory.", "label": "Impairment of inventory" } } }, "localname": "ImpairmentOfInventory", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mots_IncreaseDecreaseInDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about increase decrease in discount rate.", "label": "Increase (decrease) in discount rate" } } }, "localname": "IncreaseDecreaseInDiscountRate", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "mots_InventoryCurrent": { "auth_ref": [], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory, current.", "label": "Inventory, current" } } }, "localname": "InventoryCurrent", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/BalanceSheets", "http://motusgi.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "mots_IsraeliNationalAuthorityForTechnicalInnovationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Israeli National Authority For Technical Innovation [Member].", "label": "Israeli National Authority For Technical Innovation [Member]" } } }, "localname": "IsraeliNationalAuthorityForTechnicalInnovationMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_IssuanceOfCommonStockForBoardOfDirectorsCompensation": { "auth_ref": [], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for board of directors compensation.", "label": "IssuanceOfCommonStockForBoardOfDirectorsCompensation", "verboseLabel": "Issuance of common stock for board of directors\u2019 compensation" } } }, "localname": "IssuanceOfCommonStockForBoardOfDirectorsCompensation", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mots_IssuanceOfCommonStockUponExerciseOfWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock upon exercise of warrants.", "label": "Issuance of common stock upon exercise of warrants, net of financing fees of $366" } } }, "localname": "IssuanceOfCommonStockUponExerciseOfWarrants", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "mots_IssuanceOfCommonStockUponExerciseOfWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock upon exercise of warrants, (shares).", "label": "Issuance of common stock upon exercise of warrants, shares" } } }, "localname": "IssuanceOfCommonStockUponExerciseOfWarrantsShares", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "mots_KreosLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kreos Loan Agreement [Member]", "label": "Kreos Loan Agreement [Member]" } } }, "localname": "KreosLoanAgreementMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_LiabilitiesDueToTerminationOfEmploymentAgreementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liabilities due to termination of employment agreements [Policy Text Block]", "label": "Liabilities due to termination of employment agreements" } } }, "localname": "LiabilitiesDueToTerminationOfEmploymentAgreementsPolicyTextBlock", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "mots_LicenseFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of license fees.", "label": "License fee" } } }, "localname": "LicenseFees", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mots_LicensingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licensing percentage.", "label": "Licensing percentage" } } }, "localname": "LicensingPercentage", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "mots_LoanPayments": { "auth_ref": [], "calculation": { "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loan payments.", "label": "End of loan payments" } } }, "localname": "LoanPayments", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "mots_LondonInterbankOfferedRate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "London inter bank offered rate.", "label": "LIBOR interest rate" } } }, "localname": "LondonInterbankOfferedRate", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mots_LossOnChangeInFairValueOfContingentRoyaltyObligation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Refers to amount of loss on change in fair value of contingent royalty obligation.", "label": "Gain on change in fair value of contingent royalty obligation" } } }, "localname": "LossOnChangeInFairValueOfContingentRoyaltyObligation", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mots_LossOnChangesInFairValueOfContingentRoyaltyObligation": { "auth_ref": [], "calculation": { "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss on changes in fair value of contingent royalty obligation.", "label": "LossOnChangesInFairValueOfContingentRoyaltyObligation", "negatedLabel": "Gain (loss) on change in estimated fair value of contingent royalty obligation" } } }, "localname": "LossOnChangesInFairValueOfContingentRoyaltyObligation", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "mots_MachineryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Machinery [Member]", "label": "Machinery [Member]" } } }, "localname": "MachineryMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails", "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails" ], "xbrltype": "domainItemType" }, "mots_NetSalesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net sales percentage.", "label": "Net sales percentage" } } }, "localname": "NetSalesPercentage", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "mots_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Accounting Pronouncements Not Yet Adopted [Policy Text Block]", "label": "Accounting Pronouncements- Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "mots_NewWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Warrants [Member]", "label": "New Warrants [Member]" } } }, "localname": "NewWarrantsMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_NonEmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non Employee [Member].", "label": "Non Employee [Member]" } } }, "localname": "NonEmployeeMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_NonrecurringCharges": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non recurring charges.", "label": "Non recurring charges" } } }, "localname": "NonrecurringCharges", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mots_OfficeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office [Member].", "label": "Office [Member]" } } }, "localname": "OfficeMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_OperatingLossCarryforwardsUtilizationLimitation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards utilization limitation.", "label": "Operating loss utilization limit" } } }, "localname": "OperatingLossCarryforwardsUtilizationLimitation", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mots_OrchestraBioMedIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Orchestra Bio Med Inc [Member].", "label": "Orchestra Bio Med Inc [Member]" } } }, "localname": "OrchestraBioMedIncMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_PaymentsForEquityFinancingFees": { "auth_ref": [], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for equity financing fees.", "label": "PaymentsForEquityFinancingFees", "negatedLabel": "Equity financing fees" } } }, "localname": "PaymentsForEquityFinancingFees", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mots_PercentageOfPaymentAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of payment amount.", "label": "Percentage of payment amount" } } }, "localname": "PercentageOfPaymentAmount", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "mots_PrepaymentOfLeaseObligation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepayment of lease obligation.", "label": "Prepayment of lease obligation" } } }, "localname": "PrepaymentOfLeaseObligation", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mots_ProceedsFromLicensingBasedRoyaltyAmounts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from licensing based royalty amounts", "label": "Proceeds from licensing based royalty amounts" } } }, "localname": "ProceedsFromLicensingBasedRoyaltyAmounts", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mots_PurchaseOfFixedAssetsInPrepaidExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase of fixed assets in prepaid expenses.", "label": "Reclassification of prepaid expenses to fixed assets" } } }, "localname": "PurchaseOfFixedAssetsInPrepaidExpenses", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mots_PurchaseOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase of property and equipment in accounts payable and accrued expenses.", "label": "Purchase of fixed assets in accounts payable and accrued expenses" } } }, "localname": "PurchaseOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mots_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Receivables trade and other accounts receivable allowance for doubtful accounts [Policy Text Block]", "label": "Accounts receivable and allowance for doubtful accounts" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicyTextBlock", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "mots_ReplacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Replacement Warrants [Member]", "label": "Replacement Warrants [Member]" } } }, "localname": "ReplacementWarrantsMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_ReverseStockSplitPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reverse stock split [Policy Text Block]", "label": "Reverse Stock Split" } } }, "localname": "ReverseStockSplitPolicyTextBlock", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "mots_RoyaltiesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties on revenues, percentage", "label": "Royalties percentage" } } }, "localname": "RoyaltiesPercentage", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "mots_RoyaltyIncomeNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Royalties income", "label": "Royalties income" } } }, "localname": "RoyaltyIncomeNet", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mots_RoyaltyPaymentDicountPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage relating to royalty payment.", "label": "Royalty payment, percentage" } } }, "localname": "RoyaltyPaymentDicountPercentage", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "mots_RoyaltyPaymentRightsCertificatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Payment Rights Certificates [Member].", "label": "Royalty Payment Rights Certificates [Member]" } } }, "localname": "RoyaltyPaymentRightsCertificatesMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_ScheduleOfEffectiveIncomeTaxRateReconciliationNetOperatingLossTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Effective Income Tax Rate Reconciliation Net Operating Loss [Table Text Block]", "label": "Schedule of Reconciliation of NOL" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationNetOperatingLossTableTextBlock", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "mots_ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Fixed Assets are Stated at Cost Less Accumulated Depreciation [Table Text Block]", "label": "Schedule of Fixed Assets are Stated at Cost Less Accumulated Depreciation" } } }, "localname": "ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationTableTextBlock", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationTables" ], "xbrltype": "textBlockItemType" }, "mots_ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of lease cost and supplemental balance sheet information table text block.", "label": "Schedule of Lease Cost and Supplemental Balance Sheet Information" } } }, "localname": "ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationTableTextBlock", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "mots_ScheduleOfStockholdersStockOptionAndEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of stockholders stock option and equity note warrants or rights text block.", "label": "Schedule of Stock option and Warrants" } } }, "localname": "ScheduleOfStockholdersStockOptionAndEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceTables" ], "xbrltype": "textBlockItemType" }, "mots_ScheduleofMeasurementofLeaseLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of measurement of lease liability table text block.", "label": "Schedule of Measurement of Lease Liability" } } }, "localname": "ScheduleofMeasurementofLeaseLiabilityTableTextBlock", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "mots_ServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Services Agreement [Member].", "label": "Services Agreement [Member]" } } }, "localname": "ServicesAgreementMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the share based compensation arrangement by share based payment award non option equity instruments cancelled.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled", "negatedLabel": "Shares Underlying Warrants, cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "mots_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercisable.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable", "periodEndLabel": "Shares Underlying Warrants, exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "mots_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the share based compensation arrangement by share based payment award non options outstanding intrinsic value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue", "periodEndLabel": "Aggregate Intrinsic Value, outstanding ending", "periodStartLabel": "Aggregate Intrinsic Value, outstanding beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "mots_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award non options outstanding weighted average exercisable.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisable", "periodEndLabel": "Weighted Average Exercise Price, exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisable", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "mots_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Weighted Average Exercise Price, outstanding ending", "periodStartLabel": "Weighted Average Exercise Price, outstanding beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "mots_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the share based compensation arrangement by share based payment award options cancelled in period.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod", "negatedLabel": "Shares underlying options, cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "mots_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsCancelledWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award non options cancelled weighted average exercise price.", "label": "Weighted Average Exercise Price, cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsCancelledWeightedAverageExercisePrice", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "mots_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the share based compensation arrangement by share based payment award non options exercised in period weighted average exercise price.", "label": "Weighted Average Exercise Price, exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "mots_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExpiredPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award non options expired weighted average exercise price.", "label": "Weighted Average Exercise Price, expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExpiredPrice", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "mots_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award non options feitures in period weighted average exercise price.", "label": "Weighted Average Exercise Price, forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "mots_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.", "label": "Weighted Average Exercise Price, granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "mots_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the share based compensation arrangement by share based payment award options cancelled in period weighted average exercise price.", "label": "Weighted average exercise price, cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "mots_SharedSpaceAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shared Space Agreements [Member].", "label": "Shared Space Agreements [Member]" } } }, "localname": "SharedSpaceAgreementsMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_StateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "State [Member]", "label": "State [Member]" } } }, "localname": "StateMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_StockIssuedDuringPeriodFractionalSharesSettledInCashPursuantToReverseStockSplitShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period fractional shares settled in cash pursuant to reverse stock split shares.", "label": "Fractional shares settled in cash pursuant to reverse stock split, shares" } } }, "localname": "StockIssuedDuringPeriodFractionalSharesSettledInCashPursuantToReverseStockSplitShares", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "mots_StockIssuedDuringPeriodFractionalSharesSettledInCashPursuantToReverseStockSplitValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period fractional shares settled in cash pursuant to reverse stock split value.", "label": "Fractional shares settled in cash pursuant to reverse stock split" } } }, "localname": "StockIssuedDuringPeriodFractionalSharesSettledInCashPursuantToReverseStockSplitValue", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "mots_TrancheAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche A [Member]", "label": "Tranche A [Member]" } } }, "localname": "TrancheAMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_TrancheBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche B [Member]", "label": "Tranche B [Member]" } } }, "localname": "TrancheBMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_TrancheCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche C [Member]", "label": "Tranche C [Member]" } } }, "localname": "TrancheCMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_TwoThousandSixteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2016 Equity Incentive Plan [Member]", "label": "2016 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandSixteenEquityIncentivePlanMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "mots_UnamortizedDebtIssuanceCost": { "auth_ref": [], "calculation": { "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unamortized debt issuance cost.", "label": "UnamortizedDebtIssuanceCost", "negatedLabel": "Less unamortized debt issuance costs of non-current portion long-term debt" } } }, "localname": "UnamortizedDebtIssuanceCost", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "mots_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [Member]", "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://motusgi.com/20221231", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r258", "r259", "r260", "r261", "r317", "r469", "r480", "r500", "r501", "r519", "r530", "r536", "r593", "r644", "r645", "r646", "r647", "r648", "r649" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative", "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative", "http://motusgi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r258", "r259", "r260", "r261", "r317", "r469", "r480", "r500", "r501", "r519", "r530", "r536", "r593", "r644", "r645", "r646", "r647", "r648", "r649" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative", "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails", "http://motusgi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r228", "r474", "r520", "r534", "r588", "r589", "r596", "r651" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r228", "r474", "r520", "r534", "r588", "r589", "r596", "r651" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r258", "r259", "r260", "r261", "r310", "r317", "r347", "r348", "r349", "r445", "r469", "r480", "r500", "r501", "r519", "r530", "r536", "r585", "r593", "r645", "r646", "r647", "r648", "r649" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative", "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative", "http://motusgi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r258", "r259", "r260", "r261", "r310", "r317", "r347", "r348", "r349", "r445", "r469", "r480", "r500", "r501", "r519", "r530", "r536", "r585", "r593", "r645", "r646", "r647", "r648", "r649" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative", "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative", "http://motusgi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r229", "r230", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r521", "r535", "r596" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative", "http://motusgi.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r229", "r230", "r486", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r521", "r535", "r596" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative", "http://motusgi.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r580", "r641" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r232", "r233" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r65", "r151" ], "calculation": { "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r5", "r533" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r356", "r357", "r358", "r576", "r577", "r578", "r634" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r102", "r103", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r73", "r79", "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Issuance of warrants associated with convertible note and long- term debt" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based compensation expenses" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r158", "r234", "r240", "r242", "r243" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r31", "r41", "r123", "r293" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "verboseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfInterestExpenseForLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r26", "r293", "r411", "r571" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative", "http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r128", "r136", "r153", "r179", "r219", "r222", "r226", "r238", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r381", "r383", "r397", "r533", "r591", "r592", "r642" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r146", "r161", "r179", "r238", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r381", "r383", "r397", "r533", "r591", "r592", "r642" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r322", "r323", "r324", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r346", "r347", "r348", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative", "http://motusgi.com/role/ScheduleOfRestrictedStockUnitAwardsActivityDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r43", "r149", "r503" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets", "http://motusgi.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r36", "r43", "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF PERIOD", "periodStartLabel": "CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r36", "r122" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r155", "r156", "r157", "r179", "r197", "r198", "r201", "r203", "r208", "r209", "r238", "r262", "r264", "r265", "r266", "r269", "r270", "r300", "r301", "r302", "r303", "r305", "r397", "r502", "r557", "r572", "r579" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r85", "r86" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Exercise price", "verboseLabel": "Warrants exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Warrants to purchase of common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrant issued to purchase common shares" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r19", "r131", "r141" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingent liabilities (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r69", "r256", "r257", "r487", "r590" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common stock available for future grant" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r576", "r577", "r634" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative", "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity", "http://motusgi.com/role/StatementsOfChangesInShareholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r4", "r79" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r4", "r533" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock $0.0001 par value; 115,000,000\u00a0shares authorized; 4,659,769 and 2,416,021 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r72", "r271", "r272", "r283", "r284", "r285", "r289", "r290", "r291", "r292", "r293", "r514", "r515", "r516", "r517", "r518" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r29", "r179", "r238", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r397", "r591" ], "calculation": { "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Costs of revenue - sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r27" ], "calculation": { "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r77", "r178", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r287", "r294", "r295", "r297" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Convertible Note, Term Debt and Long-Term Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r2", "r129", "r135", "r298" ], "calculation": { "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "totalLabel": "Total future principal payments" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r74", "r273" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt instrument, convertible, conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r17", "r124", "r290" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r18" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt instrument, periodic payment, principal" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r18", "r80", "r81", "r82", "r83", "r123", "r124", "r126", "r134", "r181", "r271", "r272", "r273", "r274", "r275", "r277", "r283", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r296", "r412", "r514", "r515", "r516", "r517", "r518", "r573" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r123", "r126", "r594" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Advance payment" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r123", "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Debt instrument, unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "auth_ref": [ "r123", "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.", "label": "Debt instrument, unamortized discount, non-current" } } }, "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r575", "r630", "r631" ], "calculation": { "http://motusgi.com/role/ScheduleOfReconciliationOfNolDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "U.S. Federal NOL\u2019s", "verboseLabel": "Deferred Federal Income Tax Expense (Benefit)" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative", "http://motusgi.com/role/ScheduleOfReconciliationOfNolDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r626" ], "calculation": { "http://motusgi.com/role/ScheduleOfReconciliationOfNolDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Total NOL\u2019s" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfReconciliationOfNolDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r112", "r575", "r630" ], "calculation": { "http://motusgi.com/role/ScheduleOfReconciliationOfNolDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Israel NOL\u2019s", "verboseLabel": "Deferred Foreign Income Tax Expense (Benefit)" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative", "http://motusgi.com/role/ScheduleOfReconciliationOfNolDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r575", "r630", "r631" ], "calculation": { "http://motusgi.com/role/ScheduleOfReconciliationOfNolDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "U.S. State NOL\u2019s", "verboseLabel": "Deferred State and Local Income Tax Expense (Benefit)" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative", "http://motusgi.com/role/ScheduleOfReconciliationOfNolDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r367" ], "calculation": { "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Net deferred tax assets before valuation allowance", "verboseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative", "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r628" ], "calculation": { "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets after valuation allowance" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r628" ], "calculation": { "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "auth_ref": [ "r111", "r629" ], "calculation": { "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.", "label": "Net operating loss carryforwards \u2013 Israel" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r111", "r629" ], "calculation": { "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Net operating loss carryforwards \u2013 Federal and state" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r111", "r629" ], "calculation": { "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "verboseLabel": "Share-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r111", "r629" ], "calculation": { "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Accrued liabilities and reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r368" ], "calculation": { "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred tax assets valuation allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative", "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r105", "r628" ], "calculation": { "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r111", "r629" ], "calculation": { "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r41", "r63" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/FixedAssetsNetDetailsNarrative", "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r113", "r114", "r115", "r116", "r505" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DirectTaxesAndLicensesCosts": { "auth_ref": [ "r567" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax incurred and cost of license directly related to good produced or service rendered.", "label": "License fees" } } }, "localname": "DirectTaxesAndLicensesCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r309", "r520", "r521", "r522", "r523", "r524", "r525", "r526" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r321", "r352", "r353", "r355", "r360", "r531" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based compensation and Common Stock Issuance" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuance" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted loss per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r170", "r187", "r188", "r189", "r190", "r191", "r197", "r201", "r202", "r203", "r204", "r387", "r388", "r476", "r479", "r510" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss attributable to common shareholders" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r52", "r53" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Basic and diluted net loss per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r180", "r363", "r376" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "U.S. federal statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r627", "r632" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "negatedLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r627", "r632" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "U.S. vs. foreign tax rate differential" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r627", "r632" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "negatedLabel": "Non-deductible expenses" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Foreign exchange adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r627", "r632" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "State income taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStock-basedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r625" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Unamortization stock compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r625" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Stock based compensation for stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails", "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r79", "r144", "r165", "r166", "r167", "r182", "r183", "r184", "r186", "r192", "r194", "r207", "r239", "r307", "r356", "r357", "r358", "r373", "r374", "r386", "r402", "r403", "r404", "r405", "r406", "r407", "r430", "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative", "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative", "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity", "http://motusgi.com/role/StatementsOfChangesInShareholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r41", "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair value of warrant" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfEstimatedFairValueOfLevel3ContingentRoyaltyObligationDetails", "http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r389", "r390", "r395" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfEstimatedFairValueOfLevel3ContingentRoyaltyObligationDetails", "http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r285", "r311", "r312", "r313", "r314", "r315", "r316", "r390", "r442", "r443", "r444", "r515", "r516", "r527", "r528", "r529" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfEstimatedFairValueOfLevel3ContingentRoyaltyObligationDetails", "http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r389", "r390", "r392", "r393", "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r285", "r311", "r316", "r390", "r442", "r527", "r528", "r529" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r285", "r311", "r316", "r390", "r443", "r515", "r516", "r527", "r528", "r529" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r285", "r311", "r312", "r313", "r314", "r315", "r316", "r390", "r444", "r515", "r516", "r527", "r528", "r529" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfEstimatedFairValueOfLevel3ContingentRoyaltyObligationDetails", "http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency." } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Change in estimated fair value of contingent royalty obligation" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfEstimatedFairValueOfLevel3ContingentRoyaltyObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r118" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance at December 31, 2022", "periodStartLabel": "Balance at December 31, 2021" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfEstimatedFairValueOfLevel3ContingentRoyaltyObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r285", "r311", "r312", "r313", "r314", "r315", "r316", "r442", "r443", "r444", "r515", "r516", "r527", "r528", "r529" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfEstimatedFairValueOfLevel3ContingentRoyaltyObligationDetails", "http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r394", "r396" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfAssetsAcquired": { "auth_ref": [ "r45", "r46", "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The fair value of assets acquired in noncash investing or financing activities.", "label": "Reclassification of inventory to fixed assets" } } }, "localname": "FairValueOfAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r119", "r121" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair value of financial instrument" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r235", "r236", "r241", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r296", "r304", "r385", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r513", "r581", "r582", "r583", "r652", "r653", "r654", "r655", "r656", "r657", "r658" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative", "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r398", "r399", "r400", "r401" ], "calculation": { "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": 6.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign currency loss" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Functional currency and foreign currency translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r41", "r75", "r76" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Loss on extinguishment of debt", "negatedLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows", "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r30" ], "calculation": { "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStock-basedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r41", "r62", "r67" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of fixed assets" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/FixedAssetsNetDetailsNarrative", "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r254", "r255" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStock-basedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStock-basedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://motusgi.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://motusgi.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r180", "r364", "r365", "r371", "r375", "r377", "r378", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r164", "r361", "r362", "r365", "r366", "r370", "r372" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r627" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Accumulated gross amount" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": { "auth_ref": [ "r627" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.", "label": "Research and development costs" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r40" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r40" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r40" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r570", "r639" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r40" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Other current and non-current liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r40" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r60", "r471", "r472", "r473", "r475", "r506" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Patent costs" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestAndOtherIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest income and income classified as other.", "label": "Schedule of Interest Expense for Loan" } } }, "localname": "InterestAndOtherIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r125", "r133", "r168", "r218", "r410" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Total interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfInterestExpenseForLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Contractual interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfInterestExpenseForLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r173", "r175", "r176" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r561" ], "calculation": { "http://motusgi.com/role/ScheduleOfInventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r160", "r504", "r533" ], "calculation": { "http://motusgi.com/role/ScheduleOfInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r558" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, non-current" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets", "http://motusgi.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r148", "r159", "r205", "r251", "r252", "r253", "r470", "r507" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r563" ], "calculation": { "http://motusgi.com/role/ScheduleOfInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r59", "r564" ], "calculation": { "http://motusgi.com/role/ScheduleOfInventoryDetails": { "order": 4.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedLabel": "Inventory reserve" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r562" ], "calculation": { "http://motusgi.com/role/ScheduleOfInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r41" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of common stock for consultants" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r425", "r532" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Operating lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/LeasesDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails", "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Operating lease, description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r640" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of Future Minimum Lease Payments for Operating Leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r426" ], "calculation": { "http://motusgi.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r426" ], "calculation": { "http://motusgi.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r426" ], "calculation": { "http://motusgi.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r426" ], "calculation": { "http://motusgi.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r426" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Description of lease term option to extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r14", "r179", "r238", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r382", "r383", "r384", "r397", "r511", "r591", "r642", "r643" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r9", "r130", "r139", "r533", "r574", "r584", "r637" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r16", "r147", "r179", "r238", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r382", "r383", "r384", "r397", "r533", "r591", "r642", "r643" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r2", "r129", "r137", "r284", "r299", "r515", "r516" ], "calculation": { "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Total balance" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Current portion of long-term debt, net of unamortized debt discount of $182 and $271, respectively", "verboseLabel": "Long term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets", "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r70", "r181", "r289" ], "calculation": { "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "verboseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r70", "r181", "r289" ], "calculation": { "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "verboseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r70", "r181", "r289" ], "calculation": { "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "verboseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.", "label": "Long-Term Debt [Member]" } } }, "localname": "LongTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r154" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-term debt, net of unamortized debt discount of $135 and $317, respectively" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r18", "r71" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ManufacturingCosts": { "auth_ref": [ "r28" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred in the production of goods for sale.", "label": "Manufacturing Costs" } } }, "localname": "ManufacturingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r635" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r635" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r635" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r635" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/FairValueMeasurementsDetailsNarrative", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/FairValueMeasurementsDetailsNarrative", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r210", "r215" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Description of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/DescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r174" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r174" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r36", "r39", "r42" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r24", "r42", "r132", "r142", "r145", "r162", "r163", "r167", "r179", "r185", "r187", "r188", "r189", "r190", "r193", "r194", "r199", "r219", "r221", "r225", "r227", "r238", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r388", "r397", "r512", "r591" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "negatedLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/GoingConcernDetailsNarrative", "http://motusgi.com/role/StatementsOfCashFlows", "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity", "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r187", "r188", "r189", "r190", "r195", "r196", "r200", "r203", "r219", "r221", "r225", "r227", "r512" ], "calculation": { "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements- Recently Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails", "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r566" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Expense for director services" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OffsettingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Assets [Line Items]" } } }, "localname": "OffsettingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r22", "r23" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r219", "r221", "r225", "r227", "r512" ], "calculation": { "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r419", "r532" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost, net of related party license fee" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r638" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating lease, expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of comprehensive income that includes operating lease income.", "label": "Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "OperatingLeaseIncomeComprehensiveIncomeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLeaseIncome": { "auth_ref": [ "r206", "r428", "r429" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income", "verboseLabel": "Revenue recognized in accordance with ASC 842" } } }, "localname": "OperatingLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r414" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Total lease liabilities", "totalLabel": "Total liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails", "http://motusgi.com/role/ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r414" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities - current", "verboseLabel": "Operating lease liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets", "http://motusgi.com/role/ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r414" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities - non-current", "verboseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets", "http://motusgi.com/role/ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r415", "r421" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "negatedLabel": "Cash paid for amounts included in measurement of lease liabilities:" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfMeasurementOfLeaseLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r413" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-use assets", "verboseLabel": "Operating lease, right-of-use- asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets", "http://motusgi.com/role/ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r571" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization on operating lease right of use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r424", "r532" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r423", "r532" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining lease term - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r109" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating loss" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r152" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r15", "r533" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r171" ], "calculation": { "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other income" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForCommissions": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for commissions during the current period.", "label": "Commissions paid" } } }, "localname": "PaymentsForCommissions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r34" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of debt issuance costs", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative", "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Financing fees" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r32" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of fixed assets" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r3", "r300" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r3", "r300" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r3", "r533" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock $0.0001\u00a0par value; 10,000,000 shares authorized; zero shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r565" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r172" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from net of issuance costs" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r33" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common shares", "verboseLabel": "Proceeds from common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative", "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r33" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Borrowings under convertible note and long-term debt" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRoyaltiesReceived": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received for royalties during the current period.", "label": "Royalty received" } } }, "localname": "ProceedsFromRoyaltiesReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r568" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise and purchase of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductLiabilityContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Liability Contingency [Line Items]" } } }, "localname": "ProductLiabilityContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProductLiabilityContingencyTable": { "auth_ref": [ "r260", "r586", "r587", "r588" ], "lang": { "en-us": { "role": { "documentation": "Information and financial data about the reasonably possible loss or the recognized and additional reasonably possible loss from product liability related to an individual product.", "label": "Product Liability Contingency [Table]" } } }, "localname": "ProductLiabilityContingencyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/LeasesDetailsNarrative", "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails", "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r68", "r488", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "verboseLabel": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/FixedAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Useful lies, description" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r64", "r150" ], "calculation": { "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/LeasesDetailsNarrative", "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails", "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r66", "r140", "r478", "r533" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Fixed assets, net", "totalLabel": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets", "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r66", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Fixed Assets Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/FixedAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/LeasesDetailsNarrative", "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails", "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r431", "r432", "r433", "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r569" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedLabel": "Repayment of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r104", "r143", "r650" ], "calculation": { "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStock-basedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfRestrictedStockUnitAwardsActivityDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r6", "r84", "r138", "r484", "r485", "r533" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets", "http://motusgi.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r144", "r182", "r183", "r184", "r186", "r192", "r194", "r239", "r356", "r357", "r358", "r373", "r374", "r386", "r481", "r483" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r216", "r217", "r220", "r223", "r224", "r228", "r229", "r231", "r308", "r309", "r474" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue recognized in accordance with ASC 606" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r508", "r509" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r169", "r179", "r216", "r217", "r220", "r223", "r224", "r228", "r229", "r231", "r238", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r397", "r477", "r591" ], "calculation": { "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue", "verboseLabel": "Revenue recognized" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative", "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r422", "r532" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Operating lease liabilities arising from obtaining right-of-use assets" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r597" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Number of common stock sold, shares" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock": { "auth_ref": [ "r598" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.", "label": "Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation" } } }, "localname": "ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r99", "r101" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStock-basedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value of Financial Assets and Liabilities" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r1", "r10", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Future Principal Payments" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/LeasesDetailsNarrative", "http://motusgi.com/role/ScheduleOfFixedAssetsAreStatedAtCostLessAccumulatedDepreciationDetails", "http://motusgi.com/role/ScheduleOfFixedAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r94", "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Schedule of Stock-based Compensation" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r318", "r320", "r322", "r323", "r324", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r346", "r347", "r348", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfRestrictedStockUnitAwardsActivityDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Restricted Stock Unit Awards Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Option Pricing Model Using Weighted Average Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://motusgi.com/role/StatementsOfComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStock-basedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r559", "r560", "r595" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ServicingLiabilityAtFairValueDescriptionOfOtherChangesInFairValue": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "A description of the other changes in fair value (other than additions, disposals, or changes resulting from changes in valuation inputs or changes in assumptions).", "label": "Fair value of the liability, description" } } }, "localname": "ServicingLiabilityAtFairValueDescriptionOfOtherChangesInFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance payments" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r40" ], "calculation": { "http://motusgi.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Total", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStock-basedCompensationDetails", "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Number of Shares, nonvested granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfRestrictedStockUnitAwardsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Aggregate weighted average grant date fair value, nonvested granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfRestrictedStockUnitAwardsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r334", "r335" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Shares, nonvested ending", "periodStartLabel": "Number of Shares, nonvested beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfRestrictedStockUnitAwardsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r334", "r335" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Aggregate weighted average grant date fair value, nonvested ending", "periodStartLabel": "Aggregate weighted average grant date fair value, nonvested beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfRestrictedStockUnitAwardsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Shares, nonvested vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfRestrictedStockUnitAwardsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Aggregate weighted average grant date fair value, nonvested vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfRestrictedStockUnitAwardsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfOptionPricingModelUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfOptionPricingModelUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfOptionPricingModelUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfRestrictedStockUnitAwardsActivityDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Shares Underlying Warrants, exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "negatedLabel": "Shares Underlying Warrants, expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Shares Underlying Warrants, forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Shares Underlying Warrants, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r88", "r89" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Shares Underlying Warrants, outstanding ending", "periodStartLabel": "Shares Underlying Warrants, outstanding beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Shares underlying options, exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Shares underlying options, expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share based compnesation plan modification, incremental cost", "negatedLabel": "Shares underlying options, forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Shares underlying options, granted", "verboseLabel": "Share based compensation options, grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate intrinsic value, outstanding ending", "periodStartLabel": "Aggregate intrinsic value, outstanding beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Shares underlying options, outstanding ending", "periodStartLabel": "Shares underlying options, outstanding beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, outstanding ending", "periodStartLabel": "Weighted average exercise price, outstanding beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Common stock percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r322", "r323", "r324", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r346", "r347", "r348", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative", "http://motusgi.com/role/ScheduleOfRestrictedStockUnitAwardsActivityDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted average exercise price, exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted average exercise price, expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted average exercise price, forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted average exercise price, granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r325", "r344", "r345", "r346", "r347", "r350", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term, in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfOptionPricingModelUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual life, outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Vested and unissued restricted stock units" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Fair value of common stock" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r49", "r177" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies and Basis of Presentation" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r155", "r156", "r157", "r179", "r197", "r198", "r201", "r203", "r208", "r209", "r238", "r262", "r264", "r265", "r266", "r269", "r270", "r300", "r301", "r302", "r303", "r305", "r397", "r502", "r557", "r572", "r579" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r21", "r79", "r144", "r165", "r166", "r167", "r182", "r183", "r184", "r186", "r192", "r194", "r207", "r239", "r307", "r356", "r357", "r358", "r373", "r374", "r386", "r402", "r403", "r404", "r405", "r406", "r407", "r430", "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative", "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative", "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity", "http://motusgi.com/role/StatementsOfChangesInShareholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative", "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity", "http://motusgi.com/role/StatementsOfChangesInShareholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r182", "r183", "r184", "r207", "r474" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative", "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity", "http://motusgi.com/role/StatementsOfChangesInShareholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r45", "r46", "r47" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Warrants issued related to convertible note and long-term debt recorded as debt discount" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r3", "r4", "r79", "r84" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Issuance of common stock for board of directors' compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r79", "r84" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Issuance of common shares upon vesting of restricted stock units, shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r3", "r4", "r79", "r84", "r331" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Shares underlying options, exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r3", "r4", "r79", "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs of $368" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Issuance of common stock for board of directors\u2019 compensation" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r3", "r4", "r79", "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Issuance of common shares upon vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r4", "r7", "r8", "r57", "r533", "r574", "r584", "r637" ], "calculation": { "http://motusgi.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets", "http://motusgi.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r408", "r437" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r408", "r437" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r408", "r437" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r408", "r437" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r436", "r438" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r525", "r596" ], "lang": { "en-us": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing of Transfer of Good or Service [Axis]" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [ "r525", "r596" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredAtPointInTimeMember": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred at point in time.", "label": "Transferred at Point in Time [Member]" } } }, "localname": "TransferredAtPointInTimeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredOverTimeMember": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred over time.", "label": "Transferred over Time [Member]" } } }, "localname": "TransferredOverTimeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r235", "r236", "r296", "r304", "r385", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r581", "r582", "r583", "r652", "r653", "r654", "r655", "r656", "r657", "r658" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative", "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative", "http://motusgi.com/role/RelatedPartyTransactionsDetailsNarrative", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [], "calculation": { "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "negatedLabel": "Less unamortized debt issuance costs of current portion of long-term debt" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfFuturePrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r54", "r55", "r56", "r211", "r212", "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Basis of presentation and use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/SignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r420", "r532" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ScheduleOfLeaseCostAndSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/ConvertibleNoteTermDebtAndLong-termDebtDetailsNarrative", "http://motusgi.com/role/ScheduleOfStockOptionAndWarrantsDetails", "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/Share-basedCompensationAndCommonStockIssuanceDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r50", "r51" ], "lang": { "en-us": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Weighted average number of common shares outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://motusgi.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "https://asc.fasb.org/topic&trid=2155941", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123420820&loc=SL77919311-209978", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r537": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r538": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r539": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r541": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r542": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r543": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r544": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r545": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r546": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r547": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r548": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r549": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r551": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r552": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r553": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r554": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r555": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r556": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 86 0001493152-23-010263-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-010263-xbrl.zip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�#\&. ME%WP0>C#ZH#@R_^[.?OYXO1V7]\%=6NPQK++[2>!TS\!,4@IZO[,V0[^XAJ MQ$=.%,G)79U*@ ^U=UF@;BNTR>9A)V=7K#N 1ST?6XQ%;A\PC9WINMB*IH\W M^4*>UZVZ5%/6#0*O;],59'OX)#R#A)(Y6Q;ZUH#Z@JFG=6B #*FE)_MPV#U$ MXM8;H%%K$=7ME/H_ T5@QUZ:/\G^<(&-^0%.+P8\((?\/^RW!L\@F@+N'690 M''"'BSYR.&!<)83K3:+P.O9\SQ)M5KE/H5'^'7M1Q1?<@0L KQW9$^J"@@A4 M.PX3[ 2T]FO)-2\\V*04^M_@OLA$+8/-3W4I=90BZ"CJI'+5E-FS$FJ*IG,< MS6@J>'M#[F+W.!3><<_)F<4$[U4 5"O)VQ3B3_=,XD=ZU6;C6=A7T)!X>BCRV7=6*W+=6@=_B>NG,4;QT! M2FF2O1)EHJGCOST<5AJ$?H0Z&G[&AT/1L]P#E9:CO.W[7A <#$$]$,*Y6I': MGWYP0A\(N84=VF/BP\/.((IT6HNY$1$K'$? 77PZ$:]"X]7;R$YD64- V,3& MXU8?&(D5CAZL:8#XG6 /QJ1-'AR4B>_' Q.WDG[EW5M!/W(LGYV/+6IU)RE5 M_:IS+'\%YA#IBV@)C&R@%>J<3:J>',KZ 8T!4$UNB%QLN-PZ'(?I3V!NP *%\8)P8%DFU9R+FS@N(>S!*XT&]&Y/5%M!A%7C!'^?XCZ M7?J!'"XTRQ (<:0:@1U#;3K3>I"N(0F-J%J9JQ*]UY2L(,%9XK^FIO="207M M&<'%_P:'HG1_*!W:LS60E%H.^A_EEAOS MVJ&7-LJ6;11Q'AD+);$19@Y(6BG=Z X 0L6Y/<>1BA)<+IXL3.;"QRLYSBK1 M5+&C\1UWLFJUTOY!\XV=8VTAJQ-XI8NGA]F?*.WC,GC\(W=9J>B*G8@MT'.) M$TB]'P5UUMN34N^ECAID78#XT_Z(CVWX>>QT$T:3PT4'TD"\0W,%IH %?4M! MJZ-2CBJ0CC12:Z7FA'^+H3%"?X1W";\K3YR^H&NA=XB\2^*1#[[U']M!C9R M0*T$O:J@F4C7'YA*,0V 2>*Z\49 09X&-+\'S#Y2N7%6S<0.L>NH!3 *)0IP M!OI]HF\++=4&T,B):REWHOII,OR&AA=$@SL>HD=964'-M%TB$?- 6M^UC\# M(7TAU4VX^$[8%S1+T.^,(P2H^ZOK/=!T!WSQA],K]L=-UV!?OESOQ[8)%WBP M'M"P&P[E!!ZRVA0%RZ[ CAA2H]96CO9\T#6ZV :FY?@]XH?J\I+@X[)#8C<<2;G,!#Y@U53]*X/!UW<$8^ B8:C%M M='N^#70PLU-Y_<@LB"<<#>(17=1.0Y(0-?-&O:9O!3%*X-\C+:"P[,@LX*5D MPBEHE8>8KN\I=T(+.)GMLR]H1$A7.#OM?MDW8FNM(^VNXT-]]1DO\;7GR"@+ MF5T2,V= 9][8[I-Y>-'_9,/A:?:3LF(N/G3)$6]C?W=5^(B\C M6)8?NSA@\,ZWQG!Y<*[%^3F8DNZ IMB_$I.D^&!?P;W.-(U&;]LB,8:CUI!R M[CT'+CLF$4Z VNGF#,GGX: @%RVL3T;6!+M3FR;>JEL[A(LL_CTC':J5#Y;[ MS8\F81]#)@,>RY##&QS-HGT7 1\=>B(2=XKWUNZ'8B:*8SU@P&8/OY&!M^PO M50#ND%T!P?*>'^$63+'U8T,TUT[&62A8M9U<.Z(&Y"OWM-#*O)?BT^J=0CXL MP"WY0N#E./T F8R<;9/= \%^09ZV^K$$//L@08F!F'%J+AFRNP4 T*0".!/B M'B@!Y+ZK%=BXG]XP,:B);]^3*TNRY9V[ 3MZ<;$+EU(\2R.F3-DI3RF5",M! M4QSPH._;-.-%BJ,DRZWD4V48N3RM\MX4%FR4[U@\3U)&%M#C?,@C#V K3BA(?=$EP81JY454AGBMYF'[(;^_9OE MDK53K]4;!OHS]5,J V+NT M@H'U]\_LZL/YU;ZAQIJBUT4Y,G.648X62X_>VJ[KW0M30_UTZ/4C.:.SAQY. ME!DC^VYT8,/W_;!:B:<('H@II#CYW9IPV$=?6X]B\(X]Y'&2!PY //#Y R(_ M&%DBG=7R0U?$8P-#!JM5AH8:FCU,/D\H@F+&*V%4'-&%-96Y)&ET*F+Y$Q!.@[^!4KZWB&TC%HN![YDZ7'=D#Y)#AL M\6Z:Y"?@,#K;&AD^AUF$1-V8!&10!O2L,D@M&!#Z&7N.[9+ MO\>9E5PXI?1+I6=39K.=N_T^=\28\M1U2,@GXSNWU \\/Z8AG+-I4U9KM:(< M>&!G+\ ADR@<,'3C6O-NW'S"GMFD2"1^@!=,#X">P+RF]&$]CS>A5H/!X4@N@]T+T%(^;.U\>Y;[C9RJ<18!O)Y+EV+?.Q D3*1S OP2?3^WR45! MHE'X?/16!9[P33).$C.TW#>E7=#'"=EW$&(Q=2T+\@>K_^T#1X>DGD?T#&@3 M:D./1SH_&$D*G6/QN%>Q'W%Q\3]"3X)[ 4#7,O#G8ORCSSDR3783@?1Z-/S5 MRJ(-*'!9"EJ5U&:FX-.)4E]!"*YDG1//[X$HN@:V.+;Z='!P27,X?_?FM/L_ M/[.3KQ^N*6U97?6#@(9O4L[90,L*BV\D8%!FZ< &W4#VH+Z7:<#DVQ8394'> MYI>@ M$+7>3/#FPX7SK> ;.QO8F!(GI4;"U'2^H4D\7=3J9R:.4E0G4'%"S/L3@D=$ M*S%5K9QJ:$Z#E#!80HZ8;B@%:@BZF(HMR8"@(@]+1I/0F:HQ4HQI.%-):QI4 M*%.K%2U0U)K!HJ)Y2Z3L(Z2?1?W%*;!;[PY50E',HB6B(86+C"V\_91ETJ.O M[E/XTUG*CV^GEA;I>"[62#@RHD4Q'>DCMR88L,QH7/!1 MR&TWUIX0Q$D$)$ZZ&0K=R3=/HKI:D>&KJ^O?]R4_;1!-J>RU+&,6O.TBWALB M\ *.P<;R#=^%GWVQ[_'JAC2P&) 2GYLP 80J)Y'ZF30X3)&ED)@<7$U-\$>> MB]K[W S"/JB@EGLX0U9SJB-62"'$>K.E2<6+M7]*C6I'=]XR-^@ MQ'SB4'ML1<#*OKR<=,38VTAJ?];=F*JO4IY Y7(2%L4,]/-"-*CLZ3$:W=R, MC7V"XE3/BLP:WVFC"O8>VT7D-7R^(Y!E_("4U;$61^#A#,+(!*FW6>+!231^ M2HI,.V^JE9G:CCR7FNT.@%1!-40Z)=.0"O31\2/J>/M4=H//&N+?5I^1ONF# M(C\-U%=!-(!SC)\8<"L<&>CK\[YQ4/^#""QJ)+!/YRKU+O*38AZ!M=B,TGTT M.ED=I\GHD<[*:F7&T_9RSDI$2>RM9'G.2OWL,SX%<5?H;M.O-,?Y8M MGNNEWAB%F^O!?(S7,EMW>/Q81V;:WS1#!C(+:8:5+.^2(?B'SB7G>PB3 DJS MGGWQ\9/>-=\+YPYF_)')NZJ5E#,^O>8\QR2W^EJ]&]Y@42_H1D MS6/:T@,%"Y/4_[3A@J/[6-',%WN,_H8+. 7YSYW %5Z MYXWE/BR=)N/4.]A%]DQK6;F$E8WWP(P]D*))R2* PY-1*QK;1<^0* T%.:[S ML[V3RS_WM7)1EJX7C5N:)'9P0DNQ'^LK_>@TE:1 SBW!D^P^6.]Q)Q$$17#; MN(V'O$0J&&<>'ZMR@Q1.TBB8.!9Q/M&HY0Y;5F QIY(@R=@^FLR7..Q(&'^% MP[RW7*J7G; ]O=CR_P/:B\])\V[MRPS]!\^G4 )0]4?O#KCXE)TE596QSR_U M!DQW--OOT4/@!S';YNF)M7A)@J]Z\@)N")+HJ"^ M1^[W6'3+HEP;D^01T8FO3$-ULUH1N-;1GT-M*2KS];IFW1M*A"9%:ZIH%F[] M1-V+3")]?HFKY@N>M^!(G 9200B\YCNFHWZ.'8V'P!IB3@-("WC*7T-16&"H M]H1$D"0;$IWH$R-YDY1K8QV%%;EBL81N9\1?%(X\)*0Q_!=EM,N V"?%$K: MQ5>YLAU0K"EY+C\88>(_[F,@LFRQU -]4<&(@J=B6'DH^L( @27)ZC?*+P?P M T=KX:S5R[:#MM^V[&_9*;M:^>U0=G U>9DTML<7E"\#E>:3CD+,3Y4!O?G/\]D0M6H0(1L]J((BWT@W]!*2$N69;.4PX:(; M!+$.H;&J5E]Q+008?L"#G3&8N.*WH#3T>;8Y&K!74-2$;84JL^@S L!F$DV2 M5BNS19D('HB>@:;V3.4JL8D FKHP.81X3[A#\&:+[H36I$K]9F%69DP-?E*M():,%,6I2CW9LDPA M66EF7-58Z7NRM+8F#NF""A<7I*IVC=A>-I3Z2-+58!].Z8DO0C?#;B9#S[&] MN/*2Y&_:IHCWI*J]OB1BZY9;8Z' )5LXY;+KF!V&G"=U>RU)'K44 N!HA(XC M-91K65]R!OJ3K#C[FNJJ$K=9BWO)Q@GL4E^B6]?/A?O>IR#*H8H*\O M.N:((.IL\#K-%JA,5[;9R?. L90#;$\PBG2>7^S Z"O,B#N?6LP"$1\F3^R3 M,H_MVC[CL.X3T%D"6^SFQ$V4Y?6/X6($[O[!@75.H[S#HW MY-DK9 -S4_NDJ&O_,G+@=$XH%$,$J!&%W+Y[Q_6++1O/_05W#N.S-_V1YSE: M99BFPUUSUPVF#M@7J,4%>BHC7:'CG--!@PA 67HXM#RJFRZ(F A+/JWDTO>Q MM26?Y)*5!/\)VF7A)@Y "N"Y.;^?8?W+H^0G\BEMI MBN.U[;I6'[C$1\\;Q"6CUQ_W4QN?$#28>D%/S8?'$W]_L*;W-DCI6%(8R%!D MDYFQ;*U(5H4G?4,H1M+'AG?01EI#(?4![8=$U^=Z'6KX!++!#JX9+KL\.B_4 MA405%V%OS<^@:>DK"A2L7\Z5*$%B!B1Q=7);)4756CK?SFEF3VG9TRH#W.L- MY"!KA+RPVMZ$\DS^.)-!NRH ]\[-A,_@R=;&LSO&+GC.P"[4RT(Z5C M?(P9KL<4Y_7Y4?T$FUJ+'MD(4;Y/;X-(&K/L@Z@U(-8\;5H'1&K'F'2SSG34 M)FFA!HD7F1Q2$?@54??G;/GEHNQ.?@*X=D;DM"_1G>KKGKZ8[#4$!!NW* M/;CRPY$G8G-H$X!R,K#H34FQ3ZTE+7")(3)RA!< #N4OSW<&P PS4)R%([N/ MV9+*<[$<)!%Z%6$IN3%R(L@8DK!2E"%$)Y-Z"0(M#&)IU(H&W@E\N@V5"TT< M>)"FYXV(;LLWQ^"9S03UU4K.^M+V5/[<4TD @[CYMW:09BM%?7+?V<2(Q$-T MDMA[87H70"7RSZ1=J8<.%Z38D'IG(%:2I=)=;8P<3!G9/1SJL.H&'G;!Y_?H M?0$5U4(933%*4FNEY4>-RV>=W,_H6ZZ9X=GHA&H!A#=3NFL0C(^G7;V!E7B7 MOJ?\4HA\X\^("_#B0)-<\"N_BQPK%-W;Y7D9PD>2L[+Z5=ERUPXEG:HLM*#3/HV8 M+FY]$(38O"RG7*:9@F3%B)%TPF7R@?R$MA;;CWD")S5B8VX2-H8BE._'@DT# M%XQ]%>LS'0ND;VQ&Z5UWE BGLU4K8CQ;J=WN[LXNL#V@.,;':+>_12ZF<-9- MH9ZIOT!&@UB6R_7XG7*0X=U='(6A/I;CGO\]J5LS!$>5;KWN1?>"[8M"( XX M$NDY1]!DH7K3PM^UO9.PM9>;6R;#>'^K$G-%Y3C >KZ! MTH#S'?K[*1JIQ^#%A'(TVY$R#9Z"RXACM1IM(G"^W<JNR8U\_ M#6:-/>H.'#?5%F9VL*"/$#;PC7T-GM (7LL8C^*##?<*^].2 _.#$B @HRG4 M3EV3T:M97K,M@OT7G,;(POZV V]"0I$]^.AI0I_3@)J'QZ*^KYT4IY,2U466 M&)6)TA.O7=S+WHAOF$Q]D+?PD'7C'*"^-YG*^XH1_@$U+9AX0:B-A(P5R$]) M-3S&#V3+<#L>8:GQG'X*Y=LC^XK*""4$> MV$'?\0)LJHYI&L!R0/ /*$>-:J1 M<"<(>HJ'V=)X3M7P(_!J!\YZ3:4C!CU M1_I*,F$;([[P*M%C"=1.>R*JW3*,RDB^U52*G"^US =/63V4W"*580(+%(\ M88#_Q90?:HAO Q%9?M)W7GIN<;>#Q/2Y*KFR0QS&KE M*M\.&5O3!!06%RE).D)E8 CLQK%IN+28'Y3,4I?6C0I+438PNJ%E/H8HQ(U' MQZ"OFZK;M'BC3Q6$?=_NH4N).][#H6P')7WR4O<2I7 **A'3@X]M&M )QR>0 M!/)>?$7[>+"IVA!8/V!*>*SFM%DX9&?9JCOU*C%6B-Y)#;DP-(ICWH7"F?2* M4+VS])>D,*TT0II&?F^!>@/L$>,CP1F2N M';G0[" D'5F/A.@I%^Y KSTTA%ZI.35G0C^IL@$5=-?R"^9<320NC7Q%^\01 M];D 2)/GDF'!ZLV2J+*;0]+3DA9$3D;-.2M$.DQ?5$@T.V'%!U3E:'&/!=(>G\B_J3C\>\("S_M.-\B4TJ1C9N' M+'\[H.VK@'T\Y>QVP19?B6E0?+!O(^"QH.H*E M( QHFERJUR>Q26N(UCCY0RA=K+QN6S808K+(%8?Y*F=:*OK:,(,?OW:)S(.=&0QKQ$NPP PLB:'T\,58/A43 M]K@+-"+&+N DQ[2'/"5(!/.? RXEC^0*@GYLF=YYV(V;Q%'OWV*:'>[&X=1V M1FQ#3 >-7R EU$PSNYER?6$6"_LUY>S/QQEAQL*JX3O$VEP4BAM ?3]>2\5> M\<$&295X-X3C?XE[@Z$(0SGQ**_(C%R+3;I$KAE*L,7-#S3)IG=*FV_Q/=)5 M(XR3.3^I5G(WXHK'*4$%2QP&$=XTH.H>9RK)9#Z;D%IO$'K];YAQ@Y'HIT!! MZ,1?SUPW2J_1UV2W.;&.WZ@ M2(,6U5C]!3GQCQ]4W"*)>3P:X-IANVF[VV"98C%[\,\?+OY5,^MQ(_+SV[,+ M9IJ'*<=_.'C.WC:_F;/_/3OYX_;\SS-V4X%O2@>\1 SF.B.$&(^\AJ0-(?#_8!5D( M_V1DO)3W29K&3(*'[I0:V@$FF&)O9"9Z[:H:WVI%C!O'(@1<,'SPI 9.'7FP MF;,S3>#A@YR4-U2MQ4P8,)DYYU3]@!TYH@FI-_!^K1^AK@JAEPS> M-%9)-M@Z]<&+'.QJ>,]%#$=:7("?*!E.CCU3$M]"LJ2H;O5"#6SJES*+RCF0 M"PU+Z2 H^9..2=G#16W"YT/N^^(H,2/1=I6ZJ=P/5&JK=5-5N)/.@5=BOBQ) M>>F4*2_K37EIE2DO;S3EY5'GL?HN5CNY&4T^>UCB>N:HZ,LO..W_@8OBA!X8 MI#_\>DD5_R[.ZU)"\5IF,8@#3JO)J5^_9Q(_\3OI;2D"2:"$W2*:__E#/4O+ MCX$X3:?BMO_PZ_^!C,Z"FPM;+@YT>MZ)[=Z@%W/*Q- 7MO?C_AO:^P?/C8*W MN?4;]".IK7=1P=41P?;J;PD95V)XZ7QLF&\)&^BXNT(+1&) -U0W=U>*LOM; M+[2<=6\S=K$L$\4@V0'P.Q^3&E"Z>_[/S+_K[=5K1T:]T3'JS>9^CKB6,K_1 M_BE/]P+5 2S**;L^9!?H?L_N2?ZZ_M,<=&?TMMQWY!^J_$DS\Q,J:?SA5[3@ MYOSB"2_9.OCK4QV/VDVC5JNEO')O'"4')3(29+2/C<9QI\1(B9$%/.38Z-0: M3\'(7F-&RNT^.EJ=AM$\/GXNA6Q:< NX\=\_,QL4#_0>S4(T)UU#[6KA&:UZ M,/GRV5ST6-YRFX(E%I'% *?> G":Q0&G63...\4!IU8WVLU.4< Y:AOUSHRF MN9 1;@H4TZ@?F4:M_A8;^FMDAUSC/5O"^O('MTD#)30E-&\3FDVK,+-O MQVH@=NV-N6^Y_]F"K%F!M6_G>-:GOC8ZBSP"N[^_>>;][N_LJ&&8M?IKWE[M M^!5O[\AHF.;*V]N"QKB^O37-IM&L-9]T=L6P@_-F#LYT8WU+5G$L)HH!3KU^ M;-3JS:* 8P+!MXN#G>.&/C M]@Z;Q'-&>KPI(]BL%0?:0.[=A]SQ(]R1 @&.[?2<:J%)A.Y#=!ZF:.. X MB81.>N!1<3(@5&+=_L?HA5B^+@Z:Z9NP W./):,Z>:)F2*2>.*[$E&*(K M"K5TD<024)DR_,#OVX'>+VR.QOER7&+3;*&^FVPA6($OB -?QA:PY#]2C7V> MP1\$&!DF\3+\X0V3TGI. "VFH-%H--GV3K#]HYKYN^J-AS/7 MPOYHSG&OK\U,V<>$VKQ9/LHX[%9QFC3F@).3K698V6GFA4_H%_O7,[H98VH) MW,6QBT)A(FY./?=(4YA)\0]^>6?_6I[6=B=H424H"5X:XR2YFAA$ -]GH6J+/J]]AVV[)= M[(KC'B1M=D3_1MN]Q]E,^/, YS40',G\J4/V1]P+#WO7QAT9"<)8H<[;C8%# MX<6<4&H0J&9/P *9VI-J14W>%5V[2=_%[IZP#=D2E2: _2@+-N Q%W1E9\KV MM#8['_!AT7E *N;[F7;W,=S8@9?#<=MRK)9\)?4)$FNS'I7Q3RRQ*?T]UZ(K M.2E.5.ROWD9*E2LU?51M8!E87+1 "NSOH.B Y="G]5JUGZC5+QH*L+9[H$%? MK:2V18#-EV7 8S\ *V)C+'LRTCM[FM1]/DY4MC.PQF7_8 M]A][3/D!_/*!.T!W8R"D4:# ULZ"= M!)^KXI%K")/#\,1PD3X0\CTVIJ19E-8PQ'ZWV%">NO&$:F<3RX<;'%)7+;J> M<\>?9/I_ E$,@(!PBG6R1 " ]X!*YOQ(]?L6E#ZD. ATQL8B&:\@PTR M"R]'SEU$M.O*AN$D+3(W4>.^"0U@1S1E$N[9^T0/$\$2U<>P7#R+O*,NK<J'QGM9HT%(\O'*Z SJ',7V"M&B81GZA.N&#,JV28:^Z_"=Z)!""P: M1$EC:7J QJJ?"6OPW,5KBS1Z[0"H*=[K6,KKLH]-T$,F.KN19P/[Y@%/CAGO MC^WF8:N&;$# 322]9R,"<%!#"$_CUH7EC'/0A1V:0LI'WO,C%#]F0[ L@VX4 M!M@2;*!$6[3!F6THE'U-H!"__ .AH%XAB0B[I6[PLS@&#"P5%X!S<1;C1/J00*33Y/='"5I4=^9-=1/ V#XYH'TN&NZGL$0M M]G54T005;%:<]=VKPF>(6'@]&V<A8:*VG8-8I[,QP'1S/0+BR0 $I? M,Q(A$7^B/5"OT>&DGZG77DE_R^*#G05X43O.X[(=)WZYOG:<[;(=9X+B K7C MW!:SH.Y>.\(1INCXT#H.8FKC")E:/DG +\7-H#/[7$/]".AP@DS&97G[Z@$ MT+P.FD\UB'T7*RPL#0PRL::DUN(,6;D%/Y;\5CR\8N%ZH BDM#DIK=-'A>LN M/*Q95#,-TV)"Y'Q5 5X*9E;.O(^@/^(#G)653(FET>ZD@:; G*4511'Y]()' MD4\K.!=S=@=2,]HZS=",$ZG;/8-FUDR<1AFI% %(WCA:I*.#YE]Z\8"AOA>$PC]P]>%K%_Y$J)634U]_(WA* MPQ2/\T.@6#Y,&60BXB1QRJN3V=]BSI$W**A:F<0G)G9[SN:DR8 M(X:&BDL,2@K.-A).@?3]3GV%=KB,CN@G[_7A_@:2C]_3Q=P,U0!BN$/SJP?5 M"MY[.1*7S&29-T'[2^9E:T,1)*.8]T9E*L#O"&3T)A?=>/E ?O@01F*OPH9T?&KBLQ!&1^3%+OOI+V M*XE;1'/9Y/=BNBPI+4C>Y"Y"ECS!*80>W%R@(8Y,/*_T/F=^(,&,1$V_ SI; MJ61?2DWI!ZQ6I#^SC$ML:.[-8RE*)YB\"'<>(<>C-TE6)6NG@M_5BHQ^2T=A M7NR;/37T+?3+%7=J5"NI;>8'PU>B9F-9:%QV;<@/C2L(4JK9@B!Y#'&^"Y@T M;16G38M<+CA_9J@.GIV5#JF3!)X;+<<0(Y@NP$#$]%#X7QD'2**Z#?.PWOQI M/[51BEOE1LRU6+N.NW0H*_GYEB+M$L9+Q(:JU MF4A^G*@P=ZOK"_;C;X"OY0?[3\ZNMA/F3TTP \&.87YD'A?6% FEG58,\+IY M/C /'/DU/]84HR^.<%@RP!97.P2I4+2@D'K3:#:;8$U0#'9IG!F_S \OBPLX M$T5&GFK6:H(Z1L?$[,6@TX3G\F4A>:^)Y9W\< 5Y^#C+KGBX.B2#S"GX M&/&Q$5?$'_\N1]5FXZP4;U2QV&HE/QC+MAR+S>5IGC^'1A;$8A?B<95PK Q# MY\5C=TX?WU$S8B86H3LQXOB"[LE(+$[ER0C8O>? W;=\ "%'F3K:2L_.9ODY"1JZW$*PTY=N,7'G42K$C MR4#J#RF^VDMRJ7:Y4WP^&&_2:;DX"Z1=*[- UIL%TBFS0 J9!5*J5Q0=$,EZ M]99*WGM^9"#5A$Y,&Y_3/NB5<-3B@_U4=[PXPUQG?)9N4+V*JUS Z%9O2Q)& MFY3[B=G7*SGMV69]]H_ AZ'C8E'YV@R!+_?1BVZ#:%KD..GE*U?ST,N'YZ9H MR\P4Z?T3/ANM+@F>59Z1:J41Y_*NXMF5;WZB7S?'^:5.:';_&R]SFW'JBIP> M7&'>-M?KTYU3OU6MO(Q/E\4NW=CI1=433_/L2A0^SJ]KUBF,E>?6K5;6Y-=% M)Y_NU16V45R%LMP+NZ3&1I@RF_?"5BO+W+!L+1[8Q3[/I_+6=7L\Z5#FNSSG ME)^LW>.)W/WQY2>/]W@NP*+F[Y1AUD?5GY09$@5P;38U'2 M^[6G,56 MKE-3/I;-(H:S>5F7IHZQ) 7])5R:<5XH5AH_R:4Y5W%Z8KZF]&YNPX4Y-]^Q MWOQ)^!6?[L),+NM3LWKGYHQF')@I.5D:W=LTNO-T'MF/YSSP+9#1JIN5T"XO MO! NQJ=S=L$'Z%ICM[P_E0>P0T')]![PKJ$99P]L2JZ7 MIG)2)YR8PK(\@710I%M946R[ ]@\,+:D61N:V60%A-+ A%6'E)$&QBV2$D"J MMWDC\R*QONE;:97+:FF.3_>YY.%T=9";@+T/4P"RJQ!_ $-C3&EL M6'QMBGK]>)=I4M2*]2UWA=@ )\!$,<>" M_P=:Z<&9.Q#-#\D[:@*?$'-RRMYZ6]6[AG!-O0<2]G08 36IA*<"X0HGSYL4 MI_/:)XM69(E 7I!8JG6T]71223=='L']E$4HF73X>GUK8G-GSG%9C_P5N+?< MF@GPG@"@/=\VV&>TK) ?PYLM-SB0KU^-T<_TS\^?Q3)_YE\:LIX'!+$*YN5> M8V6!%(D?\H=$ ."(LG_^8#:R8FR!-O)(@&:5@!]^E:VH!%]\B0VWMKM?^ 3;N"_/KCX0K_^'&W>YER[0M'-EV,5[_89UO6WC% MSR0N7PD*MX0VT1 &D#>QQ;2(UTHEVF64*I-/S?U(\Q%<\Q8])Y_1<7'IA:^$ MC+:*XPL1W?]337LH"J:?(J8V)"F $$&S?UD"V(KPD^Q8M-Q_K5=I*YB,U802 ME\_&Y35EU^S]N/]*\+A-W)U:X5M@7']2W/25T,>3D/@PLD-^@*X+_C-SO0?? MFJP1L]NY?6NP3%?&:-Y>YR_ULBL_Y>=/ F8W,+:-2<:K^3&E0Z]Q]%->' :> M]<+1E%VKOEA[)V=7"NS^-IG8N/X@*/C M.2.QBX6+5W%R!R6. =H?BW\Q:$3%9N\%#<,MW(%EN;'$;'H(2;U30,A?X#H? M&\?MF?GFZR*/XR*2QTY+NX[1:#>W)^PVI6H]$]_K(HGUT\%&#]\TCHY:SS[\ M=6_ZC1[&P1LZB&=H.YOEAJW#H^>K.#F"J_YDP;6)0Y!XRPP,JQ\_V@.PB,IR M7KC\P;P%BP1-*;^*=%V/C&9M$]>U/(PG'$:K\WP].HJ@2[*AQ6-^(!&L4 M6H)1MX]&K8@BHUC0E *L2+?5I"8K;XAM%OHT2@OLY<^@WMB0!7941/GU6^1R M9IJE\"J%U^ZQR^/2^BK.892RZ^7/P#PZ[&Q$=C6+*+N2T=FE_"KEUPZRS"/# M-.MOB&T6^C#JQG&C_88.HZ@RK+&6))^\S)ZGI_9L)036)B%F%E%L% N:4H@] MG^SJAMEIOP4VMP'L$3&VK$U>M%Y*/%@N997/TO MK!5Z; U-B?4=AB;W+3NZEZ+?KK56&,W"F9J7SO9.KIY>4K13LG"--I/1:)EO MR'8M]&&4CO"7/X.C]H:<"*U"L2:)M^[$MQU&,WOK1T6";P=N:].H;R9=S:P5 MBE1VX"B.C,;&,SA+WU&13ES,I7]#\K+0IU$J+B]_!CAM:R/BJ%TH:23Q=F%- MF:C\B7W113*:BP5-*;J*=%%;QE&C-+D+_DS* M7 M"R4MB@5-*;N*=%4;1KM9RJZ"'$8INU[^#-YNX6HIODKQM6L;O@D%#[K^G&Z8*,(0&[LRC:-6F>M[.[- ME(6"Z,6Q;IOA3Z4G92W>@$;I27EI*5)*\I<_@[)RI7"V7[&@*<7-\\FN+GH= MOWXN5VAQ8QZ_I7[3114X9:%)T3A\L: IYBYL797"EJ7OX,WFX91REN2G&SM118*AY\_5RNT.+& M!!(L2S@+R]#?A5;/X?#O:N672>8TS$GX#D_D!);I^;;!/G/GGB/7A].PW.! 'LG8 M\N]L>$T-_F]GLE;51,$L=9.) )1@9GWN./!YWW;O_OE#[0?Z>V(-!NKO1Y/6 M@ST(1_AH[:9/0]MP ,,TFD=\?60$7< !A6ON0W8ZX>@VH/-QWID!^+(1/!50"D'L>A,QVF<4"V(X *7S V\20I[(@ MZO=Y$-CP-_\[LAP&__%#7 U^%826XXQIIWW8 G>1XA'PJW[HD0-%PFVY WC" M#6TWDD\@'$/;#T(!QL":XINYU1_!5[8_8("0$/_-?6X-X86'*3,@1^U[N7NP M:<*OOSG"S^2RF<>+*)_2_(I"^3CYP)0P+Z!Z)'@!1DGU@"I)/KG$/W1FR-Z+:Z_F.(IW>$Q%$_$+NE-IT++=8&^_0!O&I(_ M?#&P0GH)P?6&R:_YYL@O$^M;3(*UP_;1$WEN28&K46#KS5&@-N33/#($(1%) M7'AA%+!/Y^R"#_ (V2WOCUS/\>Y0<'^Y/65GXXGC33EG-_@F=B78WK5C(;%9 MDO<]@%@% $*0WBYZ()@5**(3/SO[#C"[=YS= E"!U<=%#/8PLD% TX^M((C& M &QO2K\".%OL[._(#J?LW.T##E!=H+?NX??__5^=>KWVGA[#3^EO\_V^ $?3 M#SAJ(GPXY'VAD_3[GC^P8$5Q!V$M&S#!_3&< ^P+UK<&>)0(BA78A'&?#QW\ M_>+M'+*6^9/UC@[PC40/AAN_Z>_6DY$:[!#@[4S1W8]PJB'APN]P]$-.9G]L&Q MX!Z8ATT /O <>Z#V$S_1(H==XE'3/6A9#UOZ'7W/<:Q) +"H?Z5<:#D[7A ^ M HZ9YW&>X]#$Z\#]C,=.1YQ"V7MV.YW ^[N^U;/[[]FE->8"K9<>(K!=TW_U M3OT,OTIH2-'/+^\ T7DX!XWZVT&/#ST?%I_0F4DLP[9V",4I=&;=Q;E8T)&' M6!5$N0L7K70B;U"_:+\Y_0*-\Z.4+,M7;H$N#FLI ^NC/0RG!^'(!PT#/D;6 MQO::C9_VT[(OT7+AA?88- 4;E%EGRJ()O)X@,6"#/J@+\2I'M>PJM$"P!M^$ M &?602%QL,Q!L<0W8=#OT]I P.^YF^RM35L38,SL#_X1JQAUH?0=HR%A![I* MXG,ZEP&>^8_'Z7-!%&E=.V!+;]A7W\4R M+K24^(]WC_B_WOP1*&J.77.9:*$Q&_XQ9GSC@@]G$N;JYB+ZUM^MO5: H4=\1K$@/Y$5&D9=?C$0A1^Q9PJ"#$BX8, M5N8"3]AF3#2/V** YTG[-)][DF^7T5%OK=? Z;;#V.;R+\E@ULO$GL"KE&Z\ MMIO\5%XE %EWC/-IO"HQ&-;)L!Y_D@*.DF$]BV&]O5RU62)=8)5@KEJG*%9) M OER.?U:K9(X?WK="R\FL$?25K4B\JCK]84F[R,S8YX@-1XI,>K/YZ0;BAIM MG,'D>[@+#_8OO5]/;9^#A0CV(9#EA+N!A<3RR[O>KSNWFQT]A%L,U@X]Q_$> MZ,926"3@<-'0FSR"NP?_.Z9CP[,SN4'#QSK97!A9_##KQ@)SJME2OU.XB5^%[UE3B43[!+1^\\?ZMDH[F,@ MG8URP[D]A[+F+-G[]2.'WW/+=U'Z^X+C3N1^-OM_-K,?XC_ =_I6,%*[V="K M]G[<5V_(DE NQ2Q@(6^8 (4"VGVP_$&P^0-CY8D]&XTR]6UK1T;%:.6I/1.3 MMQ[83KO%$3<]O$CJ(4?S3&],O9(FBY7CTO(VM1U:_2 MAU8#(Y^6U1I+%Y'EP@?S%E@#$#N!@)9IU&8[SCT.$LIPVET4U.M&:[89Q5LC MA$YCO5A8ZT##N:(JCSWY/G?9S8C[Q)_R^UBO?!1/QO^3N,^ZWO:">SIJ&$?Y M/<4>ST6*LZM\'O$*CJO5,LS&VC?&*2\#!^WX/!N_OGF^Y=U,VIZ-P,9#^ M&N]]X]AHY;>N+>]] 3?6JAOU9V_LI63\)PR=7OO1 --(\ONY%@/+K_&B-TW# M+ 7\SAQ7NV%T7H6 ]]Q_6^R2.X$'E[Y58%)ZC9>^E.X[=5SKE>Z+VN(5+JY; MUC>63?+R >V.02J%0:I^W[J[\_F=%0??1D M:8B>9H+P^;*+0A"-949;)JT, 16/(["B48)%D2F#!9RS2R_$EC>8DB*RWEP* MQ5BX@X^V"S#;EH,0AERK:%1UAP,[Z$=!@,N+7A&RW\*UY8?L_!S_,NOOS^&W MK"W_N+!MAJ66?V_?4@2+)DDXR=FQ11ZI31,"P4E(E!PYV+1WS M#38/O-49 ',CJA-49;1)FF@J152[=^G#GVUWDNGK 3QBQ!UJ:7+A'\8!-*R] M;1F-YM$;)IA=Z;OWH@2C(AI(,$=&L]YZPP2S*SWK7I1@E"M<$(Q9;[YA@MF5 M+G,O2C#2HXKTTC0:]7D-I-X"O>Q*3[B7HY?@4#GC2OZRDSU^E-G(8WJ15"*( MP@9C4]A5CLTC) ;,)4Y7.4C;=UFC.=UMI+<"J\WT7ZLE_AOIN%G4_ZU1]G]+ M,@_7T?_-+/N_O='^;X5WZ_[2^_47^]=+SSU0'4BK%54NQ]+5=9_@!E1.(ALR83WT,'FA5_F"F1 P[M M]O&Z8-\PL!1FB=D%7'7L]!PZJIT--5\FOSQPE:0@?LCE/"),3'G_9HV0M1)I M">L"6$NR*BRL.\3LJ&G R++)JR\;!) B)7MWZ=K4@^TX"WE?"[/N2R+=A7/? M;5A+LBHLK+O(^U1'[FXTL,/$#6F'(>?+N5[=: /78R5][L"1[S:L)5D5%M8= M8GMDW\9\SW*GS,.6:P+@&2<:-7=;D1.:1JO4_W:#"'8;UI*L"@LK,4*V&] 2 M)\QMAR=S%X#OR;:58\^GW%R7A0]>RE!.V\@QM\R:RSC$3205I_JS*M;9J3=+ M"M\%FMEM6$NR*BRL.\DX28V<*[HGNP/_%\3"R[\X#^7*ILF:>3NBX64@!/#6(PP#ROM>H&*J>-=I.6 M%/\T&)9AB!BO,]WXG,HR=)\/]AG-1<@5PAA[LYS 8QS>;F/(68^]N>JX]5HH MJH!R9JZ;;L# M#C\8X+RS#!F+IW'DVXI]OD41$W[,O]MBB*JLF;+5<-EJ9>(@"@$5L9DV\Q## M9]@#IZ(A:P#8$'5(G VC,/*Y&FD+H,!543V_48L1O>(E%O6&W@:@#4C %;I/ MM;+Z!&N)G,%DQK,8@4/Y!&JZ7-A' K M@?W"0V.]7E!6KN5?VYP,&Z A#WO3PP5C$VN*5*:( *G8YR*Q%SFW[$@/! 07 M7ESJG.MC+$P*-50ZCM*T TF3U_HSSEL37@A)#Y]H<^):NI\H[^DN*.>*+/[7$O M\H,YAR 2DGQN@62F;!W^';%#Z.U'OB^R:N%BNKPO!DT('@?\3US>64>0D,9* M\(XY1YX5'++SQ+3)2YL"V!M&3"WCN"13Z@MJ*'>U(FGOSN=B .2 #\5$<-NG M121Q$HU@-2L@0K(X8B2OA7^4R569#*7V-C*4,+63%K,'__SAXE\ULQ%W9S^_ M/;M@)B:8:PF=A5;/L97SVLHON9??3V<79Y2W]^?7L2_?V[)3=W%Z=_/[YZLOI MV5=XY/86'L_BH]2:MYJ)?,.!CP/715NG&X4CSX?O!\3VSX,@(COI#](QSX3& MF%)VKT%I#,H4Y:V>6+UFMJH5>1KGL?Z.1U&>Q%9/XA-WN:]:<.\8^#N*]2M0 M,9,YR&(H>S3.?OL.:C_P$O@\AS2 BSW-I&J2E^? M![[%'9O=1+T#^B;TA#G[A$73&C\\AI\J9=]@0=3[-W5T\1@5KXU@8=BJL*4L M1YGA8LRYZ.M1K:3&HM<$4EZ+(EMXL&G.TIU@!>BRF7@!5U9I?,#HA$+;5=1Y M@,DQYB YX3"YSWO3Q#6E+#!XGS<$.YEC$A :TN0(V^'+BVQR7&=D36DFX7\F%<^\Y]\*XPG%/6- B5J"/ M\-EAW.-&#G<3#ANT1=T^_ !L,[H?8V& W6/''F&!]=!Q!-:=YX>!ZN#3B\!, MIT5"B0YK<&_)07 1[@Y,;_A=$#MWDT^D3:]=%3 E/TPE>K$:-'4,!GJX LZ_ M"1\@S;,2SB5"FACJ&L']B@]$H"50^U,'&/O-A(5,OU&/(AJ^@QD#=/C='D=C MM5\LZA&N.HFU>#_J;[6;J!?8 ]O":7JOY!HO*7\]*LM?UUO^6B_+7\ORUV+R MA]RYA'$!I-XNCGR),KRFA$7:*XSFIPR!"+U(AC523Z&N9"6F;;H=1+6B?+&O MA-,^:?K?"EO;]/2_63ZXL&MH>NC?JO.<9GZ:/B/UWDO5? 2C3M(]\DO/9^]^ ME<% V5$BFGC:#%V2WDG;$=F*!%0.RT>GO1#WU-4T>-R6MKKWO^@)/CA@%IP= M\K[9(<&O8)MY1PR\9@P:(>4,W%NV0Q<)=389'["50TQPG#Q>(SC2'O^.O1RI M+8V^.C7K5#$3)QJ#B9G?4G@^CE9N7_WT 9OIEY/UTK="?N?YTZ7 ;FOBVO(# MWIM%[:*)94^BR@+MMO>F=MO?SQF*\K0-;VLD7>NG/"WU;"X/B:/G8 ]+)C)E MTL2E/L7ISQ[5JDV[UDZ/,;]20I'K-.#);\WZ5^Z)%D_:> ?^/CP;] ML'7\.,!G1W"]&.+-IF&V%DTYR[&)-C?J)/NRNU)93.7-02FR6!ON#,EBQ0=7%0SJK)MYHG@;<00$6DU&"4;>@YM, M3_$>U$@5W0DG7'>IH/#:>CVOGR1V9KS)"]' N3A@6:=U5*L99J,]KUDXN6^1 MU:SBMI?)/T:]W5FZWB3RT3$L8U3Q4@(HS%/P;7+[!K)BQT;/^%LEN;4-2'EI MMO,@ R7SXB0#CPN?1FA]HY05CZ9J4479**[I6D9$<^A'YH$)2$8 ;PI \ ; M9FMKFZGR8FQ-2K:<*6PR=9 #:%CC$H\/HPAZ(%O98Z1<2WI*MPVHMX^-9J>E M*/"!^UAB"_NR:*_.E$J+DA"8@&5(E90R "9K\D0UW\"B4CQ1H2/"\'[2F[_U MDTJ& M33"M5JX>7"Z2"U%LPC7"5+L/W.5#FQ('Q?(][R2EZ^BG/U"9;0;9$5YMKR'K3LI'Y2QJP92/S%P1]UQJ]Y>192RUX MY&%N^S<7;>_>E$6!2)%2+ *T"?RF^1.V'Z#V1SF4Q3!3;%(ZC%\([,0= M7*TDGD0[T'LM]JP &SB(>(,?.5S6%_$[Z>Z/?8PW9R>'K"NKL-D(SG>>HU*% MWF2MMUX]CS_#Q2;> Z8)>(QJU^&-[SPDJT 5]XLEXB&.^# V3NQQ3*[DZ.N@ M)P8$K"!'_!!?A?^F=F>8 AV%RJN:C8Y4*UDGBLB*MM0.5?$X_(EU$1B!3.TR M'%FA?-98U$&2GL.PBM9Z(AZC[5M+2SZ-(JP(SE!R>5+K28Q8&6[ MK%7#^)#X]"/O^1'-P*3&'?4&O99"HK(N,PD(4=N[./9CP,D DH'5&_0;#*OF M_RYNV2<[,=">TYB>A["D.:;8W%ZP?\C.OO MB!\$JITA\0WJ--#CC@U "XR1GB71!C#2.,"I-"+E4L*1C#1(5 2TI_K7VBZV MW*0&#(+:$+W5BE8IC8X:K,4[JX3/+-:TA",(< !0KUOJ.)(AY)02]I&5(LVP9LMZ6(8VR94C9 M,J28_"'?4(B3C)!5DZ)!DU7,GX0)(90TU7,=% 18//C&]OZQ_TH89,'R#C;; MA@#9%0K4K$VW0U7K73%. )4,UZ*&$CG[0KTT)Q7S;L9^EFU*<6.HUHU5_O1QG=>+9N-XR^\H;S_VW!9MQT$NY MU]PMJCFNS6L?4%+-MA@/&';*^]0V33:!MFIUV2S8MI.Y\PX';M1P-0>?8Z.T0Y==-H-LR2?U*J?-P^:\-G/+ MG2AEKYMP-Q*K59,EUNP81\=- >B"A-)T-A0-9]8R MHD03&Y47E9<+I9*@ OM[.%79H[-)4(<"D%/59D7X9S>1@+I!":^CV;-KPCEFZTJJ>\:+SGJ&)UF MY\G7M%I9'Q^9)6U0.IN-56"K5M;%0U9B'VWCN#;ORCV7?:R'F43,7<@Z5'7UY\QG.M]9A'^FU[-8'R(QJQ6(" M#A;B![B$H.\+_S .C=IH'O:] WJ$4PE0DJL%M(-_[]D 3=-HUFJK0'-Z+:%) MP'CZ^S6F8+;@-BV$8'N<-'5.1\U' 56MZ"Q49>0'= )>F#?]:.WRZC.]HU1F?6C$[[<1=H\[?:?") M<*66WFB95E#2]Q.]93M&WPVCO1VA=?<$_=]<5:)N0?^OOUVB;NT:41\;9KT8 M/+NHO9_7B?;VNLCC)7I4)R[!8Z-3+XCZGF.HFZV%[LKM.D)RX6NGX:M6UNM) M>)3_47?5U%HM.)Q->'H?[:H1)?J/9!OR0FV@'\I+EPZWRM+A]98.'Y6EPV^T M=/A-A8>W9Q?,1-+2IE$4^E["9D[.OMYVSR_9U[,OW=OSJ\N;S^?7-P+B[N6I M^/CLE-U^[5[>=$_H"8.^.3W_>G9R>_65G5^>GEV?P7\N3\ZR6]_$S2K;).6# M?85]QJH5ZF61FI)-_E,Q*(6&=.0UH=;Z&\:-YSP_H&YDP+C[OMWCLK$6-54* M8@OA2)Z 90(;%;O?+%=P86+")EHPTNS@?<$[OI&L\$4[/S0ARUS:R !A"E^Q[8_$FMU[VV_$-@GFB51K3S#E"!'C3(EJ/WJ->CU[/S\G!H-U]^? MAWS,3%/^=18OIT-P**>6[AP:=_3T?^G]^M6;6@[6*EQ;4^HC_14KM@*:S6D/ MJ3]SP [85^Y0I^9KLM_POW;?GM"AE=,YEX%]8X\C)[1<[D4!L-!X9F_?\0(9 MIM'LF(99[U0K$Y_?VV(=O25QVN=Z(^SU+EPN MEQ0)-$6O?3[D/C:?%[Y8LLC[X@$^,+ CL@7_X0>A=P#_@WV2[<"0$ZKAN[L[ MG/<9"D]M^]BH-5L+7+VRE;WK5*@JZ&5IEK;\@H-)Y*7PZXS9L_D<-1#?H\ M\R/^W1:!:7W(HOX2_7-FP5(.RFL9W)T/0K( VF)6%JTY6"*)4#NL-1,S+:8) M7_Y:V(1L8DW)_1%ZZ+'BNB:"?ZYP(G@2J:Y4HCW\RF M')$M.;.A/#IYTH[8/[N0.2O M<7O= &/'[(/MH=*(!O>?\'>$'.+\W&!?#J\/B<)GGJM6X@=OIL QL"\_/FVH M>SC3#C6MTP[Q%LD6\GG,")%XOQJ1X_!CG[4.&^:6:.+*[X\PS<-B%QFD52L* M:Y0CGH^)1R-B13P0-1T=FN9/E*6[53QSVX.0D2E.=+8,#5IG\ U0);C'WHC+J4B 4T M7"WG-3BV%R@/U!>13K2"M[##_Z,@.?")L;D 8 ?PO-P+!RA1&*;^![Z;\$>]+VQ<+*"LN(JQ35O MG5"^EKP @/]9W NM8!7DZXK<9_'[1%G#@W<4+SS8)=$2A[PVB?AC\O#OV5=G18J,I2ZLVT>_E=V!_%.A'QYD&QW&3 M]G7Z(6@*$&Y&"3EDB9CV R_]#RQV+>Z E!G.=(U9&'%3Z4UO6_]U941 M5_+R:@,_8UXH!QVF+13T)UK[S%WV''KV*4'O#@T8$$C]OA_1 -L>[WMC'KLX MX%G;D9!P$?(=VGX0QC;G(,\&$OF"^!_*]38T:)3IQ'ZLUQB@S4'33C>YSET[ M1-LZ^,5LU_)&!3NAT'$L[C4P8JW M@[O!E*8@-J,7 *0!LM<3!JM(:5J"?00&?Z2P+.Q#EC8/U1'I$WHMC.JC=R'] MK$H38#\V8J0>*H3&L$CTB3EI0YJS+(]N!4O][=8C[U;NRYM.4_K'*V;\LPK: M$@FPX@_FB@)IO.3(@V>)@ARP$IG0.&PN$@H"I)P59D7$&J1#SGMBX1!S7%U" M+ (L1TBL>D!+I(4 Y;$B8YZTF 5J9;&1LNY7D!UE^M>VW;2+RJ/;97GT>LNC MFV5Y="'+HTMFD0\V^6=5Z$K5;\5R?Z*B?)@H&-=XJ \"[.PQL7T1J1O([!0, M?4[@WQ0"$]E=HH?%*>^+N'.]CK%DLV7$12(4>9^_)(4LN=":U-)SUA0%QJ2G M""6DQ[FKX(#7C2W2!>0'4J0-(QK1NT=Q]FH%9%X_PJ0>;%EV8?G]$2S=Z.P? MLH]P:[P'I;QID"*0@#N*0$H(16[3Y\>'IF4W$D"(Y]Y1-@3#P=>A@P4W'B%C M&/E8.:BI.D.9Z0TBW_:P=D8'5&(6?NSU86=Q4%5 JNWCM4S++CS8'WCXP#%K M+"9@4Q#P,2E]2;KHD4J[>* L2QR!+LB -$JLUQR*B[D*9:6FJ.M9990.U&P< MUK:2($5)!_-R&$47S#7E2[+'I$NF,Q-%-L/*J8GI@8F/20)CLNQ@2*_Y8O0W9HSU M#!,3HG=[$_1SB,PH^6Z]G9<%/[+OD4_J]?4]Q=^EG/512*]=NI:"%$/OPGD! M,JP+M$UU3H+MYU^&LK)E>V"?PP50_2-B+89,;=*]Z?;(K G0-]3AZ2Y >;8L M/MHX&V_!$>?Q.]ED8Q,,;PF7T7\1IUVOG^&M $G"[X22]32&%W?_N,,6SVC= MQ6="M(SL<00@0L=H;PK_BP>".W0X.4N' M5A]4/'%.'V$Q]L6*X%0'EL,-]M'Q?'M@I0CIVN=C.TB*@@0^D7E[$AB12HNU M3PAA7] %_"4,3>+C:A%#(@$]RJ#+XD?,FL _O]M8!0MTUTBJ3]2/I,6JWP>1 MSROZ*4SPWZ"0^D3F8$Q.2:*GEVW5$,?MVNSB@*0;4%ND,5RK'U&M5OKRS3F; MB04$'@6J4 RN-!MR0L*/]WW(V-%FUU:5&+@ 7@ ME5$]K+!"TNC]T6S5F=HMF\'^C^9Q)_ZZ6I$>^3NXI6[&S3Z(?&5[8YYW9A,) MG@Y9BMG.)FL]B'&4<)07%AUCW4BEE:69*0 $JPX(._)H;I"@!^R&+E;R7E"B M,_GH\2_%"Y#PX?#N:769RY:_%GL PA;T*RS3XX3V)S'MNX.,5>FH WW<"=7- MY(2$5)P]IGJ[EGEFZ5$):T\_JSF;36@4'[;=%)$2-TRAULT8R^U =X$5CJ\*QC6SU40] !2WYG]"Y;/G:^!):)JD/, M&VQJN':/2@[6ST:R+AB9U^#>0D$\VEX@FT^.&1_86U-X%&+#A1A6!F-1[/:P>")2%?Y MLJKG5^)(7A(][931T_5&3UME]+20T=,UBV>UF1V4Q #]-=S,JWPW-1BA2!]Y$N"TF>)!3(;E%E&FV>8?F2''! MTG>Y/&?NR!XH*;^*,1MS(1='ME,797(Y5I#;9<706G;%<;6\GEVRC5ANZR[A MWL!0L>V/L<*^[_D33]C4U$=,Q!G(VV63TB&UAX6+VF#IC2>.-Q7!=!I@-Q'1 M&/Q[ J84=A!R1&,P^%*VE@54![;0Q,4WXEW".4YKBZ,A]/AQC&(&F2-[$K<7 M8WO(A469.N!#^GE\>?^DRUUS]\A9)+%BE]5^K)0#GQ2>2"@^7A1*:]8&X&04 M=D'U/"Y!UC^8\G>B04XW&MA4ZT_OQD1+2IN401\X'=OO1V-,#>USF3G0S\1( M,DL3///@/T(0HBZ>B)5B7IL M?1GV0-KF_-YP\9F-<1BB2"#MD7L@"6@C,FF/8JH+;=*0A*2"8RDTS6 I7H%I M"R!FL+T2?S#HZ.P!EYXENB'H.;BW'/*6B3_(\8F_P5Q*<@W@E1"DBL["P'*, M_%=)'^=2D&PZ* 4,_29NGC>$TXHOO79\!OJ;9+0:N Q0)!*S ]=+H ]=DIRN M=.:'^#9LRT_M!ER/VK7"6^Z!%U 4'YF2^#)QOUCW%MQ:&>2'[R-7;T&D5S$* MXPA?&8 N1VVEY8W/H6AI6BD7.%UN41(:R2?DBX5K%]%'.PH BWW1X0 ]KI8O MIA"I"GK9S!IMJ\31E'Y7BEJI6UW[?9!0I4P#TK#V2NR7XH,-^M1I')1 MPWF M>:'27ZI++Z\NT>T./>\;R0WDH?@]WEF\AU*D2VF5?* ](SA>X-12RF'G!I^>PA^741#TK&B,>8<@#D1@2\2]]$@=86-$>?@62/!LU,/<%TO_[J'3 M?"K^N/8CP+%HS!/ F[B#*M; (Z$AQ;2^+0&ND.+$%8?81S!N[Y>:[9J<80BT M.+A3L9B^Y?M3$IY27<*J"I1QL8L,5=9TR@6]EHY/,.I ]RS!EJ52I[U2*G0@ ME*7+C7SV6I5"(I&^1EI;G$LK&%A_8S;G-Q[&]'AS=K*#21GE%(),>?'+3)%I M9J;('.W6%)GKK^>7)^?7W2^L>W)R]*C5),A]C,[ .L.\:JO2]?KH6FH4M;G]]AKS-\ M?$+M9K!L$\E!:"M@= IS5Q.HR? ,?5I&.8YG$X+PJ?V\M1SUV9;OF>K:;4\&?3V!Y/9[\N]Y>O79DU!L=H]YL[N<0 MH23R5NVGO#"4\%FAB,GN)FZL-@>[F>!5[NH_SEG4;&4>IRZ/@-5VW6BTCN?] M*O<=A8#[J&4LC0;^$JEC,SN<<]@'*G*E'_I"5*V GQR-6K.U?N M=1V'T6S)7!;^&&&YLH!< ;6/6V1K_&*.?%Y&:#N)S1E&]:3-;YM_S=)Y72#Y MEEJJK$+C]2>>"OV.#3RPM_C3CV7^*FNG\D:M9IBH*ZU$Z_7GT7K!L=HP:T;G M>*E"OA(29EU>NVLW%Q[L7WJ_RE0 <;=+Q];VP*:(B\0^NK!4)RC*5PA$)G*F MWJ+6CI-#?ERMH,7LU/$G$CT8/D)' :V )K2A6G)1;H]!];Q#E7J5[TF+ X)V M_H@JBRQ:F9)AN2XV'Z//,*IHNY9+:49!"'L2*<\J1I0$/JFX^>_(\D.J+OF$6[UO$UXREMW6H9R"I7".L*P&K>^)S MS%B*,\XPUX#:/=(;Y(L:G=5?A(LB^)$C.J+$F4]!X/6UKB?S7RXX"<7Y^Z*. ML%J)6\E,?+M/*0CX4GLC;0L*66HUW6WK_9Y]KT_H@+ZKDC#)_-G,@'XB5'Z>E[N1:Y!2HU@+=.+> M7=%PW[L1P/(!,Q]II"[E[TO;0_1OD&T"@FO$^&PZ2Y MC@7G]&.RN2F15\V\MWK 4) 9D:9,TZ'E$.:Q!;P(_C]>D$SJCE9AH.4[XZOR MLH2IM"1%OUJN#ID!:JRW@N"0=1U']A:+?TC/B%N5M.S((DUOY(/YL:Q^4#.I M?22_BT0^,+LY^%\MBS9%_O(2RN(*A+Y:079"/4 2%E->C())3N'#$ET_!VP MY!4%@1*1"[U@DM1=T$!%/X0 _SLM0L7$\6.Z'O2G%^'+X1 9*OD7="%X6)[-$&J"X5@XRD MH*8++(4(S/T$),D>J$ B#;8?0L+U#YZ_ABH^N#W5\(\%KL; M.K72W;!>=T.G=#<4Q=V0=\ Z&FL8;!Q;'IA9R)3N-UO;U,[4-C5WJ[;I['\_GW\XOQ553!_/+[N7 M)^?=+P+DF]LN;.GL\I;=G'P^._WC2UG?],*^V#UKOUKY(L-QIUX_$FKCT'9$ M$S2LVA?:.9@V7TEC+-VSVSTA0H_2JSHW\2*?GDHVRY FY>WHF+0 MKA=2\PWO3CC'8A-1V5W#K.L*K6-T.UDAZ;\!^WA@QIUL/A[46YG1,F??R2,M M[Z^E&?6]N"[QO8:=UZ@2* M7W";KC]V?U#WTZ"_$E]8W+Y(;[R!_3/PEP]VD/APRONVQ?O6@/LF>6PI7[0:,N C&B.[D>B7DM=[!8YO[*%=RK>4:R1JDX_J6&=-[B>146 M*U>Z+5HDJ89NSZN&[BVN+%IY_^>9>_)5W9.U8>19Q_,1+_A\3\#SZ_QS\+C MR[,RW)<1MH):BL/X5>:\-SVBBF=F*ZN3/SNEV#K-!7]AH#7\/QW]9(849R// M("2\ .S26^[IVX%34<16G+T\[V#0W 8C>#FKW(&S^0Q<'_6HI_#:?+?ZX\&H M'YKL_UV/%/[%8B-0^?[YPR@,)\'/[]X]/#P.?=O^OZ_9%]SX-W?'!G M^>\&5FB],UN=5J=9>U>KU]8;[CW^L'YN$H',>R^ !6.@!0 M?*L/NH_4()?MCF;7:/JBFN-@,.&\2X;.BJ'),2*L%Q/ -P?F"ZL C4;CH%ZO M'QV]-"! FR\,@?FN^0[HHK-Q,!Y95+[Z[5^':KP>_;I\?A>>WZ;L::SI?J]9 M\C36(7FTB<3HJ$],/M+V2RE3'"FS+BHLI4PI9\51CAD@H?':W=&CKE 6Q#-N&A9G ^3JOMLA//)?1BB<(U575@72,U MSBZ -"JC2&LWW9\ACLHH4BF,WM3SVQ5&[0((HY;9;+>/4!@UVHW:N\"L'7<: M[7]MWT6WHP++K!W\3VD_%<1^:@KSJ918Q>6PY?-%IK[%U^NHF#G>1^N05%3Q MB%))&R2DBZ@"B)HBV4;LA2%9%RF6QE$I:LKGBRAJ"IGH?;2.1&\E:E:Q<$H1 M5%3WW+HHM)1 I00JGR^B!"I"DG>.!&JL3P+%S13^LGS?-ZB-]9G^=&> [.[XW65X. MVEDTB]PL9Y'KJ'W^+/+C2KZBVS\EP[H M\OG7[8!>3]^%MX_7)GEONLFON(_AEE+.80N:EFW^40J84,F_K^>T*&7,] M Q+6)67,AED3K3=J:\SAW)&XYKMN*7?63)?/$3R@[Y22I\BE3TJ:P?6PVW@6F:7;:K7^MN?G3;Y'+,:VS4\RTSK+78('Z/W7> 1V6@+%O%&468[X*(7/VWI^R\*G"+VBZF;C MN%:KFS6SV3H^>C#R%>YK_&N/P]CM[Y#F#YTLBK7Y%[R/EA@&[X?W( MMT.;!\400[^_]-0-L5IQI-&::/7I(#2 :G%>[YKFH90RIWR^&,]O6>84H6&4 ME#GP_X[ XGG'+;/>,H_:)'.4R%EC3P^?'WR,< 9\@4R=>;/@7ZTY\_))!/4. MRH_-)]&5DJ5\OA#/;UFR%*$[U +)4E^_9)$3#(LO5=ZB_^SEL'XR?HZ@*KL7E'+J+3V_93E5A%J>/#FU MSG'N42_))"B;L155U+RT!ZX4-:6H>5O/;UG4%*%H)T_4K+%:YT\OQ!:RJQA$ MPOZQQAX\G[6*\.\@]/K?,)..^P%SK3&GCWUNNZ7D*ICD>NFZGU)RE9+K;3V_ M9X'I1([^SNRPRD[=Q%\ +=+] MY=M488P=$C^(L?/X;MUR"6DPLH5$]+"-__K;/2.! /&T) 29_NF MR3LK.L-^03R(VF;[E(+9W]Q <0/U)SV?M(%*:]\&,<*IWXL,$X^E=L%6;1P& M;JNXK?JCGD_:5N72'DQ%T&R(V2&OD]VL[@^2M*@?WH5L/0I-LT? UKUR6Y4V M6_5G]RCZX,AMG<#/^WM_]_UO]V3K7C,.05_\)60_"MZO;=-QS!Y\,EJJS[[X M/X>'PJE&=/4OH2G?DX]"B_QVB:' 'LO21^&[K+NX7>'PT(=4U9[\E[5-"]RY MX>K'NJP\"N)1H>\(MJEKZM3[BXBUORG"W/OA?PS^-2.N3]>\/@.@PG%M$ M?CQLDXYIP>)]2K,@T;<&Q6/HG&3P4"P$D8=894P9Y'Z$D $GW&@]B$*PY_:U MVYH^^&O1&V=,B1OJ#D\@1Y0+ M4FJ2DBOO=XR0,PE^L,@/8:B(Q!7YN_VISHSYWQ_:GR*?"[>^'@9D("S_/2A- M2HC/".UI1;?6_AN&8EI]TZ)N27L@7),.L5 E1(:1-Y'G5-.).@G*,M[J3"Y9 MC$>/3[-'I8)FK(G62Q?=NX4X'+Y*G/6F>1A=M)7EV5\(C-;<,- !_*^/?IHO M2L]&WL!(* #"I7F4GLVLOQ>?V=*SE[<1!G.*)Z XT[.?];?S&;3^L^9TU]&U M468&HNE8%$-&((*>D.=$MHF? JCV+4T7Q!R-_TNC^#\8^W_7\%Q5DPU9.'8U MVN8D(YR?UW@:(&UI -[PD:>L^?.[G+).0Z>M4,,40:O'^7WQA8YIX3DJQ6Z; MNJ,.Q/E7'8@4P2)Q8Y0V8\2[/G)CQ)_?96,438^(&(Q1%)VS-&.\0,>/F*X@ M&*(=\_.+SDRKY%ZSA9KOQ&#CR5)@L !1?-A8@)TW M;;T_2!6<-A91^P9NEOCSJ7@^:;.4IOY<1;%0*N4Q@*I4LN('6Q2E"$#U(+$ZBTJVU-OP0U:;)X7-VCE@0<:]AI_THKEA9-I@P-''4F#FFL(*]8\4;S-:)!;1UDLAM MW3H91'_9C=NZ3=\89JOE0""P;".:M"8W:_SY=#R?M%E+0R<+9LX@/I.*N4KN M0Z?\B!^)%7;&Y9NS"/K_F?!'M#,MHKB6YH24&'MX>]]H"5H<5J:;JF MF 8V1=?)0#B6C4=6L>'7('XV:9M .S7EAOP0+$6'8*+T02SS0(U;M#_H^:0M M6OA=S?BB,/BQ5"F)7A3F62T_"GN[T?IBTAX7U,J$Q&)+V[13TK9U_ @-LN(#C&:'@.V8!!8 MC@\"&Q$\BD%@(A\$-D+Q9@>!3+C MO5)*&#[>*_HP//S<(>D2E4JT)2HW7B2]S9K>]^=!Y M12,\'_H'+Y*P(LZMD@N**!]:R1:D#T06I6RA7(ZZMN($ QM+UF?I66_<8I8E M/(.%\,&_2_Z?VZP@<(XVSLQ2Q6-J.EGM/*O6(@;E+"2IG5?0E^N_)_]!S*V8 M)4U-_0/7VW^*WE[%=8A&;TMYJ5"F>KLHYDM1Z^TFA#O$J]HFAA+B)WN=8:7R M#-U>?43N4 M87H625HMA]\H3U@M2]&IY>%$6):^P(:F31= DVVRNH:>YR@36>D.E[;P1HY% M'),KYK=E,[ABYHHYG8LDK9C#;T;'F7#.Y@L2S7/D\G[".4)_V5?,/V3+DL%K MKK\02]'"M+*?699*PVN/RZMEO!F)'Y/9UR"Y*DZ-CRQ^D$HKYI5C$U>N;U.U M2-+Z-GSV?,+Z-D)'^)PXL/,UM.LR:8G _7.N9M/O\:9)S7*/=UL625H#KW"2 M'9$&SI7*3 /G\WDI\I,]6DHQK7]=?>!-"PM1OE\M8@YG*L\\J(+HB*%QH:ZP&,W)SQKO 4>,>AID:OJ[5"0Z5DD:56]PNV?125^<2GRE5SI MV<5N8^HZ7$W//ZB3PTLPN[V*+KT+)*TRDVZ.T.H4LU%YQU'IW*I M#\R=VS?R%]>T7-.F(53B*X*N:J>)=5TL7?% M;E6=S#WA")@ND0MU7/UNC])+SR()J]]\TG?M0M5O,3KU>]L2&K!W72>*XX+N M[%MF'] WF'/9F?O%J5',B;0]1A>A9)6C&+PK^24LWY2DXL2)*4S99! M*CZPY$0$\Y,O9!OKTUINOZ^'79YCUYXG]>Z7(Z$%7Z,M3AJ&ZN(L2V)/%T'P M)A.19B02*7W(?9 JJ'I7N9(4*H,;[/:8Y]T>1P2/HMNCQ+L]CE#\1W5[3!.$ MV]6),MS3>'-S,4E<, 8DV$XLOG$W(:VQ)'%4MQE-9ZQSS7;H-5*W;6NJ)E,O M WY?IO!]>71,/;DF91:.6UL#E'6Y9+FA-6P\W/-;\0Q9) M,M:4\H68:-H""NK6NV0:QJKT^A(7GY\WH@K94DG'# MB\RGRL_X6FUR99*F19)4)KE9EGBA,LF)2RH3A+P#L&._:%0IM:Y&.GC57'%I MR[RK#OP5U$O?M6Q79AU/KUUPY<62@FR=G>1 MA/706EV/J!Z2WJ"'3C5#-A1-UKD>2MTB7 _Q19+60]*1*/S?_ZVIBJ2(72(\ M/EM&38EEX?:H=50[PJ()NJB8*V2YIY4KJD)NN*J[.8[5PS'MO8OIIK%JY9N&;91 M!W'5PE7+SJN6E28P+"@J!BCI+;(99T7O.J;5DQVOU4I0"^$QN +KR?")B@=. M=79AQ(:EQ?=4GFP;4=K3.( MDA;_S]R;-,M#'3.859O!UB=63Z-JIST0&@[I"<6L^*[]_IWT'FMSKLF]G_5M M'7[- /=8J(@$6^D2U=7AE8XI.%W-%F3_OKS0E4&SX1EY&^_'=T"[J0+.(L2S M[B/AI@L\R>ZK 65TG8'1<2U#L[N"C9?OZ3*RK@\$&1[M#Q 0?-ST(/5?SMY- MA%:])KA] -'"R[CVN!L69C$VQXLQ4Q5[>$GYC]O!@@T#V](XQ.-$^ J81\I! M:.[01&+)*?(*.-^R8UH#H:_+QI]+W? .&ZD#L\9TA*=?3 NUAW=5%?2$=]U5 M>*=YY*>:AS)N]N/_^W__]W__'_U9_/B>*1*J1'S)!]?HF;#/5>*@ZD*?Z)WX M7H 5-5:9 UX4 .;U0 (UQN" /Z*J< 9]^)^N[ 3OS0J.163PIV#UOJ4]P?<9 MXQD=305VA+7^7)Z;40V:.CC!K##@E&!YJ>T;EC'/6:!UKFP\+BW'4M%RJ6A. M9,6W3919JX:!7;FN";*Q !:&SHS$R\V4N]!^>9;.7\-C9&KU/$;V+)Q)JU;[ MILWN;0]K5[ @.#ZB]*5#0@6J@J]B"A6 M!!,4SHBQ+7*OV0Z=:FGWB4+Q ?;4$P5#,0$."U4OR@V(GT4Z@ U#(3,8_4UN M[[1S/=[L I:8ZC'">AQP!SE9!WGZ%GD,DOIWVUM,4V&ENVRV-.QFT;BI7[!] MB$7@Q/:G[= ]L*/3JVL?97L!I*M!2NR4NC2- M@(I;'^JTJK0%O: *O!=4D&)O[P65X[V@1BC>;"^H%(@DV %_VP&]'XMNC%ZC M3YGE\M LMQIGE]6;V^MZ*]*-<0.V.MA-[][;_I[G^6/*2[-HVF0\K,AA#"L6 MWJGOEXXO)B*'+L0;*C8;IK=85!816304HJ^'H,>&?<)?X'UX'M$F75GO8#R! M*[D0J%CL ;JT15P#OD57E%VG:UJP+S4*:YPL"78[EF B^(9P(D94CP4!L'?\ M^+\'TLIHC5AM7ES=W+888-CG]>K\I'%YULH(C[HS<0:,EB!ND") M$&Y=$'.IAS!?BAG$E'%/E)L]D1WR%X/D0K:4KI!CG9;#I\!M$M+CP5]S89J( MH=K3,=1&])3VZ8/]@0$+CYI.=R TCX0+$TS]WQ^T-"NIE(K]'P"6QR@,EA&W M<$[A8$V>^6&?#@;)5",/SC *IU'6<8#M9";WC$-5AF M5E44TS7H3-[YSG%TMQ,V=(J2>K 7GK\M>= V/$FCIVRTQM4[2VL3W7SVS] Z MI@Z_(>'[Q+)I&:VQO^>=LWEO"YS8(;-XW>04&8^A* SXJ-@[218;Y&BM?R M\>.FSEP M?H/)"-4UJ>2U.4A/TUUR['!"K[UEV$[G=><_@5@;>Z0-#U"M34$X&#M %A)2-&6 MGY2GE'*I &O>J: P1NX[K9BA1Z!@H0\G;72[B8*4'K%T5J:TA =K M!\#BOB,U7:;Q(,-W==ODGB/W'+GG&#^%J,@Q2'RYVUT>XF"E!ZQ=%:BM(0 ' M:P? XGZCG_)XT@SA*UXQO1]PUY&[CMQUC-]U9%+'8!F*WNZR$0$=@SV1H(3X[Q4P@ESJMT],1N=UF(@Y4F@9MG M ]_43#P%TYC7&9!>Y /2HQV0GN<#TD^WJLG5UWCBIWM1/]O=.&Y?5RUJC>BZT;N"3B_KE3;1CWQ/:6!(#)F(AQ]AB M]&TJ44R\7&7"*^E4=5TSR,&G&GP9QTX,][@K1-J5<0[1C>>NI'\\M_2?I(=_ MK->=_ZWD'&ZXG$1S?C3Z2)^2:!DMEFE0:N(,&P;3J&=>RX%/V3B>__U761+%C\()44BO32P_J2#1JZGP M@_A73,,K-L/\;V>"S46;\;+RCZ[FD+3PKRQT+=+Y[\&_.G?9K'CPZ9H-@C([ M0@.,>Y\8>+E:N*9CG8A%5*'IMG5-"7:"/-6LWM\?Y$_"NV:M>G4L-$Z$2_-( M8$!JZG\/7M27NTKV^(ZH1#L\K+JJYI@6?JNAWBDH EDQ*][=X4^BE!/O7J^^ M6KK\_7KP^5G'=/#+7X9I7+H]V(,"IM% QKA&H$\MLX??.LR*\!_'I#^+TF%. M/! ,B/[^>P!O_&OLA0>?I%+^[P]C:_I"%TTO2RY\B[=P>BAQ(S)#"*6#,9,B M',NZC&F*5I<0L",RG>PVVXJ@)'(^3HR/8SP3V$8+DIM@WH #!%Q;,WM]BW2) M8>/ BW/3MF$]B_9_&Q#9L@4T-RIG[K0P=YXKZ1E\GI_/YW3,)LZV!*TM \>; M.@2"-@T!2A^%^F]7CN[KC>OKF_V]ZY.!3S#;];A?RYOA.OZ6:-U4[^NGPC- MV^/S1DVHUFI7MYH9 E3@L6TAMNV-563+0U >H7I;^+']X(,LCGW/("U/L85 M+*)32,; LL<">64L0:N;-L"DC))9=D@RB]!D%GW+_IZ"B8#.,!% 9*7K#_A@ M"0'XR6!9@6FX#!J O4-G$9W;)Z(/X&\=8N&Q(\1E,OVZCXC.4 )&6_"QLZL!)8-WP4_MP'<.S))?JF MK:$'[N_/(\S$^:;ML1Y+;I.H*&!]EM34X1/03H2;F89 ]5$*P2/*KJKP@JHSU7D+O9GNK.>=M]U/-V]OT>QAB2 ;0&W M$*::-5MP$7Q'U@QGP!5GHHKS6+8UX!$TEI[;S)5GPG2($. 9P-Y0<0\58I1] MS[WJ@RNE,3U#W>2 KO25";S)UR]'PA6XC.-?$S1Z)@#*$SY'5>B[E((7B4TN M%PI26T:-;E*?='^/!@SVD0 !!-530I_5U(T\-5C%ZJ%R\ZONJ">'K_/*[WR% M'QS(_ 2*C^HFEHEX-^;'O1?>>8XS+=+S/64 !I0[0F&A(^]YVFT"*G!4_4=? M[OG!HP,2!@"ZRP"#I=+@9@CF[5'K2.@0%5U,P29@-I@IT>7GH6\KR/T^[ 4S MI_M[EJM[E@9V[>J>%^R1K#5: )^HO["8!('H:;:-U/#7I+L[BI/S1LG7N-X M? '63W45)!]&,8QA9N$:+:P*%+>'+,Z0 &;.M -_]DG,S-@S$="*4L2!!<>0 M@1$%WX54-MMHO>!+LFT:-/V/KHU%W\VL^'.7P#>LF;X),!>\K6,1:A6'$162 MS'\F,UQ$!?./@F99H+?A/QT+(&&F>LAK-K7.04Y%!RP#GUJP'W@7;(H8]R#. M](_>MC+(Y-Z^ Z&28#%D)D[9IG@Q(#P!/9@T2I8D"KJDX%C1[\Y(D4&WS0I M-1["X%WT7@S%.PHFOM-['T3("UXHM &QN$O_(+WO6GTD(ZSB*2'JG4WI(=+I ML*C90#TU0]"(CD) W6MJ8%2 0Q4Q<@; M%)8CH85D"3P]W!!YD3$>,.XSR"TR8,)VT"9I&!8\X?PLA7BN-(M<@+E[:%>8 MOL68!'Q[;\V9^SK:WPM@DWK?(PB>9-UE48*?)O/,5B EX:*1Q!>"&3.T#I@& M0"2 JO5H)J(G@TO>'@0,=@8#AF<"817\.WH%(Q!R-F9RO 2/'$S6A(*/]KA- M= TB)H;H@.H%K"*> ',XW6Q[_H@$XQ'-^ M94#R._&]ET]G!HOI61N-2U"+T[>C_S(T7I,IIOV]8$0%Z[^3WH,Z?S+U)\\I MI?& 1C/(X([K.CA>U,+8;ON!>2(9?"VFT'3R O13[ST]BS[=:%L!M1Q*B_T] MU23,\Y-U1#[UL0: O$%0[_I^T(PDF?Q(#)9>>NZ:.F%&UG/B8.D,&I8 3)Z= M&@=H?\\C/V6(C&<4J#L&,0YXB?"^27#"V0M-AA&TA-,4,@%0#>RYYO@$W;XT MTDYH"4]_TQ3E/7#3_MZU.0!.' A7$(K?4P;>VLTE:U-C]..C0TD5'/SIK''> MUY!CIZ>+,_(C]Y4J)UFS!/13B1^)*D.^$BR/K_NWF)%$*9/-9F==GHM4LVZAS"90*K&_1\)536C[]*@GKHLP7PCDRQX:S#,1/>$"1"R MHB\+(SONYX""P2P1SZ(_)@8U[;IEFTRR>%Q7[&7$_=O631+V0P[714CU3 M)?I8D(VK>)BET3K*OI<2H __H9(4 F=@'Y%:)U7U+JQD8Z4WM+9")\U)/=(>89U+ARSK2@;W;6W58,!0D,98A ML/L"@NMH.K"0RLY$QP&F>X)-!?@&@QD#BYM08\&ZLC[ /)>'H>#"GN2#1E:\ M(YLIE=,WT>S3]*@7:N[OL50U71%=I$"!66#QCRSJU)[>CTXZX,\:\H-"_'1\ MF-ICV7F,A'U(U!!*40L0PE ![4>=*U,W[T&8,?R=MYR/GC$7ANG(L90E_A:@ MHFQ@547@J(W@"1YJ=!2Z>V1(F]H=1>YK#EH^0Z4A-:TUT8;'<3/>YB$Q]YZF M?#W @1!=@M:-6E)%<2U9&1V/AOJ9 0J/:_CT1S@\)$L(SU[7[KIF&\2J]D"A M".?GS;&NW=NRERTE 7K9M"+-)A;U"NW00\"A8ZJA(I6R8GG[,DM;2J')GD@G MXSV1\.Y9>$>DDR]&ZT5OO3Q=R-%U1,+7'7RJ-UJ7]>OJ1;-^O;_')#:L.=+6 MXSH_CNMSDT6"X?@NGEO]SH5Q\B [?_BL//C6[FBY#N-3O:G)F?Z])#,,> MZ$^RH[-M".WF+ RTKL)II?*.7_QDJ6WF_C M3A?UGIZG^WT7)Y?-W8FB>-Z, M"H?"G%Z#:[2U7LX 3;6U5C6[K\N -W!\R!*]J\<&%HSW,3ED*13\D@Y&UD/< M4%-2"SPV\#05@1?S_]T :(35?*07ZDS9UCZ$/ "N,F M?,WDCD+!#UGQ($F,E!$C(L-(A3R5NR2%>=. M.[Y[;96,TH]S^>*"FJ5Y3/6&9F(30#,P_$V'HSPDEF&!3CB!@\]9^*YE'@Q; M,$W0A!/T>(J@-5;M.*)K5@3*VKWB]^(7_=FLW*]!V5F]#Z\C.0/J"?9NTS%"OA#+I+^!8CP[^7&U^ KPIXA MO+PDCJ=0)^7;<++2:^5;X9_;=>1[ECX/$^KI7?EP"M80T+@UZWQVF8>XF*6R M4%G((9NR1A'C+#K)$K-O15JX+&7OB.+:P/*'APWC"?9A6H,9XO/PO9/K?=M_N-3L+&9F9D[NV"-LXQ;*^* MDI4L*F,AR%+1]'S'9W%TORSSK;;24GI\"7+&+-JELKB0:6?D,);%&R=:U)JF M5%GLVJY%M,4*:$K5W("N<3Q= TKGM3V0[EZ56CE_*E8NE(:2A(665E,_-R;6 M>_Y9FB9)G2(6,KE2EJN5J"D487BFH8R M=(*"LO/]VXM4^?[:%&](K&(IX(05G<:3TQS+3UTR-# MP>*F0YLHA]K+85=350+/ ,])VDO;TK/94N[@T^'82)ZW,7(P77WE]Y8])[)- MKA&PJ\XMA#.H@2=8NN?\,$^O'XS?V74R"&N9 PK0H=DYQ.O'"Z^ MXDZ_O5FQ;0_6HC,(Q7(I%G,0K,((1/XS#<+9R\UCX=9Z/OLIQ6@09@:[%,2@ MB?A# MY0TL3MNL64EN%4BM133#1Y=C*5/$/]P+)F3$%(3UKIU_7WYX*]3G5/ M;,DR*9@L6TYG2&MR(_T>;6.ODZ7J$U9<987\2]P:HI0IYA?;I5#$KJ\E=I4N M$2;$BIEL>?'!]EITX0FQ]"3$@A67YQH;E*$1NVJH+<=4'KT)3&R,^%AQK67K MI[)Q85?[,<5 "VJ,V08#($^-P!N?@9Y&DJ0+FL5G70%LA]?E?OE=?VR4!EE"!$H!/+)>HTX3WBRK.:Z^/)'_WVL@:U_7? M^9?\MP0K=.<4\_79%EBW/[:)877%FL29,NYK5ZDM@=_8<^J58N*U?IM'8(3^ M4:90SL>23IF=E/0W.5D&Z,N@:W^I.[W7BO[/.J=4;ZNBO1J-YD)0@ZI9.-QL M@6!X[FT2F3$+G)3?UB.L-= 6G9CELO'D+*N3.-^QMB]4Y(>_*RAR]( M\O.WZ[KM?OF:[Z:E_M8/*.A$(M:B4X>-'#JP$\!MVZ$5&/BQ"W3$AU[!G\0_ MC+HPPA__/=D(*AO #&*D84"XY.+Y_^UHG1-OA2&Z&EY?!674#:#V]8LA_OIU M_8]^?R XFH,[Q@4%;;AB9APV;]%%C+@L5''[H^6PNV#TH)>Z\%.8K;T9LUY7 M@<'U^4O]O)S[\>TA19B-T%$MA9W]4\QF_$E[= #VKI^LA&BFN'V^3"&W^(HC M/P!;BTP17E/))5#X&5Z"&.YUTK,PSUJ"V7R];PWN7F_,;[7&1:DO*>FO( _Q M2G>679-V>?.94F7UT[6$GC01,_NU:5Z2\NU#K">.\]/;2=:;KY.K3:[>K[0;A;G+ M8BY"AZ'\UO.!92P4%0ULCF$Z9*9,Y4SEW,F:?7VP3GYN70OE@X8C,LF:Z;;P MS6(D&9)^">X_).-V7JZIKX6;[TU]E!>:!C,L,31V_V21-E\:R+@E-QLFN7,2 M<*4H<.WEX"SWJB(U^KWCZGUZ<1VA*2V&]<68DY+;C*,1KBQBYL->.?XTJ*D1VA MW(MAE1%_^+E.8JR>SQ36J([_T[.PRU,JPM9 &5%*]'PG&WZ^,[SDQ(PE&,UJ MJ_Y:E'[?O9JBDY=NGS_7!VIJCW;^S".=^)O@%GE?H*CI$V6@ELGS8YS=/\8) M7H*JF;V>YM"ATMBSV<^W*YX*;XQI[FZY=N%T=%MJ)=8((@"?-Z%W>+@33$J_ MPR!4J+R//2(.MNZ8F*T3P4Q%;^'9/4'$G!3L";)&:Y!=QDWNC;CA2BH]2JH8 M4%+S[F;2BWB_+VO-QJ5+BB+2>)_C#H%XB5W+'1N2 M <:H+';N7IN-QT[IYVWON9S\]9\A>/ U@"_TN&#&7IJR=671,7$JW5:36)25 M:)9'4X,)M8?CDO*[TB _RJ5ACF?RS7W9$IYP'>&=9@@G.!/.LD>C^]Y/3^NM MK0$:8MX'SDM %:^_B3__>9*.?ZEO 6Y1I]TEP(L@:FE;]PZ1Q2)^/PB27B#.YA+VXZCI=T\)4(&7 "'IOLK3?-J;CTH_!RI^'HA?G$;JEQ8#8H5:#X)1P3, MF U0>ATV7 JDU=@O#"0QFP'.P_^NRGP>SIGN'2%^F@G+"\C?L&W7([V14^]4 M)O8#H0E8#%F0%'L*/W7SJ/4.5LL M">9HM6E0%@ED."X\2:A_T^6S>SNG5O6U<5%<'Q<>% ]JI>Q>/5=/W?:*N%B9 M^QDVEA9&#"J0^Y]-2[6),9DPB4 < ]A)$51ST!2F(#:/IBB@>B66N8S*6DVI MA:HX3YC8?(O1UA*-Q.<%S.5U&XRF /9*M,U1ZQ-),=.8##W8&>PH +D]+ADO MM]VK[S\>-WE#F@$[*Q"1PK?![G?+6E]L.8/LEL,6 3N7GZMR&-=V%;S^V;!MFS0(8QK12 ( M8_(904"&%<.-9=_O<>/GRZ^OOQZSBOU:7N'] MRY(X%5'&JO!$$&*(A75C#*;PEPTT9JBC*<]Z@NE>SX^?K.N?C7ISE@I:X%,7 MYKUWTJ&>>+G>-*6\\[O\>EN8__(57.D9>T\'NZWC0J\&4#Y3+%0RI=!647.Y MS>,P\/(F*9Q?D;,\=7)9[JO5IU+[ER.NQUDGZW"6]_+KX^N<^$#NG;%:\.0X MZ^V*(V+.>CM 4B8O%C/9T-*<)3AK;C0AR#;6=IX0A?3:X-SDQ(R XD"?F_Q4 M3+CD>DEOOE#:WDBDL'84M42+0H@ D"MDO2EK:L.HR7W-D?7P@.1)SIM7EZ]G MQ6J4M\.6[$0X!%3 X7B'X' K#-;-7G2:@<#8*YWRF=S63FU8!6=1MF5');FX M=G$=D0KV/[LFCJP91*W+E@%\;5<5Q>VY.H9/)Z2C*9H3+EU*[_$A>R;=?BVN M,\ ;[J-[2^,>S>?3Q=3,G(QMP$\^&Q:WL5,KA!AW>U[3KSH M*Z5G$4^2,J7"XDM%JQ)O\?B8Z;H6KQ^.IWL<3_<$:_"J]WD M6,FTO; @9GMY>3XK3Y,Q]DY;E=+J0R3^\#KJ):D4G4-3R10+,5%I<2OE1<,- MO/L9OJ(9Z9>FKG_]_8\ZD!NE-+DYTHS;&33(75_U;/5DE$4TYK-L=H)B6S;E MYH.#O>KAY_V]T;10K.EFPKZH^GLX5Q0>S8Z_5"& &VLB,?.FRG)_ U[NIK\= M4-]TR?Z>K"AF#U8<8 80.T: *K1P (2@P?ON+9J(L>BM;Z=+;(*<14TG#1$[ MFB$;BH9N&QXOZ1K_Z&D*N_F?PT/A5".Z M^I?0E.]!>EM@(HBAP!?+E8\"/3J%-83#0U^CJ-K3\O[(HET6Z2ZI; !F=-T3 M,IHNQM\!7,7_??RE"AY<]VT SO_IH_"LJ4X7=YS]3]B%B=GW%P"^,$F>D5_Q M21AXW<>\,@+GTL?A1N!GV H&J!BE,^"I>@^!BF+TW$:2[XI0_^M_ O(_WA MZXZ_/P#JPZA@$?GQL$U $<+:?4K%(-Z+,[EK>FQQD%7ZXV\, HH;8"RQM0+Q M=WNXT?:G;=-U /R%Z;CV_MY90_@,MA)S!1FA82A'; *6V[8U59,M>E-W*_NY M7P97&+?,K<'^QG0!T$G^[PB' I!+A(6,='!ZFA;:_)$#)?8=SWYJG'^6E#:=Z^W7Y_SRL\GZ?@TIB:BGBTMYO\S MDV<\N":IZ'U3FOW%MZ7T?2O_G_6S:J'KY?^S1H+-I\UX(NW4,GLT]9D5X3^. M&>U0KB4:. 9P],93&4Y-GYHBHV:T7>8JB\_PWTI+WF0B/2T'BF&]V.O>W-RQ M^=^R?2V8NJ0X3HR;L_B1?/O5Y33J/U]G;SE7'4RUX# IVO%:MOTK% M[MVKKUOWTY_F ,MZ5&T&)TR0&E27QV!NEE=/1=]24I; MIOCFTO?MP6$.H!H2Q 82YHDDUVB_G@=60O.HS@C M!@3 .FRTJO8T0\-H'&\MSA"XLEV7ON6__FI\7Z<=1RR%\=X.J/C)8WO8]6+K M!;1+4-1+2UE67BO_9O+%H6@J&:FTV(>.L(0^/Y$HPC)=/Q](2^;O>HZO<7KV M\/CGM?C5>7T\_G)QDT_M2 .%QL"HBOQTXJYS\20!D\Q>E3/+1']<[:Q.L'B2 M9YF)WC!]=$0G,4JWK/NCI8RY27N_87Z/PL^JGE]GCOSRDZ_/9,T0WJ&">R^ T"@4<@$^([8# MK$WOSL FO+Z"9BPN.VG!@7=>=F8HOT]943>ZM])UHY)4_02"AS),QL!# MF<6YJ+&+YG+=HR0QA3UX%_@."XF?O"CO_=I#:<@:(D0V[0#.N,TMZ4)[XRVN(P M$Z70L;IODIO@Z)LKITNL2],PQZ.-2>-PJ]X_?!=OM(>;=9R[]8KK$#+PZQ"< MM)@"*9\^4[ @B@RG;W*'OK$<0@7;0)^:%H$OU^CP7F5P8\F&S5Z%5A"-X#&] MCGPCOTQR==5^+#T7CLL7-643\^$]R 7% WTL:[.]&<0%OLD*]-I$L)./<+SJ M[O>(>RLQ8TY>Q=HQCN>S4I//"AX*@G,VF:7W%3Y5_=6;U][+Z]WKX.2Q??WK MMGM^$F6>?AIZ@.8B3Q") MHXCYA) >44^T)PV<7-7&/?V0+=#?#O9]QY#G3AN%SK[05"[_>>Z?7;C-SCJ] M+=>( V8Z3PQ^0?4W('1@!\(SVP+MPXY[V'X#O&QH,CY:^0\_Q)X7T"]F_,2" MHV)&S$=XIKUT;GA,MU6?9$W'-B//XA8Q86GP>N"H]>6"5RL J.*3([P/O3Z\;NWUMEK_>?W[-:_5F ME!>7ID&F7,]N*&FZBX?]U!)@#[*@]N?WL-&T.P4\8QFD6M=^7^EF(!YX> MOQ9+QLG#_:;" >X33%B0&52+V/9+0U.1G6$JAJ,H"T>EU4(LCE!^TTI6H5= FV*#6Q09I5YW@8#HO-$%=I*$JZI&\TW98M\WB*?M\A?V"(_OUR+?%:9CWK>?*CM MP\<[;8V6^=NUQ7!78M5V^=4[4G MB0;ZY=CZYR^]_JJ-]E=^08BEC(L/QCUK!B'>5ET,9KQ 1="B>]F-Q"UY+,!) M/<93"=2"R0G'I;O Y%=/LS"U@9,X0#Q!T51?-/LNT()B>"YW0;OXW[V:S>-V M-]]^47\^;BF+5:E12CTU4PG4(A8KK,QB,X:]^^Q6NSPI?6O4U;Y=WE)V4]B& M4D_:5 (5/;]-SOWV&:W]4"I:YX[]]47;4D93V=CRU-,TE4 M8C1L?7+;&I3D MUQ\7YL.61XCX_S:RMSZXUH>:$=A8>GDKE4#%S?#1 M<;&BN#U7EVFQ1W0<"'EX-S#3:W0;Y>'RQ/H MG UXDINS@1?O\N0SYP.>&^9\L)49X(D[%+GBG8*5U%GX_[L[_$F4OE[^OJV>W%=7IZZO7QT1ZX6MMGWQ8C),K_"=*U!_+.O8$8(#* MCG!"%'H>)N3$C 8SLYEE24V,IP7G92(K@E@^,#IN%6=S]J5 PMA_V1/0N54=%P_76<5Y-6\KVH'@: [N]YA Y(YGI,#KE$LRWB6? MU87(0W)EQA#NZ$HUYT^NFL3K^)6-JGW5099G%S5\=-U-82NB*QQBIBCF,H70 MB=^1R-QF6)HKB!1@,WY!"ZXTIV]/?JR[-&=KSM;I9NOY]F/*O5S*@,RM<(NB M\;18R&1#9\QQ>>/REFIY6] N8$V!"R_QB[3M4S:7*4E;*W+ON;3]B=(6I;!% M8K 2>N!;JI":N;*KW8#*^F?['O7NN5+Z18:7SM M_',?9\)JWC2^I5ZUW CPZ'#NM[!D$$_U'G'[\'/?;>N: G_L$(LV(3$(O3?O M?^#-(85/_CVZU4ES,-ER@%)-RU0(80TT_= Z?D&7=W\LD!]DXHSL8=AT"_%E_858BF;#'[QI*?;=JY0[ M^=[.G_TRC\O;4C:6FH0E LF+YKR M@';#NNH,A0??7L.,7MQY./DY+SVT'W_\OLP/SFYZ^MSDW"(1WZ($'9V>99=I>!<3K;^/,^)TCE>/CK>GKE9H44.!JU1.@&6N8X*_6$.-^ M?0=PY/QFLEP+KI'_*2V;_UD@ K'EA$Z_O3:/[=_F[F)@=YNNA8&7DR=BV80NTNKKFD/3 M)%XVY&LN^Z#(O^6?K[F=K()9OK+%,3'\LEW=P8HLKDNBSEYD8^/GX04G-;[4 M1NNIW,E_*Q?.E,KH(M\07C^E83.(!FN+4.#&?5C;+JQ!3-&?,R-Z/AJ:^Y M@0*8;&B*FYZ0%N;4O\\: ,I5_A\@1[&3*_V(X0S%%?.Z52E;J7)9[F7V1:*J M^@!!*^W +2Y&&R^O>6,JUL -,5[(G%PLXF]_YPODTN(N/$ MW$TEM+/J)2RJD5:,:F@XV99MHM8"%[2O<1:XK3D$@'W2%,*"T&NBF/<&784= M+K_*XO'#>=4UG'-M)\^5UTTV4*P>4K0RH'G+A'3F;B(#,9$(B><,MP]O*3EW MK$0X;#GM*.>LFDY6?;/S]Q9G)677\W.9?(GWY>62F0[)7,Z(Y++\3@-G56Y$ M$KC?OQ/F(;SBO1[(4%P2IV% ;$S.\=KRZ_/CYQ.K>W.9%RN[=)PZ>HK!!,\= M%:;T[INP#XAD>] !D6]ED]BA74(?MDU+)=80A&,=J,@ $6Q3UU2V:AJY/O8] MI"]W$C7H;&^@ZXDPV M+L)U;$=AXKR^?;;V=7#L*G!,;G7#/01@'TI/VQ5 MDX)A \9)9([KW:I]U4FPHZ*4R8O%#)6@[<[;G[* MG5M*T<<^3C6'*I^K>RY#J9"A!0'JFD*40$Y)DC*E0GZKQ.B-V2,N0:F4H"@% M* +[4LD4"UL_R"\\@7.Z7@+G^J;R:)BGC8N?G=4#556S^[H,NP)LDDW5"R66 MVN$**NHT3FVS:9Q!]J%'?GZ1*T\YGL;A:1SNUZ<&;RE)XX@%GL;AK)IF/<_3 M.&GB!2Y#J90AGL;A:1PN06FQ0CR-LUROF7FS6N'%]"_VW>NITA.OOBDOWW]T M=^F&5Y3(7S"6-=@44G8.G2XY[,G6(W$$B]QKMD,LHL*W.@2)D!$,^ .LH?GS M.173=FS\Y-\,XF%Z(QN<.]J4!_02Y55G2%?\=@V_?-U,T"U%JWE2.Y+9!/)W8J60$;/%;3>Y7.7LB#NZ9/Y. MVM[9=IQ5=X15US$#XS[^BE8@[N1>)5,N;U=.@HO7[HK7LI8@PGNQ:4H]*GJLVRI9Q:V5?)& )>D&_(BADIMYEIP-S3VCZ\I20HR/'F MJYQ5MX151*]:>RQ/Z.W M6?E^>ETR%MNN^'3<;NRB+2YN-"C<;G%6YV5B_>&?G34)XANMT MR>*=*Z>+$?/)1:[W=/RS]^U7F=?H+%.C0_,"P("P6=G"NS>"JEE$<4S+_M]_ ME26Q])%/7H\U0U5:MDR'<7B\M[F,WJ^&Z>9<[:LVMR9G'M?(?=,>9YJ49IS> M4)5#:9&6VUKY3+XPYPIF"A4_][)VULM:-B#(\P)]SJI;J/]'SF;*KFE)N0*W M 5RP4B%8R]J (K(8GV .IJCZXMD.[VMR8,RPFC7O: MLDW46B#&O"80[-J:0P">)TTAC%+71#'O#;H**VAZ56Z^RU?2%RNK/_!:IG#* M400?4@PSH'D":,>UX)O'UZ<=?YSO4LEWRSJ*!7X;@K-JFAW%N/V6E.4:Q$PY M6]EV;Y1+YHY(YK)&9'LO?W!6W1%63:T1B3A9L1,&8G$WF;&)]7>O-[=/M]+U M\^.WZ\K6%Y_,&%P?)VP/.F#OK;P1.[1+J,&V::G$&H)PK /I&""";>J: MRE9-(ZO'OH?TI2Q"&68;+!3G]#^+TY?V;R,\3>/"P85CMX0CPFMK7#BX<&R% M<"R8@S46O:R884Q@&%8Y4ZA$/_1G \+[QIMO7&ZYW*XGMV].ZOQAHAD^:%U< M8]!Z_>[5E,_/>S^*[DUK:^9T+WUV.^G'3QX\7Y6*A4JF5(P^P1\JK-L867$M,WLK_U[%.TNEK"Z97Z0"^P."VR4\AK%M;1,I11_*G SMC,\'UA<+Q]XXF3+5_G/Y<_]-::' MJ9K=UV78%2"9)%HKMKF<(->*Z;^?OGHM[4OMBOQ7N-9_YXYH\'2]NI M9;;?]UHV\U?FF3\N&7^49/#,'Q=9+K+;)+(\\[=QJ>69/RZP//.W:2FT@H%KD MMTL,!;Y8$3\*]+8WK"$<'OKJ6M6>EJ^"7K3+(MTEE0W C*Y[,DMS1O@[@*OX MOX^_5#%U7>[; )S_TT?A65.=+NXX^Y\PI>=8_AJ366^ +U0QC+1.& D#KSOX M='H8Q*6/Q8_"S: /$%0MN:TI'X5+4+0,TY-@FH(9A[3ZE8A#OQ9G<-63E@*".6*4__L8@H+@!QA);*Q!_MX<; M;7_:-ET'P%^8CFOO[YTUA,]@J=$_S@@-0SD"7:<*+;=M:ZHF6QJQMW1_;#$\ M-^C<9;.% W\/M8#"WM\;G@38J-)QEHIPJIO/6[GI=PUC?\_IFJX-)(3GR(M" M4)-VF053A3ZQ_-]ZI@M[?K]M6PSW+)93__X14BY[>B>*TEW?R!FYN]?+KV7W MAU5LG[\0,!%N#_8SH ^"$O:90S@4@FPCS.*:@]71MYPU.A@>_GHO6.H4-G#8 M.L3K,&UZ![X_"+H 5*?'? VF$WGRE>A=R^/;Z3<\_OI[] M4[IN5N:?C$W=@IH ,(S#V/6,\;W-N,,SM>)!DKC)(D;$(6Y$AIOV>;7]T/S< M?CXKQ((;,1K<>*'(;#SW1J6^6^:0!GQX/;FV- =\MVK; M=C =ZK]K+?O^U\_O!_/Y[@V7^^9@BH5$M6KKLW!Z?O6C)9Q>7UT( M5\WZ=?6F<7DF5&LWC>^-FT:]]9>/R' RAD14;.UPI@E)A"U^,&S!-$$3SB2Y MF0W!-# XS.'IR9>UYO'MZ_-)'YR?7$NL_?-0NJRJ:_#$K(HNSW$IYO\3Q@$ MF-=F:WS#WK>D_\R0WO''Q-"U_SUC47$2% _U6WN].7R7H3AYOQ.(%H?]'\08 MT%S)9'.Y2- <+IBE68,%L#&BH6@Z&T)\G!_W!*L:0FR 88[(7T@ M@28C3U<-M=HS@2->Z:_ -U*877@AS]]_NL\UT8G0+"S'/$%H:=9"#L ;-P'F M:ZDYB$RPH6E!S"[45)MBX&CQ%XW.'\=>/A=6,?IV@=4W8H9-S7 M3-NQ9TEJN@.@TUFJI.T(FC]V5<$=;):'YN$V02',Y;95 M"%=&8!Q26 D;(/5V(80@60'/P^P='I[)FH&NU)51Z\K&/6D8==L!R!RBGLJ: MQ>9F=6JP7=@\>"K7YD#6G<%5&]XX-(V7GJ2JVEW/#@AKZ:+9N'@LMCH7]XG; MQW>XL_?,C0+B*G1WZ#\1?W]"!S8H/.$.V:!D?X^"Q38IF,-=QLV+\R;=OYE$ M21K=?%AMYB*.?;\948\1N_&&8?G%,=A;TR+T_LBQ/-&U?I95[IS=5YZ_Z0.B M2YNTRH$Q:!,3T#9I2<)1F8+6_MM@AE= 7AP&.)?)EZ2X;7##\QM1S0QO@9V: MUK$I6^I5YT2#:, Q+7L92?QUU?RG:IS>UA\JB9MS\ MMN2EODIE]M2)=,F*;^Y6XI;$Y*00C[\93+ZB&VZC'P[;,^HOZ&R[FMW%Y#AH M"=)VYL69/TX?[J7OK=S#4RYQHW?N!9AD#&8_)Y02246 M'S&N(P=BP!7L]2'H9)ML&$_PKVD-9EF%WT]??CY?M5N#J\1RH6 #AA BCVL^ MC)MT,<)PEF3.H[).SF/SGMG2:(OE?"&F'$8UZ'H%=GAN&O?GVA-1JZ!1'/LS MT56PJ+#Y1OT%8Z^9HG#IMO*?C<=& MKKE.3B&F,[=@(82.^V.81X%QX11=?DMJ;S\J6W,(/D'V"(W*XAN'MNU2J^1=V\2 M.<.19FEY#V@LA_.@WK#3LP1>-U'S6DAO9<6"*M:U,1J'WB[EUS^P#A?*T[E" MZ8=:H/;F26.>W-]G+YW*=7>=$M7E-+?$ OJD0OB5N2* JD1/2W/9=4QY[$4, MD>,O%CGDJSI6GID4@*%5/2(=8%E$]MZ]JJ%=.EU@L.)TG:"??3BI5+@:MR)!AL,V#OT?P]D(2<1N4K+ M!.\KB]LD+,NVJZVTIC&:2=TDS_ 6FZ"EITR'HW+[Z+BZ@EJ)D+&JJ"7^XG)&BJLGUVKUZ]HK^7YS]UKYY[*5;Y\Y0([-'7C.5&B7 MR]P(WWDA6)[D&\D^E#+YXN(SUE4E@=-S(SI-S&?RTN)\TEOTVIM]I12?7:8+ MFL7'[#-8$=/I]IR^47VM)%YCE%C:,:E]_K+=XX*AHNJ02XI"D/O.8T M5>6WJUD$^ 64E3-HZK+A5 T56[KW\1'L.A-R_-"M9^]>G;;QK?QB-;Z7Y!@" MI@E-M%SA1M.UE"[F.&;4'NZL"5J>HDG>^Y(6'ZAQ-R(J&L9R8%)**B02US)B MJ)XF0R+436,A4?;5$,O=_I/[M;2Y-.SR(9'F;Y.'1&$DWT1(Q!59DL2,-1Z* M6Z/Q8&BS;FY^L1T9-D2:$0S=V%^>Z^Z76S=5P=!IX[)Z6>/!4"1<$CSE!?90 M"%%MU#ZA5_Y#.NO^>OAR]WJ=;PXZM:^BTXBOSG%FH.,!+70 ZE'WML#E=CI$ M>;,E! LQFV1I9!:D,;UU57$@,HZ 0,Q4LF\MWIZ9G_!O$OOKRCH;!>[/8P55 M[EJX>P>[ZH*HV83NOM77M5F9"BJI#^>(IT+I)\/EI M -#W-L<:ZM+M":Q'A8T;W%!I ;UPNQ9%DI3NL &=&R_66/8B92$?[47*DQG6 MS>O'47\AEJ+9)*QE/!67J]LOYFGAI:77-FW8B ZU%4D/"XK8U MJ9C'&,F9$[ GA7BZ]5:6$ WA3*H?TH*DVB3> M$O2N2FO56F^Z%G8IA,4A2*#>IKI%O/)VZHBH74&JHE#R1#^"RY_GW%R*]LG8XR#?X.3TV+3;$?YH9/ M"9DK3-=/OSH_?CZ??9?7N7OY%M,T\R21[<"?4&[<"QVRPR>'-"\QGWY)=J4I M+FZDQD\(UR9:/&W<4E3;$'(F%5;;@*IGK+;AN7=U;(DWG=8@DHLRH9,Q/^B 7T"MJ -B&S'TA2'J/B'JJ&.?Q!XL@D1C:E.7\52=!GG"?JA_NVU\KY[7+V]:&PZLDJ7>)BKFRIF"E,XSN;03)IY3 M^U)^G=Y&BW72<50Z:8BF$\WNF[:LGX&RZ,,WX'CRC3 .6YY&NG5 MK?RJ2M_KE2^/^0@C\254STRW=Z;:$:HWPG']K'%YB75<5Z="LW[=N#K9=9\I M2<88EZFJ?=6)MD>8E%DF(\6=YG0Q0#8Z!LAFRN+B$^LW.]MI4+%U7\4:I\2Y M,5KVMZ^;<_2FM:VTA+:MP^=+ZUEI33&CWQ-4TVWK)(S&_UY*Q&:OLATR%F$U M5SZ3S:]^9UEZFY+EU-]J$[L4]7DZ(SWIC'IP9*O;[^L$3P5D'9GS5#>?Z^R# M\;L9/YO-[\WC;[\+4DS3Y)9*.;1NF\WS^@48F>JY,+RH(30N3Z^N+ZHWC:M+ M?C-C3:XHCPYG:9Y5UG VRQ@/7!;$]N_ZX*KQ.\J1:$T: MC\V8!$MB@6%"0E\2.OP!0OK[_HE=_-8I*^O,?ECA5&O"]OO [+2K,('Q) ^< M2JNW%?J3G;IE*!5'NK"XQLDX=[]2"\WBQM6^RW5I&GABF M[5HD8);3XHV=-%JU\ZO6[74=X_[+J\M#YI^-;L]>GO#&0A%;\Z''-KJ1B-6" M1+TQ6\1Q=.(UBO:ZO]N+!\2+X.9EY<]GW[K]LTZ4[85"?+K@-&B-@HTW\&P* M^%33\_@'PD^9EC=<2ZH4$KN6M!38LXO"(F*=!.M28SE/"Y9YG\J:]5W677+5 M87,2O+9 *I./LO)/U7BY[!3MF)*R878%I&')MW>+]*ISBLS*-CJ<4^*K M&29B%^<_!E]+Q^H@%^4,PN7DJC\Y56?3XL5J=Y?"7I(]N+='S-Z*P%A&R!7B M,F/3\N:WLPMVLILS561<%&^UF-9/$A@URC -R(N.P-1&> MI)G<7O&-$KFQ7&^(1;"#G>L#SKK(A/3YZ].Q8K677K\"VP_7+*++ M#@O;EK@+C^-9,5N'\LP^4/&<$\BV^8BMD"UM0<3F.XQ!#DBPW#T>FQ5H0.3+ MK %AYKDI&]Z-I6N/;ZHVWH<\\9B&L7YKT%('O9>+B^>81A!/;ZGJFQN#YB)T M %3P[ZRGF<7%[!:P.-7V*_'!U@=)P>&_$]/IK]J.K!EXT<6O8CXUK=G#T$ > MKGN#;Y]_]W[5>TJLIF#6<#,-YY!:FDWOP6(K(9-N 7^E=#\T.X!\,ORVV" "L-=7K5AK4":O?*Y_NV;(Y[= M:.OX;.L%5E:PMPJ36W,(5AHL5'+=O-X:C\PF;W) ;)>"(M:=/1DZUZ#-^"CV?&30H7@67J4[3_\#7A,TM\.J&^Z9'\/DQ<] M6'& UA"#)#25&"D)&KSOWI)U\",M*IQ.E]C8F<6@I?\TR/+N;V,32P<^H#5Z M1Q'@87KC/FX.';-/\3/\P*\ZF&[$$CU-83?_;,80WA\- 7>55[FEL9,G:?8M$NBW275#8 ,[KNU5[\]R![0'\' M-=7IXHZS_PGK:C.[- /@"SM^GR'F/@D#KSOX M='H8Q*6/Q8_"S: /$%0M,,#*1^$2]!O#]*6)."T&O_3!_Q;^9:0_?-WQ]P= M?1@5+"(_'K8):#M8NT^I&,1[<29W#5DY(*@C5NF/OS$(*&Z L<36"L3?[>%& MVY^V3=FX]K[>V<-X;.IH\S XPU#.:)9H9;;MC55@R@!4[5;N3^V&#I^ MG;ML%KP6;P^7J-3W]QP3%;A0"ZKOTZ'Z;@W5]S;N_EW#@ UV3=<&6L)SY$4A MJ%*[S)2I OCV_F\]FI-]OVU;#'D#1#%:9Q"QU*!T M[.^) BW:$3\*(RFBVY6R=Z\%S3KM95OU=D,_^'0"R+.TOG\R>^S:$$G:]I P M<0M/#%A(PGN- >R9^OP=ZCFDIY3]6&/.+?U-_/A>>);QR$XQK;YI416H&<() MT>5GT T9X?:H=50]PL]:H#](KPUJ0\J*Q2/AAJI.NA95*)IC"W; 9F3V]R@\ M H!S0Y2N 2'Q/7XNG#LJ,S'^W^&C\UJ&>MGHB!&LI23Z0/ [O>+)!4#I;<#_ MEK<#P;2$F=N+PO/FK+<0[+#3+LVW VW-/E(5J-8$;7GXW15: M QNX"WA Z!$5W6I\3@,WUNG*#OU>FQ!#4'0B6ZQ1%GX;N5,X-4V5LM.)Y=X+ M5;6G&1H6WE*%A)R_O^?QQNE)=%#@0'NH:VGJZ(+S!H6A14F2ST M3=,"1J35)OC>>QE6-C$.Q I@@)(6^ JJ:^%7<.>&:2MFGXF$]X[]O&OUL246=Q1 M_19S&/M[F,[%60HC&$,7\V)+4:RA8CTG;LC6M5Y@!60(>/2U:@-N=,"=.?R-VW(&X%[)/7M<)PXI4A"S[Q[?[^]1 MWJ6M7($,I_!&5[8& GHA+ 6/+P<.I26T04#JWUL^, @Y4ANGV&"0A\I:<]!; MI9]8Z+CZ6*;I"8 >(%9=Q3D2?)T2;;;$WZYJPG<-TZ'E'0J=TG%/#'2"".V" M0ZNWZ-';$S%<*QC#_9Q=[@T=G-UV47N7A_/\U:U6'&_7A2VQTV69KK) MQW>O+V[VJJF<*:]-Y> 3W;7@;9L[QXF#?6/N[V&,G_&"_I%'XNLI54#7H0?: MU%-2-&X&HZ0Q76L0-"!/1#"'IZJT?2<:'GNHF\&7=JG3:H]X/_ -W;1M3#ZP MR62@V$9M/H_ ;AOR/4TZ>&K4'@.6%?#0A@/C^G7.FWQ')/C%CLO\]?T]89M.U%,15Q\78=URI9]C[O15Q M,\%I;+3V IT30CO=CGD3_G=,:@JH0T?N0;?).AA>@Q$"/C1L=J@"V+MFY]F: MT=%'AGX$*>SND3C"DXE_I5:[)X/GH=*Y3+!M\%9@* MS6.@FV1FA)ZI I>R/0)WF$ !($='?H)0"M/16%3%* #H5S6&:%J.1:&'Q5A3 M:GR"XF+8_14<%FK9\4'/L1A:L:D] 9;[H(T8 ZB:;;E]]BIXUL;> 0-!Z<(7 M/6K0 U[$%)#'8H6^[1X\0,N@/-TCLDW=.D=^)'B<@MS3!T )2 X@A+Z^*ZOTK(52(X.' MJUWO(A$+,PWV"YA]H'#;2S80'\O422",D< GI$DN\!) JFSV#E-AXOEQ'#/L MCS3&\!"(CWA^N^8M[W$VLM;P\?T]V[7[X*OC\XR./,W[8XS_!'D<0:B9CRO./ B*B/[>]/O8=_KR!!4 M&XR+1D(*!+/MH:<(F'$=>@PPC.:Q+A!\7%H92"A3V()IA#'&D [XW3&M$E0[ M!$3OR:L%MG!XFP:2/N3J\(P"N+"6>HCG;0.Z%@VW8-\ND 8W8@%NAI]CF"!; M@%?3NI<-3W6A@TAY0P>)HAC6,+BALH_\!@N12:'!R((%*?!LSV9!*,*,K,;$ M;)@\'D?$$ 3&"C34I;P_4O,9E&VOI4R&D@^CA[X.7.LS :W*E-N8D,&K0R,V M -B(#*N#W:&&S .+J6"5.=5RVS)!AF!=7)OYQL@?A#WJB\/^7ILHLLL*N('2 MU#WQ?.I@R>@8:V Z3$LTL3V>0=D35UQ9"*:?;LYU+'ANL6S%QI]O>WJ M;/41+V4">F^H3IE&TR':TU143%0??9,PK,HEY>N/#KO>_)89;_CA*+Y "3)D;D&FWP!]T!'^/>X>5[+9\:[O#0-T M-SF'Q^\T'"I1,(HX5$+!:"4K9L6[._Q)E'+BW>N@:@WT7]\[OW] ".-H#N+Z MT@-OB0;5HU=%72-6&%:!%&>V?A7+1V'E8I11P?_4=8393P%0)%/;(IP0A65? M]MJ$4.(SLW"TOU>E4A?RMF="3?,4 M(4\F;LI7C$16!G1-/O]\NEE\.O9K:A#FN(RS*SC M#V2TX#+MOA:"$467MC&"3Y:A'H75H8[3V9]M&K9)9B?I71JWYS)UK!*01HV6 MGDS1H3@V18R5\]5E"VLZ[>IHC1.V!$A98T+,&"%N>Q9Z?EG0IUFS?&LO8RVU[%<;VEA M%(5 ]!S(@X)Y<#W5/[R"25UDTZ9V67"I28*_P=L(+HM%I0Y)N^1EW7B8) )S*!UPKG8>UA^DC4=O0=, MP1/FZL/';0"6)C],/PRE_ 8Q!)4:AE/D9*+Z(2-]P+LKZBNX 6-_>J];)ZRQ MB&P\8F2AT",QQU.^\ "Q32;-O4W2 J@B$E"Q2&F(*XF,88\'8+HFEV M 8+=>3@2&H87I$/,A4T<6.*05+-"ZX=X )V $G?C_;.9J&.=R:'#_4!3)GQ&3Q/YL*V MOS<)''L]4(KI<94EWJ:3A)1PHV@^D%J82U.JPD!C(3OX)V8 KTN/OR P!> B0QU\TB3BJHO<2%=C%AI$< M(<0=,^^8G3>B5C'@MQ&X(\H@0S'J!+#J@Q*-BN3)_-E@MP#U:'E'2549YZ ' M$^'85PZICR=.H:F:@ $<\CTU[LR-4]A)C9_46%CD#;K'I/J/>7J$LHBLXN;I MW[V\+W,"$!Z\A AQN \&RU%-]KE@RB@#XL%"%[]:SZ]Z\01H^LLTZ@Y>]Z*R MA6J52CWK7(+9(/00@FJRC9EF7^SF(6;KF&9C)ZDC#\Z[ ]H; (S*4"76:>H MP:EXRRUP]SKH5FK2XS^2\B!NSPEJ;N8)*D2CRI7X]>JT>-$]UT'H Y[P" ^" MCP@J!,>@RFD&HXDZW'!D=F>*G[8F#'85ST4@C@ WVW/#@G&,/*)>?T@]FN-6 M_;(E5G(UYM..7GD;],R$7BF>W+WF/Q<&RH5,SF7EX!/5&=1>]@-*@]6DL>,1 MXN^=:Y+DZS:F[N0M%OW18>ZP=H4K:W[LUZ)D+O1EBCTHVJ]7FL&B3'5$S!]#76 M#:]B9%@^[55'8[$TIOJ%AFW)!$^^6*$VAAM^Y1N6G02B- #W1H-?A)IL]8B> M\;Z:"=1<8U4X%MOZA=YCRPJS5AV6W%8A0L-"4;Q"1_?#*.3Z:>M@74: & 1/ MK0R_R'Q$1IJ K1I>P3?Q2B39Y4IV 1/S,F@?%.J8WF,,3Y^RL:; <%A&LH-I M03^P=)TNUC:P2@LD$;JP'9-6OK"=!%R(EE?D:@-]U*$+37,@U5:-(2[T\=L^ M;*I80-V.Q>F',BT<4 M&+A174(YS NK\-1[6,<%_-B3'\G(A+!,G@W>D7=$CH$9R,^HZ@9 ,BU\^3#6 M\^- +X<5Z.$Q5"ST\-?[.0QHOQ K?'G_&)F52@PS^EZE]NA;5%?208X@L(KC ML@(P>E;/YEY]S_/)SW)>?2]M]^9EF M'WQ>BD0H$KO?'%_>A+;NN":T+I/V4&N!Y7=HF#^8D2[)UT8]719]\^ZUJ/>> MVG6QW3#4E,8EURZ=R;T+@HUS*2;V]R@N!(J,;8Y@$KQO MGR0EKXS]O2\N1 %2P2^V"88*K/227NVR&$'9^8=@(SW]RFROUR,[3!N=RBB! M]OT9K-GSCA/_G3W*9K/BZ!HX^ ?HA0C4%\)%Q4/0AX=2]DAHX=^IFQ!9'_?_LO7E3XERW-_R_57Z'5->YJMKG M11]FX;K/TU6(0]NM8CNTW?T/%4B :$CH#")\^G>OM8?LA!! X(W5>=<=ZO) MSA[67O/Z+1F-$A/WZ/B[.W2,H4X355'QL,%NP)I0%K 2VHP[H 6C1&V!4*@+ M[] <6XC&"*LA$S^>P1I2QUF(-,9*D[BY#TJD.;/$9EPR!()<'5)&,8\_;=+$ M_^8/HQUDMJK\S*M5PP,E9V2.( V8F*T)" @8^H-GJ(;K';I$B?ND%N[+)*LI& M,E#F"^F(PPJ.)>RV9&F,+A;!=<0AAOV6ALL=A8H&EJ4CW%ST1^$KI=GCZ+R@ MS]$W)4IA7Z>E:403(A?>[I.+KUO/AF/3HB+"FD6-0ZBLCV6U455!E-/%)_4Q M_BYE1,-V8$JT(E]?'*NEFJ B0,XE3$JH^^SRBI,3./3B/%XT\VTGS&?"'6:VFU=J12R^[ELAB-H M,.ZE&PO4P*LMV9\-H)R[@.S+0BHB@Y4]&V%ZH)"-3X!/UF YF;6$4P(2\O[<_6K?7Q]]_2TH<+R MJC"PK5#2V*?M4XF*04"K\!?L,RNL)[Q_Q.FQ:A!Y,>O.8[#(H>]JD-WGT-'DH MXF=8#-V))FW4B=YC>%#]3TN7&YW./E;,607M@ M=(&?$E-G!<*".0IPAB; .23B1-V3TJ:#M.GH$L@&,-!,?-$?99#4")&\BG)] MO$ABQ@&(W=333>'!1&:/ BCP1<%R#,\/(LYRC+JEFX;^S%1K.N4A$32]4>B; MX+(*()XX* J*1[I*IO@;O&Y"S@@1\%#L6P#S1*9-1K)=5G<#&?52CJ"\=3;/ M!L$4?6)]W$5L/7T^[%EO3Q7L\5-M#[*S7&_2!;DN8TG4Z/!0@MT M32=8\];N6'UE"Q0!8VD+8IH BR0B ,+K.3#!3>8QK$@P/<2@2Q$/9\R7_9: MC"L('#]W]H!GSDUQ\Q) "6>V9 M*%IB<2YQ0)G3I-=U5!2P>X.T> @@=%E?F\HE8.87:X&\'7)HER:JB MQIE\BN&2R0+"D/+B84)P&Z#(=,*"P>O!"_/1LI.RRT4&B_1]BM!%Q!@6]+/, M K]/_R9XD:.K&IB0H=ISLB^\(;- $V:7'5?@8'IC)HR_BYO'MD*-KE'<#(U5 M5N/]85>>828@7Q4?1DDMC\*7&!E9(S;@,YF1QDL-#)=>.A39& 9D"@1YYF!B M@QBC,6C9.IP6IG"'[O[N3G!E1>KSS#V0OQ3> 3J]F-,2:^$,2.P05IC'KFCC MKM^&]PAY6!G\'B7(B50$=I*\S;#+60_X%>%[ M&.'AR(I"*9U_!;N[K#'Q+0- MJN7Q8I38NW80V+#,4HY]+,K9)V@6B9/?F-"N"N61W;&T&>*697^I 0#SY"4" MW J!JR' +^%!R@H]AV&R!CC(@6,!H6<))^&V@\PJT,)BYPF'[@_@\3(+SE)K M7P(]!=E!Z/E4M=WR:73VP +IL]R>%@NA]9%)D4V2J4" M3?H^0UD*C%Y$+W8QQ1P^)"[FA'FKRB!X+9T8M"% =1&!8"V&4+S[ \*(D0.. MF$4!J$$([>52>&R%I:7K#+M+WD;&!G9WKFRA4X:9"^=$\M9(1770O$0@O4@C MRT*%S%+6.;F"(GK@,-(&"X :!V&=5=*UU0F4P ^BB2Y0DE?,8_B$?*<7'S.W1W-9B'OB> M@3H;B'#:]Q,P_?J$#8)RR#JL3YH1S)FJ)GT.+:#\'I]\$*21'$PT+N#*SED^ M(J#D1(>, .$SKZ?[.K=GS#?C-@W:@W&A1'4'GANF"8D#6 M>SZ9"#=LR?#;V M8MS3<,S8T0":J?C]P*2F+J.@(.:S0=ZG1>+AN> P#$V-CZ8FC9=16KZ'RID. MR/=8@JY"IP]B9 BCBU*.6 Q^!)S^6%F'3C=T*7F&[GP0N;C^TSY&78C6V26# MG3;0ZL@E6( M/_.SQEFOVSKK7IV88E-NPD$]0K&S@=/9MJ371%*^_\R#^N-R-:RLED"PO?BJE\:+KV$L^')H["O/EMG@Y_5O\^==:!#RUCPRN5 M5W&AC=/__UO-%L[M(:-#&4 C<$Q0@GA&'%^+R4Q.4D6;XN$[!*QO=.Y8]D&C M6.JW<[H_X9U:;>'?]^W,3BHE-BA)Z_M*J//X>Z7H;\79YRA:O=UA6M M?-KG@','L1*$8H+("39_GD3)P\0 (OA:(L1"NT1C#\0,K6)5#4QWH>EHCA[ MYD.8"S/Z>,*,3A:$^'ZLNR^UXLD@NSLX"CY,2YRDU$/6"9%C[=&(F$#]9C$M M;F2R%!07 W7 ;J!9(F2.:0;B S'@OCYD-[)<;)�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